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Abstract	  
Multiple sclerosis is the commonest neurological disease affecting young adults. Whilst the 
initial relapsing-remitting disease phase is associated with inflammatory demyelination and is 
treatable with immunomodulatory drugs, the secondary progressive phase (SP-MS) is 
associated with ongoing axonal loss and cortical atrophy and is currently untreatable. Studies 
of SP-MS have revealed thW.e presence of extensive subpial demyelinated lesions within the 
cerebral cortex. This pathology is associated with a high level of meningeal inflammation, a 
gradient of cell loss from the cortical surface and high levels of microglia activation. To test 
the hypothesis that pro-inflammatory cytokines diffusing from the cerebral meninges could be 
responsible, we have established an animal model mimicking cortical grey matter pathology. 
Female DA rats were immunised with 5µg recombinant myelin oligodendrocyte glycoprotein 
(rmMOG) in incomplete Freunds adjuvant (IFA). This dose was insufficient to initiate 
encephalomyelitis, but did initiate an anti-MOG humoral immune response in the periphery. 
Twenty days post-immunisation animals received an injection of tumour necrosis factor (TNF) 
and interferon gamma (IFNγ) into the subarachnoid space at the sagittal sulcus.  
Immunohistochemistry revealed areas of subpial demyelination extending through cortical 
layers I–III. Lesions were maximal after 7 days and had resolved by remyelination at 14 days. 
A gradient of microglia/macrophage activation was present from the cortical surface. The 
extent of demyelination correlated with activation of microglia in the cortex and macrophages 
within the meninges. Activated microglia were observed contacting myelin, oligodendrocytes 
and neurons. In the demyelinated cortex, expression of the TNF receptors TNFR1A and 
TNFR1B was upregulated on oligodendrocytes and perivascular macrophages respectively. 
CD8+ T cells were observed in the meninges, corpus callosum and scattered throughout the 
grey matter, whereas CD4+ T cells and CD79a+ B cells were restricted to the meninges. 
Oligodendrocyte numbers were reduced in the upper cortical layers prior to demyelination 
(days 1 and 3 post-injection), but were still present in demyelinated lesions at day 7. Numbers 
of neurons and astrocytes were not changed. Control animals immunised with IFA and 
injected with cytokines had increased presence of inflammatory cells within the meninges but 
no demyelination. Animals immunised with rmMOG and injected with PBS had no 
demyelination or immune response within the meninges or cortex.  
Thus, acute subpial demyelination was dependent on a pre-existing immune response 
against myelin protein, coupled with generalised pro-inflammatory signalling within the 
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meninges. These findings support our hypothesis of a role for meningeal inflammation in the 
cortical pathology of MS and describe for the first time an animal model that can be used to 
study the molecular mechanisms involved. Future research will aim to maintain meningeal 
inflammation and produce a model of chronic demyelination. 
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1.1	  Multiple	  Sclerosis	  
MS is the commonest neurological disease affecting young adults, with 85,000 sufferers in 
the UK alone (The Neurological Alliance 2003). The disease is characterised by the presence 
of defined foci of inflammation and demyelination (lesions) within the central nervous system 
(CNS). Lesions are hypothesised to be caused by an autoimmune response against 
components of the myelin sheath surrounding axons in the CNS. The dissemination of 
lesions throughout the CNS results in a variety of motor, sensory and cognitive dysfunction. 
1.1.1	  Epidemiology	  and	  aetiology	  
The onset of MS is typically in young adulthood (20-40 years of age). The number of women 
affected is approximately twice as high as the number of men (Compston & Coles 2008). The 
disease occurs worldwide but is most prevalent in high and low latitudes away from the 
equator. The prevalence of MS varies between 60–200/100,000 in Northern Europe and 
North America (120/100,000 in UK), and 6–20/100,000 in low risk areas such as Japan 
(Compston & Coles 2002; Sospedra & Martin 2005).  
The precise aetiology of MS remains unknown, although it is generally understood that an 
interplay between polygenic genetic susceptibility and environmental factors is responsible. 
Prevalence is substantially increased in family members of MS patients (Dyment et al. 2004). 
Concordance rates in monozygotic twins are commonly reported at around 30%, indicating 
both a partial genetic influence, but also substantial environmental influence on susceptibility 
(Dyment et al. 2004). Genome wide studies have been performed in different MS populations, 
but no single major susceptibility polymorphism has been identified (GAMES 2003). The data 
are strongest for one or more susceptibility genes in the area of the human leukocyte antigen 
(HLA) genes on chromosome 6 (Hillert & Olerup 1993; Haines et al. 1998).  
Migration studies show that population genetics alone cannot explain MS susceptibility; 
migration from an area of high prevalence of MS to an area of low prevalence before age 15–
16, decreases the risk, whereas migration after 15–16 does not, highlighting the importance 
of immune system development in disease susceptibility (Kurtzke 1983). One proposed 
causative factor for the pattern of prevalence is the relative decrease in sunlight exposure at 
higher latitudes. UV radiation may exert its effects either by influencing immunoregulatory 
cells or by the biosynthesis of vitamin D, which itself may modulate the immune system 
(Ascherio et al. 2010). Delayed exposure or reduction in childhood infections in developed 
countries is another factor and has led to the “hygiene hypothesis”; which proposes an 
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increased propensity to develop autoimmune reactions and allergy in populations with 
delayed exposure to, or overall reduction in, childhood infections.  
Viral infection has been proposed as a potential factor in MS and in some cases can 
potentiate and exacerbate relapses (Sibley et al. 1985; Tremlett et al. 2008). For example, 
infection with Epstein-Barr virus (EBV) can increase the risk of developing MS and there is an 
increased seropositivity for anti-EBV antibodies in MS patients compared with the general 
population (Wandinger et al. 2000; Levin et al. 2005). However, the importance of EBV in the 
development and pathology of MS is highly controversial, with some studies reporting the 
presence EBV-infection in a large proportion of the B cells in the meninges and lesions of MS 
post-mortem cases (Serafini et al. 2007; Serafini er al. 2010), whereas other groups have 
failed to detect virus particles in the CNS (Willis et al. 2009; Sargsyan et al. 2010). A recent 
paper suggests that these contrasting results may be due to the use of different detection 
protocols and MS samples (Lassman et al. 2011). Furthermore, it has been suggested that 
further work should be carried out independently, using a variety of samples and 
standardised techniques. It has been hypothesised that viral agents may cause MS 
exacerbations by molecular mimicry, where immune cell receptors specific for viral antigen 
also react with self-antigen, or by bystander activation of an immune response by pro-
inflammatory factors released to target the virus (Sospedra & Martin 2005). 
1.1.2	  Clinical	  considerations	  of	  MS	  
Clinical manifestations of MS are highly varied due to the presence of isolated focal lesions, 
which can occur at any location within the CNS, with consequent dysfunction of the system 
affected. Symptoms are not disease specific and include the sensory, motor, autonomic and 
cognitive systems; unilateral loss of vision, limb weakness/pain, bladder dysfunction and 
fatigue are all commonly observed (Compston & Coles 2008). Cognitive dysfunction, such as 
memory loss and impaired attention, is present in the majority of patients with chronic 
disease, though has also been detected in approximately 1 in 4 patients after the initial 
clinical presentation (Chiaravalloti & De Luca 2008; Potogas et al. 2008). Affective symptoms 
such as depression and apathy are also common in MS, and may be related to the severity of 
disability, the degree of cognitive dysfunction and extent of MRI-visible brain lesions 
particularly in frontal areas (Bakshi et al. 2000; Zorzon et al. 2001; Tsivgoulis et al. 2007; 
Mattioli et al. 2011). 
Diagnosis of MS is made when it is established that two or more CNS locations have been 
affected on two or more occasions, i.e. “dissemination in space and time” (McDonald et al. 
Chapter 1: General Introduction 28 
 
2001). Patients entering healthcare after one episode are typically diagnosed with clinically 
isolated syndrome (CIS), until further episodes occur and relapsing-remitting (RR-MS) 
disease can be diagnosed. Magnetic Resonance Imaging (MRI) is commonly used to support 
diagnosis, with gadolinium enhancement protocols able to detect the presence of recent 
inflammatory demyelinating activity within the white matter (WM). The presence of 
immunoglobulin oligoclonal bands within cerebrospinal fluid (CSF) analysis may also be used 
for diagnostic purposes. Indeed, a recent study found oligoclonal bands in the CSF of 89% of 
411 MS patients (Franciotta et al. 2008). 
The MS disease course is extremely heterogeneous (Figure 1.). Approximately 80% of 
patients initially follow a relapsing-remitting course (RR-MS), typified by distinct and isolated 
presentation of diverse neurological symptoms (relapse) followed by periods of recovery 
(remission). The typical relapse rate is 1.5/year, although this can vary widely and be strongly 
influenced by patient factors, for example, the relapse rate decreases during each trimester of 
pregnancy (although there is often a relapse soon after birth, The Pregnancy In Multiple 
Sclerosis Group 2004) and the risk of relapse is doubled following viral exposure (Buljevac et 
al. 2002).  
After a variable period (usually 10-15 years) neurological disability gradually becomes fixed in 
90% of RR-MS patients, with full recovery following a relapse no longer attained (Noseworthy 
et al. 2000; Confavreux & Vukusic 2006a; Compston & Coles 2008). This is termed 
secondary progression (SP-MS) and represents a period of general decline continuing until 
permanent disability occurs (Weinshenker et al. 1989). This progression may be caused 
primarily by axonal loss and neurodegeneration, with no correlation with inflammatory lesion 
formation detectable by MRI (Confavreux & Vukusic 2006a; Leray et al. 2010). Recent 
research has shown that although the period of time taken to moderate disability is variable, 
the future progression of the disease once this threshold is reached is highly consistent 
(Leray et al. 2010). Moreover, a separate study found that the time taken to reach advanced 
clinical end-points, such as being bed ridden, was unrelated to the total number of relapses in 
the relapsing remitting phase (Scalfari et al. 2010). In the same study, more frequent relapses 
in the first 2 years after diagnosis, and a reduced time to achieve moderate disability, were 
highly predictive of a short disease course. A relatively small proportion (10-15%) of patients 
experience progressive disease from initial symptoms, termed primary progressive MS (PP-
MS). There are currently no efficacious therapies approved for treatment of SP-MS or PP-
MS.  
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Half of all patients diagnosed with MS will not be able to walk unaided 15 years after 
diagnosis, with disability fixed and worsening during progressive disease (Confavreux & 
Vukusic 2006a; Confavreux & Vukusic 2006b). The median time to death is approximately 30 
years from disease diagnosis, giving a reduction in life expectancy of 5-10 years compared 
with the general population. Death is attributable to complications of MS (such as infection) in 
approximately 60% of cases. 
	  
Figure 1.1 Representation of the typical disease course observed among MS patients. Approximately 80% of 
patients follow a relapsing-remitting course followed by secondary progression. The initial relapsing remitting 
disease course is primarily associated with inflammatory episodes, which may or may not be clinically evident. The 
secondary progressive course is primarily associated with chronic axonal degeneration. Adapted from Compston 
and Coles (2008). 
1.2	  Pathology	  in	  MS	  
1.2.1	  White	  matter	  lesions	  
1.2.1.1	  An	  immune-­‐mediated	  myelin	  attack	  
The pathological hallmark of MS is the sclerotic plaque (lesion), an area of focal damage to 
the CNS WM visible upon macroscopic investigation of the brain. Plaques vary widely in size 
and distribution, but commonly occur at the peri-ventricular regions of the brain (Lassmann et 
al. 2001). As a consequence of demyelination normal saltatory nerve conduction is impaired, 
which causes dysfunction of action potential propagation and the appearance of symptoms in 
the patient.  
Lesion formation within the CNS is proposed to be caused by an immune-mediated attack on 
the myelin sheaths surrounding axons, leading to demyelination (Lassmann et al. 2001). 
Peripheral inflammatory cells are thought to enter the CNS parenchyma in established 
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disease crossing activated, adhesion molecule expressing blood-brain barrier (BBB) 
endothelia. Following entry into the CNS parenchyma activated T lymphocytes (both T helper, 
Th, cells and cytotoxic T cells), B lymphocytes, plasma cells and macrophages contribute to 
the pathology, by either direct oligodendrocyte/myelin cell or antibody-mediated attack, or 
non-specifically via the release of cytotoxic molecules. 
The inflammatory activity of lesions has been studied to attempt to establish the evolutionary 
stage of lesions. Lesions are traditionally classified into three categories; active, chronic 
active and chronic inactive based on inflammatory cell infiltration and pattern of demyelination 
(Lucchinetti et al. 2000; Lassmann et al. 2007; Frischer et al. 2009). Active lesions are 
hypercellular throughout, typically containing high numbers of lymphocytes. Macrophages are 
found in high numbers, and often contain myelin fragments, indicative of ongoing 
demyelination (Frohman et al. 2006). Lesion boundaries are illdefined with demyelination 
occurring as a result of cytotoxic activity and the deposition of anti-myelin antibodies and 
complement (Genain et al. 1999; Lucchinetti et al. 2000). Chronic active lesions have a 
clearly defined boundary, with myelin containing macrophages/microglia found only around 
the edge (Frischer et al. 2009). Lesions are relatively hypocellular at the core, with reactive 
astrocytes forming a gliotic scar and unmyelinated axons present. Chronic inactive lesions 
are demyelinated but with a lack of inflammatory cells and with no myelin fragment containing 
activated microglia/macrophages at the lesion edge (Frischer et al. 2009). A sub-group of the 
inactive lesion is the so-called “shadow plaque”, which consists of well defined focal areas of 
thinner than normal myelin (as visualised by histochemical techniques). These shadow 
plaques represent lesions that have been remyelinated, a phenomenon thought to be 
common in early RR-MS, but which becomes less efficient as the disease progresses 
(Franklin 2002). 
During RR-MS, the frequency and severity of symptomatic episodes are linked to localised 
permeabilisation of the BBB and oedema, which may be visualised by MRI. The number of 
lesions visualised by MRI decreases as the disease enters the progressive stages, although 
extensive inflammation can still be present. At this stage it is thought that the fixed 
neurological deficit is due primarily to sustained axonal and neuronal loss (Figure 1.1). 
Lesions may continue to slowly expand in SP-MS, with diffuse microglial activity and 
abnormalities observed within the NAWM (Kutzelnigg et al. 2005; Howell et al. 2010). 
Examination of the pathology of active lesions, primarily derived from biopsy tissue samples, 
has led to the proposal of four main lesion subtypes, based on the proposed originating 
mechanism of demyelination (Lucchinetti et al. 2000):  
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• Type 1: Demyelination characterised by macrophage and T cell infiltration. 
The evolution of lesions is correlated with elevated levels of pro-
inflammatory cytokines such as tumour necrosis factor alpha (TNF). 
• Type 2: Humoral-mediated demyelination. Deposition of complement and 
immunoglobulin leads to antibody-mediated demyelination. 
• Type 3: Hypoxia-like damage to oligodendrocytes in the presence of T 
cells and macrophages, with oligodendrocyte apoptosis frequently 
observed.  
• Type 4: Genetic mutations leading to increased susceptibility to 
oligodendrocyte cell death. These lesions were only identified in PP-MS 
cases. 
While heterogeneity in lesion type existed between patients, lesions conformed to one sub-
type only within each individual. In addition, a study using samples from cases dying during or 
shortly after relapse identified substantial oligodendrocyte apoptosis and microglial activation, 
with a lack of lymphocyte infiltration (Barnett & Prineas 2004). A further study looking at 
chronic disease samples showed that while lesion heterogeneity may exist in the genesis of 
lesions, homogeneity of lesions exists in established, chronic disease (Breij et al. 2008). 
1.2.1.2	  Axonal	  pathology	  in	  WMLs	  
Axonal pathology in MS lesions was identified in the initial pathological reports of MS (Sander 
1898, reviewed in Kutzelnigg & Lassmann 2005). The extent of axonal loss within WMLs has 
been correlated with disease severity and progression, by both MRI and 
immunohistochemical (IHC) methods (Bjartmar et al. 2000; Evangelou et al. 2000; Schirmer 
et al. 2011). Furthermore, a significant loss of ventral horn neurons has been detected in the 
cervical and lumbar regions of the spinal cord in MS cases and is correlated with microglial 
and T cell infiltration (Schirmer et al. 2009; Schirmer et al. 2011).  
Accumulation of amyloid precursor protein (APP) at transacted axon end bulbs is used as a 
marker of interrupted protein transport, and thus axonal damage (Gentleman et al. 1993). 
Increased numbers of APP+ axons were also found in the surrounding normal appearing 
white matter (NAWM), indicating that demyelination may not be the cause of axonal damage 
(Bitsch et al. 2000). In addition, the presence of non-phosphorylated neurofilaments is a 
marker for axons under stress, with high numbers detected in WMLs, preferentially observed 
in demyelinated axons and accumulated in end-bulbs (Trapp et al. 1998). Analysis of MS 
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lesions has shown increased levels of APP+ transected axons during active demyelination 
(Ferguson et al. 1997; Trapp et al. 1998). The number of APP+ axons may be highly 
correlated with inflammatory infiltrates and the activity of lesions irrespective of disease 
course (Trapp et al. 1998; Frischer et al. 2009). Chronic animal models have also shown 
extensive axonal loss in the spinal cord, correlating with microglial activity and neurologic 
disability (Papadopoulos et al. 2006). 
The mechanisms that combine to cause neurodegeneration and axonal loss in MS are not 
well understood, though a number of different mechanisms are likely to be involved. For 
example, infiltrating inflammatory cells may have a directly toxic effect on neurons/axons; the 
number of cytotoxic CD8+ T cells infiltrating lesions has been correlated with the extent of 
axonal damage (Dutta & Trapp 2010), and CD8+ cells have been shown to initiate cell death 
in vitro (Bezzi et al. 2001; Neumann 2003). Axonal and neuronal loss may also proceed as a 
consequence of molecules released by activated inflammatory cells. For example, activated 
microglia and macrophages have been implicated in causing axonal injury through the 
release of nitric oxide (NO, Sanders & De Keyser 2007). NO has been shown to cause 
conduction block in demyelinated axons and lead to degeneration of electrically active 
neurons (Redford et al. 1997; Smith et al. 2001). In addition, CSF extracted from patients 
undergoing relapse has been shown to cause apoptosis of neurons in vitro (Cid et al. 2002). 
TNF release from astrocytes and microglia under inflammatory conditions has also been 
linked to neuronal cell apoptosis (Bezzi et al. 2001). Moreover, the release of TNF from 
activated microglia/macrophages may increase the extracellular concentration of glutamate 
by initiating release in an autocrine manner or preventing uptake by astrocytes (Ye & 
Sontheimer 1996; Takeuchi et al. 2006; Yawata et al. 2008). High levels of glutamate have 
been linked to axonal damage in WMLs in MS and it’s animal model and have been shown to 
be neurotoxic in vitro (Pitt et al. 2000; Pitt et al. 2003; Werner et al. 2001; Takeuchi et al. 
2006).  
The loss of trophic support from myelin may be another mechanism that disturbs 
homeostasis and ultimately leads to axonal loss. Recent research has shown that an energy 
crisis occurs in chronically demyelinated axons, due to the re-organisation of Na+ channels 
ultimately leading to an influx of Ca+ through a malfunctioning Na+/Ca+ exchange pump. A 
rise in intracellular calcium may lead to mitochondrial dysfunction and reduced ATP 
production, causing an energy crisis and ultimately leading to axonal degeneration and 
neurodegeneration (Dutta et al. 2006; Dutta & Trapp 2010). In support of this hypothesis, 
inhibition of the Na+ channels by flecainide was found to prevent intra-axonal accumulation of 
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Ca+ and maintain axonal integrity in animal models of MS (Kapoor et al. 2003; Bechtold et al. 
2004). 
1.2.2	  Cortical	  lesions	  in	  MS	  
1.2.2.1	  Historical	  aspects	  
MS is classically viewed as a disease affecting the WM, and the pathological importance of 
cerebral cortical grey matter lesions (GMLs) has been underestimated, even though they 
were first described in the early pathological studies (Taylor 1892, Lumsden 1972, reviewed 
in Kutzelnigg & Lassmann 2005). This may have been because GMLs proved difficult to 
detect in post-mortem studies using established histological staining techniques, and are not 
visible using traditional MRI methods (Kidd et al. 1999). In the past decade, through the 
widespread use of highly sensitive IHC techniques using anti-myelin antibodies, the full extent 
cortical demyelination in MS has been revealed. 
1.2.2.2	  Lessons	  from	  imaging	  studies	  
Due to poor contrast resolution and relative lack of BBB permeability, GMLs have proved very 
difficult to detect in conventional MRI studies. Moreover, the lack of efficacy for detecting 
GMLs, and subtle changes to NAWM, have been cited as the most likely reasons for the so 
called “clinico-radiological paradox”, the lack of correlation between MRI detected lesion load 
and patient disability, particularly during SP-MS (Barkhof 2002). The increasing research 
focus in pathological studies has led to the development of new MRI techniques, such as 3D 
double inversion recovery, with greatly increased sensitivity for GMLs, although the detection 
of chronic lesions remains difficult (Geurts & Barkhof 2008). Given the persistent difficulty in 
detecting GMLs by MRI, various studies use measurements of cortical atrophy as a marker 
for cortical pathology. Although it has been shown that atrophy of the cortex occurs in 
patients with short disease duration (De Stefano et al. 2007), the extent and rate of cortical 
atrophy has been found to be greatly increased in SP-MS patients vs. RR-MS and is 
significantly correlated with disability in longitudinal studies (Chen et al. 2004; Fisher et al. 
2008; Fisniku et al. 2008). However, recent studies have detected cortical atrophy in RR-MS 
found a strong correlation with cognitive deterioration (Amato et al. 2007). 
1.2.2.3	  GML	  subtypes	  
GM demyelination has been associated with the general cognitive and motor decline 
occurring during the progressive stage of MS (Kutzelnigg & Lassmann 2005; Kutzelnigg & 
Lassmann 2006; Wegner et al. 2006). An initial extensive study of GMLs divided them into 
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seven subtypes (Kidd et al. 1999), however, subsequent research divided into them into three 
main classifications (Figure 1.2), based on location within the cortex (Peterson et al. 2001; Bö 
et al. 2003a). 	  
• Type I lesions (leukocortical) traverse the GM-WM border, and can be 
extensive.  
• Type II lesions (intracortical) are small and are typically found around small 
vessels. 
• Type III lesions (subpial) extend from the pial surface and into the cortex 
itself. They can be extensive and in some instances have been found to 
extend through all cortical levels and over multiple gyri. 
 
Figure 1.2: GMLs in MS have been sub-divided into three types; Type I; Leukocortical lesions account for 
approximately 15-30% total GML and span the grey/white matter boundary (A). Type II; intracortical lesions are 
generally small and centred around blood vessels (B). Type III; Subpial lesions are the most common sub-type 
(50-65%) and appear to extend from the pial surface into deep cortical layers (C). Subpial lesions extending 
through each cortical layer to the grey/white matter boundary are sometimes referred to as type IV lesions. Images 
adapted from Peterson et al. 2001. 
Type III subpial GMLs are present in the highest proportion (50-65%), followed by Type I 
lesions (15-30%, (Peterson et al. 2001; Bö et al. 2003a). GMLs have been detected 
throughout the brain, but show some regional variation in frequency, most commonly 
occurring in the cingulate gyrus (17%–44%), and temporal and frontal cortices (17–28% (Bö 
et al. 2003a; Vercellino et al. 2005; Bö et al. 2007; Gilmore et al. 2009). The extent of 
cerebral GM and WM demyelination can only be weakly correlated. A recent study indicated 
an average of 25% of the cerebral cortex was demyelinated, whereas only 5% of subcortical 
WM was demyelinated (Bö et al. 2007), indicating that GM demyelination may occur at least 
partly independent of WM demyelination in the brain (Kutzelnigg et al. 2005; Vercellino et al. 
2005). The extent of cortical demyelination in the cerebellum and brain, and in different 
cerebral cortical regions is significantly correlated, which may suggest a common 
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pathogenesis related to factors present in the CSF (Bö et al. 2007; Kutzelnigg et al. 2007; 
Gilmore et al. 2009). 
1.2.2.4	  Cellular	  infiltration	  in	  GML	  
While GM and WM lesions both exhibit clearly demarcated areas of demyelination and 
oligodendrocyte and axonal loss, the pathogenesis of WM and GM lesions appear to be very 
different. In WMLs BBB disruption and the expression of adhesion molecules leading to 
peripheral inflammatory cell influx are important initiating events, whereas in GML the BBB is 
intact (van Horssen et al. 2007), and little evidence of lymphocyte or monocyte infiltration, 
either to the parenchyma or the perivascular spaces, has been observed (Peterson et al. 
2001; Bö et al. 2003b). Indeed, the number of lymphocytes in Type II GMLs was found not to 
be higher than the surrounding NAGM. The contrast in lymphocyte infiltration in WM and GM 
lesions is especially evident in leukocortical lesions that span the GM-WM boundary (Bö et al. 
2003b). CD8+ cytotoxic T cells but not CD4+ Th cells have been found scattered throughout 
GMLs, and have been observed contacting neuronal cell bodies (Peterson et al. 2001; Bö et 
al. 2003b), which may argue for a direct cytotoxic effect, thought their low abundance would 
argue against this being a significant element in disease (Bö et al. 2003b; Frischer et al. 
2009). B cells and plasma cells have been commonly found to be restricted to the meninges, 
and were present in a 10 fold lower abundance than CD3+ T cells (Bö et al. 2003b; Frischer et 
al. 2009). In contrast to WM lesions, there is a distinct lack of evidence for the involvement of 
complement-mediated demyelination within GMLs, although it is possible that complement 
deposition occurs early and is transitory (Brink et al. 2005).  
In the absence of infiltrating lymphocytes and deposition of humoral elements, activated 
microglia have been proposed as the major mediators of pathology in MS GML. They have 
been found diffusely throughout type III subpial GMLs and normal appearing grey matter 
(NAGM, (Peterson et al. 2001; Bö et al. 2003a; Magliozzi et al. 2007; Magliozzi et al. 2010). 
These cells were identified as activated microglia rather than infiltrating macrophages by their 
relatively small size and the presence of short, thick processes (Giulian et al. 1995; Peterson 
et al. 2001). In chronic active GMLs, activated microglia were present on the lesion border 
suggesting ongoing demyelination (Peterson et al. 2001; Bö et al. 2003b). Activated microglia 
in GMLs express myeloperoxidase (MPO), indicating a potential role for reactive oxygen 
species in lesion pathogenesis and cytotoxicity (Gray et al. 2008).  
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1.2.2.5	  Meningeal	  inflammation	  exacerbates	  MS	  pathology	  and	  disease	  course	  
Recently, highly organised ectopic lymphoid follicle-like structures have been found in the 
meninges of a significant number of SP-MS (but not PP-MS) cases (40-54%, Serafini et al. 
2004; Magliozzi et al. 2007; Magliozzi et al. 2010). These B-cell follicle-like structures were 
predominantly found in the meninges of the cortical sulci, as opposed to the cortical gyral 
surface, and were present in the temporal, parietal and frontal lobes, particularly in the pre-
central and cingulate gyri (Magliozzi et al. 2010). The follicle-like structures consisted of 
proliferating B cells, FDCs, CD4+ Th cells, CD8+ cytotoxic T cells and plasma cells, 
suggesting a role for antibodies, or pro-inflammatory cytokines in the pathogenesis of cortical 
lesions (Serafini et al. 2004; Magliozzi et al. 2007). Ectopic lymphoid follicles are common in 
autoimmune diseases, such as Rheumatoid arthritis and Graves’ disease (Aloisi & Pujol-
Borrell 2006). 
The subset of SP-MS patients with B-cell follicles detected within the meninges (F+ SP-MS) 
have increased cortical pathology and a substantially worse clinical outcome than patients 
with no detectable follicles (F- SP-MS, Magliozzi et al. 2007; Magliozzi et al. 2010). The age 
at onset, age when first using a wheelchair and age at death are all reached significantly 
earlier in F+ SP-MS patients (Magliozzi et al. 2007).  
Pathologically, a higher number of type III subpial GMLs and a greater extent of GM 
demyelination have been observed in F+ SP-MS cases (Magliozzi et al. 2007). A subsequent 
study revealed extensive cell loss in subpial GMLs in F+ SP-MS cases (Magliozzi et al. 2010). 
A gradient of neuron and astrocyte loss was detected, with maximal loss in cortical layer I 
adjacent to the meninges. Cells were also lost in a gradient pattern in the NAGM indicating 
either that the process of cell loss occurs independently of demyelination, or that extensive 
remyelination occurs in GML, as has been shown in an unrelated study (Albert et al. 2007; 
Magliozzi et al. 2010). Subsequent analysis revealed that the majority of neurones lost in 
layers III and V were pyramidal cells (Magliozzi et al. 2010). Cell loss occurred to a 
significantly lesser degree in F- SP-MS cases with no evident gradient. Oligodendrocytes 
were lost in significantly greater numbers in GML of F+ SP-MS cases, but with no evident 
gradient. Curiously a significant loss of oligodendrocytes occurred in the NAGM and 
oligodendrocytes survived within the chronically demyelinated subpial GML (Magliozzi et al. 
2010). 
Activated microglia expressing major histocompatibility complex-2 (MHCII) proteins were 
significantly increased in F+ SP-MS GMLs (Magliozzi et al. 2010). A decreasing gradient of 
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cell presence from the pial surface was evident only in F+ SP-MS cases. Microglia were also 
diffusely increased through the NAGM with a similar gradient evident, and were frequently 
observed in close proximity to neuronal cell bodies in GMLs and NAGM, implicating activated 
microglia in the pathogenesis of subpial GMLs (Magliozzi et al. 2010). Microglial expression 
of CD68 and iNOS was significantly correlated with the presence of lymphocytes in the 
meninges of MS cases (Dal-Bianco et al. 2008). Moreover, expression of these molecules 
was also found to be elevated in the NAGM. In addition, the integrity of the glia limitans, 
which forms the surface of the cortex, was compromised in F+ SP-MS cases (Magliozzi et al. 
2010).  
The graded cell loss and pattern of microglial activation in the GM of SP-MS cases with 
meningeal inflammation and lymphoid tissue formation, strongly supports the hypothesis that 
cytotoxic factors diffusing from the meningeal compartment contribute to grey matter 
pathology and lead to an increase in clinical disability. In support of this hypothesis, increased 
levels of the pro-inflammatory cytokines Interferon-gamma (IFNγ) and TNF in the CSF and 
meninges of F+ cases have been detected, expressed by CD8+ T cells and macrophages 
respectively (unpublished data).  
1.2.2.6	  Neurodegeneration	  and	  axonal	  pathology	  in	  GML	  
Cortical atrophy detected in MRI studies, has been observed in RR-MS and is correlated with 
cognitive deterioration (Amato et al. 2007). In addition, cortical thinning and significantly 
reduced numbers of neurons, synapses and glia have been detected in GMLs (Wegner et al. 
2006). Substantial numbers of transected neurites, with a reduced expression of 
neurofilament have been detected in GMLs, particularly in lesions with the highest microglial 
activity (Peterson et al. 2001). In the same study, the presence of apoptotic pyramidal 
neurons was observed in the upper cortical layers. In addition, there is an evident reduction in 
synaptophysin expression indicating loss of synapses in GMLs (Vercellino et al. 2007).  
The reduced cellular infiltrate observed in subpial GMLs provides evidence against the 
hypothesis of parenchymal inflammation causing neurodegeneration (Peterson et al. 2001; 
Bö et al. 2003b; Frischer et al. 2009). Furthermore, the number of APP+ axons and 
neurofilament-rich end-bulbs is low in cortical lesions, which may be reflective of chronic, 
inactive lesions (Peterson et al. 2001; Frischer et al. 2009). However, recent research has 
shown that neuronal loss may be a consequence of inflammatory processes occurring in the 
meninges; analysis of F+ SP-MS cases has revealed substantial neuronal cell loss in subpial 
GMLs (Magliozzi et al. 2010). A gradient of neuronal loss was detected, with maximal loss in 
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cortical layer I adjacent to the meninges. Cell loss was also observed in F- SP-MS cases but 
to a significantly lesser degree with no evident gradient. 
Despite the lack of a blood-borne inflammatory infiltrate, substantial activation of microglia in 
GML has been observed, which strongly implicates them in the pathogenesis (Peterson et al. 
2001; Bö et al. 2003b; Magliozzi et al. 2010). In addition, activated microglia have been found 
in contact with dendrites, axons and neuronal cell bodies in GMLs, which may implicate them 
in the neuronal pathology observed (Peterson et al. 2001; Bö, et al. 2003b; Magliozzi et al. 
2010). The presence of activated microglia in active GMLs has also been correlated with loss 
of the astroglial glutamate re-uptake transporters, EAAT1 and EAAT2 (Vercellino et al. 2007). 
This could lead to an increase in local glutamate levels, which has been shown to cause 
excitotoxicity to oligodendrocytes and neurons (Pitt et al. 2000; Werner et al. 2001; Takeuchi 
et al. 2006; Bradl & Lassmann 2010).  
1.3	  Understanding	  MS	  through	  in	  vitro	  	  	  
systems	  	  and	  animal	  models	  
Studies utilising human MS tissue are inevitably limited by the “snap-shot” effect of post-
mortem tissue representing only a single point in time per case. Furthermore, the chronic, 
highly variable nature of the disease reduces the feasibility of studies and necessitates large 
numbers of cases to be studied. In addition, the chronic nature of MS leads to a relative lack 
of availability of tissue at an early, active stage and further limits research. Therefore, there is 
a clear requirement to study the disease in model systems. Important advances in the 
understanding of MS pathology have come through the analysis of disease models, the most 
important of which is experimental autoimmune encephalomyelitis (EAE). Further 
understanding of the molecular pathways that may be responsible for enhancing and 
regulating immune responses in MS has come from studies using in vitro systems. 
1.3.1	  The	  variety	  of	  EAE	  models	  
EAE represents a group of models in which an MS-like disease phenotype is induced in 
susceptible animals by active immunisation with a myelin protein or by transfer of antigen 
specific lymphocytes. EAE was first studied in 1933 (Rivers et al. 1933) and since has proved 
an invaluable research tool for the study of CNS auto-immunity. However, critics suggest the 
model overestimates the importance of Th1 cells in disease, and cite a lack of correlation 
between therapeutic efficacy in models and the clinic (Sriram & Steiner 2005). 
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The exact nature and extent of EAE is determined by the antigen and immunisation protocol 
used as well as the genetic background of the animal immunised. Myelin oligodendrocyte 
glycoprotein (MOG) and myelin basic protein (MBP) are the most common antigens used in 
EAE studies. Commonly used species/strains are the Lewis rat, the dark agouti (DA) rat and 
the C57BL/6 mouse. In addition, there are an increasing number of genetically modified mice 
exhibiting spontaneous inflammatory demyelination, such as the 2D2 mouse which expresses 
a T cell receptor specific to the encephalitogenic MOG peptide, MOG35-55 (Bettelli et al. 
2003a; Bettelli et al. 2006). The location of lesions has been shown to be affected by the 
antigen specificity of T cells (Berger et al. 1997; Storch et al. 1998a); adoptive transfer of 
MBP-specific T cells typically resulted in a monophasic disease course with little 
demyelination and a mainly spinal cord pathology, whereas MOG-specific T cells also 
initiated lesions in the cerebellar and periventricular white matter (Berger et al. 1997). 
Severe, chronic, Th1-mediated disease can be induced in C57BL/6 mice by immunising with 
the encephalitogenic MOG peptide MOG35-55, in complete Freunds’ adjuvant (CFA). 
Lesions in this model were found to be composed of significant inflammatory infiltrates, but 
with relatively little demyelination, which may be due to the lack of humoral response (Dittel et 
al. 2000). Immunisation with MOG peptide has been shown to initiate only a T cell response 
and without significant B cell activation or antibody production, in contrast to immunisation 
with recombinant MOG protein (Berger et al. 1997). Moreover, an antibody response to MOG 
has been found to be critically important in initiating demyelination (Lassmann et al. 1988). 
The importance of an antibody response in modelling MS has also been shown with studies 
in the Biozzi mouse. The Biozzi antibody low strain is resistant to EAE, whereas the Biozzi 
antibody high (ABH) strain has been shown to faithfully replicate the disease course of MS, 
with the disease course influenced by the choice of antigen (Amor et al. 2005). For instance, 
immunisation with spinal cord homogenate or MOG protein initiated a chronic relapsing 
disease course (Amor et al. 2005), whereas immunisation with MOG35-55 initiated severe 
EAE, which rapidly progressed following an initial relapsing phase (Amor et al. 2005). 
Extensive demyelination has been observed in this model, together with gliosis, axonal loss 
and neurodegeneration (Hampton et al. 2008). 
Chronic-relapsing models can be produced using recombinant MOG protein in rats, with 
disease course affected by strain, antigen dose and formulation (Amor et al. 2005). Using 
recombinant mouse MOG (rmMOG) to establish EAE in female DA rats has been shown to 
replicate the clinical course and pathology of MS, initiating both a T cell and B cell response 
(Storch et al. 1998a). Inflammatory demyelinating lesions in this model were found to be 
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restricted primarily to the spinal cord (85–100%) and optic nerve (45–80%, (Storch et al. 
1998a). Inflammatory infiltrates were detected within the spinal cord meninges coupled with 
localised entry into the parenchyma, perivascular cuffs including T cells were frequently 
observed. Ongoing axonal loss, correlated with microglial activity, and progressive 
neurological deficits has been observed in a chronic model in this strain (Storch et al. 1998a). 
1.3.2	  The	  adaptive	  immune	  system	  
The adaptive immune system consists of a diverse range of lymphocytes that respond to 
infection in a specific manner. This response occurs via clonal expansion of cells with 
receptors specific to molecular components of the infectious agent, which are presented by 
antigen presenting cells (APCs). T cells originate from the thymus and are considered the 
major players in the adaptive immune system and consist of several subtypes.  
1.3.2.1	  CD4+	  Th	  cells	  
Th cells are a subtype of T lymphocyte that are characterised by expression of CD4. Naïve 
Th cells are activated upon binding of the αβ T cell receptor (TCR) to antigen presented by 
MHCII molecules on APCs (Storch, Stefferl, et al. 1998). Efficient activation also depends on 
the strength of co-stimulatory signals from the APC and the binding of additional receptors 
such as CD40 (APC) to CD40L (Th cell), and CD80 (APC) to CD28 (Th cell, (Kaiko et al. 
2007). Activated Th cells expand and differentiate into one of three subtypes; Th1, T helper 2 
(Th2), and T helper 17 (Th17), based on their cytokine profile and thus their function (Dittel 
2008; Zhu et al. 2010), Figure 1.3). Polarisation to one sub-type or another is dependent on 
the local inflammatory milieu, e.g. which cytokines are present, as well as the context of 
antigen presentation (Kaiko et al. 2007). 
Th1-type responses are typified by IFN-γ release, and are involved in responses to 
intracellular infections. Pathologically, excessive Th1 reactions are associated with 
autoimmunity. Activated Th1 cells release important pro-inflammatory cytokines such as 
IFNγ, TNF and GM-CSF (Dittel 2008; Zhu et al. 2010). The release of these cytokines leads 
to activation of microglia and macrophages, and the humoral immune response and 
upregulation of adhesion molecules on the BBB leading to further lymphocyte extravasation, 
as will be discussed below. Th2 responses involve the release of interleukin 4 (IL-4) and the 
upregulation of antibody production. This response is involved in the targeting of invading 
parasites but is also associated with allergy and hypersensitivity reactions. In the context of 
EAE and MS, release of Th2-associated cytokines is considered “anti-inflammatory” and 
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reflects the skewing of the inflammatory cascade away from a pathogenic phenotype. 
Release of either Th1 or Th2 cytokine acts to inhibit differentiation of the other population 
(Kaiko et al. 2007). 
 
Figure 1.3 The balance of particular cytokines in the local environment, which induce different critical transcription 
factors, governs the differentiation of naive T cells into each of the subsets. T cell subsets have profoundly 
different functions, which are related to their different cytokine release profiles Adapted from Dittel 2008. 
Adoptive transfer of Th1 but not Th2 skewed T cells has been shown to be necessary and 
sufficient to initiate EAE in the SJL/J mouse (Khoruts et al. 1995). CD4+ cells have been 
observed in WMLs in a range of EAE models, in both parenchymal and perivascular locations 
(Lassmann et al. 1988; Shin et al. 1995; Amor et al. 2005; Nikodemova et al. 2010). In a 
recent study, production of pro-inflammatory cytokines by Th1 cells was highest prior to EAE 
onset, and was required for EAE induction (Ponomarev et al. 2007). Moreover, CD4+ cells 
have been shown to accumulate in the CNS prior to the clinical onset of EAE and were 
present in lesions in high numbers during the disease course (Shin et al. 1995; Brown & 
Sawchenko 2007). The large set of data implicating this cell type in EAE led researchers to 
suspect that Th1 cells were the main protagonists in both EAE and MS. However, although 
CD4+ cells are frequently observed in the parenchyma and perivascular regions of MS WMLs, 
they are not the dominant cell sub-type (Lassmann et al. 1988; Shin et al. 1995; Amor et al. 
2005; Nikodemova et al. 2010). Moreover, anti-CD4+ therapy was found to be an ineffective 
treatment for MS, despite substantial reduction in the numbers of circulating CD4+ cells (van 
Oosten et al. 1997). 
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Recently, the description of a novel Th subset producing IL-17 has led to revision of the -
Th1/Th2 classification. Evidence in EAE implies that IL-17 producing T lymphocytes (Th17 
cells) are more pathogenic than IFN-γ+ Th1 lymphocytes (Langrish et al. 2005). In a recent 
study, they infiltrated the CNS prior to onset of EAE symptoms and were found to be more 
efficient at activating resident microglial cells than Th1 cells (Murphy et al. 2010). Th17 cells 
are now suspected to be among the main mediators of CNS autoimmunity as EAE was 
suppressed in IL-17 deficient mice (Komiyama et al. 2006), and blocking their differentiation 
by removing IL-23 left mice resistant to EAE (Cua et al. 2003). 
1.3.2.2	  CD8+	  cytotoxic	  T	  cells	  
Cytotoxic T lymphocytes are a distinct sub-type identified through expression of the CD8 
molecule on the cell surface. They detect self-antigens expressed on MHCI molecules of 
almost every cell type within the body and function as the immune system’s “targeted killer” 
cell, protecting against viral invasion by killing infected cells (Friese & Fugger 2009). They 
perform cytotoxic functions via two mechanisms; the release of cytotoxic proteins (e.g. 
granzyme/perforin) onto the cell to disrupt cell membranes, or the induction of apoptosis by 
Fas/Fas ligand binding (Russell & Ley 2002). Recent research has shown T cell killing may 
occur in a non-specific manner; oligodendrocyte specific CD8+ cytotoxic T cells caused not 
only oligodendrocyte but also apoptosis of neighbouring neuronal cells (Göbel et al. 2010). 
Furthermore, cytotoxic T cells can kill multiple targets simultaneously by forming long-lived 
synapses with targets and polarising lytic granules towards different cells (Wiedemann et al. 
2006).  
Clonal expansions of CD8+ cells have been found in the brain and CSF of MS patients, and 
persisted for over 5 years, suggestive of a role in chronic disease (Skulina et al. 2004). 
Furthermore, cytotoxic T cells were found to be the dominant T cell subtype in both GMLs 
and WMLs and were correlated with axonal damage within lesions, whereas Th1 cells did not 
(Babbe et al. 2000; Bitsch et al. 2000; Frischer et al. 2009). Adoptive transfer of myelin 
specific CD8+ T cells has been found to be sufficient to induce severe EAE, characterised by 
spastic reflexes rather than ascending flaccid paralysis (Huseby et al. 2001; Sun et al. 2001). 
This model produced lesions that were reminiscent of type IV WMLs with significant 
perivascular accumulations of cytotoxic T cells (Lucchinetti et al. 2000; Huseby et al. 2001). 
Cytotoxic T cells are capable of mediating extensive CNS tissue damage in EAE. A recent 
study with genetically modified mice established that myelin damage and oligodendrocyte 
loss were chiefly mediated by cytotoxic T cells in a perforin/granzyme B dependent manner 
(Kroner et al. 2010). Removal of CD8+ T cells was found to preserve axons in the Theiler’s 
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virus induced demyelination model indicating a role for this sub-type in mediating axonal loss 
(Howe et al. 2007). In addition, cytotoxic T cells may release pro-inflammatory cytokines such 
as TNF and IFNγ that can be directly or indirectly toxic to CNS cells. Indeed, IFNγ release is 
a key requirement for determining the pathogenicity of cytotoxic T cells (Huseby et al. 2001). 
However, studies have also indicated a potentially regulatory role for CD8+ T cells. Genetic 
deletion of cytotoxic T cells led to increased EAE severity, with enhanced CNS Th cell 
infiltration in some models (Jiang et al. 1992; Koh et al. 1992).   
1.3.2.3	  B	  cells	  
B lymphocytes play a critical role in the humoral adaptive immune response to invading 
pathogens and are derived from haematopoietic stem cells of the bone marrow. B cells may 
be activated in a T cell dependent or independent manner. Upon activation, B cells may 
differentiate into plasma cells and increase production of antigen-specific antibodies. 
Alternatively, they may become memory B cells, which are capable of responding to antigen 
re-exposure in an exaggerated manner, and interact with Th cells (Schmidlin et al. 2009). 
Engagement of antigen causes B cells to enter lymphoid follicles and form germinal centres, 
where somatic hyperrmutation, class switching and proliferation occur (Schmidlin et al. 2009). 
The role of B cells in MS has historically been somewhat overlooked. This may be a result of 
a failure to identify an antigen targeted by pathogenic antibodies common to all MS patients, 
the relatively low abundance of B cells and plasma cells in lesions and the ability to induce 
EAE with MOG peptide in the absence of a B cell response (Hjelmström et al. 1998; Frischer 
et al. 2009). However, several lines of evidence have suggested an important contribution for 
B cells in MS pathology. Significant antibody deposits have been observed in active WMLs in 
a subset of MS patients (Lucchinetti et al. 2000; Lassmann et al. 2001). It has been shown 
that B cells are critically important in EAE models induced with recombinant protein, which is 
likely to be of greater relevance to MS than T cell dependent peptide induced models (Lyons 
et al. 1999). Furthermore, a subset of MS patients with B cell containing lymphoid-like follicles 
in the meninges have recently been identified and have exacerbated pathology and an 
accelerated disease course (Serafini et al. 2004; Magliozzi et al. 2007; Magliozzi et al. 2010). 
In addition, the number of CSF memory B cells and plasma cells has been found to correlate 
with brain inflammation visible by MRI in RR-MS and CIS (Kuenz et al. 2008), and clonally 
expanded B cells producing anti-myelin antibodies have been detected in the CSF and 
meninges of patients (Mancardi et al. 2000; von Büdingen et al. 2008; Lovato et al. 2011). 
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In addition to antibody production, B cells may contribute to inflammation by acting as APCs 
(Bouaziz et al. 2007; Weber et al. 2011). Indeed, B cells express all the necessary molecules 
for antigen presentation (MHCII) and co-stimulation (CD40 and CD86) and are considered 
highly efficient activators of Th cells (Rodríguez-Pinto 2005; Dilillo et al. 2010). In contrast to 
Th cells, cytotoxic T cells are not efficiently activated by B cells (Mancardi et al. 2000; von 
Büdingen et al. 2008). Activated B cells are also important sources of pro-inflammatory 
cytokines such as lymphotoxin, IFNγ and TNF as well as matrix metalloproteinases (MMPs, 
Di Girolamo et al. 1998; Alter et al. 2003; Tumanov et al. 2004; Dilillo et al. 2010). 
The data discussed here implicates B cells as key players in the pathogenesis of MS and 
identifies them as a target for therapies. Recently, B cell depletion by anti-CD20 antibodies 
has been shown to attenuate EAE induced by recombinant MOG, by interfering with the APC 
function of B cells and antibody production in particular (Weber et al. 2011). Furthermore, 
rituximab, an anti-CD20 therapy, has been shown to be a successful treatment strategy in 
RR-MS, reducing the appearance of new gadolinium-enhancing lesions and relapses (Hauser 
et al. 2008).  
Recent studies have also shown an important regulatory role for a subset of B cells (Anderton 
& Fillatreau 2008). B regulatory cells (Bregs) are typified by the release of the anti-
inflammatory cytokine IL-10 and express lower levels of co-stimulatory molecules (Kala et al. 
2010). Transfer of Bregs attenuated EAE, reducing T cell activation, cytokine release and 
CNS infiltration (Lampropoulou et al. 2008; Matsushita et al. 2008). Moreover, it was shown 
that B cell depletion prior to EAE induction exacerbated disease by removing Breg cells and 
increasing inflammation, whereas depletion at the peak of disease ameliorated the pathology, 
presumably by eliminating pathogenic antigen presenting/antibody producing B cells 
(Matsushita et al. 2008). The signalling mechanisms governing the selection of B cell 
phenotype are not well understood, though it has been found that TLR activation can induce 
the Breg phenotype and suppress EAE (Lampropoulou et al. 2008). A better understanding of 
the dynamics of Breg differentiation may lead to the development of novel cell based 
therapies for MS. 
1.3.2.4	  Auto-­‐antibodies	  
The role of auto-antibodies in MS pathology has been extensively studied, with antibodies 
against a variety of CNS antigens detected in patients (reviewed in (Archelos et al. 2000). It is 
established that oligoclonal bands and plasma cells persist in the CSF of the vast majority of 
MS patients, indicating a chronic inflammatory process sequestered in the CNS (Mancardi et 
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al. 2000; Franciotta et al. 2008; von Büdingen et al. 2008). However, the hypothesis of a 
pathological role of anti-MOG antibodies in MS patients is controversial, as auto-antibodies 
have also been detected in non-inflammatory CNS conditions and healthy controls (Karni et 
al. 1999; Lindert et al. 1999; Reindl et al. 1999). Nevertheless, antibody deposition is thought 
to be a major mechanism of demyelination in MS and EAE as immunoglobulins have been 
frequently observed decorating degenerating myelin in actively demyelinating areas of WMLs 
(Storch et al. 1998a,b; Lassmann et al. 2001; Breij et al. 2008). Moreover, injection of purified 
anti-MOG antibodies was found to exacerbate EAE and cause widespread spinal cord 
demyelination (Mancardi et al. 2000; Franciotta et al. 2008; von Büdingen et al. 2008). 
Deposits also co-localised with myelin fragments and complement following phagocytosis by 
foamy macrophages. Furthermore, diffuse, non-specific immunoglobulin deposition has been 
frequently observed in lesions and is associated with BBB dysfunction in vessels within 
lesions (Storch et al. 1998a,b; Lassmann et al. 2001; Barnett & Prineas 2004; Barnett et al. 
2009). 
Antibodies may cause demyelination by several different mechanisms. Antibodies may 
opsonise myelin and induce phagocytosis by microglia/macrophages following Fc gamma 
receptor (FcγR) and complement receptor 3 (CR-3) engagement (Storch et al. 1998a,b; 
Lassmann et al. 2001; Breij et al. 2008). Complement fixation and activation by antibodies is 
an additional mechanism that may lead to demyelination. In this pathway, complement 
components bind to structures on bound antibodies leading to activation of the complement 
cascade. For example, the potential for demyelination by antibodies against MOG has been 
shown to be related to the ability to fix complement (Piddlesdon et al. 1993). However, 
antibody-mediated demyelination can occur via complement independent mechanism termed 
antibody-dependent cellular cytotoxicity (ADCC, Piddlesdon et al. 1991). In ADCC, cells of 
the innate immune system recognize and bind the gamma chain of the antigen-bound 
antibody complex through FcγRs (Storch et al. 1998b; Lassmann et al. 2001; Barnett & 
Prineas 2004; Barnett et al. 2009). The binding leads to the release of inflammatory, toxic 
molecules by the effector cell mediating cytotoxicity and lysis of the target (Mosley & Cuzner 
1996). For example, myelin phagocytosis results in macrophage activation and production of 
TNF and NO, which are toxic to myelin/oligodendrocytes (van der Laan et al. 1996; Mosley & 
Cuzner 1996). Anti-MOG antibodies have also been shown to crosslink with MOG to form 
complexes resulting in lipid raft formation. This activates intra-cellular stress response 
proteins and causes cytoskeleton rearrangement in oligodendrocytes (Marta et al. 2005). 
These results indicate a potential direct pathogenic effect of anti-MOG antibodies. 
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1.3.2.5	  Complement	  
The complement system consists of approximately 30 proteins that is part of the innate 
immune system and plays a key role in host responses to infection (Rus et al. 2006; Ingram 
et al. 2009). Complement activation proceeds as a cascade of enzymatic activation by the 
classical, lectin or alternative pathway. Antibody/antigen complexes typically activate the 
classical pathway, however all pathways converge on the activation of C3 (Rus et al. 2006). 
Some activated components activated C3b is detected by CR3 receptors on macrophages, 
which initiate phagocytosis the opsonised target (Brück & Friede 1990; van der Laan et al. 
1996). In addition the cascade of proteins leads to the activation of C5-C9, which deposit on 
the target cell and form the membrane attack complex (MAC, Storch et al. 1998b; Rus et al. 
2006). The MAC forms a pore in the lipid membrane of cells, disturbing homeostasis, leading 
to necrotic cell death.  
In the context of EAE and MS, deposits of MAC components (C9, C9neo) have been found 
on degenerating myelin sheaths at the active, leading edge of WMLs (Linington et al. 
1989a,b; Storch et al. 1998a,b; Lucchinetti et al. 2001; Barnett & Prineas 2004; Breij et al. 
2008). Furthermore, complement deposits have been frequently observed associated with 
blood vessels, in perivascular areas of lesions, decorating oligodendrocyte cells bodies and 
on myelin fragments ingested by phagocytic macrophages (Linington et al. 1989a,b; Storch et 
al. 1998a,b; Lucchinetti et al. 2001). 
Inhibition of the complement cascade has been shown to dose-dependently attenuate clinical 
disease and dramatically reduce demyelination in antibody enhanced EAE models (Linington 
et al. 1989a; Piddlesdon et al. 1994; Terényi et al. 2009). It has been shown that the 
demyelinating efficiency of a range of antibodies was related to the ability to fix complement, 
but may also occur independently (Piddlesdon et al. 1993; Rus et al. 2006). This data implies 
a significant contribution of the complement cascade to demyelination. However, it should 
also be noted that complement has been shown to exhibit protective properties. Sub-lytic 
formations of complement proteins have been found to have neuroprotective effects against 
glutamate toxicity (Osaka et al. 1999), and C5 knockout (KO) mice experience exacerbated 
EAE pathology with increased oligodendrocyte apoptosis (Weerth et al. 2003; Niculescu et al. 
2004).  
1.3.3	  The	  innate	  immune	  system	  
The CNS was previously considered an immune privileged organ, however, an increasing 
appreciation of the extent of immune surveillance within the brain and behind the BBB has led 
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to revision of this statement. Cells of the innate immune system are found in the CNS and 
have an essential role in the development of CNS inflammation, persisting in chronic disease 
after the resolution of lymphocyte infiltration in EAE and MS (Weerth et al. 2003; Niculescu et 
al. 2004).  
1.3.3.1	  Microglia	  
Microglia are the resident tissue macrophage of the CNS. They are a highly versatile cell 
population that perform many functions of the innate immune system, in addition to 
homeostatic functions under physiological conditions (Aloisi 2001; Ransohoff & Perry 2009). 
Microglia are distributed heterogeneously, being more numerous in the grey matter than the 
white matter in mice, and represent around 20% of glial cells (Lawson et al. 1990). In the 
normal brain “resting” microglia are highly ramified, with numerous fine processes, covered 
with shorter spines, which may extend to many times the width of the cell body (Giulian et al. 
1995). Two-photon microscopy has revealed that resting microglia actively survey the 
surrounding microenvironment, with continuous formation and withdrawal of processes 
occurring over a time-period of minutes and numerous contacts being made with local 
neurons, astrocytes and blood vessels (Nimmerjahn et al. 2005). An important function of 
microglia is the monitoring of synapse viability by direct process contact (Wake et al. 2009).  
Microglia perform their surveillance function via a vast array of receptors for “danger” signals. 
They constitutively express cytokine receptors such as IFNγ receptor (IFNγR), TNF receptors 
(TNFR1A and B), interleukin receptors (IL-1R and IL-10R), as well as pattern recognition 
receptors such as toll-like receptor (TLR4) and the complement receptors CR-1 and CR-3 
(Mosley & Cuzner 1996; Lee et al. 2002; Aloisi 2001). Upon activation, processes thicken and 
retract and the soma enlarges (Giulian et al. 1995), Figure 1.4). The spiny processes present 
in activated microglia are in contrast to the ovoid, ruffled appearance of macrophages with no 
processes, as visualised by electron microscopy (Giulian et al. 1995). Microglia and 
macrophages cannot be reliably distinguished using current IHC methods. In response to 
activating signals microglia express a vast array of molecules, including pro-inflammatory 
cytokines (TNF, IL-1β), cytotoxic molecules (reactive oxygen species) and molecules involved 
in antigen presentation (MHCII, CD40) as well as anti-inflammatory cytokines (IL-10, TGF-β 
(Aloisi 2001; Ransohoff & Perry 2009) Figure 1.4). 
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Figure 1.4 Ramified “resting” microglia express a vast array of receptors allowing both detection of invading 
pathogens and interaction with the immune system. Upon activation, microglia retract processes, enlarge the 
soma and secrete a vast array of molecules that may have a pathogenic role in MS and EAE. Figure adapted from 
Aloisi et al. 1999. 
The importance of microglia/macrophages in EAE pathogenesis has been established since it 
was shown that pharmacological inhibition by tripeptide macrophage inhibitory factor, or 
minocycline attenuates EAE (Popovic et al. 2002; Bhasin et al. 2007). Furthermore, an 
important study showed that selective microglial paralysis attenuated EAE, with little 
infiltration of lymphocytes or macrophages and little demyelination or axonal pathology 
(Heppner et al. 2005). This was coupled with a reduced release of TNF or NO in response to 
activating signals. This study achieved selective paralysis of microglia by combining 
expression of the herpes simplex virus suicide gene under the CD11b promoter, with bone 
marrow transfer to restore the peripheral macrophage population. The function of 
lymphocytes was not diminished by this treatment. 
Upon activation, microglia upregulate MHCII and co-stimulatory molecule (CD40 and CD54) 
expression (Aloisi et al. 1999a; Aloisi et al. 2000). They act as highly efficient APCs for T 
cells, causing activation and proliferation of naive cells and differentiation of cells to the Th1 
phenotype to a greater extent than B cells or astrocytes (Aloisi et al. 1999). MHCII expression 
by activated microglia and macrophages has been detected in active WMLs in MS as well as 
in EAE lesions of the spinal cord (Bö et al. 1994a; Nikodemova et al. 2007). In addition, 
minocycline administration was found to attenuate EAE, in part through inhibiting the IFNγ-
mediated upregulation of MHCii expression (Nikodemova et al. 2007). 
The presence of myelin in highly activated amoeboid microglia/macrophages, associated with 
antibody/complement components is a pathological hallmark of active WMLs in MS and EAE 
(Storch et al. 1998a; Lucchinetti et al. 2001). The phagocytosis of antibody/complement 
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opsonised myelin is achieved by engagement of Fc and complement receptors (CR-1 and 
CR-3), which are upregulated by activated microglia (Mosley & Cuzner 1996). Mice lacking 
the Fc receptor were found to be EAE resistant, with a reduced level of macrophage-
mediated demyelination (Abdul-Majid et al. 2002). Moreover, increased Fc receptor 
expression has been detected on activated microglia in chronic active lesions and was 
associated with myelin damage (Hill et al. 2004). Myelin debris has commonly been detected 
in the lysosomal membranes of activated microglia and macrophages in active EAE lesions 
and is correlated with lysosomal expression of CD68 (Storch et al. 1998a; Lucchinetti et al. 
2001). 
Indicative of their role in detecting homeostatic disturbance, leakage of serum proteins 
occurring following BBB compromise has been shown to activate microglia. Fibrinogen 
leakage activated microglia by forming a complex with the microglial integrin receptor Mac1, 
triggering activation and increasing phagocytic activity (Adams et al. 2007). Furthermore, 
leakage of albumin into the parenchyma resulted in increased inducible nitric oxide synthase 
(iNOS) expression, glutamate release and induction of a neurotoxic phenotype in microglia 
(Hooper et al. 2009). Microglial expression of iNOS has also been shown to occur following 
IFNγ signalling, in an NFκB dependent manner. The consequent release of NO radicals has 
been shown to cause oligodendrocyte apoptosis in vitro and conduction block of 
demyelinated axons in vivo (Merrill et al. 1993; Redford et al. 1997; Jana et al. 2001). 
Increased expression of iNOS has been detected on activated microglia in chronic active MS 
WMLs and in EAE lesions and was associated with oligodendrocyte damage (Hill et al. 2004; 
Adams et al. 2007; Howell et al. 2010). TNF has been shown to cause the upregulation of 
glutaminase and the production of glutamate by microglia in a dose dependent, autocrine 
manner (Takeuchi et al 2006). Glutamate release occurred through glutamate transporters 
and connexin 32 gap junction hemichannels (Takeuchi et al. 2006). Furthermore, glutamate 
release from activated microglia was found to be excitotoxic to neurons. Taken together, this 
set of data implies that microglia may play a key role in the axon loss and neurodegeneration 
observed in MS. 
Activated microglia have been associated with disturbances to axo-glial junctions in “pre-
clinical” EAE (prior to the onset of symptoms), and the attenuation of activity by minocycline 
administration inhibited this process (Howell et al. 2010). Activated microglia have been 
observed enveloping spinal cord motor neurons in chronic EAE lesions (Bauer et al. 1994), 
and have been implicated in synaptic stripping in EAE lesions in the brain (Rasmussen et al. 
2007). Synaptic stripping has been described in cerebral infarcts and in facial nerve axotomy 
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models and is believed to be a neuroprotective mechanism (Streit & Graeber 1993; Wake et 
al. 2009).   
Microglia may also play a positive role in the resolution of inflammation, through release anti-
inflammatory cytokines such as IL-10 and transforming growth factor beta (TGFβ), which 
inhibit IL-1β and TNF release (Aloisi et al. 1999b). The phagocytosis of myelin debris can 
result in an anti-inflammatory phenotype and may be necessary to aid remyelination (Streit 
2002; Boven et al. 2006). Moreover, pharmacological inhibition of microglial activity in a toxin-
induced demyelination has been shown to inhibit remyelination (Li et al. 2005). Microglia can 
also have neuroprotective effects through the release of neurotrophic factors such as 
fibroblast growth factor (FGF) and brain derived neurotrophic factor (BDNF, Liu et al. 1998; 
Stadelmann et al. 2002). 
1.3.3.2	  Macrophages	  in	  the	  CNS	  
Macrophages and dendritic cells (DCs) have been observed in the choroid plexus, on the 
inner-arachnoid layer (the subarachnoid space), and on the outer surface of the cortical pia of 
naive rats by scanning electron microscopy (McMenamin et al. 2003). These results indicate 
that immune surveillance and APC functions of the CNS occur in the CSF spaces. Another 
subset are perivascular macrophages (PVMs) that reside in between the basal lamina and 
the basement membrane of the BBB. Activation of PVMs and meningeal macrophages has 
been shown to occur prior to the clinical onset of EAE in Lewis rats, and selective depletion of 
these cells by clodronate liposomes suppressed EAE (Polfliet et al. 2002). PVMs and 
meningeal macrophages were found to upregulate MHCII expression following activation and 
are hypothesised to facilitate activation and infiltration of memory T cells in the development 
of EAE. Furthermore, the expression of CD68 in a significant population of these cells 
indicates that they are capable of phagocytosis (Bauer et al. 1994; McMenamin et al. 2003).  
1.3.4	  Immune	  cell	  entry	  to	  the	  CNS	  
While it is clear that peripheral lymphocytes and monocytes can cross the BBB by binding to 
appropriate adhesion molecules under inflammatory conditions, it has remained unclear how 
“pioneer” T cells gain access to the CNS across under physiological conditions and instigate 
auto-immune reactions. The previously accepted dogma of the CNS being an immune-
privileged organ, protected under normal conditions from immune cell entry by a rigorous 
barrier, has been shown to be false (Engelhardt & Ransohoff 2005; Galea et al. 2007). Three 
anatomically distinct routes of non-inflammatory lymphocyte entry have been proposed 
(Ransohoff et al. 2003); the blood: CSF route via the choroid plexus, blood: subarachnoid 
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space route via meningeal blood vessels and the blood: parenchymal route via CNS blood 
vessels and the BBB.  
It is now clear that under normal conditions soluble CNS antigens are able to leave the CNS 
via the CSF and are presented to lymphocytes in cervical lymph nodes (Engelhardt & 
Ransohoff 2005). CNS immune surveillance is carried out within the subarachnoid space by 
CD4+ memory T cells, which are found in large numbers in the meninges (~150,000, 
Carrithers et al. 2000; Provencio et al. 2005). T cells account for 80% of the immune cells in 
non-inflamed CSF in humans, with monocytes approximately 5% and B cells 1% 
(Svenningsson et al. 1995). Entry of T cells involved in immune surveillance is thought to 
occur via the choroid plexus or meningeal blood vessels in a P-selectin dependent manner, 
rather than via the cerebrovascular route (Kivisäkk et al. 2003).  
There has been an increasing research focus on the initiating stages of EAE in an attempt to 
provide clues to the evolution of inflammatory mechanisms in MS, and a picture of two stages 
of immune cell entry is now emerging (Ransohoff & Parsons 2009). Th cells have been found 
to infiltrate the subarachnoid CSF prior to EAE symptoms or T cell accumulation in the CNS 
parenchyma (Shin et al. 1995; Brown & Sawchenko 2007; Reboldi et al. 2009; Kivisäkk et al. 
2009). Moreover, initiation of EAE in the C57BL/6 MOG peptide model was found to be 
dependent on Th17 cells entering the CSF via CCR6-CCL20 interactions with choroid plexus 
epithelia (Reboldi et al. 2009). Memory T cells were found to be re-activated in the 
subarachnoid space following antigen presentation by CSF resident APC’s, resulting in 
localised proliferation (Shin et al. 1995; McMenamin 1999; Kivisäkk et al. 2009). Re-activated 
T cells produced cytokines and pro-inflammatory factors that stimulated BBB vessel 
endothelia to express appropriate adhesion molecules, initiating a second wave of 
lymphocyte infiltration (Bartholomäus et al. 2009; Kivisäkk et al. 2009).  
A study using intravital microscopy and fluorescently labelled anti-myelin T cells, showed that 
T cells could only cross the BBB if the parenchymal vessel had been previously activated with 
either lipopolysaccharide (LPS) or TNF (Piccio et al. 2002), which caused and increase in the 
expression of cell adhesion molecules (CAMs) such as inter-cellular adhesion molecule 
1(ICAM-1) on cerebral endothelia (Myers et al. 1992; McCarron et al. 1993). An adoptive 
transfer study showed activated anti-myelin T cells crawling along activated pial vessels, 
before emigrating across the BBB and into the CNS parenchyma to initiate tissue damage 
(Bartholomäus et al. 2009). The key step in this process was the re-encounter with antigen 
via APC presentation in the perivascular space.  
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1.3.5	  Cytokines	  
TNF and IFNγ are two cytokines that exert a wide range of effects on a variety of target cells 
and are two of the most important molecules in the propagation of immune responses. 
Dysregulation of the release of these molecules has been shown to occur in a wide range of 
inflammatory diseases, including rheumatoid arthritis, Crohns disease, dermatitis and 
diabetes (Imitola et al. 2005; McCoy & Tansey 2008). These properties have led their function 
in CNS inflammation, particularly in MS and EAE, to be extensively studied. 
1.3.5.1	  TNF	  
TNF is a 17KDa protein that is released by activated T and B cells, astrocytes and cerebral 
endothelia, though the major source is considered to be activated macrophages and 
microglia (Aloisi et al. 1999b; Tumanov et al. 2004; Imitola et al. 2005;Wieseler-Frank et al. 
2007). TNF production in a whole blood mitogen assay preceded disease relapse in MS 
(Beck et al. 1988). TNF has been found to be increased in the CSF of relapsing remitting MS 
patients (Maimone et al. 1991; Baraczka et al. 2004). Though increased levels are not always 
detected and expression is likely to be strongly influenced by disease activity (Vladic et al. 
2002). TNF expression has been detected in activated microglia/macrophages, astrocytes 
and endothelia in chronic active WMLs (Selmaj et al. 1991a). Furthermore, TNF has been 
detected in macrophages in the inflamed meninges F+ SP-MS cases as well as in activated 
microglia in active subpial GML (Magliozzi et al. 2010; unpublished data). TNF is not detected 
on astrocytes in subpial lesions, which may be related to the lack of astrogliosis in GML. 
The release of TNF has been shown to mirror the disease course in monophasic EAE in the 
Lewis rat, and in chronic progressive disease models in the DA rat (Issazadeh et al. 1995a; 
Issazadeh et al. 1996). TNF has been shown to have differential effects on glial cells, causing 
myelin damage and oligodendrocyte apoptosis in a JNK dependent manner, but promoting 
astrocyte proliferation in in vitro studies (Selmaj & Raine 1988; Selmaj et al. 1990; Selmaj et 
al. 1991b; Jurewicz et al. 2003). Furthermore, TNF strongly activates microglia, inducing NO 
and glutamate release from hemichannels in an autocrine manner (Takeuchi et al. 2006), 
which may then cause neurotoxicity and conduction block in axons (Redford et al. 1997; 
Takeuchi, et al. 2006). TNF causes significant up-regulation of adhesion molecules such as 
ICAM-1 and vascular cell adhesion molecule (VCAM-1) on brain endothelial cells (McCarron 
et al. 1993; Wong et al. 1999). Upregulation of these molecules mediates leukocyte adhesion 
to the endothelium and facilitates the induction of EAE (Yednock et al. 1992; Engelhardt & 
Sorokin 2009). 
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Soluble TNF binding proteins have been shown to almost completely attenuate EAE following 
adoptive transfer of MBP-specific T cells in the SJL/J mouse (Selmaj et al. 1995). This was 
accompanied by reduced VCAM-1 and ICAM-1 expression on cerebral endothelia, reduced 
lymphocyte and macrophage infiltration and a lack of demyelination (Selmaj et al. 1995; 
Selmaj et al. 1998). CNS specific overexpression of TNF was found to cause spontaneous 
CNS demyelination, associated with CD4+ and CD8+ T cell infiltration, microglia activation and 
focal demyelination (Probert et al. 1995). Further studies were conducted using backcrossing 
these animals with mice lacking a functional adaptive immune system. These show that 
extensive oligodendrocyte apoptosis and demyelination could occur in the absence of 
lymphocyte infiltration, but did require functional microglia/macrophages (Kassiotis et al. 
1999). 
The accumulating evidence led to the hypothesis that anti-TNF therapies would be a viable 
treatment for MS patients. However, a double-blind, placebo-controlled, phase II trial of 168 
patients with RR-MS showed no beneficial effect on lesion formation in any patient following 
treatment with the soluble recombinant TNFR1A immunoglobulin molecule, lenercept 
(Arnason & Lenercept Group 1999). Furthermore, a significantly greater number of patients 
experienced disease relapse and relapses tended to be more severe. These results led to an 
increasing appreciation of the importance of anti-inflammatory processes in MS. The role of 
TNF in anti-inflammatory processes was confirmed by studies using C57BL/6 mice lacking 
the TNF gene (Liu et al. 1998). EAE induced by rMOG protein caused an exacerbated 
disease course in mice lacking TNF compared to wild type controls. This was accompanied 
by increased demyelination and inflammatory infiltrates. The exacerbated disease was 
abrogated by administration of rTNF protein. Further research has shown that the anti-
inflammatory effects of TNF are largely mediated by the receptor TNFR1B, whereas the pro-
inflammatory effects are largely mediated by TNFR1A (McCoy & Tansey 2008). In addition, 
TNF is present in a soluble form, which is generally pro-inflammatory/apoptotic, and a 
transmembrane form, which is thought to be anti-inflammatory (Olleros et al. 2010). 
1.3.5.2	  IFNγ	  
IFNγ stimulates the differentiation and maintenance of Th1 cells, and is therefore implicated 
in autoimmune disease. A pathogenic role in MS has been suspected since the publication of 
a trial showing that administration of the protein caused disease exacerbation in RR-MS 
patients (Panitch et al. 1987). This was accompanied by increased activity of peripheral 
macrophages. Furthermore, production of IFNγ in a whole blood mitogen assay preceded 
disease exacerbation in MS (Beck et al. 1988).  
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IFNγ has been found on lymphocytes at the leading edges of actively demyelinating WMLs 
(Vartanian et al. 1995). CNS expression of IFNγ was shown to be highest during the peak of 
disease and lowest during remission in monophasic EAE induced by transfer of MBP reactive 
T cells in the Lewis rat (Issazadeh et al. 1995b). Furthermore, expression of IFNγ	   in 
oligodendrocytes of mice at 8 weeks of age, caused EAE like disease, with demyelination, 
microglial activation and lymphocyte infiltration (Horwitz et al. 1997). Conditional IFNγ 
expression by astrocytes led to reduced recovery in EAE and a toxic model of demyelination 
(Lin et al. 2006). This was accompanied with reduced remyelination and differentiation block 
of oligodendrocyte precursor cells (OPCs). Furthermore, in EAE, overexpression of IFNγ was 
accompanied by chronically increased expression of MHCI, TNF and IL-12.  
Differential effects of IFNγ on cell survival have been shown in in vitro systems. IFNγ has 
been shown not to be directly cytotoxic to human oligodendrocytes, but upregulated Fas, 
promoting FasL interactions and leading to increased susceptibility to apoptosis (Pouly et al. 
2000). In contrast, rat oligodendrocyte apoptosis was directly induced by IFNγ, whereas 
neuronal apoptosis was not (Vartanian et al. 1995). In mice organotypic slice cultures, IFNγ 
application has been shown to be toxic to oligodendrocytes by inducing IFNR/AMPA receptor 
interactions and increasing susceptibility to glutamate excitotoxicity (Mizuno et al. 2008). 
IFNγ is considered the key cytokine in T cell development and responses. It induces T cell 
proliferation and causes naive T-cells to differentiate into Th1 cells, which are implicated in 
EAE pathogenesis (Gold et al. 2006). It is released predominantly by CD4+ Th cells and CD8+ 
cytotoxic cells (McGeachy & Anderton 2005; Imitola et al. 2005). IFNγ is also a key activator 
of macrophages and microglia, causing upregulation of TNF, increased expression of the 
MHCII, CD40 and CD54, transforming microglia into highly efficient APCs (Aloisi et al. 
1999a,b; Aloisi 2001). Furthermore, IFNγ is capable of dis-inhibiting the downregulating 
effects of IL-10 and prostaglandin E2 on microglia (Aloisi, et al. 1999b). IFNγ causes 
increased expression of iNOS on macrophages, with release of NO radicals leading to a 
cytotoxic phenotype (Ding et al. 1988). Furthermore, IFNγ stimulates astrocyte proliferation, 
production of TNF and expression of MHCII and adhesion molecules (Yong et al. 1991; 
Shrikant et al. 1994; Aloisi et al. 1999a). 
However, as for TNF, the role of IFNγ in MS immune responses is complex. Administration of 
anti-IFNγ antibodies exacerbated EAE in the C57Bl/6 mouse, but ameliorated disease in the 
highly susceptible SJL/J mouse (Billiau et al. 1988). Subsequent studies with viral vectors 
expressing IFNγ, which showed that expression led to amelioration of EAE and increased 
apoptosis of CNS infiltrating lymphocytes (Furlan et al. 2001). 
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1.3.5.3	  Cytokines	  in	  GML	  
Elevated levels of IFNγ and TNF have been detected in the meninges of F+ SP-MS cases by 
real-time polymerase chain reaction (RT-PCR, unpublished data). Double-labelled IHC 
located these proteins on cytotoxic T cells and macrophages respectively. The relative lack of 
expression of these molecules in GMLs, suggests that cells infiltrating the meninges may be 
the main source of inflammatory molecules that can diffuse from the pial surface into the 
cortex inducing demyelination, neurodegeneration and microglia activation in F+ SP-MS 
(Serafini et al. 2004; Magliozzi et al. 2007; Magliozzi et al. 2010; unpublished data). 
1.4	  Animal	  models	  of	  cortical	  pathology	  
Recent research has emphasised the importance of the subarachnoid space as a site of 
chronic, compartmentalised immune responses in MS, which are coupled with increased 
cortical pathology and exacerbated disease course (Serafini et al. 2004; Magliozzi et al. 2007; 
Magliozzi et al. 2010). Current understanding of the pathogenesis of such reactions is 
inevitably limited in studies using human samples, as tissue is rarely available from patients 
with a short disease course. Therefore, there is a need for animal models that accurately 
replicate both cortical pathology and meningeal inflammation. 
1.4.1	  Incidence	  of	  cortical	  pathology	  in	  EAE	  
Cortical pathology is rare in classical rodent EAE models, although GMLs have been 
detected in the cortex of marmoset monkeys with MOG-induced EAE (Merkler et al. 2006a). 
These lesions had a lower density of CD3+ T cells and early activated macrophages 
compared to sub-cortical white matter lesions. Heterogeneity within GML subtypes was 
evident, with IgG leakage across the BBB and complement deposition on myelin in 
leukocortical and intracortical lesions, but not in subpial demyelinated areas. The model 
closely replicated the pathology observed in the cortex of MS cases and may prove useful for 
imaging studies. However, the ethical implications, husbandry considerations and lack of 
molecular reagents for the species make this model an impractical solution for high 
throughput investigations. 
An increased prevalence of GMLs has been detected in MOG-induced EAE in the Lewis rat 
(Storch et al. 2006). This pathology was strongly influenced by MHC haplotype, only the 
LEW.1AR1 and LEW.1W strains, the RT1.BuDuCu MHC haplotype, were found have 
significant cortical pathology (Storch et al. 2006).	  The forebrain was the dominant location of 
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pathology in these strains, with relatively little pathology observed in the spinal cord or optic 
nerves (Storch et al. 2006). All three subtypes of GML (subpial, leukocortical and intracortical) 
were found in the study, with large numbers of activated (CD68+) microglia and deposition of 
complement and IgG on myelin. Other strains investigated (DA, BN and other Lewis 
haplotypes) did not show cortical pathology.  
SJL/J mice immunised with proteolipid protein (PLP) in CFA develop chronic-relapsing EAE 
with forebrain (and spinal cord) pathology (Rasmussen et al. 2007). Demyelinated 
inflammatory lesions were detected in the cortex and corpus callosum of animals in both the 
acute and chronic phase of the disease. All subtypes of GML were detected and were 
associated with microglial activation rather than T cell infiltration (Rasmussen et al. 2007). 
Microglia were associated with smi32+ dephosphorylated neurofilaments and synaptic 
alterations of callosal projecting neurons.  
These models of “spontaneous” cortical pathology successfully replicate man aspects of MS 
GMLs. However, the incidence, location, type and extent of lesions in these models are 
essentially random and vary between individual animals, reducing the feasibility and practical 
efficiency of this type of model. 
1.4.2	  Chemically	  induced	  cortical	  demyelination	  
Addition of the copper chelator cuprizone (bis-cyclohexanone oxaldihydrazone) to the diet of 
mice has been shown to elicit reliable and extensive demyelination, affecting the cortex in a 
strain dependent manner (Matsushima & Morell 2001; Skripuletz et al. 2008). Demyelination 
in this model was found to be caused by oligodendrocyte apoptosis, precipitated by an 
energy crisis caused by disruption of mitochondrial function (Torkildsen et al. 2008). 
Moreover, axon loss has been reported following cuprizone administration in the C57BL/6 
mouse (Irvine & Blakemore 2006). The pathology observed in this model resembles that seen 
in type 3 and type 4 lesions, with primary oligodendropathy and primary oligodendrocyte 
damage with secondary demyelination, respectively (Lucchinetti et al. 2000). Removal of 
cuprizone from the diet precipitates remyelination in a reliable manner, beginning as little as 4 
days post-withdrawal, making this a useful model for studies of repair processes (Lindner et 
al. 2008). However, it was found that following chronic administration (>12 weeks) the 
endogenous remyelinating capacity is exhausted and oligodendrocytes are not replenished 
(Armstrong et al. 2006). 
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A major criticism of this model is that there is little or no microglial involvement in cortical 
demyelination (Skripuletz et al. 2008), which is at odds with suggested mechanisms involved 
in the formation of GMLs in the MS brain (Peterson et al. 2001; Bö et al. 2003a). The 
presence of an intact BBB also limits the role of the peripheral immune system in the disease 
course (Kondo et al. 1987). Furthermore, the model is associated with certain ethical issues; 
seizures are frequent in animals chronically fed cuprizone and death of animals is 
commonplace due to major systemic toxicity (Lindner et al. 2008). 
1.4.3	  Targeted	  demyelinating	  models	  
Injection of pro-inflammatory cytokines into the CNS has been shown to induce inflammatory 
cell infiltration in pre-symptomatic EAE (Sun et al. 2004), and in naive rats (Simmons & 
Willenborg 1990; Schnell et al. 1999). Recently, targeted EAE models have been produced in 
the relatively EAE resistant Lewis rat. The immune system is initially “primed” with a 
subclinical dose of recombinant MOG protein and a cellular immune response causing 
demyelination in the desired location is elicited via an injection of cytokines (Kerschensteiner 
et al. 2004a).  
Lewis rats immunised with rrMOG followed by injections of TNF and IFNγ into the dorsal 
funiculus showed large demyelinated lesions, encompassing the entire white matter tract, but 
rarely affecting grey matter (Kerschensteiner et al. 2004a). Targeted lesions were 
pathologically similar to white matter MS lesions, with large numbers of foamy macrophages, 
activated microglia and comparatively fewer T cells in the parenchyma. Accumulations of 
APP indicated acute axonal damage in lesions (Kerschensteiner et al. 2004a). Control 
animals immunised with IFA followed by cytokine injection had a mild influx of inflammatory 
cells, with little or no demyelination. 
Animals developed a motor deficit following cytokine injection that could be recorded with the 
clinical EAE scoring system (Kerschensteiner et al. 2004a). The motor deficit was maximal 3-
8 days post-cytokine injection, with functional recovery thereafter. The targeting of specific 
spinal tracts allows the use of highly sensitive behavioural testing e.g. grid walk test, to show 
the functional effects of a single lesion. The functional impairment observed was correlated 
with the extent of the corticospinal tract lesions (Kerschensteiner et al. 2004a). Functional 
recovery was shown to involve a combination of mechanisms; remodelling of projecting 
neurons in the motor cortex, sprouting of interneurons close to the lesion site and descending 
axonal projection to establish a “detour” circuit (Kerschensteiner et al. 2004b). 
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Inflammatory demyelination has also been produced in the spinal cord of the Lewis rat by 
immunisation with MOG followed by injection with vascular endothelial growth factor (VEGF) 
into the dorsal funiculus (Sasaki et al. 2010). VEGF is known to mediate BBB disruption 
(Dobrogowska et al. 1998), and in this model allows recruitment of anti-MOG lymphocytes 
and antibodies into the spinal cord. Demyelinated lesions consisted of activated microglia, 
with scattered CD3+ T cells, and were accompanied by a reproducible motor deficit, 
comparable to that observed in disseminated EAE. Lesions produced in this model are 
relatively long lasting; with remyelination and functional recovery complete 21 days post-
injection (Sasaki et al. 2010). 
1.4.3.1	  A	  targeted	  model	  of	  cortical	  demyelination	  
The principles of targeted EAE were recently used to produce a model of cortical 
demyelination. Lewis rats were immunised with recombinant rat MOG (rrMOG) and 
subsequently injected into the motor cortex with TNF and IFNγ (Merkler et al. 2006b). The 
injection of cytokines elicited extensive demyelination, with subpial, leukocortical and 
intracortical lesions being produced. The contralateral cortex had no demyelination. 
Demyelination was maximal 3 days post-injection and thereafter was reduced, until 14 days 
post-injection when full remyelination had occurred. 
The extent of cortical demyelination was highly correlated with the presence of activated 
microglia/macrophages. During active demyelination microglia/macrophages that had 
ingested MBP+ myelin fragments were found within lesions. Significantly more CD4+ Th cells 
infiltrated the parenchyma and perivascular areas in response to cytokine injection in MOG-
immunised animals than in those immunised with IFA alone. CD8+ cytotoxic T cells and 
perivascular deposition of complement were also reported. The number of APP+ damaged 
axons was significantly correlated with the number of CD68+ activated microglia/ 
macrophages. No reduction in axonal density was reported, although activated caspase3+ 
neurons undergoing apoptosis were detected (Merkler et al. 2006b). 
Whilst this model has promise and successfully generates all subtypes of GML (Peterson et 
al. 2001; Bö, et al. 2003b), induced lesions typically resolve within 14 days, with full 
remyelination and no lasting reduction in axonal density. The validity of the model must also 
be called into question, as it involves a direct injection into the cortex, with associated tissue 
destruction and extensive BBB breach, a situation that does not occur in association with 
GMLs in MS. 
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1.5	  Hypothesis	  
It is suggested that B-cell follicle-like structures may form as a consequence of severe 
chronic inflammatory processes occurring within the meninges of a sub-group of SP-MS 
patients and create an inflammatory milieu. Subpial GMLs may therefore be the result of pro-
inflammatory/toxic molecules diffusing from the chronically inflamed meninges into upper 
cortical layers (Magliozzi et al. 2007). 
Here we test the hypothesis that the presence of TNF/IFNγ in the subarachnoid space 
overlying the cerebral cortex of rmMOG-immunised animals will precipitate an influx of 
lymphocytes and macrophages into the meninges and produce pathology in the underlying 
cortical grey matter, reminiscent of that observed in MS.  
1.6	  Aims	  of	  this	  thesis	  
This thesis aimed to produce a chronic inflammatory model of subpial cortical demyelination, 
replicating the pathological features found in SPMS cortex. The model was then used to 
study the cellular and molecular mechanisms involved in the grey matter demyelination, 
which may give clues to the pathogenesis of subpial lesions occurring in MS. 
In order to produce such a model a number of studies were undertaken: 
• Identification of a subclinical dose of rmMOG in the DA rat 
• Reproduction of motor cortex targeted demyelination in the DA rat 
• Establishment of a novel model of targeted demyelination caused by 
inflammation in the subarachnoid space 
• Analysis of cortical lesion pathology in the model 
• Elucidation of molecular mechanisms occurring in the model 
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2.1	  Expression	  and	  Purification	  of	  recombinant	  mouse	  
MOG	  
2.1.1	  Expression	  Vector	  
Glycerol stock of E.coli, transformed with complementary DNA (cDNA) corresponding to the 
N-terminal 1-116 a.a. of mouse MOG, was a gift from Dr D. Pham-Dinh, University of Paris. 
The mouse MOG sequence is ligated to the pRSET-A (Invitrogen) expression vector (Figure 
2.1), which also contains a sequence encoding an N-terminal 30 a.a. fusion peptide upstream 
of the inserted MOG sequence. The fusion peptide encodes six histidine residues that 
function as a metal binding domain, allowing later protein purification using a metal affinity 
chromatography system.   
 
Figure 2.1: MOG expression vector comprises an N-terminal 30 a.a fusion peptide containing six histidine 
residues, allowing later metal affinity chromoatographic separation (A). 
2.1.2	  Expression	  of	  recombinant	  mouse	  MOG	  protein	  
Glycerol stock was thawed and streak plated on ampicillin (100µg/ml) and chloramphenicol 
(17µg/ml) containing agar plates. A single colony of vector transformed E.coli cells was grown 
overnight (at 37˚C) in SOB medium containing the same concentration of ampicillin and 
chloramphenicol. The culture was diluted 1:100 and growth was monitored 
spectrophotometrically. When the OD600 reached 0.3 (the mid-logarithmic phase of growth) 
expression of rmMOG protein was induced by the addition of 1mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG). IPTG dis-inhibits the lac operon of the host cell chromosome, 
inducing expression of T7 polymerase and subsequent expression from the PT7 promoter. 
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Growth was continued until the OD600 reached 0.8-1.2, whereupon bacterial cells were 
harvested by centrifugation at 4,000rpm (10 minutes, 4˚C). To extract protein, cells were 
lysed with pH 8.0 lysis buffer (8M Urea) and cell debris was removed by repeated sonication 
and centrifugation cycles (25 minutes, 13,500rpm, 4˚C). The supernatant was kept after each 
round.	  
2.1.3	  Purification	  and	  concentration	  of	  soluble	  MOG	  protein	  
Talon metal affinity resin (Clontech Laboratories Inc.) was used in a gravity flow column 
system for rmMOG protein purification. The resin was equilibrated with 5 volumes of lysis 
buffer, centrifuged and the supernatant discarded. Supernatant containing rmMOG fusion 
protein was added to the resin, and agitated at room temperature. The resin-protein complex 
was washed with 10 volumes of lysis buffer, centrifuged and the supernatant discarded. The 
washes were repeated three times, before the resin-protein was added to the column. The 
resin-protein complex was washed on the column with 5 volumes of wash buffer (pH 7.0), 
before protein elution was achieved by adding elution buffer (pH 5.3) to the column. UV 
absorbance at 280nm was used to detect protein eluted from the column and fractions were 
collected. Eluted protein was dialysed against four volumes of 1M Arginine in phosphate 
buffered saline (PBS pH 7.4), at 4˚C overnight. The resulting dialysate was concentrated by 
centrifugation (4000g at 4˚C) using Amicon Ultra15 concentrating tubes (Millipore, UK). The 
final concentration of protein was assessed using a Nanodrop spectrophotometer (Labtech 
International, UK) at 280nm. 
2.1.4	  SDS-­‐PAGE	  and	  Western	  blotting	  
RmMOG samples were diluted in sample buffer (Invitrogen). Two controls were used for 
comparison, a 2mg/ml solution of bovine serum albumin (BSA), and a batch of rmMOG 
previously expressed, isolated and concentrated in this laboratory. Samples (10µg protein in 
20µl) were loaded onto 4-12% Bis-Tris gels (Invitrogen), and MES running buffer added. 
Molecular weight standards (Invitrogen) were also added. The gel was run at 150v for 1hour. 
Protein bands were detected by immersion of the gel in Coomassie brilliant blue (Sigma), and 
washing in de-staining solution (50% (v/v) methanol with 10% (v/v) acetic acid), to leave a 
clear background.  
Western blotting to detect mouse MOG protein was performed. Separated proteins were 
electro-transferred to 0.2µm nitrocellulose membranes (Invitrogen) by a semi-dry transfer 
method. Nitrocellulose membrane was pre-soaked in transfer buffer, and placed onto the gel 
and between pieces of filter paper. The transfer was then performed at 200mA for 30 
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minutes. The membrane was briefly rinsed in TRIS buffered saline pH 7.4 with 0.1% Tween 
20 (TBST). Non-specific binding sites were blocked by immersion of the membrane in 5% 
(w/v) skimmed milk powder in TBST, under agitation, for 1 hour. After washing in TBST for 10 
minutes, the membrane was incubated under agitation for 1 hour with rabbit anti-mouse MOG 
antibody (R&D systems), 1:10,000 dilution, in blocking solution (5% w/v dried skimmed milk in 
TBST). The membrane was washed three times for 5 minutes in TBST, before incubation for 
1 hour with horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG secondary 
antibody (Sigma), diluted 1:10,000 in blocking solution. After washing in TBST for 30 minutes 
bands were detected with chemiluminescence (ECL kit) and exposed on HyperfilmECL films 
according to manufacturer instructions. All incubations were carried out at room temperature 
unless stated. 
The monomer: dimer ratio of protein was assessed by light intensity measurement, using the 
line profile tool of ImagePro Plus software. An average of 3 light intensity readings was used. 
A low monomer: dimer ratio has been linked with a high incidence of non-responding animals 
within this laboratory (unpublished data).  
2.2	  Induction	  of	  EAE	  in	  DA	  rats	  
2.2.1.Housing	  of	  animals	  
Female DA rats (Harlan, UK) were used in all experiments (8-12 weeks old, approximately 
160g). Animals were housed in Imperial College London CBS (Hammersmith Hospital 
campus) and food and water were available ad libitum with a light: dark cycle of 12:12. All 
experiments were performed under UK Home Office project license 70/6282. Animals spent 
at least 5 days in the unit prior to immunisation.  
2.2.2	  Immunisation	  protocol	  
Under isofluorane anaesthesia, rats were immunised intra-dermally at the base of the tail 
(dorsal aspect) with 5, 20 or 50µg rmMOG (diluted in phosphate buffered saline; PBS) 
emulsified in an equal volume of IFA (Difco, UK), 100µl total volume. Control animals 
received an injection of 50:50 IFA in PBS (100µl total volume).  
2.2.3	  Clinical	  evaluation	  of	  EAE	  
Following immunisation rats were weighed and assessed daily. A clinical score was assigned 
based on the level of neurological deficit present, and modified from Storch et al (2008), 
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Papadopoulous et al. (2006). Increasing scores corresponded to increasing neurological 
deficit.  
0 = no deficit  
0.5 = half tail paralysis 
1 = full tail paralysis 
2 = monoparesis  
3 = monoplegia, hemiparesis  
3.5 = hemiplegia  
4 = quadriparesis  
5 = moribund 
In accordance with Home Office requirements animals were removed from the experiment by 
a Schedule 1 method if they lost more than 20% of their starting body weight, or were 
moribund for a period of 24 hours. 
2.3	  Assessment	  of	  EAE	  
2.3.1	  Tissue	  preparation	  
At the termination of experiments animals were injected i.p. with an overdose of 200mg/ml 
sodium pentobarbital (Euthatal, Merial Animal Health, UK). Respiratory arrest was confirmed 
and animals were perfused through the left ventricle with PBS followed by 4% 
paraformaldehyde (PFA w/v). The right atrium was cut to allow blood to escape. The brain, 
spinal cord and cerebellum were extracted and post-fixed in 4% PFA overnight at 4°C before 
cryo-protecting in 30% Sucrose (w/v) for 72 hours, or until tissue had equilibrated with the 
solution.  
Tissue was rinsed with PBS and placed in a cuboid plastic mould filled with OCT (CellPath, 
UK). The mould was then placed in a bath of isopentane on dry ice, and left to freeze. 10µm 
sections were obtained using a cryostat and stored at -20°C. The brain was sectioned in the 
coronal plane; cerebellum and brain stem were sliced along the midline and sectioned in the 
sagittal plane. The spinal cord was divided into 8 sections of 8mm length giving two cervical 
level segments (1st and 5th cervical), four thoracic segments (1st, 5th, 9th and 13th thoracic), 
and two caudal segments (4th lumbar and 2nd sacral). 
2.3.2	  IHC	  	  
Sections were removed from storage at -20°C and rehydrated immediately with PBS 0.1% 
(v/v) Triton X100 (PBST). Antigen retrieval was required for some antibodies, and was 
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performed using a pH 6.2 retrieval kit (Dako, UK). Sections were incubated in retrieval 
solution for 10 minutes at room temperature, heated until boiling in a microwave, and boiled 
for 3 minutes. Following rinsing with PBST, endogenous peroxidase activity was quenched by 
incubating sections with 0.3% H2O2/0.3% normal horse serum (NHS) in PBST for 10 minutes. 
Sections were then blocked for 1 hour in 5% NHS/1% BSA in PBST. Primary antibodies were 
diluted in 1% NHS/1% BSA (Table 2.1) and incubated overnight at 4°C. After three washes in 
PBST secondary antibodies were incubated for 1 hour. Rabbit antibodies were detected 
using biotinylated goat anti-rabbit (Vector Labs, UK); mouse antibodies were detected using 
biotinylated horse anti-mouse, diluted 1:500 in 1% NHS/1% BSA in PBST. After three PBST 
washes sections were incubated with streptavidin–biotin–peroxidase conjugate (Vectastain 
ABC kit, Vector Labs) for 1 hour and washed with PBST. Bound antibody was visualised 
using a nickel intensified 3, 3′-diaminobenzidine (DAB) reaction (DAB Kit, Vector Labs). A 
subset of sections were stained with Mayers’ haematoxylin (Sigma) for 1 minute before 
washing in tap water for 2 minutes. Sections were then stained with 1% Eosin solution for 2 
minutes before washing again in tap water. Sections were dehydrated through graded 
alcohols and xylene, and mounted with DPX. All incubations were carried out at room 
temperature unless stated 
Table 2.1 Details of antibodies used for IHC analysis 
Antigen Specificity Species Dilution Source 
CD3 T cell Mouse 1:500 BD Biosciences, UK 
OX-42 Microglia/Macrophages Mouse 1:100 R.Reynolds 
CD4 T helper cells Mouse 1:2000 AbD Serotec 
CD81 Cytotoxic T cells Mouse 1:2000 AbD Serotec 
CD79a1 B cells Mouse 1:2000 Thermoscientific, UK 
APP1 Axons Mouse 1:500 Millipore 
NFH1 Axons Mouse 1:1000 Chemicon 
IFNγ2 Cytokine Mouse 1:100 Santa Cruz 
TNFR1A2 Cytokine receptor Mouse 1:1000 Santa Cruz 
TNFR1B2 Cytokine receptor Goat 1:1000 Santa Cruz 
1Denotes 1-hour dry, heat-mediated Citrate buffer pH 6.1 retrieval prior to staining. 
2 Staining performed on snap frozen sections, 10 minutes -20°C Methanol prior to staining for fixation (see 2.6.1 
for sample preparation). 
2.3.3	  Double-­‐labelling	  immunofluorescence	  
Double-labelling immunofluorescence (IF) was performed to enable visualisation of multiple 
proteins on the same section. Sections to be stained with myelin antibodies were immersed in 
ice-cold methanol for 6 minutes before washing in PBST. Antigen retrieval was carried out as 
above where necessary. Blocking solution (5% normal goat serum, NGS) was added and 
incubated for 1 hour at room temperature. Primary antibody was then diluted according to 
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Table 2.2, in PBST with 1% NGS, and incubated overnight at 4°C. Sections were washed 
with 3 times with PBST before incubating with secondary antibody for 1 hour at room 
temperature. Rabbit antibodies were detected with goat anti-rabbit Cy3 (Jackson) diluted 
1:1000 and mouse antibodies were detected using fluorescein isothiocyanate (FITC) 
conjugated goat anti-mouse (Invitrogen) diluted 1:100 in 1% NGS in PBS. Sections were 
washed with PBST and mounted with Vectashield mounting medium (Vector Labs) containing 
4', 6-diamidino-2-phenylindole (DAPI) to allow visualisation of cell nuclei. All incubations were 
carried out at room temperature unless stated. 
Table 2.2 Antibodies used in double-labelling IF studies 
Antigen Specificity Species Dilution Source 
Iba1 Microglia/Macrophages Rabbit 1:2000 Wako, Japan 
C93 Complement component Rabbit 1:5000 Gift, P. Morgan 
Act Caspase3 Apoptotic Cells Rabbit 1:1000 Cell Signalling 
Anti-IgA, -G, -M Plasma Cells/Plasmablasts Rabbit 1:1000 Dako 
GluR2/31 Pyramidal Neurons Rabbit 1:100 Chemicon 
iNOS Inducible nitric oxide synthase Rabbit 1:500 Chemicon 
MBP Myelin/oligodendrocytes Rabbit 1:1000 Dako 
TNF3 Cytokine Goat 1:100 R&D Systems 
Anti-rat IgG3 Immunoglobulins Goat 1:2000 Jackson 
APC (CC1)1 Oligodendrocyte cell bodies Mouse 1:500 Calbiochem 
MHC class 2 Antigen presenting cells Mouse 1:500 Abcam 
S100β Astrocyte cell bodies Mouse 1:1000 Chemicon 
CD68 Phagocytic Macrophages/microglia Mouse 1:1000 AbD Serotec 
GFAP Astrocytes Mouse 1:2000 Sigma 
NFH Neurons Mouse 1:1000 Chemicon 
NeuN Neuronal Nuclei Mouse 1:1000 Chemicon 
MOG2 Myelin/oligodendrocytes Mouse 1:50 R. Reynolds 
CNP Myelin/oligodendrocytes Mouse 1:1000 Chemicon 
 
1Denotes air dry for 1 hour, heat-mediated Citrate buffer pH 6.1 retrieval prior to staining. 
2Denotes air dry for 1 hour prior to rehydration and -20°C Methanol for 6 minutes retrieval prior to staining 
3 Staining performed on snap frozen sections, 10 minutes -20°C Methanol prior to staining for fixation (see 2.6.1 
for sample preparation). 
2.3.4	  Quantification	  of	  CD3+	  cells	  
Digital images of sections were obtained using the 10x objective of a Nikon Eclipse 50i 
microscope with a Qimaging Qi-Cam digital camera. Images were analysed using Image Pro-
PLUS 6.0 software (Media Cybernetics). This equipment allowed multiple images to be tiled 
automatically by the software to give high resolution images of complete spinal cord sections. 
Captured images were coded to ensure quantification was performed in a blinded manner. 
The total number of infiltrating CD3+ T cells/mm2 was assessed in the spinal cord (Figure 
2.2). The images were converted to grey scale (8bpp). The outline of parenchymal tissue was 
selected manually, as an area of interest (AOI) to exclude the meningeal layer, and the 
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background of the images was removed using the flatten background filter. The number of 
CD3+ T cells was counted automatically via the application of set parameters, which were 
optimised prior to analysis; pixel intensity (0-180), the cell roundness (1-4) and total area (20-
400 pixels). All analyses were checked to remove artifacts and cells in vessels, using the 
“toggle off” function of the software. The AOI was then converted to an object and the area of 
analysis was calculated. The total number of infiltrating CD3+ T cells was then divided by total 
parenchymal area to give the total cells/mm2. 
2.3.5	  ELISA	  analysis	  for	  peripheral	  anti-­‐MOG	  antibodies	  
Blood was taken at weekly intervals from a subset of animals. Animals were incubated in a 
hot-box at 40˚C before placing in a restraint tube. Blood was collected from the lateral tail 
vein into a sterile 1ml syringe using a 23G needle. A maximum of 250µl per sample was 
taken per rat. Samples were centrifuged, serum was separated and assessed by enzyme 
linked immunosorbant assay (ELISA) for the presence of anti-MOG antibodies. rmMOG was 
coated on 96 well plates overnight at 4°C at a concentration of 10µg/ml, and subsequently 
washed 5 times with PBS. The plate was then blocked with 2% (w/v) bovine serum albumin 
(BSA) in PBS for 1 hour. Serum diluted in 1% BSA/PBS (according to Table2.3), was added 
in triplicate and the plate was incubated for 2 hours. After washing with PBS, Rat IgG-specific 
alkaline phosphatase-linked secondary antibodies diluted in 1% BSA/PBS (according to 
Table 2.3), were incubated for 1 hour, and washed with PBS. Bound antibody was then 
detected with p-Nitrophenyl phosphate tablet set (Sigma). Optical density was measured at 
405nm. All incubations were at a temperature of 37°C unless stated. Between all incubations 
plates were washed 5 times in PBST. All incubations were carried out at room temperature 
unless stated. 
Table 2.3 Details of the antibodies used for ELISA analysis 
 
  
Secondary 
Antibody ID 
Serum 
Concentration 
Secondary 
Antibody 
Concentration 
Secondary 
Antibody 
Manufacturer 
Total IgG 1-4000 1-5000 Southern Biotech 
IgG1 1-1000 1-100 Serotec 
IgG2a 1-2000 1-500 Serotec 
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2.4	  Focal	  Lesion	  Induction	  
2.4.1	  Surgical	  Protocol	  
Rats were immunised intra-dermally with 5µg rmMOG emulsified in IFA and assessed daily 
as above. Nineteen to twenty-two days after immunisation an injection of pro-inflammatory 
cytokines was made into one of two sites. The motor cortex was targeted with an intracortical 
injection 0.9mm caudal to bregma, 2.5mm lateral to the midline and to a depth of 1.5mm 
(Figure A). The subarachnoid space of the sagittal sulcus was targeted 0.9mm caudal to 
bregma and to a depth of 2.5mm (Figure 2.2 B). These co-ordinates were obtained using a 
stereotactic atlas, in order to target the motor cortex (Paxinos & Watson 1998). 
Rats were anaesthetised with isofluorane and mounted on a stereotactic frame. The skull 
surface was accessed and a fine hole was drilled. The injection was made using a finely 
calibrated glass capillary attached to 26S Hamilton syringe (Figure 2.3, 2.4). The sample was 
injected at a rate of 0.20µl/min using an automated injection system (KD Scientific). Three 
different concentrations of cytokines were injected over the course of the project. In a pilot 
study the same quantities used in a previously published model (Merkler et al. 2006b); 250ng 
recombinant rat TNF (rrTNF, R & D systems)/15ng recombinant rat IFNγ (rrIFNγ, Peprotech, 
UK), were injected. In a subsequent study 500ng rrTNF/30ng rrIFNγ or 1.25µg rrTNF/75ng 
rrIFNγ were injected into each animal. Control animals were either immunised with rmMOG 
and subsequently injected with PBS, or immunised with IFA and injected with cytokines. A 
total volume of 1µl was injected, and Indian ink (Stephens Ink, UK) was added as a tracer. 
The needle was left in place for 5 minutes to allow diffusion of cytokines away from the area. 
Cicatrin antibiotic powder (GSK, UK) was placed on the skull surface and the wound closed 
using Prolene 4-0 suture material (Ethicon, USA). Animals were injected s.c. with 0.01mg/kg 
buprenorphine (Vetergesic, Reckitt Benckiser, UK) for analgesia, this dose has been shown 
to have no effect on inflammatory cell activity (Carrigan et al. 2004). Post surgical recovery 
was uneventful in all cases, and no clinical signs of EAE were observed. Animals were kept 
for varying time-periods after surgery, before processing tissue as above. 
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Figure 2.3 Rats received a stereotactic injection into the motor cortex (A), co-ordinates -0.9mm from bregma, 
+2.5mm from midline and to a depth of 1.5mm from the dura. Alternatively rats were injected into the subarachnoid 
space of the sagittal sulcus (B). This was targeted -0.9mm from bregma, and to a depth of 2.5mm from the dura. 
	  
Figure 2.4 A finely calibrated glass capillary (black arrow, A) was attached to a 26S Hamilton needle using 
commercial available nail varnish (white arrow). This created a watertight seal. The tip of the needle was typically 
30µm wide (black arrow (B) the barrel extended up to approximately 80µm (red arrow B). 
2.5	  Analysis	  of	  focal	  lesion	  neuropathology	  
2.5.1	  Quantification	  of	  Demyelination	  
IF images of sections stained with anti-MOG antibody were used to quantify demyelination 
(Figure 2.5). Tiled digital images of sections were obtained using the 4x objective of a Nikon 
Eclipse 50i microscope with Qimaging Qi-Cam digital camera. Images were subsequently 
analysed using Image Pro-PLUS 6 software (Media Cybernetics). Captured images were 
coded to ensure quantification was performed in a blinded manner. Grey scale images were 
processed using the display range function, so that the pial surface could be differentiated 
from the black slide background. Demyelinated areas of tissue were selected manually as an 
AOI. The AOI was then converted to an object and the area calculated. Three sections per 
animal were analysed and an average calculated.  
A B
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2.5.2	  Quantification	  of	  lymphocyte	  infiltration	  
Immune cells were quantified on adjacent sections stained for CD4 (Th cells), CD8 (Cytotoxic 
T cells and CD79a (B cells, Figure 2.6, Table 2.1). Bound antibody was detected using DAB 
visualisation, and sections were counterstained with 1% eosin. In all cases the number of 
cells in the meninges, grey matter parenchyma and corpus callosum were quantified, in an 
area of the cortex from the sagittal sulcus to an area defined by the position of the lateral 
blood vessels present in the meninges.  
For CD8+ and CD79+ quantification, tiled digital images of sections were obtained with the 
10x objective of a Nikon Eclipse 50i microscope with Qimaging Qi-Cam digital camera. 
Images were analysed using Image Pro-PLUS 6 software (Media Cybernetics). Captured 
images were coded to ensure quantification was performed in a blinded manner. The images 
were converted to grey scale (8bpp). The outline of the grey matter parenchymal tissue or 
corpus callosum was selected manually, as an area of interest (AOI) to exclude the 
meningeal layer, and the background of the images was removed using the flatten 
background filter. The number of CD8+ and CD79+ cells was counted automatically via the 
application of set parameters, which were optimised prior to analysis; pixel intensity (0-80), 
the cell roundness (1-4) and total area (20-400 pixels). All analyses were checked to remove 
artefacts and cells in vessels, using the “toggle off” function of the software. The AOI was 
then converted to an object and the area of analysis was calculated. The total number of 
infiltrating cells was then divided by the total area to give the total cells/mm2. Three sections 
per animal were analysed and an average calculated. 
It was not possible to accurately optimise automatic cell counts for CD4+ IHC or for the 
number of grey matter perivascular cells for all cell types. To ensure reliable counts the 
number of CD4+ cells and the number of grey matter perivascular cells were counted 
manually using the 10X objective of a Nikon E800 microscope. The number of perivascular 
cells was subtracted from the number of cells counted in the grey matter parenchyma. In all 
cases the number of lymphocytes was quantified on three sections and an average obtained. 
2.5.3	  Quantification	  of	  CNS	  cells	  
In order to visualise the individual cortical layers, sections were labelled by double IF with 
NeuN and GluR2/3 antibodies (as Table 2.2, Figure 2.7 A). Digital images of sections were 
obtained with a 10x objective of a Nikon E800 microscope with a motorized stage and NIkon 
digital camera. The thickness of cortical layers positioned lateral to the sagittal sulcus stained 
by GluR2/3 was measured using ImagePro Plus analysis software (see Figure 2.7 B). Three 
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locations from the corpus callosum to the sagittal sinus were analysed, in three sections per 
animal. The thickness of layers II–II and IV were calculated across time-points and 
experimental groups and found to not statistically differ; results were pooled and averaged 
(see Figure 2.7 C). A macro was created to apply specific “guides” of the appropriate average 
length to each image using the “annotate” function, these were then individually positioned to 
the correct location. To detect potential oedema, the thickness of layer I was measured 
across experimental groups using DAPI stained images. No statistically significant differences 
were detected across time-points and experimental groups. 
Composite images consisting of the marker of interest plus DAPI were analysed for each cell 
type being studied. Neurons (NeuN), microglia/macrophages (Iba1/CD68), astrocytes 
(S100β) and oligodendrocytes (APC+/GFAP-) were quantified. Layer I was defined using 
DAPI staining, as an area of sparse cellularity between the meninges and the high nuclear 
density of Layer II–II. For quantification of cells in layers II–III and IV the “guides” were 
applied and moved to the correct location on the image. An AOI was carefully drawn around 
the cortical layer being studied on both hemispheres, and cells with positive staining together 
with a nucleus were manually quantified (see Figure 2.7 D–H). Cells were quantified in layers 
I–IV in the cortex from the corpus callosum to the level of the sagittal sinus. The AOI was 
converted to an object the area measured and cell density calculated.  
2.5.4	  Statistical	  analysis	  
GraphPad Prism 4.0 was used in all cases to present data and conduct statistical analysis. All 
data represents the mean and standard error of the mean (SEM). Individual comparison was 
by Student T test. Group comparisons were separately analysed by one-way analysis of 
variance (ANOVA) with Tukey correction. Only scientifically valid group comparisons were 
analysed. For example, each experimental condition at an individual time-point was 
compared, as were values across the time-points for each individual experimental condition. 
It was not necessary to compare one experimental group at time-point “x”, to another 
experimental group at time-point “y”. Values for naïve animals were included in each 
comparison. For correlated data, Pearson rank correlation was used to assess the slope of 
the correlation and significance. A p value of <0.05 was considered significant in all cases.	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Table 2.4: Number of animals within each investigation group. Animals were immunised with 5µg rmMOG or IFA 
and 20 days later received an injection into the subarachnoid space at the sagittal sulcus of either 1.25µg TNF/ 
75ng IFNγ or PBS. Animals were culled at different time-points post-injection and serial coronal brain sections 
were taken. Sections were processed by IHC to study pathology.  
Days Post Stereotactic 
Injection 
Investigation Group Number of animals 
(N) 
- Naive 3 
1 
rmMOG/Cytokine 8 
IFA/Cytokine 3 
rmMOG/PBS 4 
3 
rmMOG/Cytokine 8 
IFA/Cytokine 3 
rmMOG/PBS 3 
7 
rmMOG/Cytokine 10 
IFA/Cytokine 7 
rmMOG/PBS 4 
14 
rmMOG/Cytokine 6 
IFA/Cytokine 3 
rmMOG/PBS 3 
21 
rmMOG/Cytokine 4 
IFA/Cytokine 3 
rmMOG/PBS 3 
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2.6	  Molecular	  Analysis	  of	  Sub-­‐Pial	  Lesions	  
2.6.1	  Tissue	  Preparation	  
Subpial lesions were induced in female DA rats as above, control animals were immunised 
with 5µg rmMOG and received a PBS injection, or were immunised with IFA and received an 
injection of cytokines. At 7 days post-surgery animals were injected into the peritoneal cavity 
with an overdose of 200mg/ml sodium pentobarbital. After confirmation of respiratory arrest 
animals were perfused through the left ventricle with sterile PBS. The brain was extracted, 
immediately placed in an OCT filled plastic mould and placed in ice-cold isopentane. Brains 
were stored at -80˚C. The number of animals in each group is detailed in Table 2.5. 
Table 2.5: Number of animals within each investigation group.  
Days Post Stereotactic 
Injection 
Investigation Group Number of animals 
(N) 
7 
rmMOG/Cytokine 8 
IFA/Cytokine 6 
rmMOG/PBS 5 
2.6.2	  Laser	  Capture	  Microdissection	  
Cortical layers I–IV at the sagittal sulcus were isolated by laser capture microdissection 
(LCM) using the PALM system (Carl Zeiss, Germany). Ten micron cryosections were cut at -
15˚C and placed on sterile, RNase free PET membrane coated slides. Sections were air dried 
for 2 minutes and fixed in ice cold 95% ethanol. Sections were placed in 70% ethanol at room 
temperature, stained in 1% cresyl violet (in 70% ethanol) for 1 minute, and dehydrated 
through 75% ethanol, 95% ethanol and 2X 100% ethanol steps, before air drying for two 
minutes and storing at -80˚C in a sealed container with silica bead desiccant. 
Slides were removed from storage and placed in a falcon tube with desiccant for 10 minutes. 
When they had equilibrated to room temperature they were placed on the microscope stage. 
The area to be extracted was outlined at 10x microscopy (Figure 2.8). The tissue was then 
cut by laser and catapulted into an eppendorf cap containing 70µl Qiazol (Qiagen), by laser 
pressure catapult. The cap was then carefully placed on to an eppendorf tube containing 
130µl Qiazol and placed on dry ice. Layers I–IV were extracted from 4–5 sections per animal 
before storing at -80˚C.  
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2.6.3	  RNA	  Extraction	  
Ribo nucleic acid (RNA) was extracted from brain tissue using the RNA Mini Lipid Tissue Kit 
(Qiagen) according to the manufacturer’s instructions Samples were removed from storage 
and thawed on ice, samples from each animal being pooled to give a total volume of Qiazol of 
800-1000ml. Samples were vortexed and stored at room temperature for 5 minutes. 200µl 
chloroform per ml Qiazol was added to each tube and shaken vigorously by hand for 30 
seconds and incubated at room temperature for 2 minutes. Samples were centrifuged at 
13,000rpm for 15 minutes at 4˚C. The aqueous phase was then carefully removed, placed in 
a new tube and one volume 70% ethanol was added. Samples were transferred to filtration 
columns and washed with manufacturer supplied, ethanol based solutions by centrifugation at 
13,000rpm. The final concentration of RNA was measured at 260nm using a Nanodrop 
ND1000 spectrophotometer. Reverse transcription was then immediately performed on each 
sample. 
2.6.4	  Quantitative	  RT-­‐PCR	  
Samples were kept on ice, before reverse transcription (RT) of RNA using the QuantiTect 
Reverse Transcription Kit (Qiagen). Contaminating genomic de-oxy-ribo nucleic acid (gDNA) 
was removed by incubating samples for 2 minutes at 42˚C in gDNA wipeout buffer. RT was 
then performed by incubating the 150ng RNA of each sample at 42˚C for 15 minutes with RT 
master mix containing Quantiscript Reverse Transcriptase, RT buffer, and RT primer mix. RT 
was de-activated by heating the sample to 95˚C for 3 minutes. cDNA was then stored at -80% 
until required. 
Detection of gene specific cDNA was carried out using the Quantitect SYBR Green 
quantitative polymerase chain reaction (qPCR) kit (Qiagen), together with Quantitect Primer 
Assays for genes of interest (see Table 2.5). Briefly, 1µl complimentary DNA (cDNA) were 
added to each reaction, together with SYBR green master mix, and 2.5µl primer. The final 
reaction volume was 25µl. qPCR was then performed in triplicate for each sample on a 
Stratagene MXP4000 system (according to parameters in Table 2.6).    
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Table 2.6 Summary of primers used for qPCR. All primers were obtained from Qiagen. 
Protein Name Gene Name Assay Name Cat. Number 
Inducible Nitric Oxide Synthase (iNOS) Nos2 Rn_Nos2_1_SG QT00178325 
TNF Tnf Rn_TNF_1_SG QT00178717 
IFNγ Ifng Rn_Ifng_1_SG QT00184982 
TNF Receptor 1A (TNFR1A) Tnfrsf1a Rn_Tnfrsf1a_2_SG QT01599738 
TNF Receptor 1B (TNFR1B) Tnfrsf1b Rn_Tnfrsf1b_1_SG QT00195377 
GAPDH Gapdh Rn_Gapd_1_SG QT00199633 
HPRT Hprt1 Rn_Hprt1_2_SG QT00365722 
Table 2.7 Parameters used for qPCR, conducted on a Stratagene MXP4000 system. 
Step Time Temperature (˚C) Ramp rate (˚C/min) 
PCR Activation 15 min 95 20 
Denaturation 15s 94 20 
Annealing 30s 55 20 
Extension 30s 72 2 
 
 
Figure 2.9: qPCR was performed in triplicate for each sample for each gene of interest (A) on a Stratagene 
MXP4000 with a cycling thermal profile (B).  
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2.6.5	  Positive	  control	  preparation	  
To act as a positive control for each gene of interest, the spinal cords of two animals with 
disseminated EAE (clinical score at termination = 3) were removed and snap frozen as 
above. Ten 50µm sections of each animal were cut on a cryostat and placed in eppendorf 
tubes. RNA extraction and qPCR were then performed as above. The spinal cord of one 
naive rat was processed in an identical manner. 
2.6.6	  PCR	  Efficiency	  and	  RNA	  quality	  
The efficiency of the qPCR reaction of each gene of interest was calculated. cDNA from 
pooled EAE spinal cord samples was used. 400ng, 40ng, 4ng and 0.4ng cDNA was added for 
each primer, three replicates per dilution were used. qPCR was performed for each gene of 
interest according to the parameters above. 
The Ct value for each gene of interest was taken where the fluorescence reading was 
increasing in a logarithmic fashion for each dilution. Ct values for each dilution were averaged 
and plotted against the quantity of cDNA loaded using GraphPad Prism 4.0 software. A line of 
best fit was plotted using linear regression and the slope and r2 for the goodness of fit was 
calculated. The efficiency of the reaction (E) was calculated according to the following 
formula (Pfaffl 2001): 
E = 10^(-1/slope) 
PCR products for each gene of interest were tested to ensure the specificity of primers. 20µl 
of PCR product (plus 4µl 6x loading dye, Invitrogen) was added to a 2% agarose gel 
containing 0.1% ethidium bromide, with Tris-boric acid-EDTA pH 8.0 (TBE) running buffer. 
The samples were run at 120V for ~45 minutes with a <1kb DNA ladder (Invitrogen). Gels 
were observed under ultraviolet (UV) illumination with a GeneGenius illuminometer (Syngen, 
USA) and images were obtained using provided software. 
In order to test RNA quality, 5 samples were pooled and concentrated using a Christ Speed-
Vac RVC 2-18 (Christ, Germany), to approximately 50ng/µl. 500ng of RNA was loaded to a 
1% agarose gel, with 4µl 6x loading buffer. 500ng RNA isolated from the spinal cord of a rat 
with EAE was used as a positive control. Samples were run at 120V for 45minutes with a 
>1kb DNA ladder. RNA bands were detected using a UV camera as above.  
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2.6.7	  Data	  Analysis	  of	  Gene	  Expression	  
Ct values for samples were obtained where fluorescence for each sample was increasing in a 
logarithmic way. Data was exported to Microsoft Excel and the average Ct for each sample 
was calculated. The coefficient of variance for each housekeeping gene was calculated, and 
the housekeeping gene with least variance was used in subsequent calculations. The relative 
gene expression of samples was calculated using the comparative Ct method, according to 
the following equation (Pfaffl 2001): 
           Etarget(ΔCtTarget)   
     Relative Expression = 
     ERef(ΔCtRef)  
 
Where E = Efficiency of the primers, and ΔCt = control Ct – sample Ct. 
GraphPad Prism 4.0 was used to present data and conduct statistical analysis. Data 
represents the mean ± SEM. Individual group comparison were made using the Mann-
Whitney non-parametric test. A p value of <0.05 was considered significant in all cases. 
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3.1	  Introduction	  
3.1.1	  Myelin	  Oligodendrocyte	  Glycoprotein	  
3.1.1.1	  Structure	  and	  function	  
MOG is a CNS specific protein expressed on the external surface of the myelin sheath during 
the final stages of oligodendrocyte maturation and myelination (Scolding et al. 1989). It is a 
member of the immunoglobulin superfamily, consisting of 218 amino acids, with a molecular 
weight of approximately 28KDa and accounts for 0.05% of total myelin protein (Amiguet et al. 
1992). The mature protein is highly conserved (~90%) between mouse, rat and human 
species (Johns & Bernard 1999).  
 
Figure 3.1: Proposed model for native MOG protein structure (Johns & Bernard 1999). The protein consists of an 
immunoglobulin like extracellular domain, hydrophobic membrane spanning region, and a hydrophobic domain 
that does not span the membrane. The immunoglobulin-like extracellular domain (red) is isolated for use in EAE 
studies (Storch et al. 1998a; Papadopoulos et al. 2006). It has been hypothesised that Gal-C may form bonds with 
the hydrophobic intra-membrane domain (Johns & Bernard 1999).  
The precise function of MOG has been difficult to identify, although three possible functions 
have been postulated (Johns & Bernard 1999). The external localisation, immunoglobulin-like 
domain and L2/HNK-1 epitope of the native MOG protein indicates a potential role in cellular 
adhesion. The L2/HNK-1 carbohydrate epitope is known to be important for the adhesive 
properties of myelin associated glycoprotein (MAG) and P0 myelin proteins (Burger et al. 
1992). It has been suggested that MOG acts as an adhesion molecule between neighbouring 
myelin sheaths (Bernard et al. 1997), which in the CNS are in close proximity compared to 
the peripheral nervous system, which lacks MOG expression. However, a MOG-specific 
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ligand has yet to be found. The immunoglobulin-like properties of MOG indicate the potential 
for immune system interaction. Moreover, it has been shown that purified MOG protein can 
activate the C1q component of the complement cascade in a dose-dependent manner (Johns 
& Bernard 1997). 
MOG has also been suggested to have a role in microtubule stability following experiments 
showing depolymerisation of microtubules after anti-MOG antibody addition to 
oligodendrocyte cultures (Dyer & Matthieu 2002). Microtubule depolymerisation is believed to 
be caused by antibody-induced degradation of myelin basic protein (MBP). 
3.1.2	  MOG	  as	  an	  auto-­‐antigen	  in	  MS	  
The properties of MOG protein have led to the hypothesis that it may be a key auto-antigen in 
the pathology of MS. It is expressed only in the CNS, consistent with the CNS specific nature 
of MS lesions. The proteins’ CNS localisation, coupled with low abundance means that it has 
not been detected in the thymus (Bruno et al. 2002), which will inhibit the development of 
immune tolerance, a factor that is important in EAE pathogenesis (Delarasse et al. 2003). 
Peripheral T cells from MS patients have been shown to proliferate when stimulated with 
MOG in culture, more than in response to any other myelin antigen (Kerlero de Rosbo et al. 
1993). MOG specific T- and B-cell responses may be preferentially sequestered in the CNS 
compartment (Sun et al. 1991; Xiao et al. 1991). 
The external localisation of the protein on the myelin sheath provides an available target for 
recognition by components of the immune system. The hypothesis of a pathological role of 
anti-MOG antibodies in MS patients is controversial, with auto-antibodies detected in CSF 
from MS patients and to a lesser extent non-inflammatory CNS conditions and healthy 
controls (Lindert et al. 1999; Reindl et al. 1999). Binding of antibodies isolated from the sera 
of MS patients was studied using human MOG protein expressed on the cell surface of a cell 
line. Only one of 17 patients had antibodies that bound the native protein, indicating that 
pathogenic, conformation-dependent, anti-MOG antibodies are present in only a subset of 
MS patients (Haase et al. 2001). However, the possibility that pathogenic antibodies are 
sequestered in the CNS, behind the BBB, still exists and expansions of plasma cells 
secreting anti-myelin antibodies have been detected (von Büdingen et al. 2008). The 
deposition of anti-MOG antibodies has been noted on myelin in acute MS lesions (Genain et 
al. 1999). Moreover, anti-MOG antibodies have been shown to be more pathogenic than 
antibodies directed against other myelin proteins in animal studies (Morris-Downes et al. 
2002). Furthermore, antibodies directed against the conformational epitope of the external 
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portion of MOG have been identified in MS patients. The administration of these antibodies to 
animals with acute EAE caused increased demyelination and axonal pathology in the WM 
(Zhou et al. 2006). 
Antibodies may cause demyelination by several different mechanisms. Adoptive transfer 
models have shown that the demyelinating potential of anti-MOG antibody isotypes was 
related to their ability to fix complement (Piddlesdon et al. 1993). Furthermore, co-deposition 
of C9 and antibody on myelin in active WMLs in MS and in EAE models suggests antibody-
mediated complement activation and formation of the MAC as the mechanism of 
demyelination (Linington et al. 1989b; Storch et al. 1998a,b). However, the extensive 
demyelination and inflammation observed following de-complementation in antibody-
mediated EAE, has shown that alternative pathways to demyelination can occur (Piddlesdon 
et al. 1991). The major effector mechanism may be opsonisation of myelin and induction of 
phagocytosis by macrophages following Fc receptor engagement (Abdul-Majid et al. 2002). 
The production of the cytotoxic molecules TNF and NO by macrophages following myelin 
opsonisation links this cell type to the antibody-dependent cell-mediated cytotoxicity (ADCC) 
response (Trotter et al. 1986; Sadler et al. 1991; van der Laan et al. 1996). Pathogenic anti-
MOG antibodies have also been shown to crosslink with MOG, forming complexes resulting 
in lipid raft formation, activation of stress response proteins and changes to the cytoskeleton 
of oligodendrocytes (Marta et al. 2005). These results indicate a potentially direct pathogenic 
effect of anti-MOG antibodies. 
Many studies have shown that MOG protein is highly immunogenic for both T and B cells 
(Storch et al. 1998a; Weissert et al. 1998; Iglesias et al. 2001). Furthermore, it is possible to 
closely mimic the clinical course and pathology of MS by immunising several species of 
animals with MOG protein. 
3.1.3	  MOG	  induced	  EAE	  
EAE is initiated by injection of a myelin protein, or peptide thereof, together with inflammatory 
adjuvant. This combination raises an autoimmune response against the endogenous form of 
the protein, resulting in an inflammatory demyelinating disease similar to MS. The antigen 
used, concentration, species and strain of the host can be varied to produce a range of 
pathologies and reproduce the clinical courses that are characteristic of MS. Of the many 
myelin proteins capable of initiating EAE, MOG is the only one to initiate both a T cell and a 
demyelinating auto-antibody response (Iglesias et al. 2001; Gold et al. 2006), and thus more 
accurately replicate the range of pathology observed in MS (Lucchinetti et al. 2000).  
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MOG induced-EAE can also be achieved by adoptive transfer of MOG peptide (92-106) 
specific T cells in SJL/J mice, leading to a severe disease phenotype (Devaux et al. 1997). In 
addition, experiments with B-cell deficient mice indicate that demyelination occurs via a TNF 
dependent pathway (Hjelmström et al. 1998). B-cell depleted mice are less susceptible to 
EAE, but can develop a mild disease with a reduction of spinal cord T-cell infiltrates and 
greater prevalence of macrophages. This may indicate the importance of B cells functioning 
as APCs for the activation and maintenance of T cell responses (Lyons et al. 1999). 
In contrast to murine models, pathology in MOG induced EAE has been shown to be antibody 
and complement dependent in both the rat and marmoset (Iglesias et al. 2001). In spinal cord 
homogenate induced EAE, MOG specific antibody titres were found to correlate with 
demyelination and inflammation (Linington & Lassmann 1987). Moreover, inhibition of the 
complement cascade by cobra venom factor, or soluble CR-1, reduced the ability of anti-
MOG antibody to enhance inflammation and mediate demyelination (Linington et al. 1989b; 
Piddlesdon et al. 1994). A Th cell response is required in rodents to initiate CNS inflammation 
by damaging/opening the BBB. BBB disruption allows MOG specific antibodies to enter the 
CNS and bind to the auto-antigen, triggering complement-mediated demyelination and 
phagocytosis of myelin (Litzenburger et al. 1998). Furthermore, T cell activation has also 
been shown to be required for the recruitment and activation of macrophages and microglia in 
the CNS, through expression of macrophage inflammatory protein 1-alpha (MIP-1α) and 
monocyte chemotactic protein-1 (MCP-1, Vass et al. 1992; Kawakami et al. 2004). These 
results indicate the importance of interactions between all facets of the immune system in 
EAE pathology and disease course. 
3.1.3.1	  MOG-­‐EAE	  in	  the	  DA	  rat	  
Immunising female DA rats with soluble recombinant MOG, emulsified in IFA, has been 
shown to closely replicate the clinical course and pathology of MS (Storch et al. 1998a; 
Lucchinetti et al. 2000). Encephalitogenic doses of protein are typically ≥50µg, with clinical 
disease onset around 8-12 days post-immunisation. The pathological characteristics of MOG-
EAE are highly dependent on the immunisation protocol. Immunisation with a high dose 
(200µg) of rmMOG in IFA has been shown to produce a predominantly relapsing-remitting 
disease course, whereas a dose of 50µg elicited a chronic progressive disease course in a 
subset of animals under the same protocol (Papadopoulos et al. 2006). Gender differences 
have been observed following immunisation with 75µg rmMOG in IFA (Storch et al. 1998a), 
with higher inflammation, demyelination and optico-spinal disease incidence in females.  
Chapter 3: MOG-EAE in the DA rat – Introduction  88 
 
The disease course has also been shown to be dependent on the formulation of antigen; for 
example, immunisation with 50µg soluble protein in CFA led to 100% incidence of acute 
disseminated leuco-encephalopathy with little demyelination (Storch et al. 1998a). In contrast, 
immunising female rats with 50µg precipitated protein in CFA led to a very high degree of 
optico-spinal disease (80%), with no cerebellar involvement and more extensive 
demyelination than immunisation with soluble rmMOG. Furthermore, anecdotal evidence from 
this laboratory has shown that differences in individual batches of recombinant protein (e.g. 
low monomer: dimer ratio) influence disease incidence, course and severity (unpublished 
observations). 
Following immunisation with 75µg rmMOG in IFA, inflammatory demyelinating lesions were 
most commonly observed in the spinal cord and optic nerve (44%), are restricted to the spinal 
cord in 38% cases, with cerebellar involvement in a further 10% cases (Storch et al. 1998a). 
Active lesions were characterised by the deposition of immunoglobulin and neoC9 on the 
surface of the myelin sheath and the presence of a large number of highly activated, 
amoeboid macrophages/microglia containing myelin products (Storch et al. 1998a). In 
addition, T-cells have been detected in the spinal cord meninges coupled with localised entry 
into the parenchyma, with perivascular cuffs frequently observed. Therefore, pathology is 
reflective of the pattern II type WMLs characterised in MS (Lucchinetti et al. 2000), and is said 
to occur via an antibody-mediated, T cell dependent process (Iglesias et al. 2001). Under a 
similar induction protocol, ongoing spinal cord axonal loss has been shown to begin early in 
the disease course and strongly correlates with microglia/macrophage activity. Progressive 
neurological deficits are observed in a chronic relapsing disease course and correlate with 
axonal loss, rather than demyelination or inflammatory activity (Papadopoulos et al. 2006), a 
parallel of the relationship between axonal loss and neurological disability occurring in MS  
The complexity of the immune response, coupled with the chronic relapsing disease course 
and prevalence of axonal pathology makes the MOG-EAE in the DA rat a highly attractive 
model for the investigation of novel therapeutic strategies in MS. Indeed, it is widely used in 
pre-clinical testing by pharmaceutical companies. For example, preclinical testing of 
teriflunamide by Sanofi (Merrill et al. 2009), and fingolimod by Novartis (Foster et al. 2009), 
has utilised the DA rat model. 
3.1.3.2	  MOG-­‐EAE	  and	  focal	  lesions	  	  
There is currently no reliable animal model of MS GML, as EAE rarely affects the brain, and 
lesions are seldom observed in the cortex. Targeted EAE models have recently been 
Chapter 3: MOG-EAE in the DA rat – Introduction  89 
 
produced in the Lewis rat by “priming” the immune system with a subclinical dose of rmMOG 
and subsequently activating a cellular immune response in the desired location via an 
injection of TNF and IFNγ (Kerschensteiner et al. 2004a, Merkler et al. 2006b). The desired 
subclinical dose of rmMOG does not produce behavioural signs of EAE, although anti-MOG 
antibodies can be detected in the periphery in a similar quantity to levels found in animals 
with clinical manifestations of EAE. Analysis of the pathology in the CNS of subclinically 
dosed animals indicates a lack of immune cell infiltration and an absence of demyelination.  
3.1.4	  Aims	  of	  this	  study	  
This study aimed to identify a suitable subclinical dose of rmMOG for use in a focal model of 
demyelination in the DA rat. A suitable dose should elicit a peripheral anti-MOG antigen 
response, but not cause immune cell infiltration into the CNS, demyelination or clinical 
symptoms of EAE. The study aimed to; 
• Express and isolate rmMOG using E.coli  
• Identify clinical signs of EAE in the DA rat 
• Identify pathological hallmarks of EAE by IHC 
• Identify a suitable subclinical dose of rmMOG 
• Investigate the peripheral anti-MOG response by ELISA 
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3.2	  Results	  
3.2.1	  Expression	  and	  Purification	  of	  rmMOG	  
RmMOG was expressed by E.coli cells transfected with pRSET A expression vector 
containing a.a. 1-119 of mouse MOG protein. The expressed protein contained six histidine 
residues allowing purification by metal affinity chromatography. The eluted protein was then 
concentrated in 1M arginine solution.  
Protein concentration was measured at 280nm using a Nanodrop ND-1000 
spectrophotometer and found to be 2.56mg/ml (average of 3 readings, Figure 3.2 A). SDS-
PAGE electrophoresis, followed by Coomassie blue staining, revealed major protein bands at 
approximately 20, 50 and 66KDa. The bands were present in the experimental batch of 
protein and a previously produced batch of rmMOG (Figure 3.2 B). The three major bands 
represent monomeric (20KDa), dimeric (50KDa) and trimeric (66KDa) forms with further 
multimers present in both batches. The monomer:dimer ratio measured by pixel intensity 
analysis, was 2.62:1 (Figure 3.2 C). The monomer: dimer ratio was calculated from the 
Coomassie stained gel, as this represented the total protein present in the gel. Performing the 
ratio analysis on Western blot may introduce confounding variables. For example, the 
efficiency of transfer from gel to nitrocellulose membrane is likely to differ according to the 
quantity of protein present, the molecular weight of protein and the quality of the protein. 
Furthermore, the antibody system used to detect MOG protein may bind preferentially to 
multimeric forms of protein, indeed multimers were heavily stained in the experimental batch 
of MOG (Figure 3.2 B). The antibody system highly amplifies the signal, and in this 
experiment it is likely that the signal was quickly over-exposed. Western blot analysis with 
anti-MOG antibody confirmed the identity of all protein bands as rmMOG. Multimeric forms 
were present in both batches, but were much more prominent in the experimental batch of 
protein. As expected, BSA proteins were not detected by Western blot.  
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3.2.2	  Induction	  of	  EAE	  
3.2.2.1	  DA	  rats	  immunised	  with	  5µg	  rmMOG	  had	  no	  clinical	  signs	  of	  EAE	  
Female DA rats were immunised with various doses of rmMOG (5, 25 and 50µg; n = 6 per 
group) emulsified in IFA (50:50). Control animals were injected with IFA in PBS (50:50 n = 6). 
Doses of 25 and 50µg rmMOG elicited severe clinical disease in all animals, with a 
progressive disease course. Mean day of disease onset was 11 (25µg) and 9 (50µg) days 
post-immunisation (dpi, Figure 3.3 A). Symptoms of disease followed an ascending pattern, 
beginning with tail paralysis and progressing to hemiparesis/plegia of the hindlimbs. 
Autonomic nervous dysfunction causing bladder dysfunction and incontinence was common 
in animals with hemiplegia. Two animals immunised with 50µg rmMOG experienced hemi-
paresis of the left side of the body. One animal immunised with 25µg rmMOG showed 
spasticity in all limbs. The animal subsequently experienced involuntary axial rotation, which 
may indicate presence of a brainstem/cerebella lesion. 
The maximum-recorded clinical score in these groups was 4, corresponding to quadriparesis, 
typically with total hind-limb paralysis. Three animals in each of these groups experienced an 
especially severe disease course and were culled due to humane end-points being exceeded 
(>20% weight loss for two consecutive days). The average score of animals surviving to the 
termination of the experiments was 2 for those immunised with 25µg rmMOG, and was 3 for 
those immunised with 50µg (Table 3.1). 
One animal receiving 5µg rmMOG had mild, transient symptoms of EAE, first present at 17 
dpi (Figure 3.3 A, Table 3.1). The maximum clinical score of this animal was 2, corresponding 
to tail paralysis and single hind-limb weakness or apparent gait abnormality. At the 
termination of the study the animal had a score of 0.25, corresponding to loss of tail tone at 
the tip. The average clinical score for animals immunised with 5µg rmMOG was 0. Animals 
immunised with IFA did not show any clinical signs of EAE, though one animal did exhibit 
adjuvant-induced arthritis. This was characterised by severe swelling of both hind limbs, 
causing the animal distress. The animal was culled via a Schedule 1 (ASPA 1988) method. 
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Table 3.1: Details of clinical disease following immunisation of DA rats with increasing doses of rmMOG. Data 
presented as an average of animals surviving to the termination of the experiment (5µg n = 6, 25 and 50µg n = 3). 
Data in brackets in 5µg group represents the single symptomatic animal. 
3.2.2.2	  Rats	  without	  clinical	  signs	  of	  EAE	  had	  no	  demyelination	  
At the termination of the experiment the brain and spinal cord of each animal was processed 
for pathological analysis. Double IF staining for myelin (MOG) and microglia/macrophages 
(Iba1) revealed extensive demyelination and inflammatory activity in the spinal cord of all 
animals with clinically manifest EAE (Table 3.2).   
Spinal cord demyelination was observed in every animal with clinical signs of EAE (Table 
3.2). The dorsal funiculus at the lower thoracic and lumbar levels was typically demyelinated 
(Figure 3.3 B, D), but in animals with severe disease it could envelop the entire spinal cord 
section and was observed even at the cervical level. Areas of demyelination were associated 
with high numbers of microglia/macrophages in the spinal cord parenchyma. Microglia/ 
macrophages in lesions typically had an activated spherical, amoeboid morphology with no 
processes. The expression of CD68 in this cell type indicated a phagocytic phenotype (Figure 
3.4 A, C). CD68+/Iba1+ cells macrophages were also observed in the meninges of animals 
with EAE. Animals with no overt clinical signs of EAE, that were immunised with 5µg rmMOG, 
had no demyelination and had a comparable level of ramified, resting microglia to control 
animals injected with IFA alone (Figure 3.4 B, D). One out of 6 animals immunised with 5µg 
rmMOG presented mild, transitory symptoms of EAE and had evident demyelination in 
lumbar sections of the spinal cord (Table 3.2). This lesion had the typical amoeboid microglia/ 
macrophage infiltration observed in other cases of EAE. 
C9 and IgG deposition was detected in animals with EAE, within areas of demyelination, and 
was associated with areas of high microglial/macrophage activity (Figure 3.5 A, C). Deposits 
were detected on myelinated axons at the edge of highly activated lesions, indicating ongoing 
demyelination. Extensive deposition was also detected in the meninges of animals with EAE. 
No complement or IgG was present in the meninges, or deposited in the parenchyma of 
control animals, or animals injected with 5µg rmMOG without clinical disease.  
Demyelination coupled with inflammatory activity was observed in the cerebellum (Figure 3.6 
A, C) of a subset of animals with severe EAE. Demyelination was particularly evident in the 
rmMOG 
Dose (µg) 
Disease 
Incidence 
Disease 
Onset (dpi) 
Number of 
Relapses 
Maximum 
Score 
Average 
Score 
5 17% 0 (17) 0 (2) 2 0 (1) 
25 100% 11 2 4 2 
50 100% 9 2 3 3 
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white matter tracts, and was associated with a high number of highly activated, amoeboid 
microglia/macrophages. Increased numbers of ramified microglia were also evident in the 
cerebellar grey matter. Demyelination of one or both the optic nerves was also detected in a 
number of animals with severe EAE (Figure 3.7 E, F). Demyelination could occur across the 
whole cross section of the nerve affected, and was associated with extensive infiltration of 
highly activated microglia/macrophages. It was associated with increased monocyte 
infiltration of the neighbouring meninges, and increased microglial activity in the neighbouring 
brain region, particularly around the third ventricle (Figure 3.7 B, E). This increased activity 
was not associated with demyelination. Neither demyelination, nor increased microglial/ 
macrophage activity was found at any of four levels throughout the cortex, corresponding to 
approximately bregma +0.70mm (forelimb motor cortex region, separated optic nerves), 
bregma -0.80mm (cingulate cortex, third ventricle visible, optic chiasm), bregma -2.60mm 
(retrosplenial cortex, hippocampal formation evident) and bregma -6.80mm (occipital cortex, 
lateral hippocampal formation, cerebral aquaduct present, Figure 3.7 A-D (Paxinos & Watson 
1998). 
Table 3.2: Incidence of demyelination in CNS areas of rmMOG-immunised animals. N = 6 (5µg), 3 (25-50µg). 
Numbers in brackets include animals not surviving to the termination of the experiment (N = 6 each group). 
 
  
rmMOG 
Dose (µg) 
Demyelination 
(Spinal Cord) 
Demyelination 
(Cerebellum) 
Demyelination 
(Optic Nerves) 
Demyelination 
(Forebrain) 
5 17% 0% 0% 0% 
25 100% 66% (50%) 66% (50%) 0% 
50 100% 33% (33%) 33% (33%) 0% 
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3.2.2.3	  Rats	  without	  clinical	  signs	  of	  EAE	  had	  no	  lymphocyte	  infiltration	  in	  the	  CNS	  
Immunohistochemistry was used to assess the infiltration of CD3+ T lymphocytes into the 
CNS. Tiled images of spinal cord sections were then acquired for each animal at each of 8 
sampled levels of the spinal cord (1st Cervical to 2nd Sacral levels). The number of CD3+ T 
cells was then counted automatically using ImagePro Plus software.  
CD3+ T cells were present in large numbers in the spinal cord parenchyma in all symptomatic 
rats (25µg = 10.14±3.36 cells/mm2, 50µg = 33.67±3.46), whereas few were found in animals 
immunised with 5µg rmMOG (0.79±0.06 cells/mm2). Control rats immunised with IFA alone 
had few CD3+ cells (0.81±0.08 cells/mm2, Figure 3.6). A high number of CD3+ cells were 
observed in the meninges of rats with EAE, with many fewer in the meninges of rats with no 
EAE symptoms. Numbers of CD3+ T cells were highest in the lower levels of the spinal cord 
in rats immunised with higher doses of rmMOG (Figure 3.5 E). Animals immunised with 25 
and 50µg rmMOG had significantly more parenchymal CD3+ T cells in the whole area of the 
spinal cord studied (1st cervical to 2nd sacral: p<0.01 and p<0.05 respectively, Figure 3.6 F). 
The total number of CD3+ T cells was not different between 5µg rmMOG-immunised animals 
and control animals receiving IFA alone (Figure 3.6 F). Animals immunised with 50µg 
rmMOG had a higher number of CD3+ T cells than those immunised with 25µg at each spinal 
cord level studied, although the difference did not achieve significance. High numbers of 
CD3+ T cells were observed in areas of the cerebellum with myelin damage. Perivascular 
cuffs of CD3+ T cells were also observed in the hippocampal areas of one animal with severe 
EAE, although no demyelination or microglial/macrophage activity was observed in adjacent 
sections. 
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3.2.2.4	   Rats	   without	   clinical	   signs	   of	   EAE	   had	   a	   peripheral	   anti-­‐MOG	   immune	  
response	  
Animals dosed with 5µg rmMOG had no demyelination, little microglia/macrophage activity 
and no CD3+ T cell infiltration in the CNS. Blood samples were taken at weekly intervals 
following immunisation, and at the termination of the experiment (32 dpi). ELISA assessed 
serum levels of anti-MOG antibodies, in order to answer the question of whether the 
peripheral immune system recognises and responds to lower doses of rmMOG in animals 
without overt clinical sings of EAE.  
No significant difference in levels of anti-MOG antibodies was observed across doses of 
rmMOG (Figure 3.7 A, B, C), for total IgG, the IgG2a isotype (which is linked to pathogenic 
Th1-type responses) or IgG1 (linked to Th2-type responses) from rats 32 dpi. Levels of anti-
MOG antibodies were also assessed at various time-points following immunisation with 5µg 
rmMOG (Figure 3.7 D, E, F). Levels of anti-MOG IgG and IgG2a were maximal at 32 days, 
although this was not significantly greater than levels of serum from 23 days. Anti-MOG IgG1 
levels peaked at day 32 and remained relatively low until this point. 
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3.3	  Discussion	  
3.3.1	  Expression	  of	  rmMOG	  protein	  
Soluble recombinant mouse MOG protein (1-116a.a) was successfully expressed and 
isolated from E.coli cells transfected with plasmid containing cDNA. Separation of the protein 
by gel electrophoresis and subsequent visualisation by Coomassie blue staining revealed 
major bands of protein at ~20, 40 and 60 KDa. The prominent protein band at 20KDa is the 
monomeric form of the protein, with each subsequent band being dimer, trimer and further 
multimers (Bettadapura et al. 1998). Lack of lower molecular weight products indicates that 
the expressed protein has undergone little or no degradation. Western blotting confirmed that 
all bands consisted of MOG protein. A lack of non-MOG protein bands confirmed the purity of 
the isolated protein. Data from this laboratory has linked a low monomer: dimer ratio to an 
increase in the number of DA rats not manifesting EAE symptoms following immunisation 
with 100µg rmMOG (unpublished observations). The monomer:dimer ratio on the Coomassie 
stained gel was found to be 2.62:1, which is considered to be an excellent ratio for EAE 
induction.  
3.3.2	  MOG-­‐EAE	  in	  the	  DA	  rat	  
The soluble rmMOG protein was used in our subsequent study with the aim of obtaining a 
subclinical dose of rmMOG for use in a focal EAE model (Kerschensteiner et al. 2004a; 
Merkler et al. 2006b). It was first essential to establish the encephalitogenicity of the rmMOG 
protein produced. Immunisation of DA rats has been shown to elicit an antibody-mediated, 
Th1 dependent disease (Storch et al. 1998a; Iglesias et al. 2001). Macrophage infiltration and 
complement/antibody deposition are significant pathological features and are reflective of the 
pathology of the predominant subset of WMLs in MS (Lucchinetti et al. 2000). The chronic 
relapsing disease course and progressive axonal pathology observed in MS are also 
recreated in this model (Papadopoulos et al. 2006).  
3.3.2.1	  Disseminated	  EAE	  was	  elicited	  by	  high	  doses	  of	  rmMOG	  
Immunisation with 25 or 50µg rmMOG in IFA was sufficient to initiate severe clinical disability 
with 100% incidence. In a subset of animals, disease was acute and led to severe weight 
loss, necessitating removal from the study via Schedule 1 method. These results are in 
agreement with previously published work in this lab (Papadopoulos et al. 2006), and other 
groups (Storch et al. 1998a). Furthermore, the chronic-progressive disease course initiated at 
these doses has been previously reported (Papadopoulos et al. 2006). In this study, relapses 
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were rare in animals with established EAE, in contrast to animals immunised with higher 
doses of rmMOG (Papadopoulos et al. 2006).  
IHC for MOG protein revealed that clinical disease was always associated with demyelination 
of the spinal cord, with involvement of the optic nerve or cerebellum in a subset of animals. 
Interestingly, cerebellar and optic nerve involvement was more prominent in animals 
immunised with 25 as opposed to 50µg rmMOG, indicating dose dependent effects on the 
location of the immune response. The proportion of animals with optic nerve demyelination 
was approximately equal to a previously published report (33-66% vs. 44%), with a similar 
induction protocol (75µg rmMOG in IFA, Storch et al. 1998a). However, the involvement of 
the cerebellum was lower in this study than the data presented here (10% vs. 33-66%). This 
may be due to subtle effects of the batch of rmMOG produced here, such as differential 
solubility, the effects of housing conditions/environment, or effects of rmMOG dose. 
Alternatively, this difference may be due to chance due to the low numbers of animals used in 
this study. Cortical pathology was not observed in MOG-EAE even in animals with severe 
EAE, in keeping with previously published studies in the DA rat (Storch et al. 1998a; Storch et 
al. 2006). A recent study of disseminated MOG-EAE linked the extent of cortical pathology 
with MHC haplotype (Storch et al. 2006). In the relatively EAE resistant Lewis rat, extensive 
inflammatory subpial lesions in the cortex were present despite a relatively mild disease 
course. This pathology was only present in Lewis rats with an RT1.BuDuAq haplotype and was 
in contrast to the DA rat, which has the RT1AV1 MHC haplotype and had no cortical 
involvement despite a relatively severe disease course (Storch et al. 2006). 
The cellular composition of lesions was in agreement with previously published data for 
MOG-EAE lesions in the DA rat (Storch et al. 1998a; Storch et al. 2006; Papadopoulos et al. 
2006), and was reflective of pattern II type WMLs in MS (Lucchinetti et al. 2000). T cells were 
present, in perivascular, parenchymal and meningeal compartments. Active lesions were 
characterized by the presence of a large number of highly activated, amoeboid 
macrophages/microglia containing myelin products. Deposition of immunoglobulin and C9 on 
the surface of the myelin sheath provided evidence that demyelination was caused via an 
antibody-mediated mechanism (Storch et al. 1998a,b; Storch et al. 2006).  
3.3.2.2	  IFA	  caused	  arthritis	  in	  DA	  rats	  
The finding of adjuvant induced arthritis (AA) when immunising with IFA is consistent with 
previous reports. Indeed the DA rat is known to be particularly susceptible to AA (Holmdahl 
1998; Svelander et al. 2001). The presentation of AA in this study was typical of published AA 
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models in the DA rat (Svelander et al. 2001). AA is a chronic inflammatory disease commonly 
used as a model of rheumatoid arthritis in humans. The disease is mediated by T cells and is 
not thought to be antigen dependent (Svelander et al. 1997; Holmdahl 1998). IFA is 
considered to be a non-specific activator of the immune system, which may explain the 
elevated levels in total anti-MOG IgG in animals immunised with IFA compared to naive rats. 
Anti-MOG antibodies are known to be present in the periphery in naive rats and non-specific 
activation of the immune response by IFA triggers increased antibody production by B cells 
and plasma cells (Ohtani et al. 2011).   
3.3.3	  Sub-­‐clinical	  MOG-­‐EAE	  in	  the	  DA	  rat	  
Initiating subclinical MOG-EAE in the DA rat offers distinct advantages over the Lewis rat. 
EAE in Lewis rats is typically an acute monophasic disease process, heavily dependent on 
Th1 cells with a lower extent of demyelination and limited antibody involvement (Storch et al. 
1998a; Weissert et al. 1998). The Lewis rat is considered to be resistant to MOG-induced 
EAE due to the influence of MHC haplotypes (Storch et al. 1998a; Weissert et al. 1998). In 
contrast, the DA rat is considered highly susceptible to EAE induction. Furthermore, EAE in 
the DA rat has been shown to cause substantial axonal loss, which proceeded after the 
resolution of inflammation in a chronic progressive disease model, thus more accurately 
reflecting MS pathology (Papadopoulos et al. 2006). 
The desired subclinical dose of MOG protein for use in focal models is insufficient to induce 
clinical disease, demyelination or lymphocyte extravasation but raises an immune response 
in the periphery (Kerschensteiner et al. 2004a; Merkler et al 2006b). These requirements limit 
the effect of confounding variables in the pathogenesis of focal lesions induced following 
cytokine injection. The necessity of these requirements was highlighted by recent research 
showing diffuse gene expression changes in the cerebral cortex in DA rats with EAE, in the 
absence of overt cortical pathology (Zeis et al. 2008). The expression of mitochondrial genes 
and glutamate receptor subtypes were downregulated, potentially indicating changes to 
neuronal energy production and protective mechanisms against excitotoxicity. These 
alterations were hypothesised to be caused by retrograde degenerative mechanisms elicited 
by inflammatory lesions in the spinal cord. In a model of cortical demyelination, it is 
imperative to establish that any cell loss detected is only due to cortical pathology. Therefore, 
due to the potential influence of spinal cord demyelination on the viability of cortical neurons 
and glia, animals with EAE symptoms cannot be used for focal model studies. 
Chapter 3: MOG-EAE in the DA rat – Discussion  107 
 
3.3.3.1	   No	   clinical	   disease	   or	   demyelination	   following	   immunisation	   with	   5µg	  
rmMOG	  	  
The lack of clinical EAE symptoms and associated spinal cord pathology in animals 
immunised with 5µg rmMOG indicated that this dose was insufficient to initiate CNS 
inflammation. Furthermore, it identifies this dose as a potential subclinical dose for use in a 
focal model of demyelination. The subclinical dose of rmMOG in the DA rat is lower than the 
dose used in previous models of focal demyelination in the Lewis rat (Kerschensteiner et al. 
2004a; Merkler et al. 2006b). This difference may reflect the differing susceptibility to MOG 
protein known to exist between these strains (Storch et al. 1998a). Previous research has 
shown that the RT1AV1 MHC haplotype present in DA rats confers greater susceptibility to 
immune challenge than the RT11 haplotype of Lewis rats (Weissert et al. 1998; Stefferl et al. 
1999). Furthermore, the dose of antigen required to elicit EAE was found to be strongly 
influenced by MHC haplotype (Weissert et al. 1998).  
The influence of other genetic factors has been highlighted by studies utilising the PVG and 
Lewis RT1AV1 rats, which remained relatively EAE resistant despite having an identical MHC 
haplotype to the DA rat (Lorentzen et al. 1997; Wallstroem et al. 1997; Weissert et al. 1998). 
Indeed, the development of EAE, extent of inflammation, demyelination and disease 
incidence were significantly greater in DA rats following identical immunisation protocols and 
have been shown to be related to the efficiency of T- and B-cell responses to MOG 
(Issazadeh et al. 1996; Lorentzen et al. 1997; Weissert et al. 1998). Furthermore, the 
influence of alternative genetic loci on chromosome 4, conferring increased titres of the Th1 
associated IgG2c antibodies in autoimmune models has been demonstrated (Marta et al. 
2010). DA rats have been shown to have a higher expression of IL-2 and IL-17 receptors on 
naive T cells (Hedreul et al. 2009), indicative of a skewing of T cell differentiation towards the 
formation of Th1 and Th17 cells in the DA rat, which are highly pathogenic in MOG-EAE 
(Momcilović et al. 2008; Markovic et al. 2009). Furthermore, T cells are more resistant to 
apoptosis in the DA rat and macrophages are more readily activated to produce TNF in the 
DA rat compared to resistant strains (Lukic et al. 2001; Gillett et al. 2010). This increased 
efficiency of the pathogenic T and B-cell response in DA rats is the most likely reason why 
EAE is elicited at rmMOG doses that are subclinical in the Lewis rat, and why the subclinical 
dose for the DA rat is very low. 
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3.3.3.2	  No	  lymphocyte	  infiltration	  in	  subclinical	  EAE	  
Lack of clinically evident EAE indicated that there may have been little anti-myelin immune 
response occurring in the CNS. However, the presence of increased lymphocyte infiltration 
has been observed in the absence of demyelination or clinical symptoms in adoptive transfer 
models (Kawakami et al. 2004). Therefore, peripheral lymphocytes (CD3+ T cells) were 
quantified in the spinal cord parenchyma. Whilst T cells infiltrated the spinal cord in large 
numbers in clinically evident EAE, few cells were present in animals with subclinical EAE. 
T cell infiltration into the CNS has been shown to occur through the choroid plexus and 
meninges prior to the onset of EAE symptoms in murine models (Brown & Sawchenko 2007; 
Reboldi et al. 2009). The location of extravasation is hypothesised to be caused by 
expression of CCL20 by the choroid plexus and the lack of expression of appropriate 
molecules on the resting BBB (Reboldi et al. 2009). Memory T cells (specific to MOG) may 
then re-encounter the cognate antigen on APCs resident in the CSF space, become activated 
and infiltrate the spinal cord parenchyma (Kivisäkk et al. 2009; Bartholomäus et al. 2009). 
Whilst the initiation of EAE has been shown to be dependent on T cells accessing the un-
inflamed CNS via CCR6-CCL20 interactions at the choroid plexus, T cells with no CCR6 
expression are capable of adherence to activated cerebral endothelia and have been found in 
spinal cord lesions of animals with established disease (Reboldi et al. 2009). These results 
indicate that inflammation proceeds in two waves in EAE, and implicate activation or 
disruption of the BBB in the initiation of the second wave. Activated T cells have been shown 
to activate the meningeal vasculature endothelium to express adhesion molecules such as 
VCAM-1 and ICAM-1, via release of pro-inflammatory cytokines such as IFNγ, TNF and IL-17 
(Cavender et al. 1989; Myers et al. 1992; McCarron et al. 1993; Wong et al. 1999; 
Bartholomäus et al. 2009). Endothelial activation facilitates migration of T cells across the 
BBB, initiating parenchymal inflammation and leading to clinical disease (Bartholomäus et al. 
2009). The lack of CD3+ infiltrating cells in animals receiving a subclinical dose of EAE 
indicates that either the primary event (re-activation in the CSF space), or the second wave 
(extravasation across an activated BBB) has not occurred. This may be because T cells are 
not sufficiently activated (either in number or extent) to initiate the second wave of CNS 
inflammation. At this stage of the investigation, an alternative hypothesis was that the low 
dose of rmMOG was insufficient to generate an anti-MOG immune response. In order to test 
this hypothesis, ELISA analysis of blood samples was used to quantify antibody production in 
immunised rats. 
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3.3.3.3	  Peripheral	  humoral	  anti-­‐MOG	  response	  in	  subclinical	  MOG-­‐EAE	  	  
ELISA analysis of serum samples revealed that rats dosed with subclinical EAE had a similar 
peripheral humoral immune response to symptomatic rats immunised with higher doses. 
Analysis of a time-course of animals immunised with 5µg rmMOG revealed that this response 
was maximal at 3 weeks post-immunisation, similar to that observed in targeted EAE models 
in the Lewis rat (Kerschensteiner et al. 2004a; Merkler et al 2006b). A similar profile was 
obtained when analysing the IgG subtypes IgG1 and IgG2a. IgG2a is linked with Th1-type 
immune responses and has been shown to bind complement more efficiently than the Th2 
associated IgG1, and produce greater demyelination in the spinal cord in MOG-EAE in the rat 
(Piddlesdon et al. 1993). These results indicate that an injection of 5µg rmMOG in IFA 
efficiently initiates an adaptive immune response against MOG protein, an essential pre-
requisite for focal demyelinating models (Kerschensteiner et al. 2004a; Merkler et al 2006b). 
Furthermore, the similar Th1-associated antibody profile across doses may indicate that the 
subclinical dose of rmMOG does not skew the immune response to a non-pathogenic Th2 
profile, as suggested in studies with low doses of other antigens (Hosken et al. 1995; Grakoui 
et al. 1999). 
The systemic injection of anti-MOG antibodies has been shown to exacerbate EAE and 
causes widespread demyelination within the spinal cord (Linington et al. 1988; Lassmann et 
al. 1988). However, this response is dependent on pre-existing BBB dysfunction, mediated by 
the transfer of encephalitogenic activated T cells. Furthermore, in genetic “knock-in” studies, 
animals with high serum titres of anti-MOG antibodies were clinically healthy until immune 
challenge with peripheral immunisation with PLP (SJL mice) or MOG (C57Bl/6 mice), 
whereupon EAE disease course was exacerbated compared to wild-type controls 
(Litzenburger et al. 1998). No CNS disease was caused by treatments not leading to BBB 
breakdown, such as systemic pertussis toxin injection or foreign antigen (Litzenburger et al. 
1998). These studies indicate that CNS-specific antibodies are not sufficient to initiate EAE 
alone and explain the apparently paradoxical nature of a high titre of pathological anti-MOG 
antibodies in the periphery but a lack of CNS infiltration, demyelination and disease in this 
study.  
3.3.3.4	  Why	  was	  the	  immune	  response	  to	  low	  dose	  rmMOG	  subclinical?	  
Adoptive transfer of MOG-specific T cells was found to be highly pathogenic in the DA rat but 
not in the Lewis rat (Kawakami et al. 2004), while the converse was true for MBP-specific T 
cells. The difference in pathogenicity was related to the level of activation achieved following 
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re-stimulation with antigen in the target tissue, rather than the extent of infiltration, migration 
or differences in gene expression. The inter-strain differences in T cell activation were 
proposed to be caused by the MHC haplotype in this study (Kawakami et al. 2004). 
In subclinical EAE animals, T cells failed to produce MIP-1α and MCP-1 (Kawakami et al. 
2004), two macrophage attracting chemokines important in EAE (Izikson et al. 2002). 
Ablation of either chemokine attenuates EAE (Youssef et al. 1999). The infiltration and 
activation of macrophages appears to be a key determining factor in the severity of EAE in 
adoptive transfer models in Lewis rats and is determined by the activity and quantity of Th1 
cells transferred (Lassmann et al. 1988; Linington et al. 1993). Activated macrophages are a 
crucial effector cell population in EAE; depletion and inactivation of macrophages suppresses 
clinical disease, but does not reduce T cell extravasation to the CNS (Tran et al. 1998). The 
presence of activated macrophages was associated with severe clinical disease following 
immunisation with high doses of rmMOG in this study, whereas subclinical EAE was not 
associated with macrophage infiltration, or activation of resident microglia. 
T cell activation is highly variable and is determined by the context of antigen presentation by 
APCs, the strength of the signal and the surrounding environment (Itoh & Germain 1997; 
Grakoui 1999). The dose of antigen has been shown to be critically important in determining 
the fate of T cell populations; low doses of antigen favour Th2 cell differentiation, 
characterised by synthesis of IL-4, whereas increasing dose concentrations increases Th1 
differentiation (Hosken et al. 1995; Grakoui et al. 1999). Very high doses have been found to 
skew differentiation to a Th2 phenotype (Hosken et al. 1995). EAE is considered to be a Th1-
mediated disease and it is possible that subclinical EAE following low dose of antigen in this 
study is due to a skewing of T cell differentiation to a Th2 non-pathogenic response. The 
threshold between Th2 and Th1 responses occurred within 1 log scale (Grakoui et al. 1999), 
comparable to the ten-fold difference between the highest encephalitogenic dose and the 
non-encephalitogenic dose used in this study. Furthermore, the presence of mild EAE 
symptoms in 1 of 6 animals immunised with the subclinical dose, indicates that it is very close 
to the undefined threshold needed to initiate disseminated EAE. Further study may utilise flow 
cytometry to determine the phenotype of peripheral T cells in subclinical EAE and compare it 
to the phenotype observed in EAE animals. An alternative method to establish T cell 
phenotype would be to measure the level of IFNγ and IL-4 following the re-stimulation of T 
cells isolated from animals immunised with different doses of rmMOG. 
Data presented in this chapter may indicate that either the level of initial T cell activation, the 
phenotype produced following activation, or the extent of reactivation in the subarachnoid 
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space has a critical bearing on the expression of clinical disease. It is hypothesised that 
numbers of MOG-specific memory T cells reactivated within the subarachnoid space of 
animals injected with 5µg rmMOG are insufficient to cause BBB activation. This prevents a 
second wave of lymphocyte and macrophage infiltration, which is followed by an integrated 
cellular and humoral attack on myelin and the expression of EAE symptoms. Immunisation 
with higher doses of rmMOG either results in an increased number of activated T cells, or 
activation results in higher Th1 cytokine/chemokine expression and results in the upregulation 
of adhesion molecules on the BBB and leads to macrophage and lymphocyte infiltration to 
the CNS, infiltration of humoral components and EAE. 
3.3.4	  Determining	  the	  T	  cell	  responses	  in	  subclinical	  EAE	  
The set of experiments presented in this chapter utilised the expression of anti-MOG 
antibodies as a read-out of peripheral immune responses to MOG protein. The similar level of 
antibodies across doses in the periphery indicates that low doses of rmMOG are sufficient to 
raise an immune response to the protein. However, this does not explain why animals do not 
develop the severe EAE observed following immunisation with higher doses. The responses 
of T cells to low and high doses of rmMOG have not been studied, and it may be pertinent to 
investigate further. Such investigations may utilise flow cytometry or in vitro proliferation 
assays. 
This study used samples from animals taken at late time-points after disease induction, 
therefore, the dynamics of T cell infiltration in “pre-clinical” EAE and “pre-sub clinical” EAE 
cannot be compared. It is certainly clear that there is no increased spinal cord infiltration of T 
cells at later time-points compared to control. In order to elucidate the dynamics of T cell 
infiltration, it may be pertinent to quantify levels of T cells in the meningeal compartment. This 
could be achieved by taking samples at early “pre-clinical” time-points and comparing the 
number of T cells and macrophages in each compartment, across doses by IHC. In order to 
establish the activation status of T cells in the CSF and spinal cord, flow cytometry for 
common activation markers such as CD69, OX-40 and IL-2 receptor may be used at different 
time-points following immunisation (Kivisäkk et al. 2009; Bartholomäus et al. 2009). 
Furthermore, the presence of key inflammatory proteins such as IFNγ, TNF and MIP-1α and 
MCP-1 would yield supporting data to that end, and could be achieved by ELISA analysis in 
these samples. An investigation of the expression of key adhesion molecules, such as ICAM-
1 and VCAM-1, at early time-points would give an indication of the functional effects of T cell 
infiltration on BBB integrity. It is likely that adhesion molecule expression by BBB endothelia 
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would be low in animals immunised with 5µg rmMOG, but that there would be significant 
expression in animals with immunised with higher doses.  
3.3.5	  Conclusions	  
The data presented here represent the initial stages in the development of an animal model 
of the subpial (type III) cortical lesions seen in secondary progressive MS tissue (Bo et al. 
2003a; Magliozzi et al. 2007). This study successfully produced immunogenic rmMOG protein 
and identified an immunisation protocol capable of inducing subclinical EAE in the female DA 
rat. An anti-MOG immune response is elicited in the periphery, but T cells do not gain access 
to the CNS, demyelination does not occur and the animal has no clinical manifestations of 
EAE. Subsequent experiments aim to produce a targeted model of cortical demyelination. DA 
rats will be immunised with 5µg rmMOG in IFA and 19-22 days post-immunisation animals 
will receive a combined intracortical injection of IFNγ and TNF.  
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4.1	  Introduction	  
4.1.1	  The	  barriers	  of	  the	  CNS	  
4.1.1.1	  The	  blood	  brain	  barrier	  
The blood brain barrier (BBB) functions to tightly regulate the traffic of molecules and cells 
from the blood to the CNS and so to protect the brain from harmful substances present in the 
blood. The BBB also aids the regulation of tissue osmolarity and pH (Engelhardt & Sorokin 
2009). These functions are achieved in large part by the specially adapted cerebral-
endothelial cells of CNS blood vessels. Individual cells are joined by relatively impermeable 
tight junctions and have a very low rate of pinocytosis. These properties prevent the 
unrestricted flow of hydrophilic substances, but are not effective against lipid soluble 
molecules. However, cerebral endothelia also express a variety of receptors such as P-
glycoprotein that actively remove unwanted substances from the perivascular spaces. In the 
same way, nutrients are transported into the brain by specialised receptors. Ion exchange 
proteins in the endothelial membrane also aid ion homeostasis in the brain (Engelhardt & 
Sorokin 2009; Alvarez et al. 2010). 
 The BBB surrounding larger pial vessels is composed of cerebral endothelia with an 
associated basement membrane, these overly the pia mater, a layer of fibroblast-like cells 
that is relatively permeable to solutes (Figure 4.1 A). Between these two layers is the peri-
vascular space, which contains perivascular macrophages that express MHCII and CD68, 
indicating that they are important APC and phagocytic cells in the CNS (McMenamin 1999; 
McMenamin et al. 2003). Astrocyte end-feet then form the perivascular glia limitans and 
complete the barrier. As arterioles continue into the brain to form capillaries, the pia mater is 
absent, with the remaining glia limitans being separated from the capillary by a single 
basement membrane (Krisch et al. 1983; Krisch et al. 1984; Krstic 1991). 
BBB abnormalities such as redistribution of tight junction proteins and basal lamina disruption 
are commonly detected in active WMLs in EAE and MS (Leech et al. 2007; Alvarez et al. 
2010; Bennett et al. 2010). Moreover, disruption to the BBB has been found to correlate with 
disease severity and entry of lymphocytes in a variety of models (Fabis et al. 2007). 
Lymphocyte sub-sets (Th1 and cytotoxic T cells) are commonly found in large numbers in the 
parenchyma of active WMLs and in the perivascular spaces (Lucchinetti et al. 2000; Frischer 
et al. 2009; Nikodemova et al. 2010). However, lymphocytes require activation of the cerebral 
endothelia in order to cross the barrier into the parenchyma (Piccio et al. 2002). In vitro 
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studies have also replicated these findings, revealing that cerebral endothelia do not express 
key adhesion molecules such as ICAM-1, VCAM-1 and P-selectin under physiological 
conditions (Cavender et al. 1989; Myers et al. 1992; Piccio et al. 2002). These results indicate 
that the initial cause of encephalitogenesis is unlikely to be antigen-specific lymphocyte 
extravasation across the naive BBB, and imply that the initial T cell re-activation occurs 
elsewhere in the CNS. 
	  
Figure 4.1: The BBB is composed of cerebral endothelial cells, joined by tight junctions, overlying an endothelial 
basement membrane. The perivascular space contains macrophages and overlies the pia mater and glia limitans, 
which consists of an additional basal lamina and a network of astrocyte end-feet (A). The blood-CSF barrier in the 
choroid plexus is comparatively permeable, and consists of endothelial cells with fenestrations and no tight 
junctions (B). The underlying cuboidal epithelial cells are responsible for secreting CSF and are highly ciliated. The 
ventricular space underlying this layer contains CSF and abundant macrophages (diagrams adapted from 
(Engelhardt & Sorokin 2009; Wilson et al. 2010).  
4.1.1.2	  The	  blood-­‐CSF	  barrier	  in	  the	  choroid	  plexus	  
CSF is produced by the choroid plexus, a specialised group of epithelial cells found in the 
lateral ventricles. Production of the CSF depends on the free diffusion of water and solutes 
from the blood to the choroid plexus, this is achieved as the blood vessel endothelia are 
fenestrated and do not have tight junctions (Engelhardt & Sorokin 2009). Choroid plexus 
epithelia are cuboidal cells joined by tight junctions, and are ciliated on the ventricular aspect 
(Figure 4.1 B). In the ventricular space there are an abundance of MHCII expressing 
macrophages. The co-expression of the phagocytic marker CD68+, has led to the hypothesis 
that they have important functions in EAE and MS (McMenamin 1999; McMenamin et al. 
2003). 
There is evidence to suggest that the blood-choroid plexus barrier is a preferential site of 
initial lymphocyte extravasation in EAE and may be the primary route of leukocyte entry for 
immune surveillance under physiological conditions (Kivisäkk et al. 2003; Reboldi et al. 
2009). Epithelia constitutively express ICAM-1 and VCAM-1 on the apical surface, and 
expression has been found to be upregulated in EAE and MS, although trafficking under 
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physiological conditions may also be mediated by P-selectin (Engelhardt et al. 2001; Kivisäkk 
et al. 2003). Furthermore, the expression of CCL20 has been shown to be required for EAE 
initiation in adoptive transfer models; the infiltration of encephalitogenic Th17 cells was found 
to be dependent on CCL20-CCR6 interactions (Reboldi et al. 2009).  
4.1.1.3	  The	  blood-­‐sub	  arachnoid	  space	  barrier	  	  
The blood-CSF barrier also surrounds meningeal vessels in the subarachnoid space and is 
thought to form a more permeable barrier than the BBB, due to the lack of a functional glia 
limitans surrounding the blood vessels. The subarachnoid space is defined as the space 
between the pia mater that overlies the cortical grey matter and the outer arachnoid 
membrane above, and contains the CSF and numerous blood vessels (Figure 4.2 A). The pia 
mater is bound to the outer arachnoid membrane by the subarachnoid traberculae, which are 
composed of mesothelial cells and collagen deposits (Krisch et al. 1983; Krstic 1991). The pia 
mater is a thin barrier between the subarachnoid space and cortical parenchyma. It is 
composed of a thin layer of elongated fibroblast-like cells with a layer of fibrous collagen 
above (Figure 4.2 B, Krisch et al. 1983; Krstic 1991). Two thin membranes enclose the pia 
mater, the inner arachnoid membrane above and the inner pial membrane below, and is 
positioned over the glia limitans (Lopes & Mair 1974). The pia mater and inner arachnoid 
membrane are present around arachnoid vessels (Krisch et al. 1983; Krstic 1991). The glia 
limitans is composed of the basement membrane (the basal lamina) that contacts the pia 
mater, and a dense network of astrocyte end-feet 5-12 layers (10-25µm) thick (Lopes & Mair 
1974; Krstic 1991). Astrocyte end-feet form a continuous membrane and express an 
abundance of aquaporin channels, indicating that an important function in water homeostasis 
(Badaut et al. 2002).  
In contrast to the relatively “leaky” gap junctions present in cells of the pia mater, the glia 
limitans is relatively impermeable due to the presence of multi-layered astrocyte lamellae 
(Ghersi-Egea et al. 1996; Brightman 2002; Johanson et al. 2005; Weller et al. 2009). 
Macrophages are not present in between these layers but are found closely linked to the 
inner arachnoid membrane in the subarachnoid space (Lopes & Mair 1974). The pia mater 
and glia limitans form the fenestrations accompanying each blood vessel that enters the 
parenchyma from the subarachnoid space (Lopes & Mair 1974; Krstic 1991). The space 
between the pia mater and the basement membrane of the vessel is called the Virchow-
Robin space. As arterioles continue into the brain to form capillaries, the pia mater is absent, 
with the remaining glia limitans being separated from the capillary by a single basement 
membrane (Krisch et al. 1984; Krstic 1991).  
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Figure 4.2: The structure of the subarachnoid space. Traberculae connect the pia mater to the overlying inner-
arachnoid membrane (A). Meningeal blood vessels run through the subarachnoid space and into the cortex 
(adapted from McMenamin et al. 2003). The pia mater is composed of the inner arachnoid membrane and inner 
pial membrane containing fibroblasts and collagen (B). The pia mater covers the glia limitans, which is composed 
of the basal lamina and a network of polarised cortical astrocyte end-feet (adapted from Lopes & Mair 1974; Krstic 
1991). 
4.1.1.4	  Subarachnoid	  space	  involvement	  in	  EAE	  and	  MS	  
Large numbers of activated memory Th cells have been observed in the subarachnoid space 
of post-mortem cases with no suspected neuro-inflammatory disease (Kivisäkk et al. 2003). 
The expression of P-selectin and ICAM-1 observed on meningeal vessels and the choroid 
plexus implicated these molecules as key entry points for immune surveillance. This data, 
together with the finding of large numbers of MHCII expressing cells in this region, implicates 
the subarachnoid space as the site of CNS immune surveillance (McMenamin 1999; 
McMenamin et al. 2003).  
Lymphocyte extravasation into the meningeal subarachnoid space has been shown to 
precede parenchymal infiltration in EAE models (Shin et al. 1995; Brown & Sawchenko 
2007). Furthermore, the activation of anti-myelin memory T cells following interaction with 
MHCII+ APCs in this compartment is considered a key event in the initiation of EAE and 
precedes clinical symptoms (Kivisäkk et al. 2009). Lymphocytes extravasating from 
meningeal vessels have been observed crawling along the outer vessel walls (Bartholomäus 
et al. 2009). This local activation of lymphocytes induces cytokine expression, inducing 
adhesion molecule expression and facilitating further extravasation (Bartholomäus et al. 
2009). Lymphocyte extravasation through activated meningeal vessels into the subarachnoid 
space is thus thought to be a key event in EAE initiation, as part of the “second wave” of 
infiltration following initial activation of the vessels by T cells activated in the subarachnoid 
space (Ransohoff & Parsons 2009; Bartholomäus et al. 2009). 
The involvement of the subarachnoid space has long been established in MS, due to the 
presence of oligoclonal immunoglobulin bands in the CSF. For example, a recent study 
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showed that oligoclonal bands were present only in the CSF (and not serum) of 89% of 
patients (Franciotta et al. 2008). Indeed, oligoclonal bands are so frequently observed in CSF 
that they are commonly used to support diagnosis. In addition, the extent of cortical microglial 
activation has been highly correlated with the extent of meningeal infiltration by lymphocytes 
(Dal-Bianco et al. 2008). Recent studies of MS have found extensive cortical meningeal 
infiltrates with organised lymphoid follicle-like structures in a significant sub-population of SP-
MS cases (Serafini et al. 2004; Magliozzi et al. 2007; Magliozzi et al. 2010). These infiltrates 
were composed of large numbers of CD8+ cytotoxic T cells, follicular dendritic cells (FDCs), 
immunoglobulin secreting plasma cells, proliferating B cells and CD4+ Th cells (Serafini et al. 
2004; Magliozzi et al. 2007). A recent study in this lab has shown large increases in gene 
expression of the key pro-inflammatory cytokines IFNγ (by CD8 cells) and TNF (by 
macrophages, Magliozzi et al. Unpublished data). The integrity of the glia limitans, as 
assessed by GFAP staining, was found to be compromised in these cases with leakage of 
fibrinogen into the underlying cortex (Magliozzi et al. 2010; unpublished data). These 
infiltrates were associated with a substantially worse clinical outcome compared to patients 
with no detectable follicles (Magliozzi et al. 2007; Magliozzi et al. 2010). The age at onset 
(mean age 23.5 vs. 34 years), age when first using a wheelchair (approximately EDSS 7; 33 
vs. 47) and age at death (42 vs. 55) were all significantly earlier in patients with follicles 
(Magliozzi et al. 2007). These cases were also associated with more extensive cortical 
pathology. 
4.1.2	  Cortical	  pathology	  in	  MS	  
Grey matter demyelination has been associated with the general cognitive and motor decline 
occurring during the progressive stage of MS (Kutzelnigg & Lassmann 2006; Wegner et al. 
2006). Grey matter lesions have been classified into three types, based on location in the 
cortex (Peterson et al. 2001; Bö et al. 2003a). Type I lesions (leukocortical) traverse the GM-
WM border. Type II lesions (intracortical) are small and are typically found around small 
vessels. Type III lesions (subpial) extend from the pial surface and into the cortex itself. This 
latter type can be extensive and in some instances have been found to extend through all 
cortical levels and over multiple gyri (these are sometimes referred to as Type IV lesions). 
Type III subpial GMLs are present in the highest proportion (50-65%), followed by Type I 
lesions (15-30%, (Peterson et al. 2001; Bö et al. 2003a; Magliozzi et al. 2007) and cannot be 
detected by existing MRI protocols. 
The extent of cerebral GM and WM demyelination are only weakly correlated. A recent study 
indicated an average of 25% of the cerebral cortex GM was demyelinated, whereas only 5% 
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of subcortical WM was demyelinated (Bö et al. 2007), indicating that GM demyelination may 
occur at least partly independent of WM demyelination in the brain (Kutzelnigg et al. 2005; 
Vercellino et al. 2005). The extent of cortical demyelination in the cerebellum and brain has 
been significantly correlated, which may suggest a common pathogenesis related to factors 
present in the CSF (Bö et al. 2007; Kutzelnigg et al. 2007; Gilmore et al. 2009).  
Activated microglia have been observed diffusely throughout type III subpial GML and normal 
appearing grey matter (NAGM, (Peterson et al. 2001; Bö et al. 2003a; Magliozzi et al. 2010). 
Microglial expression of CD68 and iNOS was significantly correlated with the presence of 
lymphocytes in the meninges of MS cases (Dal-Bianco et al. 2008). Furthermore, expression 
of these molecules was also found to be elevated in the NAGM. The pattern of microglial 
activation and demyelination in the GM of SP-MS cases and its association with meningeal 
inflammation and lymphoid tissue formation, strongly supports the hypothesis that cytotoxic 
factors diffusing from the meningeal compartment contribute to grey matter pathology and 
lead to an increase in clinical disability (Magliozzi et al. 2010). However, the identity of the 
key cytotoxic factors is currently unknown and further research is hampered by the lack of an 
animal model of meningeal inflammation driven subpial demyelination with which to test these 
hypotheses. 
4.1.2.1	  A	  targeted	  model	  of	  cortical	  demyelination	  	  
Cortical pathology is rare in disseminated EAE models. However, targeted EAE models have 
recently been produced in the relatively EAE resistant Lewis rat. In these models, the immune 
system was “primed” by immunisation with a subclinical dose of rmMOG and focal 
inflammatory demyelination was subsequently elicited via an injection of pro-inflammatory 
cytokines (Kerschensteiner et al. 2004a; Merkler et al 2006b; Sasaki et al. 2010).  
The same principles of targeting CNS inflammation have recently been used to produce a 
model of cortical demyelination. Lewis rats were immunised with 50µg rrMOG in IFA and 
250ng TNFα/150U IFNγ subsequently injected into the motor cortex (Merkler et al. 2006b), 
The injection of cytokines elicited extensive demyelination, with subpial, leukocortical and 
intracortical lesions being produced. The contralateral cortex exhibited no demyelination. 
Control animals immunised with MOG and injected with PBS had some demyelination close 
to the needle track, whereas animals immunised with IFA and injected with cytokines had no 
demyelination. These results indicate that an immune response against a myelin protein is 
required to initiate cortical demyelination following injection of cytokines in this model. 
Demyelination was maximal 3 days post-injection and thereafter was reduced, until full 
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remyelination had occurred at 14 days post-injection. The extent of cortical demyelination 
was highly correlated with the presence of CD68+ activated microglia/macrophages. 
While this model has promise and successfully generates all subtypes of GML, the lesions 
produced had typically resolved by 14 days, with full remyelination and no lasting reduction in 
axonal density (Peterson et al. 2001; Bö et al. 2003a; Magliozzi et al. 2010). The validity of 
the model must also be called into question, as it involves a direct injection into the cortical 
parenchyma, with associated tissue destruction and extensive BBB breach, a situation clearly 
at odds with the aetiology of GML in MS. 
4.1.3	  Aims	  of	  this	  study	  
This study aimed to produce a focal cortical demyelinating model in the DA rat that reflects 
the involvement of meningeal inflammation seen in SPMS. The model was based on the 
targeted EAE model first described by Kerschensteiner et al. (2004a), and involved 
immunisation with a subclinical dose of rmMOG (determined in Chapter 3), followed by an 
injection of the pro-inflammatory cytokines TNF and IFNγ directly into the motor cortex or into 
the subarachnoid space at the sagittal sulcus. The study aimed to: 
• Reproduce cortical demyelination following motor cortex injection of 
cytokines in rmMOG-immunised animals 
• Assess neuropathology 
• Induce cortical demyelination following injection of cytokine to the 
subarachnoid space 
• Assess neuropathology 
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4.2	  Results	  
4.2.1	  Subpial	  demyelination	  following	  motor	  cortex	  injections	  
4.2.1.1	  Injection	  of	  low	  doses	  of	  TNF/IFNγ	  
Female DA rats, immunised with 5µg, rmMOG received a stereotactic injection of 250ng 
rrTNF/15ng rrIFNγ into the motor cortex (see Chapter 2). Control animals were either 
immunised with IFA and injected with cytokines, or immunised with rmMOG and injected with 
PBS (n=3 per group). Animals were sacrificed 3 or 7 days post-cytokine injection (Figure 4.3 
A).  
Subpial demyelination reminiscent of type III GMLs was observed in all animals injected into 
the motor cortex, regardless of the experimental protocol (Figure 4.3 C, D). Demyelination 
was limited to layers I–II of the cortex neighbouring the injection site, and the area 
surrounding the injection site. No areas of demyelination reminiscent of type I (leukocortical) 
or type II (intracortical) lesions were observed in any animal. 
Animals immunised with rmMOG followed by cytokine injection had significantly more 
demyelination than animals immunised with IFA and injected with cytokines, at both 3 and 7 
days post-injection (Table 4.1, Figure 4.3 B). However, animals immunised with rmMOG and 
injected with PBS had a similar area of demyelination to those injected with cytokines. There 
was a trend for greater demyelination in these animals than those injected with cytokines, 
although this was not significant. For each experimental condition the extent of demyelination 
was very similar at both time-points studied. All animals had extensive tissue damage 
surrounding the injection site (Figure 4.3 C, D).  
Table 4.1 The extent of demyelination in the cortex following intracortical injection of cytokines. One way ANOVA 
with Tukey post-test * P<0.05, ** P<0.03. 
 Demyelination (days post-injection) 
Experimental group 3 days (± mm2) 7 days (± mm2) 
rmMOG/Cytokines 0.47 (0.13) 0.50 (0.04) 
IFA/Cytokines 0.26 (0.04)* 0.09 (0.01)** 
rmMOG/PBS 0.67 (0.02) 0.74 (0.07) 
IF for Iba1 revealed extensive infiltration of amoeboid macrophages into the cortex in each 
experimental condition (Figure 4.3 C, D). Macrophage infiltration was confined to the area of 
the cortex closest to the injection site. An increased presence of microglia with an activated 
morphology (i.e. shortened processes and an enlarged cell body), was detected throughout 
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the ipsilateral cortex. Little meningeal infiltration by macrophages was observed and microglia 
in the contralateral cortex had a ramified morphology.  
IHC for CD3+ T cells revealed lymphocyte infiltration into the cortical parenchyma in all 
animals. Significantly higher numbers of CD3+ cells infiltrated the cortex of animals immunised 
with rmMOG and injected with cytokines compared to controls (Table 4.2, Figure 4.3 E). The 
number of CD3+ cells was consistent across time-points within each group. T cells typically 
infiltrated cortical areas close to the injection site and were not found in the contralateral 
cortex (Figure 4.3 F, G). 
Table 4.2 The extent of T cell infiltration in the cortex following intracortical injection of cytokines. One way 
ANOVA with Tukey post-test ** P<0.03, *** P<0.01. 
 CD3 cell density (days post-injection) 
Experimental group 3 days (± cells/mm2) 7 days (± cells/mm2) 
rmMOG/Cytokines 3.60 (0.15) 4.31 (0.18) 
IFA/Cytokines 1.25 (0.10)** 0.77 (0.34)*** 
rmMOG/PBS 1.07 (0.49)** 2.02 (0.35)** 
 
4.2.1.2	  Injection	  of	  higher	  doses	  of	  cytokines	  
The demyelination observed in this model was less than that observed in a previous model of 
cortical demyelination in the Lewis rat, which used the same concentration of cytokines 
(Merkler et al 2006b). Therefore, in a subsequent experiment a higher dose of cytokines was 
used; 500ng rrTNF/30ng rrIFNγ or 1.25µg rrTNF/75ng rrIFNγ. Control animals were used as 
for previous experiments. Animals were sacrificed 7 days post-injection (Figure 4.4 A).  
Double-labelling IF revealed extensive demyelination of the layers I–IV of the ipsilateral 
cortex surrounding the injection site (Figure 4.4 C, D, E). As in the previous experiment, 
demyelination was present in subpial areas reminiscent of type III GML. Animals immunised 
with rmMOG and injected with either dose of cytokines had significantly more demyelination 
than either control group (Table 4.3, Figure 4.4 B). The extent of demyelination was not 
different between doses, but was greater than that observed in the previous experiment with 
lower doses of cytokines (Section 4.2.1.1). In particular, demyelination extended laterally from 
the injection site to a greater degree (Figure 4.4). No intracortical or leukocortical lesions 
were observed and no demyelination was observed in the contralateral cortex. Demyelination 
was observed in control animals to a similar extent as in the previous experiment.  
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Table 4.3 The extent of demyelination in the cortex following intracortical injection of high doses of cytokines. One 
way ANOVA with Tukey post-test * P<0.05. 
Experimental group Demyelination (± mm2) 
rmMOG + 500ng TNF/ 35ng IFNγ 1.59 (0.47) 
rmMOG + 1.25µg TNF/70ng IFNγ 1.41 (0.25) 
IFA + 1.25µg TNF/70ng IFNγ 0.45 (0.17)* 
rmMOG + PBS 0.28 (0.03)* 
The path of the needle was clearly visible with extensive tissue damage observed in each 
animal (Figure 4.4 C, D, E). All animals had an increased number of Iba1+ microglia/ 
macrophages surrounding the injection site, many of them having an amoeboid, macrophage-
like morphology (Figure 4.4 C, D, E). There were also a high number of macrophages in 
perivascular regions, having appeared to infiltrate the cortex through cerebral blood vessels 
close to the injection site (Figure 4.4 C, D, E). There was a visibly greater degree of 
macrophage infiltration in the meninges in animals injected with cytokine compared to 
animals injected with PBS, though numbers were not quantified.  
Microglia were distributed diffusely throughout the ipsilateral cortex and in the neighbouring 
corpus callosum, many of which had an activated morphology (Figure 4.4 C, D, E). Activated 
microglia were particularly prominent in animals injected with cytokines, regardless of a pre-
existing anti-MOG response. As in the previous experiment, no microglial activation was 
observed in the contralateral cortex. 
No demyelination or inflammatory activity was observed in the contralateral hemisphere of 
any animal. The extent of demyelination in animals immunised with rmMOG and injected with 
cytokines was consistent up to 400µm from the injection site in each direction along the 
rostral/caudal axis (Figure 4.5 A, B, C, D). The extent of demyelination was not significantly 
different across any cytokine dose, at any distance from the injection site. 
In order to test BBB integrity, IF for the serum protein fibrinogen was carried out. This 
revealed profound and diffuse leakage of fibrinogen into the cortex in every animal receiving 
a motor cortex injection (Figure 4.6 A, B). This leakage occurred in areas neighbouring the 
injection site and along the pial surface close to the injection site. There was also a greater 
degree of fibrinogen staining in the meninges of the ipsilateral cortex. In contrast, little 
infiltration of fibrinogen was evident in the contralateral cortex, but may be decorating blood 
vessels (Figure 4.6 C, D). 
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4.2.2	  Subpial	  demyelination	  following	  subarachnoid	  space	  injection	  of	  
cytokines	  in	  rmMOG-­‐immunised	  animals 
4.2.2.1	  Injection	  of	  low	  doses	  of	  cytokines	  
Female DA rats were immunised with 5µg rmMOG and subsequently received a stereotactic 
injection of 250ng rrTNF/15ng rrIFNγ into the subarachnoid space at the sagittal sulcus 
(Chapter 2). Control animals were either immunised with IFA and injected with cytokines, or 
immunised with rmMOG and injected with PBS (n=3 per group).   
Addition of Indian ink to the cytokine solution was used to verify the subarachnoid location of 
the injection in each animal (Figure 4.7 A, B). Following injection, ink was confined to the 
meninges of the sagittal sulcus. If the injection was unsuccessful, entering the cortex, a large 
bolus of ink could be observed, with substantial tissue damage associated with it. Following 
subarachnoid injection, ink could be seen throughout the sagittal sulcus and was found in 
areas far rostral and caudal to the injection site. Ink was occasionally found on the dorsal 
surface of the cortex. IHC with OX-42 revealed that ink was phagocytosed by meningeal 
macrophages (Figure 4.7 C, D). 
The presence of demyelination was assessed by IF for MOG protein. A small area of possible 
subpial demyelination was observed in one of three animals immunised with rmMOG and 
injected with cytokines and sacrificed 7 days post-injection (Figure 4.8 B, C). Demyelination 
was confined to cortical layer I, in the dorsal aspect of the sulcus of one hemisphere and was 
accompanied by an increased presence of activated microglia/macrophages, in the 
parenchyma close to the pial surface and meninges. The distribution of ramified microglia 
was normal in areas away from the site of demyelination. Control animals had no 
demyelination at any time-point and a normal distribution of ramified “resting” microglia in the 
cortex (Figure 4.8 B, D). 
To further assess the effects of cytokine injection on inflammation, the number of CD3+ T 
cells was quantified. The number of T cells in the cortical parenchyma was highest at 3 days 
post-cytokine injection in rmMOG-immunised rats, and was significantly greater than at 7 
days (Table 4.4, Figure 4.8 E). Lymphocytes were scattered throughout the grey matter and 
often found in the perivascular (Virchow-Robin) space (Figure 4.8 F). Large numbers of cells 
were also observed in the corpus callosum, both in the white matter parenchyma and in 
perivascular spaces of callosal blood vessels (Figure 4.8 F, G). In addition cells were 
observed in the meninges of animals injected with cytokines. 
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Table 4.4 The extent of T cell infiltration in the cortex following subarachnoid space injection of cytokines. One 
way ANOVA with Tukey post-test ** P<0.03, *** P<0.01. 
 CD3 cell density (days post-injection) 
Experimental group 3 days (± cells/mm2) 7 days (±cells/mm2) 
rmMOG/Cytokines 3.22 (0.39) 1.43 (0.10) 
IFA/Cytokines 0.37 (0.07)** 0.25 (0.05)*** 
rmMOG/PBS 1.15 (0.13)** 0.53 (0.02)*** 
 
4.2.2.2	  Injection	  of	  higher	  doses	  of	  cytokines	  
Previous experiments established that the dose of cytokines that caused demyelination when 
injected directly into the motor cortex (Merkler et al 2006b), was insufficient to cause 
demyelination when injected into the sagittal sulcus. The increased numbers of lymphocytes 
in the cortex of animals immunised rmMOG and injected with cytokines indicated that 
injections into the sagittal sulcus could initiate cortical inflammation. Therefore, in a 
subsequent experiment female DA rats were immunised with rmMOG and injected into the 
subarachnoid space with higher doses of cytokines; 500ng rrTNF/30ng rrIFNγ or 1.25µg 
rrTNF/75ng rrIFNγ. Control animals were immunised with IFA and received an injection of 
1.25µg rrTNF/75ng rrIFNγ, or were immunised with rmMOG and injected with PBS as before. 
Animals were sacrificed 7 days post-injection. 
IF for myelin protein revealed extensive demyelination in cortical layers I–III of the post-
genual medial anterior cingulate cortex (ACg), in animals immunised with rmMOG and 
subsequently injected with cytokines (Table 4.5, Figure 4.9 A, C). No demyelination was 
observed in either control group of animals (Table 4.5, Figure 4.9 A, D, E). Demyelination 
occurred in both hemispheres in all animals and extended from the GM adjacent to the 
sagittal sulcus overlying the corpus callosum and over the dorsal surface of the cortex 
spreading in the lateral plane from the injection site. There was no statistically significant 
difference in the extent of demyelination between doses of cytokine (Table, 4.5, Figure 4.9 A).  
Table 4.5 The extent of demyelination in the cortex following subarachnoid space injection of high doses of 
cytokines. One way ANOVA with Tukey post-test *** P<0.01. 
Experimental group Demyelination (± mm2) 
rmMOG + 500ng TNF/ 35ng IFNγ 2.85 (0.73) 
rmMOG + 1.25µg TNF/70ng IFNγ 2.28 (0.19) 
IFA + 1.25µg TNF/70ng IFNγ 0.05 (0.03)*** 
rmMOG + PBS 0.01 (0.01)*** 
In a separate experiment DA rats were immunised with 5µg rmMOG, 20-23 days post-
immunisation they received a stereotactic injection of 1.25µg rrTNF or 75ng rrIFNγ into the 
Chapter 4: Focal lesion induction – Results 130 
 
subarachnoid space of the sagittal sulcus. Injection of either cytokine alone failed to elicit the 
same degree of demyelination as the injection of both cytokines (Figure 4.9 B). Furthermore, 
the demyelination observed after combined cytokine injection was more extensive than the 
effect of single cytokine injections even if results from TNF and IFNγ were added together. 
Demyelination typically extended from the GM/WM border over the corpus callosum to the 
dorsal surface of the cortex, from the pial surface into layer III (Figure 4.9 C). This pattern of 
demyelination was reminiscent of type III GML in MS cortex. 
IF for Iba1 was used to assess microglia/macrophage activity and revealed that most cells in 
the cortex of animals with demyelination had an activated microglia phenotype, with enlarged, 
amoeboid cell bodies and short, thick processes (Figure 4.9 C). There were more cells in 
animals immunised with rmMOG and injected with cytokines than in control animals. Control 
animals immunised with rmMOG and injected with cytokines had a greater presence of 
activated microglia than in the cortex of animals injected with PBS, but no demyelination was 
present (Figure 4.9 D). Indeed, animals immunised with rmMOG and injected with PBS had 
no demyelination and no microglia activation in the cortex (Figure 4.9 E). 
Large numbers of Iba1+ macrophages were present in the meningeal compartment in animals 
injected with cytokines, regardless of the immunisation protocol (Figure 4.9 C, D). However, 
macrophage infiltration into the meninges was particularly prominent over areas of subpial 
demyelination and in the sagittal sulcus (Figure 4.10 A, E, F). Extensive microglial activation 
occurred throughout the cortex but was particularly evident close to the pial surface and at 
the “leading” edge zone of active demyelination (Figure 4.10 A, D).  
A type II-like intracortical lesion was observed in one animal in the deep grey matter close to 
a subpial lesion (Figure 4.10 B). Possible WMLs in the corpus callosum were found in 2 
animals and were small and centred on blood vessels in the WM (Figure 4.10 C). These 
lesions were associated with profound microglia inflammation. Furthermore, extensive 
microglial activation throughout the cortex was detected, in GMLs and NAGM and in the WM 
of the corpus callosum (Figure 4.11 B). This was not confined to the area of demyelination 
(Figure 4.11 A, C). 
Double IF for heavy chain neurofilament (NFH) and myelin basic protein (MBP) revealed that 
naked axons were present in demyelinated areas (Figure 4.12 A, B, C, D). Furthermore, the 
extent and pattern of demyelination observed with MBP IF was similar to that observed with 
anti-MOG antibodies. The integrity of the BBB was assessed by IF for the serum protein 
fibrinogen. No fibrinogen leakage was observed in animals receiving an injection into the 
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sagittal sulcus even when demyelination was present (Figure 12 E, F). Fibrinogen was 
detected in the meninges and cerebral blood vessels of all animals. 
A similar degree of demyelination was present for up to 400µm from the injection site along 
the rostral/caudal axis (Figure 4.13 A, B, C, D). In a subsequent experiment demyelination 
was induced as above and brains were sectioned in the sagittal plane, revealing the maximal 
extent of demyelination to be 1.1mm in layer I close to the sagittal sulcus (Figure 4.14 A, C). 
In addition, a high degree of macrophage infiltration into the subarachnoid space was 
observed (Figure 4.14 A). This increased macrophage infiltration was evident close to the 
area of demyelination, but occurred all around the brain including in ventral areas and over 
the cerebellum. This infiltration was not observed in control animals (Figure 4.14 B, D). 
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4.3	  Discussion	  
4.3.1	  Cortical	  demyelination	  induced	  by	  injection	  of	  TNF	  and	  IFNγ	  into	  
the	  motor	  cortex	  
4.3.1.1	  Extensive	  tissue	  damage	  caused	  by	  intracortical	  injection	  
This study successfully produced cortical demyelination in the motor cortex following 
intracortical injection of TNF and IFNγ in rmMOG-immunised DA rats, in keeping with 
previous published research demonstrating targeted GMLs in Lewis rats (Merkler et al. 
2006b). The demyelination observed in our study was reminiscent of type III subpial lesions in 
SP-MS (Peterson et al. 2001; Bö et al. 2003a), but in contrast to the previous model, no 
intracortical lesions were observed (Merkler et al. 2006b), which may indicate that different 
pathological mechanisms were in action. 
In contrast to this previous study (Merkler et al. 2006b), demyelination was observed in 
control animals immunised with IFA and injected with TNF/IFNγ, and in rats immunised with 
rmMOG and injected with PBS. Moreover, intracortical injection caused substantial localised 
tissue damage in the motor cortex and BBB breakdown in all experimental groups. Therefore, 
it is highly likely that the tissue damage and BBB breach caused by intracortical injection 
contributed to the demyelination observed. This suggests that the pathology was non-
specific, unrelated to injection of TNF and IFNγ or to a pre-existing immune response to 
rmMOG and is a direct result of tissue damage caused by the injection. Indeed, it has been 
previously shown that cortical stab wounds caused by a variety of implements, including 26 
gauge Hamilton needles, cause extensive tissue damage, microglial activation, macrophage 
infiltration, BBB breakdown and astrogliosis (Giulian et al. 1995; Xie et al. 1995; Fujita et al. 
1998). Furthermore, cortical injury has been shown to exacerbate EAE and lead to local BBB 
breakdown, lymphocyte infiltration and reactive gliosis (Phillips et al. 1995; Sun et al. 2000). It 
should be noted that no study has examined the effects of cortical stab injury using finely 
calibrated glass needles. For reasons of feasibility, PBS injections into IFA immunised or 
naïve animals were not studied here, although it is hypothesised that such pathological 
features would be replicated under these conditions. 
The substantial tissue damage reported here was not observed in the previous study and the 
reasons for this are unclear (Merkler et al. 2006b). The cytokines used in this study were 
obtained from the same suppliers. Therefore, it is likely that differences in experimental 
conditions or strain differences may have been responsible for the discrepancy in tissue 
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damage between studies. Injections in both studies were performed using finely calibrated 
glass capillaries, the volume of injection was equal to previously published data (1µl), and the 
rate of injection was similar (Merkler et al. 2006b). It is possible that data was not obtained 
from sections taken directly at the injection site in the previously published work, which may 
have led to the observed disparity. Alternatively, the difference may be related to strain 
differences in the immunological response to the presence of pro-inflammatory cytokines 
(Kjellén et al. 1998), the DA rat being more susceptible to EAE compared to the resistant 
Lewis rat (Storch et al. 1998a; Weissert et al. 1998). Furthermore, studies involving cortical 
impact injury to naive rats have established that damage is more extensive in DA rats 
compared to PVN rats and that there is a concurrent exacerbation of microglia activation and 
lymphocyte infiltration (Bellander et al. 2010). Although no direct comparisons between Lewis 
rats and DA rats in cortical injury models have been published, it is likely that strain 
differences play a major role in determining the nature of the inflammatory response to 
intracortical injection. 
4.3.1.2	  Mechanisms	  of	  cortical	  pathology	  
Stereotactic injection into the motor cortex was associated with an increase in numbers of 
microglia/macrophages throughout the ipsilateral cortical parenchyma, with many displaying 
an activated, amoeboid morphology. This extensive microglial/macrophage response to 
cytokine injection has been observed with cortical lesion models (Merkler et al. 2006b). This 
response occurred in each experimental condition, indicating that the injection itself was 
capable of activating microglia and causing tissue damage and macrophage infiltration. 
Extensive tissue damage, microglial activation and macrophage infiltration has been 
observed in cortical stab wounds to naive rats (Giulian et al. 1995; Xie et al. 1995; Fujita et al. 
1998). Macrophage infiltration was likely to be caused by BBB breakdown, which was 
revealed to be extensive by IHC for the serum protein fibrinogen. Leakage of serum proteins 
such as, albumin and fibrinogen has been shown to cause microglial activation via the Mac-1 
receptor (Adams et al. 2007; Hooper et al. 2009). Elucidating the precise role of 
microglia/macrophages in mediating cortical demyelination will require further study in order 
to accurately establish the phenotype. 
The relative lack of demyelination in IFA immunised, low dose cytokine-injected animals and 
presence of demyelination in animals with a humoral anti-MOG response and injected PBS, 
indicates that demyelination is cytokine independent and occurs via humoral-mediated 
mechanisms such as the action of anti-myelin antibodies secreted by plasma cells. It has 
been previously shown that anti-myelin antibodies require a permeable BBB in order to 
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initiate demyelination (Litzenburger et al. 1998), which is provided mechanically in this model, 
as illustrated by the significant fibrinogen leakage into the cortex of all animals. Furthermore, 
complement deposits have been detected in GMLs in a similar focal model of cortical 
demyelination, although the presence of antibody deposits was not reported (Merkler et al. 
2006b). Although some demyelination was noted following PBS injection in animals with a 
humoral anti-MOG response in a previous study, this was not quantified but was noted to be 
observably less than demyelination augmented by cytokine injection (Merkler et al. 2006b).  
When injecting animals with greater doses of cytokines (2 or 5 fold higher doses), 
demyelination is increased in IFA immunised cytokine treated animals, indicating a direct 
inflammatory, demyelinating effect of TNF and IFNγ which has been seen in vitro (Selmaj & 
Raine 1988; Selmaj et al. 1991b; Vartanian et al. 1995; Jurewicz et al. 2003; Mizuno et al. 
2008). Furthermore, the greatly exacerbated demyelination in cytokine as opposed to PBS 
injected animals with a pre-existing humoral anti-MOG response indicates that, at higher 
doses, cytokines play a significant role in demyelination. Taken together, this data indicates 
that the pathology observed in these studies is caused both by the cytokines injected and 
humoral mechanisms.  
4.3.1.3	  Strain	  differences	  in	  cortical	  pathology	  
Given the increased susceptibility of DA rats to autoimmunity (Storch et al. 1998a; Weissert 
et al. 1998), it may have been expected that an identical dose of cytokines would cause an 
equal or greater demyelination and cerebral inflammation than was observed in Lewis rats 
(Merkler et al. 2006b). However, this was not the case, demyelination was less extensive 
than previously published, being localised to the area surrounding the injection site and with 
no intracortical lesions observed. Furthermore, T cell infiltration was 6-8 fold higher in Lewis 
rats compared to DA rats in this study (Merkler et al. 2006b). 
It is possible that genetics play a role in susceptibility to cortical demyelination. A study of 
disseminated MOG-EAE in the Lewis rat revealed substantial cortical involvement with 
extensive GMLs, despite a relatively mild disease course (Storch et al. 2006). This cortical 
involvement was found to be MHC haplotype dependent, with intracortical lesions present in 
Lewis rats with the common RT11 haplotype (Storch et al. 2006). This pathology was in 
contrast to the highly EAE susceptible DA rat, with the RT1AV1 MHC haplotype, which had no 
cortical involvement despite a relatively severe disease course (Storch et al. 2006). Taken 
together, these results may indicate an increased susceptibility to cortical inflammation and 
demyelination in Lewis rats compared to DA rats. Furthermore, the data implies that the 
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mechanisms of inflammatory demyelination in the WM and GM are uncoupled i.e. significant 
cortical GM demyelination can occur in the absence of extensive spinal cord demyelination 
(Storch et al. 2006). In order to fully answer this hypothesis of differential susceptibility to 
cortical demyelination in focal models, a study directly comparing DA rats to Lewis rats under 
identical housing and experimental conditions will be required, as unidentified experimental 
factors could play a role in the contrasting results of these two studies. 
4.3.1.4	  Intracortical	  cytokine	  injection	  as	  a	  model	  of	  MS	  pathology	  
The data presented in this chapter indicates why this model is not a valid model for MS 
cortical pathology. The significant tissue damage and blood vessel disruption elicited by 
intracortical injection is not reminiscent of MS cortical pathology in which the BBB is intact 
(van Horssen et al. 2007). Furthermore, the injection causes significant oedema and 
fibrinogen infiltration, which has not been detected not in MS cortex (van Horssen et al. 
2007). Complement deposition has not been observed in MS GML, but is a feature of this 
model as a consequence of BBB breakdown (Brink et al. 2005; Merkler et al. 2006b). Focal 
cortical demyelination has also been associated with significant lymphocyte and macrophage 
infiltration, which is not reminiscent of MS GML pathology (Peterson et al. 2001; Bö et al. 
2003a; Frischer et al. 2009). Furthermore, the significant meningeal inflammation that occurs 
in the brain of MS cases is not accurately modelled using this approach (Merkler et al. 2006b; 
Magliozzi et al. 2007; Frischer et al. 2009; Magliozzi et al. 2010). Due to the failings of this 
experimental approach, it will not be studied further in this thesis. This chapter provides 
additional evidence of the need for a novel model of demyelination that more accurately 
replicates the pathology observed in MS GML.  
4.3.2	  Stereotactic	  injections	  into	  the	  subarachnoid	  space	  
In studies involving direct tissue injection, tracers are often added to the bolus in order to 
verify the injection location in tissue processing. Indian ink is a commonly used tracer 
composed of carbon particles and has been shown to persist at the sight of injection over 
many weeks (Zhang et al. 1992; Kida et al. 1993). Addition of injection ink to the bolus 
revealed the accuracy of the subarachnoid space injection in this study. Ink particles were 
phagocytosed by macrophages infiltrating the meninges, a phenomenon observed in similar 
studies (Zhang et al. 1992; Kida et al. 1993). Indeed, ink particles have been observed in 
meningeal macrophages up to 2 years post-injection, indicating stability over time and space 
(Zhang et al. 1992). 
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In this study, ink was only detected in the sagittal sulcus, extending in the rostral/caudal axis 
and did not spread laterally over the cortex or into the cortex. This is in contrast to the 
drainage pathways that exist from the subarachnoid space over the lateral cortex, which carry 
Indian ink laterally to the ventral surface of the brain and indicates that the drainage pathways 
from the subarachnoid space over the cortex may be location dependent (Zhang et al. 1992). 
The classical drainage pathway for CSF in the subarachnoid space is via the arachnoid villi 
and into the sagittal sinus. However, in the rat, it is estimated that up to 50% of the CSF 
drains to the ventral surface of the brain, then in the anterior direction towards the cribriform 
plate, nasal mucosa and to the cervical lymph nodes (Zhang et al. 1992; Kida et al. 1993; 
Weller et al. 2009; Boulton et al. 1999). Based on the drainage of tracers, the rate of CSF 
flow has been calculated as approximately 2µl/min in rats, with a relatively rapid turnover of 
approximately 2 hours (Mann et al. 1979; Whittico & Giacomini 1988). However, the rate of 
flow over the cortex has not been calculated, but studies showing lack of tracer deposition in 
this region following cisterna magna injection indicate that the rate may be low (Ghersi-Egea 
et al. 1996; Nagaraja et al. 2005). 
4.3.3	  Subpial	  demyelination	  induced	  by	  injection	  of	  TNF	  and	  IFNγ	  into	  
the	  subarachnoid	  space	  
4.3.3.1	  Cortical	  pathology	  and	  meningeal	  inflammation	  in	  MS	  
Meningeal inflammation has been found to be extensive in a sub-set of SP-MS patients and 
is associated with the presence of organised, ectopic lymphoid follicle-like structures in the 
subarachnoid space (Serafini et al. 2004). The presence of these structures has been 
associated with exacerbated disease course as well as extensive subpial demyelination and 
a gradient of microglial activation and cell loss (Magliozzi et al. 2007; Magliozzi et al. 2010). 
In addition, the extent of lymphocyte infiltration in the meninges has been correlated with the 
extent of cortical microglia activation in MS cases (Dal-Bianco et al. 2008). Taken together, 
this data has led to the hypothesis that factors diffusing from the subarachnoid space to the 
cortex are responsible for subpial demyelination in MS, though the identity of these factors is 
unknown. Prime candidates are pro-inflammatory cytokines, the most studied of which are 
TNF and IFNγ. Studies have established that levels of these proteins in the CSF correlate 
with disease exacerbation in MS (Beck et al. 1988; Maimone et al. 1991; Baraczka et al. 
2004). Recent research within this laboratory has found expression of TNF by macrophages 
and IFNγ by cytotoxic T cells in the meninges of F+ SP-MS patients, suggesting a primary role 
for these cytokines in subpial demyelination in MS (unpublished data). The primary aim of this 
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thesis was to establish the first animal model of cortical demyelination elicited through 
meningeal inflammation.  
4.3.3.2	  Cortical	  demyelination	  in	  an	  animal	  model	  of	  meningeal	  inflammation	  
The extensive demyelination in the upper cortical layers, when injecting pro-inflammatory 
cytokines (1.25µg TNF/75ng IFNγ) into the subarachnoid space of rmMOG-immunised 
animals, demonstrates conclusively that a pro-inflammatory milieu in the meninges can give 
rise to subpial demyelination. It is thought that this is the first demonstration of cortical 
demyelination elicited primarily through meningeal inflammation in an animal model.  
The subpial demyelination seen in these experiments was reminiscent of type III subpial 
lesions in SP-MS (Peterson et al. 2001; Bö et al. 2003b; Magliozzi et al. 2007), and appeared 
to emanate from the pial surface and extend into the cortex. The entire cortical area adjacent 
to the sagittal sulcus and occasionally the dorsal surface of the cortex was demyelinated to 
approximately cortical layer III. Sagittal sections close to the midline revealed lesions 
extending up to 1mm in the anterior-posterior plane around the injection location. This set of 
results implies that the extent of demyelination was intimately linked to meningeal 
inflammation, which was not localised to the sagittal sulcus but extended over the dorsal 
surface towards the lateral edges of the cortex, as shown by the widespread presence of 
macrophages. This wide spread infiltration to the meninges was not present in animals 
injected with PBS, and was exacerbated in animals immunised with rmMOG, implying that 
both cytokines and antigen-specific localised reactivation of lymphocytes is responsible for 
activating meningeal blood vessels and initiating macrophage recruitment (Bartholomäus et 
al. 2009; Kivisäkk et al. 2009). This widespread infiltration laterally over the dorsal surface of 
the cortex is indicative of lateral meningeal vessel activation and may indicate that CSF 
drainage pathways do exist from the sagittal sulcus over the dorsal surface of the cortex in a 
lateral direction (Zhang et al. 1992).  
Individual injections of the maximal dose of TNF and IFNγ failed to elicit the same extent of 
demyelination as a combined injection, indicating that they caused demyelination in a 
synergistic, as opposed to an additive, manner. This may indicate the importance of positive 
feedback loops in immune cell activation and cytokine release as being critical to the extent of 
demyelination. For example, stimulation of microglia by IFNγ or TNF has been shown to 
highly upregulate expression of TNF (Aloisi et al. 1999b), which may act on microglia in an 
autocrine manner to release more TNF (Aloisi et al. 1999b; Aloisi 2001; Takeuchi et al. 2006). 
A previous study involving cytokine injection into the spinal cord of naive rats, found that TNF 
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and IFNγ initiated lymphocyte infiltration in an additive but not synergistic manner, although 
demyelination was not studied (Simmons & Willenborg 1990). These results may indicate that 
factors other than lymphocyte infiltration are responsible for demyelination in this model, 
although due to the differing experimental conditions, strain used and location of injection, 
comparisons may be unreliable.  
No leukocortical lesions were observed following subarachnoid injection of cytokines and 
intracortical lesions were detected in only one animal, which may indicate that the 
pathogenesis of subpial lesions and other cortical lesions is distinct. Indeed, the location of 
intracortical lesions around cortical blood vessels, and their relatively small size and location 
away from the pial surface compared to subpial lesions supports this view (Peterson et al. 
2001; Bö et al. 2003b; Magliozzi et al. 2010). These results also imply that the potential for 
drainage of solutes from the meninges to the deeper cortical tissue, via perivascular 
pathways, may be limited. This hypothesis is supported by the lack of Indian ink tracer 
detected in the cortical parenchyma following subarachnoid space injection in this study. 
The corpus callosum immediately below the injection site was not demyelinated indicating 
that the mechanism of demyelination in the induced subpial lesions differs from that which 
causes WMLs. Indeed, the extent of WM demyelination does not correlate with the extent of 
GM demyelination in MS brain (Kutzelnigg et al. 2005; Vercellino et al. 2005; Bö et al. 2007). 
The barrier separating the sagittal sulcus from the corpus callosum is not permeable to serum 
proteins such as fibrinogen, which was detected in the subarachnoid space but not the 
corpus callosum in this study. However, the presence of lymphocytes and in perivascular 
cuffs and activated microglia in lateral regions of the corpus callosum of cytokine-injected 
animals indicates that drainage pathways do exist from the sagittal sulcus and that those 
cytokines can activate callosal blood vessels and local glia. In support of this hypothesis, a 
study found that ink injected into the lateral corpus callosum spread laterally along axon tracts 
and was found in perivascular regions (Zhang et al. 1992). Increased numbers of 
inflammatory cells, both lymphocytes and microglia have been routinely observed in the 
NAWM in both MS and EAE models (Linington et al. 1993; Storch et al. 1998a; Frischer et al. 
2009). The question of why there is lymphocyte infiltration and microglial activation in the 
corpus callosum but no demyelination remains unanswered in this study, but it may be 
hypothesised to be caused by a lack of BBB impairment and lack of deposition of anti-myelin 
antibodies, which has been shown to be a key step in initiating WM demyelination in the 
presence of lymphocyte infiltration (Lassmann et al. 1988; Linington et al. 1988; Litzenburger 
et al. 1998). 
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4.3.4	  The	  potential	  mechanisms	  of	  demyelination	  
4.3.4.1	  Involvement	  of	  the	  humoral	  immune	  system	  
The lack of demyelination in animals immunised with IFA and injected with cytokines 
suggests that a direct effect of the injected cytokines is not responsible for demyelination. 
Furthermore, it establishes that a pre-existing anti-MOG immune response is also necessary. 
The requirement for a humoral response to MOG may be indicative of antibody-mediated 
demyelination, which is likely to also involve complement activation and deposition on myelin 
(Linington & Lassmann 1987; Linington et al. 1988; Piddlesdon et al. 1993). Indeed, 
complement deposition has been detected in focal models of GML and in the subpial GMLs 
of animals with disseminated EAE with cortical involvement (Merkler et al. 2006a; Storch et 
al. 2006). However, it should be noted that complement deposition is not a feature of MS 
GMLs, though actively demyelinating GMLs have not been studied (Brink et al. 2005). In 
addition, the functionally intact BBB and pial surface present in this model would limit the 
access of humoral elements to the cortex (Litzenburger et al. 1998). Further experiments 
investigating the deposition of complement and antibodies will test the hypothesis of the 
involvement of humoral elements in demyelination. 
The requirement for a humoral response to myelin in initiating demyelination is highly 
suggestive of a role for B cells in the pathogenesis. B cells and plasma cells have been 
consistently shown to be important in the pathogenesis of disseminated EAE initiated with 
recombinant MOG proteins (Storch et al. 1998a; Lyons et al. 1999). Recent research has 
indicated that B cells can play a key role in inflammatory processes by releasing pro-
inflammatory cytokines and acting as APCs for T cells (Tumanov et al. 2004; Rodríguez-Pinto 
2005). In order to establish the role of B cells within this model, IHC for B cell and plasma cell 
markers will be carried out and cell numbers quantified in the meninges. It is not expected 
that large numbers of B and plasma cells will infiltrate the cortex (Frischer et al. 2009). 
4.3.4.2	  Involvement	  of	  T	  lymphocytes	  
Injection of the lowest dose of cytokines caused little or no demyelination, but with some 
parenchymal T cell infiltration, particularly to the corpus callosum, and microglial activation. 
However, increasing the dose by 2 or 5 fold caused extensive demyelination in animals with a 
pre-existing immune response, indicating a threshold effect of cytokine dose. This threshold 
may be caused by the removal of low doses of cytokines either by CSF flow from the site of 
injection, dilution effects of the CSF, or cleavage of cytokines by CSF proteases before they 
are able to initiate significant inflammatory processes. The injection of higher doses of 
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cytokines overcame these effects and resulted in extensive macrophage infiltration to the 
meninges, which may indicate direct cytokine activation of meningeal blood vessels to 
express adhesion molecules such as ICAM-1 and VCAM-1 (McCarron et al. 1993; Wong et 
al. 1999; Engelhardt & Ransohoff 2005).  
The infiltration of lymphocytes to the meninges or cortex following high doses of cytokine was 
not studied in this chapter. However, it may be expected that lymphocytes would infiltrate the 
meninges following cytokine injection in the same way macrophages have been 
demonstrated to. Furthermore, significant lymphocyte infiltration to the meninges has been 
observed in MS and EAE (Storch et al. 2006; Brown & Sawchenko 2007; Bartholomäus et al. 
2009; Frischer et al. 2009; Magliozzi et al. 2010). Parenchymal infiltration of large numbers of 
lymphocytes is not a feature of GMLs (Peterson et al. 2001; Bö et al. 2003b; Frischer et al. 
2009). However, T cells are thought to play a significant pathogenic role in WMLs in MS, are 
necessary and sufficient to initiate EAE, and infiltrate the cortex in large numbers in a focal 
model of cortical demyelination (Lassmann et al. 1988; Linington et al. 1993; Lucchinetti et al. 
2000). In this study, a significant increase in the number of infiltrating T cells was observed 
after low doses of cytokines in the absence of demyelination. Therefore, a further pertinent 
study would be to assess the numbers of lymphocyte subtypes infiltrating the meninges and 
parenchyma, their association with areas of demyelination and how infiltration changes over 
time. These studies will aim to elucidate the role of lymphocytes in subpial GML 
pathogenesis. 
4.3.4.3	  The	  role	  of	  microglia/macrophages	  
Areas of demyelination were associated with the presence of high numbers of microglia, 
particularly at the “leading edge”, nearly all of which with an activated morphology with an 
enlarged soma and maintenance of short processes (Giulian et al. 1995), which is highly 
suggestive of a significant role in active cortical demyelination. High numbers of activated 
microglia with a similar morphology have been observed in subpial GML in SP-MS cases 
(Peterson et al. 2001; Frischer et al. 2009; Magliozzi et al. 2010). The absence of large, 
amoeboid “foamy” macrophages, which are features of WMLs in MS and EAE (Storch et al. 
1998a; Lucchinetti et al. 2000), is in agreement with MS GML pathology and indicates that 
the pathogenesis of WMLs and GMLs may be distinct (Peterson et al. 2001; Bö et al. 2003a; 
Magliozzi et al. 2010).  
Microglial activation may lead to demyelination via several different mechanisms. For 
example, in response to stimulation by TNF or IFNγ, microglia release glutamate and NO 
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which have been shown to cause myelin and oligodendrocyte pathology (Merrill et al. 1993; 
Takeuchi et al. 2006; Ding et al. 1988). Microglia are also capable of phagocytosis of 
complement opsonised myelin via the CR3 receptor (Brück & Friede 1990; Mosley & Cuzner 
1996). In addition, activated microglia also release TNF and IFNγ that can both damage 
myelin and initiate oligodendrocyte apoptosis (Selmaj & Raine 1988; Selmaj et al. 1991b; 
Vartanian et al. 1995; Jurewicz et al. 2003; Mizuno et al. 2008). 
Previously, release of TNF from leptomeningeal cells following systemic inflammation has 
been shown to activate microglia and astrocytes close to the pial surface (Wu et al. 2005) and 
injection of IFNγ into the subarachnoid space over the spinal cord dramatically increased the 
number of MHCII+ activated microglia parenchyma (Vass & Lassmann 1990). In this study 
increased numbers of activated microglia/macrophages were observed throughout the cortex 
and meninges of animals immunised with IFA and injected with cytokines, despite the lack of 
demyelination in these animals. These results indicate that the transmission of inflammation 
can occur from the subarachnoid space to the CNS parenchyma via diffusion, or indirectly via 
local cell activation and cytokine release. Furthermore, they support the hypothesis of soluble 
factors diffusing from the meninges to cause demyelination in MS tissue. They may also 
indicate that microglial activation is not the causative agent in demyelination, although further 
study will be required to examine the extent of microglial activation in these control animals.  
The cellular phenotype of microglia and the number present in each condition of this model is 
so far unresolved. CD68 expression by microglia/macrophages is a well-studied marker of 
phagocytosis, which is expected to be increased in animals with ongoing demyelination 
(Bauer et al. 1994). Further study will be required to determine the role of microglia in 
demyelination, this can be achieved by quantifying the cells through time, across 
experimental groups and establishing the phenotype of microglia using IHC methods. 
4.3.5	  Potential	  functional	  effects	  of	  demyelinated	  lesions	  
The prefrontal cortex is composed of many sub-divisions, and has many diverse functions 
including cognition and working memory (Dalley et al. 2004). The demyelination induced by 
the subarachnoid injection of cytokines occurred only in the superficial layers of the medial 
post-genual ACg and precentral cortex (PrC). The ACg contributes to learning and 
conditioned fear responses, possibly through direct connections to the hippocampus and the 
retrosplenial cortex (Fisk & Wyss 1999; Vann & Aggleton 2004; Vann et al. 2009). The ACg 
also has projections to the amygdala, thalamus, hypothalamus and brainstem (Fisk & Wyss 
1999). Rats with lesions of the medial prefrontal cortex are impaired on tasks that require 
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behavioural responses to be carried out sequentially (Kolb & Gibb 1990), and ACg lesions 
impair memory for the temporal order of spatial information (Kesner et al. 2000), and cause 
increased motor impulsivity (pre-mature responses) on certain tasks (Muir et al. 1996). 
An investigation of behavioural changes caused by cortical demyelination was planned for 
this thesis. However, an experimental approach investigating the pathology of the induced 
subpial lesions was prioritised. It was noted that no overt behavioural signs, e.g. 
impaired/reduced mobility, were observed in animals with GM lesions compared to controls. It 
is hypothesised that chronically demyelinated lesions with substantial neurodegeneration may 
give rise to cognitive deficits that are measurable using behavioural tests. 
4.3.6	  Conclusions	  
The current study has successfully induced subpial demyelination via injection of TNF/IFNγ in 
animals with a pre-existing cellular and humoral immune response to MOG. The 
demyelination induced is phenotypically similar to type III GML observed in post-mortem 
SPMS patients and is associated with the presence of high numbers of 
microglia/macrophages with an activated morphology. This is the first description in an animal 
model of subpial cortical demyelination initiated through meningeal inflammation and 
supports the hypothesis that cytotoxic factors in the subarachnoid space, released by locally 
activated inflammatory cells, play a causative role in subpial GML formation in MS. 
Furthermore, it successfully overcomes the main drawback of a previously published focal 
model of cortical demyelination by not disrupting BBB integrity. 
Data presented in this chapter provides only a snapshot of demyelination at one time-point. In 
order to fully elucidate the evolution of cortical pathology in this model it will be necessary to 
study a time-course of animals. Quantifying the numbers of lymphocyte subtypes and 
microglia/macrophages within the cortex and meninges will more accurately determine the 
inflammatory effects of cytokine injection. Furthermore, a study of the effects of demyelination 
on CNS cells will be necessary in order to evaluate the model against MS GML pathology. Of 
particular interest are cortical neurons, which are lost in a gradient from the pial surface in F+ 
SP-MS, a pattern highly suggestive of a role for meningeal inflammation in the pathology of 
these cases (Magliozzi et al. 2010).  
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5.1	  Introduction	  
5.1.1	  The	  pathology	  of	  subpial	  demyelination	  in	  MS	  
The recent research focus on MS cortical pathology has indicated that the pathogenesis of 
demyelination in GM and WM may be distinct. Extensive infiltration of T lymphocytes, both 
into the parenchyma and perivascular spaces, has been observed in WMLs (Lucchinetti et al. 
2000; Frischer et al. 2009). In contrast, in subpial cortical lesions infiltrating lymphocytes are 
notable by their absence, with numbers typically not higher than in control cases or normally 
myelinated regions (Peterson et al. 2001; Bö, et al. 2003b; Frischer et al. 2009). However, it 
should be noted that CD8+ cytotoxic T cells have been observed scattered throughout active 
GMLs associated with neuronal cell bodies, implicating this subtype in the neuronal loss 
observed in a subset of patients (Frischer et al. 2009; Magliozzi et al. 2010). BBB disruption 
and the expression of adhesion molecules leading to peripheral inflammatory cell influx are 
thought to be important initiating events in WMLs, and have been shown to occur to a greater 
extent than in GMLs where the BBB is functionally intact (van Horssen et al. 2007). The 
contrast in lymphocyte infiltration in WMLs and GMLs is especially evident in lesions 
spanning the GM-WM boundary (Peterson et al. 2001). These lesions have many more 
lymphocytes and MHCII activated microglia in the WM portion than the GM portion, with a 
sharp demarcation between the two areas.  
B cells have been detected in the perivascular space of active WMLs but not in the 
demyelinated cortex where they are present in the meninges only, in a 10 fold lower 
abundance than CD3+ T cells (Frischer et al. 2009). Plasma cells have also been found in the 
meninges but not the parenchyma (Frischer et al. 2009; Magliozzi et al. 2010). Furthermore, 
there is a distinct lack of evidence for the involvement of complement-mediated demyelination 
in GML, although it is possible that complement deposition occurs early and is transitory 
(Brink et al. 2005). 
In contrast to WML, the infiltration of large, amoeboid, foamy macrophages containing myelin 
components or humoral elements has not been observed in GML (Bö et al. 2003b; Frischer et 
al. 2009; Magliozzi et al. 2010). The major mediator of pathology is therefore suspected to be 
activated microglia, which have been found throughout type III subpial GML and NAGM, 
Peterson et al. 2001; Bö et al. 2003b; Magliozzi et al. 2007; Magliozzi et al. 2010). Activated 
microglia expressing myeloperoxidase have been described in GML, indicating a potential 
role for reactive oxygen species in lesion pathogenesis (Gray et al. 2008). They have been 
observed closely apposed to neuronal cell bodies and damaged axons in cortical lesions 
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(Peterson et al. 2001). Moreover, in a recent study, the extent of microglial activation in the 
cortex of MS cases was positively correlated with the number of lymphocytes infiltrating the 
meninges, highlighting the importance of the meningeal compartment in the disease (Dal-
Bianco et al. 2008). 
5.1.1.1	  Meningeal	  inflammation	  exacerbates	  MS	  pathology	  and	  disease	  course	  
An increasing realisation of the extent of immunological compartmentalisation in the CNS has 
highlighted the influence of meningeal inflammation on GM pathology. Extensive meningeal 
inflammation with the presence of organised ectopic lymphoid follicle-like structures has been 
found in the meninges of a significant number of SP-MS cases (40-54%, Serafini et al. 2004; 
Magliozzi et al. 2007; Frischer et al. 2009; Magliozzi et al. 2010). The presence of these 
structures was associated with an accelerated disease course.  
Pathologically, cases with follicles (F+ MS cases) were found to have a higher number of type 
III subpial GML and a greater extent of GML demyelination than F- SP-MS (5.3 and 5.7 fold 
increase respectively, Magliozzi et al. 2007). A subsequent study revealed extensive cell loss 
in subpial GML in F+ SP-MS cases (Magliozzi et al. 2010). A gradient of neuronal (maximum 
loss 65% vs. control) loss was detected, greatest in cortical layer I adjacent to the meninges. 
Cells were also lost in a gradient pattern in the NAGM to a slightly reduced extent. 
Subsequent analysis revealed that the majority of neurons lost in layers III and V were 
pyramidal cells. Cell loss occurred to a significantly lesser degree in F- MS cases with no 
evident gradient.  
This gradient of cell loss was also evident for astrocytes in the GML of F+ SP-MS (maximum 
loss 42% vs. control). A similar number of astrocytes were lost in NAGM in F+ SP-MS 
compared to GML of F- cases, with no gradient pattern evident. In contrast, oligodendrocytes 
were lost in significantly greater numbers in GML of F+ SP-MS cases (layer I 61% vs. 39% F- 
SP-MS), but with no evident gradient. As expected, oligodendrocyte loss was detected in 
GML although 40% survived in the chronically demyelinated subpial GML. Curiously, a 
significant reduction in oligodendrocyte density was also detected in the NAGM of both F+ SP-
MS and F- SP-MS cases (36% vs. 20% layer I), which may indicate that cell loss may precede 
myelin loss or that remyelination requires fewer oligodendrocytes. Furthermore, the integrity 
of the glia limitans, which forms the surface of the cortex, was compromised in GML 
(Magliozzi et al. 2010). Leakage of fibrinogen has been shown to activate microglia in vivo 
(Adams et al. 2007), highlighting a potential contributing factor to pathogenesis. 
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Microglia have been hypothesised to be important in the pathogenesis of GML due to several 
lines of evidence. Activated MHCII+ microglia were significantly increased in F+ SP-MS GML, 
and were found in the largest number (70% increase vs. control) in cortical layer I close to the 
pial surface. A decreasing gradient of cell presence was evident only in F+ SP-MS cases. 
Microglia were also diffusely increased throughout the NAGM with a similar gradient evident, 
and were frequently observed in close proximity to neuronal cell bodies in GML and NAGM. 
No macrophages and very few CD68+ phagocytic cells were detected. Abundant iNOS and 
TNF positive macrophages were found in the meninges and active lesions of F+ MS cases 
(Magliozzi et al. 2010). Expression of TNF and iNOS by activated microglia has also been 
detected in the active subpial lesions (Magliozzi et al. 2010). Together this data strongly 
implicates microglial activation in the pathogenesis of subpial demyelination in MS. 
The generalised graded cell loss and pattern of microglial activation in the GM of SP-MS 
cases with meningeal inflammation, supports the concept of non-specific cytotoxicity. It is 
suggested that cytotoxic factors diffusing from activated lymphocytes and macrophages in the 
meningeal compartment contribute to grey matter pathology directly and/or by chronically 
activating microglia. The presence of B cell aggregates in the meninges of non-MS 
inflammatory conditions affecting the CNS in the absence of neighbouring subpial GML may 
argue for a role for antigen specific responses in MS GML, although this may depend on how 
chronic the inflammation is. 
5.1.2	  Focal	  models	  of	  cortical	  pathology	  
The study of post-mortem tissue of a chronic disease inevitably leads to difficulty in 
establishing causative factors of the observed pathology. Therefore, animal models of 
disease are required in order to elucidate the pathogenesis of the disease. Typical EAE 
models of MS do not involve the cortex; therefore, novel models have been created to study 
cortical pathology. 
5.1.2.1	  Subpial	  demyelination	  following	  intracortical	  cytokine	  injection	  
Lewis rats immunised with rrMOG and subsequently injected into the motor cortex with 
TNF/IFNγ exhibited extensive demyelination, with subpial, leukocortical and intracortical 
lesions being produced (Merkler et al. 2006b). Demyelination was maximal 3 days post-
injection and thereafter was reduced, until 14 days post-injection when full remyelination had 
occurred.  
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The extent of cortical demyelination was highly correlated with the presence of activated 
microglia/macrophages. During active demyelination, microglia/macrophages with ingested 
MBP+ myelin fragments were found in lesions. All animals injected with cytokines had 
extensive infiltration of macrophages into the meninges, irrespective of a humoral anti-MOG 
response. Significantly more CD4+ Th cells infiltrated the parenchyma and perivascular 
spaces in response to cytokine injection in MOG-immunised animals than in those immunised 
with IFA alone, and their numbers were significantly correlated with the extent of 
demyelination. Cytotoxic (CD8+) T cells infiltrated the parenchyma following cytokine injection, 
with a reported peak in number corresponding to the greatest extent of demyelination. 
However, due to technical issues the cells were not quantified. Perivascular deposition of 
complement was reported in lesions (Merkler et al. 2006b).  
Demyelination was associated with a 50% reduction in oligodendrocyte cell density in cortical 
layers III-V, which later returned to normal levels upon remyelination. Moreover, remyelination 
was confirmed by G-ratio measurements with remyelinated cortex showing a significantly 
reduced ratio compared to control animals, indicating a thinner myelin sheath (Merkler et al. 
2006b). APP+, axons indicative of impaired axonal transport, were detected in demyelinated 
areas of animals with a pre-existing anti-MOG response injected with cytokines. Furthermore, 
the number of APP+ axons was significantly correlated with the number of CD68+ activated 
microglia/macrophages. It should be noted that APP+ axons were also observed close to the 
needle track in control animals injected with cytokines. No reduction in axonal density was 
observed, although rare activated caspase3+ neurons undergoing apoptosis were detected 
(Merkler et al. 2006b).  
These results indicate the involvement of both the adaptive and innate immune responses in 
the pathogenesis of GMLs in this model. However, the rapid resolution of lesions produced in 
this model leads to no lasting reduction in axonal density. The validity of the model must also 
be called into question, as it involves a direct injection into the cortex, with associated tissue 
destruction and extensive BBB breach, a situation that does not occur in association with 
GMLs in MS. This BBB breakdown may, in full or in part, explain the differences between 
pathology in this model and post-mortem MS cases, in particular the deposition of 
complement components and cortical infiltration of Th cells is not a feature of GML pathology 
in MS (Peterson et al. 2001; Bö et al. 2003b; Brink et al. 2005). 
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5.1.2.2	  Subpial	  demyelination	  induced	  by	  meningeal	  inflammation	  
Previous experiments, described in chapter 4, induced subpial demyelination by first 
immunising rats with a subclinical dose of rmMOG, and subsequently injecting TNF/IFNγ into 
the subarachnoid space at the sagittal sulcus. The GML produced in this model are 
phenotypically similar to those found in post-mortem MS tissue. Lesions appear to extend 
from the pial surface into the cortex and are associated with the presence of activated 
microglia throughout the parenchyma and macrophages in the meninges. No demyelination 
was observed in control animals immunised with IFA and injected with cytokines, or in 
animals immunised with rmMOG and injected with PBS. Previous experiments established 
that BBB breakdown is not a feature of this model as no leakage of fibrinogen was observed. 
5.1.3	  Visualisation	  of	  cortical	  layers	  
Neurons in the cortex are organised into functional layers, from the pial surface into the brain. 
Layer I is closest to the surface and is composed largely of axons and dendritic processes 
with few neuronal cell bodies. Layers II, III, IV contain large numbers of neurons, both 
excitatory glutamatergic neurons, and gamma-aminobutyric acid (GABA) containing inhibitory 
interneurons. Cells in deep cortical layers (V and VI) are predominantly glutamatergic 
pyramidal cells. Two types of glutamate receptor, the fast ligand-gated ionotropic and 
metabotropic G-protein coupled receptors, mediate glutamate neurotransmission at the 
synapses. Ionotropic receptors are further subdivided into N-methyl-D-aspartate (NMDA) 
receptors, α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptors, and 
kainate receptors. AMPA receptors are composed of one of 4 glutamate receptor subunits 
(GluR1-4), which have different properties. GluR2/3 receptors are present in the greatest 
number on pyramidal cells in layer II–III, V and VI (Ryoo et al. 2003). A study examining the 
development of the rat cortex confirmed GluR2/3 expression was organised into these layers 
in retrosplenial cortex close to the midline of the adult rat (Ichinohe et al. 2003). The 
distribution of GluR2/3 receptor allows the delineation of cortical layers and the quantification 
of cells in different laminae.  
5.1.4	  Aims	  of	  this	  study	  
Experiments in this chapter aimed to study the evolution and cellular pathology of subpial 
demyelination elicited by injection of TNF/IFNγ into the subarachnoid space of rmMOG-
immunised rats. Control rats were immunised with IFA and injected with cytokines, or 
immunised with rmMOG and injected with PBS. It was hypothesised that injection of 
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cytokines into the subarachnoid space would precipitate infiltration of lymphocytes into the 
meninges and cause microglial activation in the cortex, leading to demyelination, thus 
mimicking the pathology observed in MS. The specific aims were to: 
• Study the evolution of subpial lesions 
• Measure extent of demyelination at different time-points 
following injection 
• Analyse lymphocyte infiltration of subpial lesions 
• Th (CD4+), cytotoxic T cells (CD8+) and B cells (CD79a+) 
cells 
• Quantify cells in the meninges, GM parenchyma GM 
perivascular cells and corpus callosum 
• Analyse cortical cell populations in layers I–IV of subpial lesions  
• Activated microglia/macrophages (Iba1+/CD68+), neurons 
(NeuN+), oligodendrocytes (APC+) and astrocytes (S100β+) 
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5.2	  Results	  
5.2.1	   Subpial	   demyelination	   was	   maximal	   7	   days	   post-­‐cytokine	  
injection	  
Female DA rats immunised with 5µg rmMOG received a stereotactic injection of 1.25µg 
rrTNF/75ng rrIFNγ into the subarachnoid space of the sagittal sulcus 20-23 days post-
immunisation. Control animals were either immunised with rmMOG and injected with PBS, or 
immunised with IFA and injected with cytokines (Figure 5.1 A). Animal numbers in each group 
are listed Table 2.4. Demyelination was first evident in the molecular layer of the cortex (layer 
I) one day post-cytokine injection (Figure 5.1 A, B), and was associated with the presence of 
amoeboid Iba1+ cells, which given the small size and spheroid morphology are thought to be 
monocytes (Figure 5.1 E, F). Control animals did not show demyelination at any time-point 
(Figure 5.1 A). The maximal area of demyelination occurred 7 days after rmMOG-immunised 
animals were injected with cytokines (1.22mm2 ±0.36), The area of demyelination at this time-
point was significantly higher than at all other time-points in these animals and all controls 
(Figure 5.1 A, P<0.03). As previously described, demyelination occurred in cortical layers I 
and II–III of the ACg (Figure 5.1 C). This is the cortical area closest to the injection site in the 
sagittal sulcus, with demyelination typically extending from the cortex overlying the corpus 
callosum to the dorsal surface. Demyelination was absent at 14 days and 21 days post-
injection (Figure 5.1 A, D). 
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5.2.2	  Lymphocytes	  infiltrated	  the	  CNS	  following	  cytokine	  injection	  
Lymphocytes were visualised using DAB IHC, and quantified in the dorsal cortex, corpus 
callosum and the meninges overlying the dorsal cortex as described in Chapter 2. Th cells 
and cytotoxic T cells were visualised using anti-CD4 and anti-CD8 antibodies respectively. B 
cells were identified using anti-CD79a antibody. Lymphocytes were observed in the meninges 
at the injection site and overlying the dorsal cortex, extending laterally from the sagittal sulcus 
(Figure 5.2 A, B). Lymphocytes infiltrating the parenchyma did not appear to associate with 
lesions but isolated cells were scattered throughout the grey matter (Figure 5.2 A, C, D). 
Lymphocytes were also commonly observed infiltrating the corpus callosum, particularly in 
the cingulate area and periventricular areas (Figure 5.2 A, E) 
5.2.2.1	  The	  number	   of	   lymphocytes	   in	   the	  meninges	  was	  maximal	   one	   day	   post-­‐
cytokine	  injection	  
CD4+ and CD8+ T lymphocytes were present in the meninges in the naive animal. CD4+ cells 
were present in significantly greater numbers than CD8+ cells (ratio 20:1 – Figure 5.3, A, B). 
CD79a+ B cells were not observed in the meninges of naive animals (Figure 5.3 C). The 
number of each lymphocyte sub-type in the meninges was maximal one day post-stereotactic 
injection in each experimental condition, decreased at day 3, increased at day 7 and again 
deceased at subsequent time-points (Figure 5.3 A, B, C). Cells were initially observed close 
to meningeal blood vessels, suggesting these as the site of infiltration (Figure 5.3 D, E). The 
number of lymphocytes in animals injected with cytokines (rmMOG or IFA immunised) was 
similar, and was higher than animals immunised with rmMOG and injected with PBS, one-day 
post-immunisation (see Table 5.1). CD8+, CD4+ and CD79a+ cells were not significantly 
increased in animals immunised with rmMOG and injected with PBS, though there was a 
trend towards increased CD8+ cells. The greatest increases compared to naive animals were 
found in CD8+ and CD79a+ cells one-day post-injection of cytokine in rmMOG-immunised 
animals (Table 5.1). 
Table 5.5: Ratio of lymphocytes present in the meninges of animals one-day post-stereotactic injection relative to 
the number present in naïve animals. * ratios for CD79a+ cells are calculated against rmMOG/PBS treated 
animals, due to no cells being present in naive animals.  
Experimental Group CD8+ CD4+ CD79a+* 
rmMOG/Cytokine 37 3 26 
IFA/Cytokine 28 2 19 
rmMOG/PBS 8 1 1 
Naive 1 1 - 
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CD4+ cells were present in the meninges in the highest number at each time point, followed 
by CD8+ and CD79a+ cells (approximate ratio 5:3:1 one day post-injection, 16:5:1 7 days 
post-injection). Each cell type was present in elevated numbers 7 days following cytokine 
injection compared to naive cells and rmMOG/PBS controls (Table 5.2, Figure 5.3 B, C). 
CD8+ T cells and CD79a+ B cells had the greatest increase over controls, due to the scarcity 
of each cell type under normal conditions. 14 days post-injection the number of cells present 
in the meninges returned to a similar number to naive animals for each cell type. A number of 
IgA, IgG, IgM+ plasma cells were observed in the meninges (Figure 5.3 F). 
Table 5.2: Ratio of lymphocytes present in the meninges of animals seven days post-stereotactic injection relative 
to the number present in naïve animals. * ratios for CD79a+ cells are calculated against rmMOG/PBS treated 
animals, due to no cells being present in naive animals.  
Experimental Group CD8+ CD4+ CD79a+* 
rmMOG/Cytokine 14 2 17 
IFA/Cytokine 17 2 24 
rmMOG/PBS 2 1 1 
Naive 1 1 - 
5.2.2.2	   Cytotoxic	   T	   cells	   were	   the	   most	   prevalent	   lymphocyte	   infiltrating	   the	  
cortical	  parenchyma	  
The number of lymphocytes in the cortical grey matter (and in the Virchow-Robin space 
surrounding cortical blood vessels) was quantified in the dorsal aspect of the cortex. 
Lymphocytes did not appear to infiltrate demyelinated subpial lesions specifically, but were 
scattered throughout the cortex (Figure 5.2 A, C, D). 
Lymphocytes were very rarely observed in the cortical parenchyma or in perivascular spaces 
of the naive rat (Figure 5.4, 5.5 A, B, C). One day post-cytokine injection the numbers of T 
and B lymphocytes was significantly increased compared to naive animals. The number of 
lymphocytes was increased following injection with PBS, though to a much lesser extent than 
cytokine injection. The number of lymphocytes present following PBS injection was not 
significantly higher than naive animals at any time-point. The number of cells decreased with 
time in all experimental conditions and for each cellular sub-type. The number of CD4+ cells 
infiltrating the parenchyma of animals immunised with rmMOG and injected with cytokines 
was not significantly higher than controls at any time-point (Figure 5.4 A). CD8+ cytotoxic T 
cells were present in the highest number when compared to other cell types; the ratio of cells 
present in the grey matter parenchyma was 2:1 (CD8:CD4) throughout the experiment in 
rmMOG/Cytokine treated animals. The number of CD8+ cells in the parenchyma was higher 
in animals immunised with rmMOG and injected with cytokines than controls immunised with 
IFA and injected with cytokines (7 days post-injection), corresponding to the greatest extent 
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of demyelination (Figure 5.4 B). The number of perivascular CD8+ cells was highest one-day 
post-cytokine injection. CD79a+ B cells were rarely observed in the cortex, but were present in 
greatest numbers one day post-injection. CD4+ and CD8+ lymphocytes were observed in 
close opposition to resident cortical cells with morphological characteristics of neurons 
(Figure 5.4 D, E, F). 
Table 5.3: Ratio of CD8+ cells in the cortical parenchyma across time-points following stereotactic injection, 
relative to the number present in naïve animals. 
CD8+ Days Post Injection 
Experimental Group 1 3 7 14 21 
rmMOG/Cytokine 55 29 23 10 6 
IFA/Cytokine 41 20 12 8 5 
rmMOG/PBS 8 15 7 10 6 
Naive 1 1 1 1 1 
Lymphocytes of each sub-type were detected in the perivascular regions of vessels 
throughout the cortex (Figure 5.4 D). Each lymphocyte sub-type had significantly more 
perivascular cells than naive animals (P<0.05) one-day post-cytokine injection. The number 
of perivascular cells decreased at each subsequent time-point for CD8+ and CD79a+ cells but 
the number of CD4+ lymphocytes was maintained to 7 days post-injection and subsequently 
decreased (Figure 5.5 A, B, C).  
5.2.2.3	  The	  greatest	  number	  of	  lymphocytes	  in	  the	  corpus	  callosum	  coincided	  with	  
the	  extent	  of	  demyelination	  
Lymphocytes were quantified in the corpus callosum, both in the perivascular space and 
white matter. Lymphocytes were spread throughout the corpus callosum, particularly 
observed in perivascular spaces close to the ventricles. The number of T cells in the corpus 
callosum was increased one-day post-cytokine injection, but not PBS injection (Figure 5.5 E, 
F, G). The number of CD79a+ B cells was not increased one-day post-injection. The number 
of cells in the corpus callosum was maximal 7 days post-injection, coinciding with the greatest 
extent of demyelination in the cortex. There were more CD8+ T cells than CD4+ and CD79a+ 
cells (ratio 20:11:1), 7 days post-cytokine injection in rmMOG-immunised animals. In contrast 
to other cell subtypes, there were significantly more CD8+ T cells in animals immunised with 
rmMOG and injected with cytokines than in either set of control animals (P<0.05).
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5.2.3	  CNS	  resident	  cells	  were	  affected	  by	  cytokine	  injection	  
5.2.3.1	   Cortical	   microglia/macrophage	   activation	   correlated	   with	   the	   extent	   of	  
demyelination	  
The number of Iba1+ microglia/macrophages was quantified in cortical layers I–IV in the ACg 
close to the injection site and in the meninges. In response to cytokine injection, the number 
of Iba1+ cells with an activated morphology was increased throughout the cortex far from the 
injection site at the sagittal sulcus, particularly in areas close to the cortical surface (Figure 
5.6 C). There also an increase in the number of Iba1+ cells in the corpus callosum, although 
this was not quantified. 
In naïve animals, cells were evenly distributed throughout the cortex (Figure 5.6 A). The 
number of microglia in naive animals was approximately 100 cells/mm2 in each cortical layer 
studied (Figure 5.7 A). One day post-injection there was a significant increase in the number 
of Iba1+ cells in rmMOG/cytokine treated animals in layer I compared to naive animals (Figure 
5.7 A, P<0.05). Many of these cells had a small amoeboid morphology reminiscent of 
monocytes (Figure 5.6 B and as previously described in Figure 5.1E, F). The location of these 
cells close to the pial surface may indicated that they originated in the meninges and crossed 
the pial membrane into the cortex. Control animals also had increased numbers of Iba1+ cells 
at each time point studied, but were not significantly increased compared to naive animals. 
The number of Iba1+ cells was maximal 7 days post-cytokine injection in rmMOG-immunised 
animals, and was 6 times that in naive animals (Table 5.4). The number of cells was 
significantly greater than controls (P<0.01) and other time-points in the same experimental 
group (Figure 5.7 A, B, C, P<0.01). Iba1+ microglia were present in the greatest number close 
to the pial surface in cortical layer I, in animals immunised with rmMOG and injected with 
cytokines (Figure 5.7 D). This gradient was evident to a lesser extent in animals immunised 
with IFA and injected with cytokine, but was not present in animals immunised with rmMOG 
and injected with PBS or in naive animals. This gradient was evident at each time-point 
studied. The number of Iba1+ cells strongly correlated with the extent of demyelination (Figure 
5.7 E, R = 0.63 P<0.01). Cells in rmMOG/cytokine treated animals an enlarged soma but 
retained short processes, identifying them as activated microglia rather than amoeboid 
macrophages (Figure 5.7 F).  
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Table 5.4: Ratio of Iba1+ cells in cortical layers I–IV across experimental groups and time-points, relative to the 
number present in naïve animals.  
Iba1+ Days Post Injection 
Experimental Group 1 3 7 14 21 
rmMOG/Cytokine 2 3 6 2 1 
IFA/Cytokine 2 2 3 2 1 
rmMOG/PBS 2 2 2 2 2 
Naive 1 1 1 1 1 
The number of CD68+/Iba1+ phagocytic, activated microglia was quantified in an identical 
manner to Iba1+ cells. No CD68+/Iba1+ were present in naive DA rats. One day post-cytokine 
injection a large number of cells were CD68+/Iba1+ in layer I, in all experimental conditions, 
with rmMOG/cytokine treated animals having the highest number (Figure 5.8 A). CD68+/Iba1+ 
cells had the enlarged soma and short processes typically of activated microglia, and were 
not confined to areas of demyelination (Figure 5.8 F). The number of CD68+/Iba1+ cells was 
maximal 7 days post-cytokine injection in rmMOG-immunised animals in each cortical layer 
studied, significantly higher than controls and other time-points, and 24 times that found in 
rmMOG/PBS treated controls (Table 5.5). The number of phagocytic microglia/macrophages 
was decreased to near background levels 14 and 21 days post-injection. The number of cells 
was lower in layers II–III and IV compared to layer I, in each condition and at all time-points 
(Figure 5.8 B, C). CD68+/Iba1+ phagocytic microglia/macrophages were present in the 
greatest number close to the pial surface in cortical layer I, in animals immunised with 
rmMOG and injected with cytokines 7 days post-injection (Figure 5.8 D). This gradient was 
evident to a lesser extent in animals immunised with IFA and injected with cytokine, but was 
not present in animals immunised with rmMOG and injected with PBS. This gradient was 
evident at each time-point studied. The number of CD68+/Iba1+ cells strongly correlated with 
the extent of demyelination (Figure 5.8 E Pearson R = 0.74, P<0.01). Cells in 
rmMOG/cytokine treated animals had an enlarged soma but retained short processes, 
identifying them as activated microglia rather than amoeboid macrophages (Figure 5.8 F). 
Table 5.5: Ratio of CD68+/Iba1+ cells in cortical layers I–IV. There were no cells present in the naive rat, numbers 
are relative to the rmMOG/PBS group at each time-point. 
CD68+/Iba1+ Days Post Injection 
Experimental Group 1 3 7 14 21 
rmMOG/Cytokine 2 1 24 0 1 
IFA/Cytokine 2 0 7 0 1 
rmMOG/PBS 1 1 1 1 1 
Naive - - - - - 
 



Chapter 5: Analysis of subpial demyelination – Results 172 
 
5.2.3.2	   Meningeal	   monocyte/macrophage	   activation	   correlated	   with	  
demyelination	  
One day post-injection there was a significant increase in the number of Iba1+ cells in 
rmMOG/cytokine treated animals compared to naive animals in the meninges (Figure 5.9 A 
P<0.03). Control animals also had increased numbers of Iba1+ cells at each time point 
studied, but were not significantly increased compared to naive animals due to low N 
numbers. The number of Iba1+ cells was maximal 7 days post-cytokine injection in rmMOG-
immunised animals in the meninges, this was significantly higher than controls and other 
time-points, and was 8 times that found in naive animals (Table 5.6). There was a greater 
number of Iba1+ cells in the meninges of animals immunised with IFA and injected with 
cytokines than those immunised with rmMOG and injected with PBS at each time-point. The 
number of Iba1+ monocytes/macrophages in the meninges correlated with the extent of 
demyelination (Figure 5.9 B Pearson R = 0.85 P<0.01). 
Table 5.6: Ratio of Iba1+ cells in meninges across time-points and experimental groups, relative to the number 
present in naïve animals. 
Iba1+ Days Post Injection 
Experimental Group 1 3 7 14 21 
rmMOG/Cytokine 7 5 8 3 2 
IFA/Cytokine 6 6 6 3 2 
rmMOG/PBS 4 3 2 3 2 
Naive 1 1 1 1 1 
 
One day post-injection there was a significant increase in the number of CD68+/Iba1+ 
activated monocytes/macrophages in rmMOG/cytokine treated animals compared to naive 
animals in the meninges (Figure 5.9 C P<0.03). Control animals also had increased numbers 
of CD68+/Iba1+ cells at each time point studied, but were not significantly increased compared 
to naive animals due to low N numbers. There was a greater number of CD68+/Iba1+ cells in 
the meninges of animals immunised with IFA and injected with cytokines than those 
immunised with rmMOG and injected with PBS at each time-point. The number of 
CD68+/Iba1+ activated monocytes/macrophages in the meninges correlated with the extent of 
demyelination (Figure 5.9 D Pearson R = 0.95 P<0.01). 
Examination of the pial surface revealed the maintenance of a strict barrier between the pia 
and the meninges; monocytes were only observed in the meninges, and all cells present in 
the neighbouring cortex had a phenotype consistent with activated microglia (Figure 5.9 E, F).  
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5.2.3.3	  Microglia	  may	  be	  responsible	  for	  demyelinating	  pathology	  
Microglia/macrophages express MHCII molecules in the cortex of animals injected with 
cytokines, potentially functioning as APC’s to lymphocytes (Figure 5.10 A). MHCII/Iba1+ cells 
were widely distributed throughout the cortex, and were not confined to the area of 
demyelination. Activated microglia/macrophages were observed contacting oligodendrocyte 
cell bodies and damaged myelin fragments, within the demyelinated cortex (Figure 5.10 B, 
C). This may indicate a role for microglia not only in mediating demyelination but also a direct 
effect on oligodendrocytes in demyelinated lesions. Many microglia/macrophages with an 
activated morphology were observed closely apposed to neuronal cell bodies in the 
demyelinated cortex, particularly in layer III (Figure 5.10 D).  
5.2.3.4	  Loss	  of	  oligodendrocytes	  following	  cytokine	  injection	  
Immunofluorescence for CNPase revealed the presence of numerous oligodendrocyte cells in 
demyelinated areas (Figure 5.11 A, B). These cells could be oligodendrocytes that have lost 
myelin sheaths, or may be newly differentiated OPCs. 
Oligodendrocytes were quantified in cortical layers I–IV of the ACg cortex by double label IF 
for adenomatous polyposis coli protein (APC), and glial fibrilliary acid protein (GFAP). 
APC+/GFAP-/DAPI+ cells were considered to be oligodendrocytes, as previously described in 
Chapter 2. 
Quantification of APC+/GFAP- oligodendrocytes in layer I revealed a significant reduction in 
cell density one day after injection of TNF/IFNγ in rmMOG-immunised animals (42% of Naive, 
P<0.05 Figure 5.12 A), and at 3 and 7 days post-injection (P<0.05). Control animals 
immunised with IFA and injected with cytokines or immunised with rmMOG and injected with 
PBS had a non-significant reduction in cell density (55 and 66% of naive respectively). Later 
time-points were not significantly different to naive animals for any experimental condition, 
although animals immunised with rmMOG and injected with cytokines had a lower cell density 
than naive animals 3 days after injection (see Table 5.7). 
Table 5.7: APC+/GFAP- cells in cortical layer I, % compared to average of three naive animals. 
APC+/GFAP- Days Post Injection 
Experimental Group 1 3 7 14 21 
rmMOG/Cytokine 42 66 84 94 73 
IFA/Cytokine 55 79 91 79 94 
rmMOG/PBS 66 91 88 88 89 
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There were no significant differences in APC+/GFAP- oligodendrocyte cell density in cortical 
layers II–III and IV at any time-point compared to controls (Figure 5.12 B, C). However, 
oligodendrocytes were non-significantly reduced 3 days post-cytokine-injection in layer II of 
rmMOG/cytokine treated animals, with only 59% the density of naive cells compared to 79% 
(IFA/Cytokine) and 83% (rmMOG/PBS) for controls. The density of oligodendrocytes was 
significantly lower than animals in the same experimental group at day 7 (Figure 5.12 B 
P<0.05). When considering cell density in cortical layers I–IV, there were non-significant 
reductions in cytokine treated animals one and 3 days post-injection (Figure 5.12 D).  
APC+/GFAP- oligodendrocytes were characterised by a highly spheroid morphology and 
relatively intense staining, whereas APC+/GFAP+ astrocytes were ramified in morphology and 
had less intense APC staining (Figure 5.12 F). Oligodendrocytes were present in large 
numbers in all cortical layers, with a general pattern of increasing density from the upper 
cortical layers to deeper layers with a higher abundance of densely packed myelin sheaths 
(Figure 5.12 E). The white matter of the corpus callosum had characteristic “chains” of 
oligodendrocytes consisting of 2-7 cells located in very close proximity to each other in a 
linear fashion. The presence of apoptotic oligodendrocytes in demyelinated cortex was 
revealed by double IF for APC and activated caspase 3 (Figure 5.12. G). Apoptotic 
oligodendrocytes were relatively rare, and scattered throughout the cortex. Single double 
positive cells were detected in lesions at early time-points following injection (up to 7 days). 
5.2.3.6	  Astrocytes	  may	  be	  lost	  following	  to	  cytokine	  injection	  
Astrocytes were quantified in cortical layers I–IV of the ACg by IF for S100β. S100β+/DAPI+ 
cells were considered to be astrocytes, as previously described in Chapter 2. S100β+ was 
used to quantify astrocytes as it stained the major processes and cell soma, whereas GFAP 
was located solely in the processes, making accurate quantification more difficult. S100β+ 
staining was observed continuously on the pial surface, forming the glia limitans (Figure 5.13 
E, F). Cells in this region were not included in the final analysis as it was not possible to 
differentiate between cells and accurately quantify them.  
S100β+ astrocytes were distributed evenly throughout the cortex. The density of S100β+ 
astrocytes was non-significantly reduced compared to naive animals one-day post-injection in 
all experimental conditions (Figure 5.13 A, Table 5.8). The density of S100β+ cells was slightly 
increased 7 days post-injection, compared to earlier time-points, in cortical layer I of animals 
immunised with rmMOG and injected with cytokines. In cortical layers II–III and IV there were 
no significant differences compared to naive animals (Figure 5.13 B, C, D).  
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Table 5.8: S100β+ cells in cortical layer I, % compared to three naive animals. 
S100β+ Days Post Injection 
Experimental Group 1 3 7 14 21 
rmMOG/Cytokine 83 92 110 104 96 
IFA/Cytokine 90 93 100 105 91 
rmMOG/PBS 83 102 101 111 109 
 
5.2.3.7	  No	  evidence	  of	  neurodegeneration	  following	  cytokine	  injection	  
Neurons were quantified in cortical layers I and II–III of the ACg by IF for NeuN. NeuN+/DAPI+ 
cells were considered to be neurons, as previously described in Chapter 2. Neurons in the 
ACg were sparse in layer I when compared to the high numbers of cells elsewhere in the 
cortex (Figure 5.14 A, E, D, H). There was a non-significant trend for reduced cell density and 
cell numbers in cortical layer I in animals immunised with rmMOG and injected with cytokines, 
7 days post-injection. There was a reduced cell number and density in rmMOG/cytokine 
treated animals 7 days post-injection compared to 21 days post-injection, but this difference 
was not significant. There was no significant difference in the cell density, number of cells or 
area counted in across experimental conditions, or time-points in either cortical layer II–III 
(Figure 5.14 E, F, G). In order to test whether oedema resulting from the surgery could 
account for the reduced cell density, the area in which cells were counted was calculated, but 
found to be similar across time-points and experimental groups in each layer studied (Figure 
5.14 C, G). 
5.2.3.8	  Evidence	  of	  axonal	  stress	  in	  subpial	  demyelinated	  areas	  
IHC for NFH and APP was used to assess axonal pathology. APP+ spheroids were found in 
animals injected with cytokines directly into the motor cortex, close to the injection site (Figure 
15 A, B, C). APP+ cells with microglia/macrophage-like morphology were also observed close 
to the injection site (Figure 15 B). NFH+ axonal spheroids were observed close to the injection 
site (Figure 15 C). No APP+ spheroids were observed in the cortex following injection of 
cytokines into the sagittal sulcus. However, APP+ monocyte/ macrophage-like cells were 
observed in the meninges (Figure 15 D). NFH+ axonal spheroids were observed in the 
demyelinated molecular layer close to the injection site, though this staining may be due to 
the orientation of axons in this location (Figure 15 E, F). 
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5.3	  Discussion	  
5.3.1	  The	  pathology	  of	  focal	  subpial	  lesions	  
The acute demyelination and rapid resolution found in this model mirrors a similar focal model 
of cortical demyelination (Merkler et al. 2006b). The peak of demyelination occurred 3 days 
post-cytokine injection following a direct intracortical injection and 7 days post-injection in the 
present study. This discrepancy may be due to the lack of direct BBB disruption and tissue 
damage elicited following subarachnoid space injection (as discussed in chapter 4), and 
indicates that a different pathogenic mechanism may be occurring in this model, which we 
feel more accurately reflects the pathology in the cortical grey matter of MS cases. 
5.3.1.1	  Meningeal	  immune	  cell	  infiltration	  precedes	  demyelination	  
Th cells were present in the meninges of the naive rat confirming previous reports suggesting 
that this cell type are responsible for CNS immune surveillance (Kivisäkk et al. 2003; Kivisäkk 
et al. 2009). The presence of high numbers of lymphocytes in the meninges following 
cytokine injection, irrespective of a pre-existing anti-myelin immune response, indicates that 
TNF and IFNγ directly stimulate the infiltration of lymphocytes into this compartment. TNF 
and IFNγ activate endothelial cells to express adhesion molecules such as VCAM-1 and 
ICAM-1, which will facilitate lymphocyte entry (Cavender et al. 1989; Myers et al. 1992; 
McCarron et al. 1993; Wong et al. 1999). The lack of infiltration following PBS injection 
indicates that the disturbance in homeostasis caused by the injection is not sufficient to 
initiate significant lymphocyte infiltration. 
The close proximity of many lymphocytes to meningeal blood vessels implicates these as the 
most likely location of lymphocyte entry into the CNS. Furthermore, the wide distribution of 
cells over the dorsal cortex may be a consequence of CSF drainage pathways. Although 
drainage pathways from the sagittal sulcus have not been established previously, it has been 
shown that Indian ink in the subarachnoid space over the cortex drains laterally (Zhang et al. 
1992; Kida et al. 1993). In this model, such drainage would cause the activation of vessels in 
the sagittal sulcus and laterally over the cortex. Although Indian ink is not detected over the 
cortex following injection, the injected cytokines are likely to be more readily diffusible. It was 
previously shown that ink was phagocytosed by macrophages in this model, which would limit 
dispersal in the subarachnoid space (Chapter 4). 
The high number of all lymphocyte subtypes in the meninges of control animals injected with 
cytokines indicates that the activation status of lymphocytes may be an important factor in 
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cortical demyelination. Lymphocytes in rmMOG-immunised animals will re-encounter cognate 
antigen in the subarachnoid space (Kivisäkk et al. 2009), and become activated to release 
pro-inflammatory mediators, whereas lymphocytes in IFA immunised animals, whilst 
infiltrating the meninges in great numbers do not encounter antigen and are not activated. 
The activity status of meningeal lymphocytes is currently unresolved in this model, but could 
be assessed by flow cytometry of CSF/meningeal explants for common activation markers 
such as CD69, OX-40 and IL-2 receptor (Bartholomäus et al. 2009; Kivisäkk et al. 2009).  
The level of T and B lymphocytes in the meninges was maximal one day post-injection and 
rapidly decreased, indicating a highly efficient regulatory apoptosis, which may in fact be 
partly caused by the injected cytokines (Furlan et al. 2001). The increase in number of Th 
cells from 3 days to 7 days post-injection may indicate a secondary wave of extravasation. 
This may be initiated by cytokine release from activated macrophages and lymphocytes that 
are activated following re-encounter with antigen (Bartholomäus et al. 2009). It is expected 
that IFNγ and TNF will be two of the major cytokines released from activated lymphocytes 
(Bartholomäus et al. 2009). Moreover, increased expression levels of TNF and IFNγ have 
been detected in the meninges of F+ SP-MS cases, expressed by activated macrophages and 
cytotoxic T cells respectively (unpublished data). These cytokines would increase the 
adhesion molecule expression by cerebral endothelia and re-initiate the infiltration of T cells 
(Cavender et al. 1989; Myers et al. 1992). Furthermore, studies increasing CSF IFNγ 
concentrations by either viral vector delivery or direct injection, have found microglial and 
astrocyte activation close to the pial surface (Vass & Lassmann 1990; Furlan et al. 2001). 
These results indicate that pro-inflammatory signalling in the meninges spreads to the cortex 
either by direct diffusion of cytokines across the pia mater/glia limitans or is transduced by 
immune-competent meningeal cells (Wieseler-Frank et al. 2007). 
5.3.1.2	  B	  cell	  follicles	  are	  not	  a	  feature	  of	  the	  model	  
The infiltration of B cells exclusively to the meninges is consistent with the distribution 
observed in GMLs of MS cases (Frischer et al. 2009; Magliozzi et al. 2010). Due to 
inconsistency of staining, quantification of plasma cells could not be carried out, but they 
were detected in the meninges of animals with demyelination and have been detected in the 
meninges of SP-MS cases with extensive subpial lesions (Magliozzi et al. 2007; Frischer et 
al. 2009). These findings, together with the requirement for an anti-MOG humoral response 
suggests that antibodies may play a primary role in the pathogenesis of cortical 
demyelination. The failure to detect significant complement and immunoglobulin deposition in 
MS GMLs has been suggested to show that this mechanism is not involved in GML 
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pathogenesis (Brink et al. 2005; Frischer et al. 2009). However, due to the chronic nature of 
the disease, it is possible that the relative inactivity of the vast majority of GMLs studied in MS 
and the acute, transitory nature of immunoglobulin/ complement-mediated demyelination has 
led to an underestimation of this mechanism in the pathogenesis of GML. Further studies 
investigating the deposition of complement /immunoglobulin in this model will be necessary to 
evaluate this hypothesis.   
It has recently been shown that the meninges of MS patients are able to support the 
formation of ectopic lymphoid-like germinal centre reactions similar to those occurring in the 
B-cell zones of secondary lymphoid organs upon antigenic stimulation (Serafini et al. 2004).	  
These B cell follicles are present in other chronic autoimmune diseases, such as rheumatoid 
arthritis, and are believed to have a role in propagating the immune response in the target 
organ (Aloisi & Pujol-Borrell 2006). In addition, B cell follicles are detected in the cerebral 
meninges of SJL and Biozzi ABH mice with chronic relapsing EAE (Magliozzi et al. 2004). It is 
highly likely that the effect of B cell follicles will be the maintenance of a compartmentalised 
immune response and a highly pro-inflammatory microenvironment (Uccelli et al. 2005; Aloisi 
& Pujol-Borrell 2006). Indeed, the presence of follicles in MS cases is associated with an 
accelerated disease course and exacerbated cortical pathology (Magliozzi et al. 2007; 
Magliozzi et al. 2010).	  
The germinal centre of lymphoid follicles is the site of clonal expansion of antigen-activated B 
cells and differentiation into memory B cells and plasma cells secreting high affinity 
antibodies (Uccelli et al. 2005; Aloisi & Pujol-Borrell 2006). In F+ SP-MS cases, B cell follicles 
consisted of networks of proliferating memory B and T cells, antibody secreting plasma cells, 
and a network of supporting FDCs (Serafini et al. 2004; Magliozzi et al. 2007; Magliozzi et al. 
2010). The presence of these follicles was associated with increases in the number of 
meningeal macrophages secreting TNF and IFNγ secreting cytotoxic T cells (Magliozzi et al. 
2010; unpublished data). Follicles are believed to form during chronic, high levels of 
inflammation and are associated with the expression of key attractant chemokines such as 
CXCL13 (B cell chemoattractant), B cell activating factor (BAFF) and CCL21 (Magliozzi et al. 
2004; Uccelli et al. 2005; Aloisi & Pujol-Borrell 2006). Data presented in this chapter show 
that although B cells infiltrate the meninges, large collections of cells reminiscent of B cell 
follicles do not occur at any time-point in the experiment. 
Studies in EAE models have established that follicle formation occurs only in those animals 
experiencing a particularly high degree of meningeal inflammation, which is sustained in 
chronic disease (Magliozzi et al. 2004). Furthermore, follicle formation was found to require 
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signalling by the TNF-related cytokine, lymphotoxin α1β2 (Columba-Cabezas et al. 2006). It is 
hypothesised that the failure to reproduce lymphoid follicle neogenesis in this model is due to 
the rapid loss of the pro-inflammatory microenvironment in the meninges. A further 
explanation could be that injection of TNF and IFNγ does not cause sufficient release of 
molecules such as CXCL13, BAFF and lymphotoxin α1β2, which have been shown to facilitate 
follicle formation (Magliozzi et al. 2004; Columba-Cabezas et al. 2006). In order to test this 
hypothesis studies may require the incorporation of the chemokines mentioned above into the 
cytokine injection. Alternatively studies may aim to utilise slow release mechanisms in order 
to maintain a pro-inflammatory microenvironment in the meninges. These are discussed at 
greater length elsewhere. 
5.3.1.3	  Cytotoxic	  T	  cells	  are	  the	  most	  prevalent	  lymphocyte	  in	  the	  parenchyma	  
The relative paucity of T cells in the parenchyma and the scattered distribution away from 
areas of demyelination supports the hypothesis that direct action of lymphocytes may not be 
an important factor in GML pathogenesis. T cells were relatively rare in the cortex with a clear 
preponderance of cytotoxic T cells, a similar finding to that observed in GML of SP-MS 
patients (Peterson et al. 2001; Bö et al. 2003b; Frischer et al. 2009). This relative lack of Th 
cell infiltration is in contrast to lesions produced in a similar focal model involving direct 
intracortical injection (Merkler, Ernsting, et al. 2006), indicating a key advantage of the 
present model in accurately replicating MS GM pathology. As previously discussed, this 
difference is likely to be due to the maintenance of BBB integrity in the present study.  
Cytotoxic T cells were found in significantly greater numbers in rmMOG-immunised animals 
than IFA immunised animals, indicating that anti-MOG specificity is important in initiating and 
maintaining lymphocyte presence in the parenchyma. This data supports the hypothesis of 
antigen-specific reactivation of anti-MOG lymphocyte clones in the meninges. Thus, the 
environment in this compartment would be more pro-inflammatory in rmMOG-immunised 
animals than in IFA immunised animals. Antigen-specific cytotoxic T cells have been shown 
to be highly efficient at crossing the BBB via induction of tight junction abnormalities and 
astrocyte activation in a perforin dependent manner (Suidan et al. 2008). These results 
indicate that cytotoxic cells can enter the cortical parenchyma via a different mechanism than 
Th cells and may explain the increased number of cytotoxic T cells in the absence of Th cell 
infiltration in this model. 
It has been reported that CD8 expression by microglia/macrophages interfered with 
quantification of cytotoxic T cells in a focal EAE model targeting the cortex (Merkler et al. 
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2006). No expression of CD8 was found on cells with a microglia/macrophage-like 
morphology in this model. The presence of CD8 expression on highly activated amoeboid, 
foamy macrophages in the inflamed spinal cord of DA rats with disseminated EAE (data not 
shown, (Schroeter et al. 2003), argues against strain differences in CD8 expression and 
indicates differential pathogenesis between white matter and grey matter demyelination, as 
well as between this model and a model of GML involving loss of BBB integrity and 
macrophage invasion. 
The lack of lymphocyte infiltration in the GM in this model is in contrast to the spinal cord 
WMLs in disseminated EAE, where Th1 and cytotoxic T cells are present in abundance and 
are thought to play a key role in pathogenesis (Lassmann et al. 1988; Storch et al. 1998a; 
Dittel 2008). This data supports the hypothesis that the mechanisms of demyelination are 
different in the WM and GM. However, the number of T cells infiltrating the corpus callosum 
was higher than the corresponding GM in this model, in the absence of demyelination, which 
may indicate that lymphocyte infiltration alone is not sufficient to cause WM demyelination. 
The location of many callosal infiltrating lymphocytes in perivascular spaces, identifies WM 
blood vessels as the points of entry. The location of these cells far from the injection site 
indicates the presence of CSF drainage pathways from the sagittal sulcus into the corpus 
callosum. Although no studies have investigated drainage pathways from the sagittal sulcus, 
studies with injection into the caudate putamen have shown that Indian ink drains laterally 
along the axon tracts of the corpus callosum (Zhang et al. 1992; Kida et al. 1993). Although 
Indian ink was not observed to drain along this route in the present study, it is possible that 
the injected cytokines may be more readily diffusible. Alternatively, the activation of callosal 
endothelia may be caused by secondary cytokine release from activated lymphocytes. The 
requirement for anti-MOG specificity for infiltration of cytotoxic T cells, and time-point of 
maximal infiltration in the model supports the latter hypothesis.  
5.3.1.4	  Microglia/macrophage	  activation	  is	  correlated	  with	  demyelination	  
As previously discussed, the infiltration of lymphocytes to the meninges precedes the 
maximum extent of demyelination and microglia activation. Microglia are not activated to the 
same extent by cytokine injection in animals without a pre-existing immune response against 
myelin. This may imply that cytokine release by anti-MOG re-activated lymphocytes, present 
in the meninges, is required to activate parenchymal microglia. Furthermore, activated 
monocytes/macrophages were present in the meninges after lymphocyte infiltration, and were 
highly correlated with demyelination. This data supports the view that infiltration of 
monocytes/macrophages into the meninges is enhanced by localised lymphocyte activation. 
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The correlation of cortical microglial activation with demyelination in this model strongly 
implicates this cell type in the pathogenesis of GMLs. These findings replicate data from a 
similar model of GMLs, elicited following direct intracortical cytokine injection (Merkler et al. 
2006b). In addition, a gradient of activated microglia was present with the highest number in 
layer I close to the pial surface at the peak of demyelination. This gradient was also observed 
in subpial GML in F+ SP-MS cases with significant meningeal inflammation (Magliozzi et al. 
2010). The number of microglia in the cortex of MS cases was found to significantly correlate 
with the number of lymphocytes (Dal-Bianco et al. 2008). Furthermore, subpial microglial 
activation has been observed in the spinal cord following subarachnoid injection of IFNγ 
(Vass & Lassmann 1990). Taken together this data strongly supports the role of meningeal 
inflammation in the activation of cortical microglia and subsequent demyelination. However, 
the correlation between microglial numbers with demyelination does not necessarily imply 
that they are main effector cell in lesion formation. For example, the presence of microglia is 
also highest at the peak of demyelination in the cuprizone model, where demyelination is 
caused by toxin-induced oligodendrocyte apoptosis (Mason et al. 2004). In this model, 
microglia are not thought to play a significant role in pathogenesis, but carry out the 
phagocytosis of myelin debris. However, it has been reported that microglial inhibition by 
minocycline administration can attenuate demyelination in the cuprizone model, though the 
reason for this is unknown as no effect on oligodendrocyte was noted (Skripuletz et al. 2010). 
The widespread activation of microglia indicates that secondary inflammatory signalling is 
occurring, as it is highly unlikely that the injected cytokines would diffuse so extensively 
throughout the cortex. Furthermore, the greater number of microglia in animals with a pre-
existing anti-MOG response implies a degree of antigen specificity in the propagation of 
inflammation. The upregulation of MHCII molecules by activated microglia is well established 
(Aloisi et al. 1999a). This upregulation makes microglia highly efficient APCs for T cells, 
causing activation and proliferation of naive cells and differentiation of cells to the Th1 
phenotype to a greater extent than B cells or astrocytes (Aloisi et al. 1999a). However, the 
fact that very few lymphocytes are present in the parenchyma argues against this process 
being important in the pathogenesis of this model.  
Microglia were observed in close contact with neuronal cell bodies within the focal lesions 
and in the NAGM, replicating data from MS GML (Peterson et al. 2001). This may be 
indicative of synaptic stripping occurring in the cortex. Synaptic stripping is believed to be a 
neuroprotective mechanism and has been hypothesised to occur in the demyelinated cortex 
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of MS cases and in EAE lesions in the brain and spinal cord (Streit & Graeber 1993; Bauer et 
al. 1994; Rasmussen et al. 2007; Vercellino et al. 2007; Wake et al. 2009). 
Microglia may cause demyelination by several different mechanisms. They release 
components of the complement pathway, which can lead to formation of the MAC and direct 
cytotoxicity of oligodendrocytes/myelin. Microglia also phagocytose antibody/complement 
opsonised myelin through engagement of Fc and complement receptors (CR-1 and CR-3, 
Mosley & Cuzner 1996). Increased Fc receptor expression is detected on activated microglia 
in chronic active lesions and is associated with myelin damage (Hill et al. 2004). The 
expression of CD68 and close proximity to myelin/oligodendrocytes implies that microglia 
have a phagocytic phenotype in this model (Bauer et al. 1994; Damoiseaux et al. 1994). 
Moreover, CD68 expressing microglia were mainly localised to areas of demyelination and 
few were present in the cortex of control animals. 
Activated microglia release IFNγ, which activates Th1 cells and is inhibitory to myelination 
(Lin et al. 2006). Activated microglia also release TNF, which may induce apoptosis of 
oligodendrocytes and neurons through TNFR1A receptor signalling and caspase activation 
(Akassoglou et al. 1998; Selmaj et al. 1998). In addition, the release of TNF from activated 
microglia can cause excitotoxicity, through impairment of glial glutamate transporters 
(reviewed Pickering et al. 2005). TNF stimulates expression of the glutamate synthesising 
enzyme glutaminase, and glutamate release in microglia, via activation of the TNFR1A 
receptor (Takeuchi et al. 2006). TNF activates microglia to release more glutamate and cause 
greater neurotoxicity than other cytokines (Takeuchi et al. 2006). Activated microglia increase 
expression of iNOS and release NO, which may have many pathological effects in MS, 
including direct toxicity to myelin and oligodendrocytes, conduction block in axons and 
reducing the integrity of the BBB (Merrill et al. 1993; Mitrovic et al. 1995; Mitrovic et al. 1996; 
Redford et al. 1997; Smith et al. 2001). However, recent research has indicated that NO may 
also mediate anti-inflammatory effects through increased apoptosis of inflammatory cells 
(Willenborg et al. 2007).  
Microglia may also play a positive role in the resolution of inflammation, through release of 
anti-inflammatory cytokines such as IL-10 and TGFβ, which inhibit IL-1β and TNF release 
(Aloisi et al. 1999b). The phagocytosis of myelin debris can result in an anti-inflammatory 
phenotype with increased expression of IL-10 (Boven et al. 2006), and may be necessary to 
aid remyelination (Kotter et al. 2001; Streit 2002; Kotter et al. 2005; Neumann et al. 2009). 
Moreover, pharmacological inhibition of microglial activity in a model of toxin-induced 
demyelination has been shown to inhibit remyelination (Li et al. 2005). Microglia can also 
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have neuroprotective effects through the release of neurotrophic factors such as FGF (Liu et 
al. 1998), BDNF (Stadelmann et al. 2002) and insulin-like growth factor 1 (IGF-1, Mason et al. 
2000).  
Data presented in this chapter has therefore associated microglia with cortical demyelination, 
but the potential mechanistic implications have not been fully studied. Further experiments 
will be needed to elucidate the function of this cell type in the model. Important lines of 
investigation will include the potential ingestion of immunoglobulin/complement/myelin 
components. Studies will also seek to elucidate the expression of important pro-inflammatory 
molecules such as iNOS, TNF and IFNγ that have each been shown to be toxic to 
oligodendrocytes and myelin. 
5.3.1.5	  Oligodendrocyte	  loss	  may	  precede	  demyelination	  
The significant reduction in oligodendrocyte density in the upper cortical layers at early time-
points indicates that oligodendrocyte loss may precede demyelination in this model. 
Oligodendrocyte loss precedes demyelination in the cuprizone induced model of cortical 
demyelination and in genetic models of oligodendrocyte cell death (Mason et al. 2000; Mason 
et al. 2004; Pohl et al. 2011), and is the primary factor in a subset of WM MS lesions, and in 
recently described “pre-phagocytic” lesions (Barnett & Prineas 2004). Furthermore, the 
finding of reduced oligodendrocyte numbers even in the apparently normal myelinated cortex 
in SP-MS cases may indicate that demyelination follows oligodendrocyte loss (Lucchinetti et 
al. 2000). 
At the peak of demyelination in the present study, the number of APC+ oligodendrocytes was 
similar to that seen in the naive rat. APC expression has recently been found to occur in post-
mitotic, but not yet myelinating NG2+ cells (Kitada & Rowitch 2006). Therefore, it is 
theoretically possible that newly differentiating OPC’s within demyelinated lesions were 
counted as oligodendrocytes in this study. Previously, the maximal number of maturing 
OPC’s was found to coincide with the maximal area of demyelination, with rapid 
differentiation and restoration of mature oligodendrocyte cell bodies also preceding 
myelination (Mason et al. 2004). However, a separate study indicated that APC is expressed 
at a similar time to other commonly used myelin markers (NogoA, PLP) in OPC differentiation 
during remyelination (Kuhlmann et al. 2008). Furthermore, the observation of scattered 
oligodendrocytes with a ramified appearance expressing MOG in areas of demyelination, 
replicates GML pathology in MS patients (Magliozzi et al. 2010). It is currently unclear 
whether these cells are recently differentiated oligodendrocytes in the process of myelination, 
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or mature oligodendrocytes that have lost their myelin sheath. Complement and antibody-
mediated demyelination has been shown to mediate myelin phagocytosis with survival of the 
oligodendrocyte soma (Keirstead & Blakemore 1997). However, following demyelination, 
post-mitotic oligodendrocytes have been shown to be incapable of regenerating a functional 
myelin sheath (Keirstead & Blakemore 1997). Therefore, it is possible that these cells are 
OPC’s, which have been shown to express “mature” myelin markers in vivo (Li et al. 2002). 
However, further studies will be required to differentiate between these two possibilities. 
The non-significant trend for loss of oligodendrocytes in layer I in control animals, indicates 
the potential non-specific effects of surgery causing oligodendrocyte cell loss. However, the 
absence of significant demyelination in control animals at any time-point argues against this 
hypothesis, as loss of the cell body would be expected to initiate myelin breakdown and 
phagocytosis by resident microglia. Furthermore, it is possible that the expression of APC 
protein is reduced in times of cell stress, but there is currently a lack of available data for this.  
The contradictory results observed in this study highlight the need for the use of multiple 
markers in quantifying oligodendrocyte loss. A typical marker of oligodendrocyte cell bodies is 
NogoA (Kuhlmann et al. 2008). However, in the present study reliable NogoA staining could 
not be achieved. Staining with cell body/myelin markers such as CNPase was successful, 
however, it was deemed unfeasible for the reliable quantification of oligodendrocytes due to 
the high density of myelin in deeper cortical layers. A feasible method of quantifying mature 
oligodendrocytes may be the detection of mRNA expression of late stage myelin genes (e.g. 
PLP by in situ hybridisation). In addition, it has been reported that the transcription factor 
Olig1 is present in the cytoplasm of mature oligodendrocytes (Ligon et al. 2006). However, its 
presence in the nucleus of OPCs may impair the reliability of quantification.  
5.3.1.6	  Astrocyte	  changes	  in	  the	  demyelinated	  lesion	  
The reduction in density of astrocytes in layer I at early time-points and slight increase 7 
days-post-injection, could be indicative of rapid cell loss and replacement in response to 
cytokine injection, but is more likely to reflect reactive gliosis occurring in the upper cortical 
layers in response to demyelination/cytokine injection. Astrocyte activation and reactive 
gliosis has been reported in demyelinating models following intra-parenchymal injection of 
IFNγ and TNF (Sun et al. 2004; Merkler et al. 2006b), following subarachnoid space injection 
of IFNγ (Vass & Lassmann 1990), as well as in transgenic animals with over-expression of 
TNF and in vitro systems (Probert et al. 1995; Probert et al. 2000; Selmaj et al. 1990).   
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These results are in contrast to the pathology observed in F+ SP-MS cases, which exhibited a 
graded loss of astrocytes from the pial surface (Magliozzi et al. 2010). Furthermore, in these 
cases there is significant disruption to the glia limitans at the pial surface of lesions, indicating 
that cytotoxic molecules may be diffusing into the cortex from the meninges. This difference is 
likely to be due to the acute and transitory nature of the inflammatory process occurring in the 
model, compared to the chronic inflammation occurring in GML of SP-MS cases. An 
assessment of the integrity of the glia limitans in this model was carried out in a BSc research 
project under the author’s supervision. The results of this research are detailed in Appendix 
A1. The project described the changes occurring to the pial surface within this model of 
cortical demyelination. Disruption of the glia limitans at the pial surface and surrounding 
cerebral blood vessels has been detected in GML of cases with exacerbated meningeal 
inflammation (Magliozzi et al. 2010). Disruption of the pial surface (GFAP expression) was 
evident in each experimental condition following injection. Disruption was most severe one 
day following sagittal sulcus injection, but was not present at the peak of demyelination. 
Disruption of the pial surface was associated with fibrinogen leakage into the cortex, and 
reduced expression of aquaporin 4 in astrocytes. Immunofluorescence for laminin revealed 
little change to the basement membrane following injection. These results indicate that 
changes caused by the injection are short lived and that morphology at the peak of 
demyelination reflects the intact BBB observed in intracortical vessels of SP-MS cortex (van 
Horssen et al. 2007). These results further suggest that a chronic inflammatory environment 
is required to cause significant damage to the glia limitans (Magliozzi et al. 2010). The 
leakage of fibrinogen at early time-points may be responsible for the increased microglia 
numbers in layer I of all cases (Adams et al. 2007; Hooper et al. 2009). Furthermore, the 
disruption to the pial surface could be responsible for the influx of monocytes observed at 
early time-points post-injection. The lack of demyelination in rmMOG-immunised animals 
injected with PBS argues against the surface disruption allowing pathogenic anti-MOG 
antibodies into the cortex and causing demyelination.  
5.3.1.7	  Neurons	  were	  not	  lost	  following	  acute	  subpial	  demyelination	  
Measurements of neuronal density established that neurodegeneration is not a feature of the 
acute model of sup-pial GMLs developed in this thesis. This is in contrast to the extensive 
neurodegeneration observed in F+ SP-MS cases, which exhibit a graded loss of neurons and 
the presence of apoptosing cells (Peterson et al. 2001; Magliozzi et al. 2010). The lack of 
neurodegeneration in a similar model of transitory GM demyelination supports the hypothesis 
that a chronic inflammatory environment is required to cause neuronal loss (Merkler et al. 
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2006b). For example, the chronic expression of high levels of TNF in the substantia nigra of 
rats by a viral vector system caused substantial microgliosis and neurodegeneration, over a 
time-period of 100 days (Chertoff et al. 2011). 
In light of the lack of neuronal loss, acute markers of axonal pathology were investigated. The 
presence of axonal pathology in MS lesions was first detected in Charcot’s initial studies in 
the mid-19th Century. In recent years, imaging studies have suggested that axonal loss 
begins in the earliest stages of MS and correlates with disability (Bjartmar et al. 2000; Filippi 
et al. 2003). In studies of pathology, axonal stress is typically defined using IHC for APP 
(Gentleman et al. 1993). APP is transported efficiently in the normally functioning axon. 
However, following transection, or at times of axonal stress, normal transport is disrupted and 
APP accumulates in “axonal spheroids”. APP+ spheroids are present in each stage of MS, in 
both acute and chronic lesions (Trapp et al. 1998; Bitsch et al. 2000; Frischer et al. 2009), 
and have been found in GM lesions (Peterson et al. 2001). APP+ spheroids correlate with the 
presence of inflammatory cells in WMLs (Ferguson et al. 1997; Bitsch et al. 2000; Frischer et 
al. 2009), and with activated microglia in GMLs (Peterson et al. 2001), and an animal model 
of GMLs (Merkler et al. 2006b). There is some debate as to whether axons with APP 
accumulation are irreversibly damaged (Ferguson et al. 1997; Trapp et al. 1998; Bitsch et al. 
2000).  
In this study, APP expression was detected in the cortex following injection of cytokines into 
the motor cortex. This is in accordance with a model of focal demyelination in the cortex of 
the Lewis rat following injection of cytokines (Merkler et al. 2006b). No APP+ spheroids were 
detected in subpial lesions following sagittal sulcus injection of cytokines. However, APP was 
detected in many cells infiltrating the meninges, which are likely to be macrophages and in 
blood vessel endothelia. APP expression has been detected in these cells in human tissue 
(Gehrmann et al. 1995). Transected axons and dendrites can also be detected using IHC for 
neurofilament proteins, with spheroid end-bulbs visible (Trapp et al. 1998). In this study some 
evidence of spheroids was observed in the molecular layer of subpial lesions. However, this 
evidence is not conclusive due to the interlaced nature of dendrites in this layer. Whilst 
evidence of axonal stress within this model is lacking, the possibility of more subtle changes 
cannot be ignored. Research has indicated that synapses are lost in GML in SPMS cases 
with a high proportion of activated microglia (Vercellino et al. 2007). In order to answer these 
questions the expression levels of markers of synapses, such as synaptophysin, or proteins 
involved in responses to excitotoxic processes, such as pJNK, could be studied across time-
points (Vercellino et al. 2007). 
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5.3.2	  The	  resolution	  of	  subpial	  lesions	  
5.3.2.1	  The	  resolution	  of	  inflammation	  
In the present model, the single injection of pro-inflammatory cytokines is sufficient to elicit 
immune cell infiltration, activation and demyelination. However, over time pro-inflammatory 
cytokine release is reduced, and anti-inflammatory cytokine release may be increased. As a 
result, endothelial cells of meningeal blood vessels will become de-activated and down 
regulate expression of the adhesion molecules necessary for leukocyte infiltration. It seems 
likely that maintaining the release/presence of pro-inflammatory cytokines, in the 
subarachnoid space, will cause chronic inflammation in this compartment and possibly lead to 
chronic demyelination and cortical cell loss.  
Recent research has suggested that the resolution of inflammation is an active process and 
not merely the loss of pro-inflammatory signalling (Serhan et al. 2007; Perretti & D'Acquisto 
2009). A recently identified CD4+ T cell subset has been shown to possess important 
regulatory functions (Anderton & Liblau 2008). Tregs are characterised by expression of 
CD25 and the transcription factor FoxP3. Tregs play an essential role in maintaining T cell 
tolerance in the normal mammal and their depletion of lowers the threshold for initiation of 
EAE i.e. a lower dose of myelin protein is required to initiate disease (Kohm et al. 2006). 
MOG-specific Tregs proliferate during EAE and are essential for disease resolution in a 
monophasic mouse model (McGeachy et al. 2005). It is highly likely that Tregs play a role in 
the resolution of inflammation in this model. IHC methods of detection on cortical sections 
were investigated in these experiments; however, reliable staining could not be achieved. 
This cell type is typically identified by flow cytometry for the FoxP3 transcription factor, future 
studies could be conducted utilising demyelinated tissue, meningeal explants or CSF for use 
in flow cytometry studies.  
Subsets of cytokines are considered anti-inflammatory in autoimmune models, that is, they 
skew the immune response away from Th1 responses to a Th2 response. TGFβ, which may 
be released by activated microglia, plays a role in EAE resolution. Administration of blocking 
antibodies to TGFβ exacerbates EAE, whereas exogenous administration attenuates EAE 
(Racke et al. 1991). Recovery in EAE models is associated with expression of IL-10 and IL-4 
(Kennedy et al. 1992). IL-10 may be particularly important in EAE resolution as IL-10 KO 
mice exhibit severe EAE (Bettelli et al. 2003b) and direct CNS administration of IL-10 
attenuates EAE (Croxford et al. 2001). B cells have been identified as important sources of 
IL-10 in EAE. Preventing IL-10 release specifically from B cells produces severe EAE that 
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does not resolve (Fillatreau et al. 2002). In order to answer questions on the dynamics of pro-
inflammatory vs. anti-inflammatory signalling, further study will be required. This could take 
the form of measuring expression or concentration of these proteins using RT-PCR or ELISA 
analysis. 
5.3.2.2	  Remyelination	  in	  the	  cortex	  
Remyelination is the process of regenerating a functional myelin sheath to demyelinated 
axons and is observed in GML in SP-MS (Albert et al. 2007) and in animal models of cortical 
demyelination (Merkler et al. 2006b; Skripuletz et al. 2008). While remyelination successfully 
restores saltatory conduction, the thickness of the regenerated myelin sheath is reduced 
compared to normal myelin (Blakemore 1974). The gold standard for identifying remyelination 
is the use of electron microscopy to measure the G-ratio, the relationship between the 
diameter of an axon and the diameter of the myelin sheath surrounding it. Since 
remyelination forms a thin myelin sheath, a larger than average G ratio, i.e. a relatively 
enlarged axon diameter, indicates remyelination. Due to the orientation of axons in the medial 
areas of the cortex close to the sagittal sulcus, obtaining suitable sections for electron 
microscopy would represent a significant technical challenge. For this reason, a fully 
controlled, extensive study of the G-ratios present in remyelinated tissue was not considered 
feasible. Nevertheless, the extensive demyelination observed in the cortex of animals seven 
days post-injection and phenotypically normal myelin distribution observed in animals culled 
14 days post-injection, indicates that remyelination has taken place. Furthermore, the 
remyelination observed in this study occurs over a similar time-period to a similar model 
involving direct intracortical cytokine injection, which was demonstrated using electron 
microscopy (Merkler et al. 2006b).  
The finding that cortical remyelination is complete within seven days is in contrast to a similar 
model of focal demyelination in the spinal cord white matter, which remyelinated over a 
longer timescale (Kerschensteiner et al. 2004a). This data indicates that WML and GML may 
differentially support inflammatory and remyelinating processes. Post-mitotic 
oligodendrocytes cannot remyelinate bare axons (Keirstead & Blakemore 1997). 
Remyelination is carried out by maturation of OPC’s, a population of cells distributed 
throughout the CNS that migrate to, proliferate and mature in sites of demyelination 
(Reynolds et al. 2003; Franklin & ffrench-Constant 2008). OPCs exist in a 1:1 ratio with 
oligodendrocytes in the GM, compared to 1:4 in spinal cord WM (Reynolds et al. 2003). This 
indicates that one round of cell division is sufficient to repopulate any lost oligodendrocytes in 
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the GM, and may contribute to the relatively rapid remyelination observed in focal GMLs 
compared to focal WMLs (Kerschensteiner et al. 2004a; Merkler et al. 2006b).  
Recent reports have suggested a critical role for components of the immune response in 
OPC differentiation. Indeed, acute inflammation has been shown to stimulate OPC 
differentiation in chronically demyelinated tissue (Foote & Blakemore 2005). Phagocytosis of 
myelin by macrophages has been shown to stimulate OPC differentiation and remyelination 
in a toxin induced model of WML (Kotter et al. 2001; Kotter et al. 2005). Microglial 
proliferation accompanies the expansion of OPCs and numbers of both these populations 
correlate with the maximal extent of cuprizone-induced demyelination (Matsushima & Morell 
2001). This proliferation may be associated with the need for efficient myelin removal by 
phagocytosis before remyelination can occur (Kotter et al. 2001; Kotter et al. 2005; Pohl et al. 
2011). The release of IGF-1 from microglia and astrocytes plays an important role in 
facilitating remyelination (Matsushima & Morell 2001; Mason et al. 2004). Moreover, the 
overexpression of IGF-1 protects oligodendrocytes during demyelination and accelerates the 
remyelination process (Mason et al. 2000). TNF, via activation of TNFR1B has been shown to 
facilitate remyelination in the cuprizone model, whereas IFNγ expression has been shown to 
be inhibitory to remyelination (Arnett et al. 2001; Lin et al. 2006). 
Data presented in this chapter suggests that this model is a viable model of GM 
remyelination. In contrast to toxin-induced models, this model accurately reflects the 
inflammatory demyelination observed in MS GMLs. In order to further evaluate the dynamics 
of remyelination it may be desirable to calculate the number of cells expressing the 
chondroitin sulphate proteoglycan NG2, an established marker of OPC’s (Reynolds et al. 
2003). The study of the expression IGF-1 may also shed light on the dynamics of GM 
remyelination. Other mediators that have been shown to have an influence over remyelination 
in the forebrain include, platelet-derived growth factor (PDGF), and fibroblast growth factor 2 
(FGF-2, Franklin & ffrench-Constant 2008; Kipp et al. 2009). Investigation of the expression 
of these proteins may elucidate the mechanisms of remyelination in this model and provide 
insight into remyelination in GML of MS cases (Albert et al. 2007). It is not known why 
remyelination eventually fails in MS patients, but it has been hypothesised that inhibitory 
factors, or the absence of stimulating factors, in chronically demyelinated lesions prevents 
OPC differentiation (Foote & Blakemore 2005; Franklin & ffrench-Constant 2008; Kuhlmann 
et al. 2008). Furthermore, given that MS is a chronic disease, the effects of aging on the 
efficiency of remyelination need to be considered. The effect of repeated episodes of 
demyelination may be to reduce or exhaust the pool of OPCs. This hypothesis is 
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controversial, although the number of OPC’s is reduced in chronically demyelinating models 
(Mason et al. 2004). However, this finding has not been repeated in models of repeated focal 
demyelination (Penderis et al. 2003).  
5.3.3	  Conclusions	  
The data presented in this study show acute subpial demyelination in response to 
subarachnoid space injection of cytokines in rmMOG-immunised animals. The pattern of 
lymphocyte and microglial/macrophage distribution is reminiscent of that seen in GML of F+ 
SP-MS cases. The extensive infiltration of lymphocytes and macrophages in the meninges 
supports the hypothesised role for meningeal inflammation in GML pathogenesis. 
Furthermore, the gradient pattern of microglial activation and correlation of microglial activity 
with demyelination indicates a key role of this cell type in cortical demyelination. The 
pathological features of this model compare favourably with existing models of GML, which 
do not accurately replicate the cellular distribution observed in MS GMLs. 
Subsequent experiments will seek to elucidate the mechanism of demyelination occurring in 
this model. Immunohistochemistry will be used to detect antibody/complement deposition on 
myelin and oligodendrocytes. LCM by quantitative RT-PCR will uncover the influence of 
cytokines and their receptors in the pathogenesis of the induced GML.  
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6.1	  Introduction	  
6.1.1	  Immunoglobulins	  and	  complement	  in	  MS	  
6.1.1.1	  Complement	  and	  immunoglobulins	  in	  WMLs	  
Antibody and complement deposition is thought to be a major mechanism of demyelination in 
MS and EAE as deposition of both elements have been frequently observed on myelin in 
actively demyelinating areas of WMLs (Storch et al. 1998a,b; Lucchinetti et al. 2000; Breij et 
al. 2008). Deposits were co-localised with myelin fragments following phagocytosis by foamy 
macrophages. Moreover, injection of purified MOG antibodies has been shown to exacerbate 
EAE and cause widespread spinal cord demyelination (Lassmann et al. 1988; Linington et al. 
1988). The potential for demyelination by anti-MOG antibodies has been related to the ability 
to fix complement (Piddlesdon et al. 1993). 
6.1.1.2	  Complement	  and	  immunoglobulins	  in	  GM	  pathology	  
Deposition of complement components has not been observed in purely intracortical lesions 
(type II and III) of SP-MS cases (Brink et al. 2005). In MS and EAE, it has been shown that 
the most extensive complement/immunoglobulin deposition occurs at the leading edge of 
highly active WMLs, with an absence of terminal complexes in chronic inactive lesions 
(Storch et al. 1998a,b; Lucchinetti et al. 2000; Barnett & Prineas 2004). Due to the lack of 
demyelinating and inflammatory activity observed in post-mortem chronic GMLs, and the lack 
of available biopsy samples it may be hypothesised that complement/antibody deposition is 
involved in GML pathogenesis but deposition is restricted to periods of active demyelination 
earlier in the disease process. It must be noted that there is currently no evidence for this 
hypothesis. 
Previous studies with a focal model of GML have observed perivascular complement and 
antibody deposits in lesions produced by pro-inflammatory cytokine injection to the motor 
cortex (Merkler et al. 2006b). However, it may be argued that since this model elicits 
substantial BBB disruption, the deposition of serum proteins is to be expected and may not 
play a significant role in lesion pathogenesis. An investigation of the role of these components 
in the pathogenesis of a model that more accurately reflects MS GML pathology would yield 
more reliable data. 
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6.1.2	  Molecular	  mechanisms	  in	  MS	  
6.1.2.1	  TNF	  pathways	  to	  demyelination	  
TNF is a key pro-inflammatory cytokine, interacting with and activating many immune cell 
subtypes. Expression by activated microglia/macrophages, astrocytes and endothelia has 
been detected in active WMLs in MS lesions and in EAE lesions (Selmaj et al. 1991a; 
Magliozzi et al. 2010), as well as in the meninges and CSF of MS patients (Maimone et al. 
1991; Baraczka et al. 2004; Magliozzi et al. 2010). The release of TNF has been shown to 
mirror the disease course in monophasic EAE in the Lewis rat, and in chronic progressive 
disease models in the DA rat (Issazadeh et al. 1995a; Issazadeh et al. 1996). CNS specific 
overexpression of TNF caused spontaneous CNS demyelination, which was associated with 
CD4+ and CD8+ T cell infiltration, microglia activation and oligodendrocyte apoptosis (Probert 
et al. 1995; Akassoglou et al. 1998). Further studies established that this could occur in the 
absence of lymphocyte infiltration, but did require functional microglia/macrophages 
(Kassiotis et al. 1999). TNF induced microglial activation has bee shown to induces glutamate 
release from hemichannels in an autocrine manner (Takeuchi et al. 2006), which can cause 
neurotoxicity and is key in the progression of disability in EAE (Pitt et al. 2000; Takeuchi et al. 
2006). In support of a direct role in demyelination, TNF has been shown to cause myelin 
damage and oligodendrocyte apoptosis in a JNK dependent manner in vitro (Selmaj & Raine 
1988; Selmaj et al. 1991b).  
TNF signalling is mediated by two receptor subtypes, the ubiquitously expressed TNFR1A 
and TNFR1B, which is expressed mainly by immune cells and microglia (McCoy & Tansey 
2008). TNFR1A interacts with a cytoplasmic death domain (FADD) and is capable of direct 
induction of caspase-mediated apoptosis (Chen & Goeddel 2002; Ihnatko & Kubes 2007). 
Other cellular effects, including cell survival and activation are mediated by TNF receptor-
associated factor 2 (TRAF2) and NFκB activation through the same receptor. Activation of the 
anti-apoptotic pathway is dependent on phosphorylation of the death domain (Ihnatko & 
Kubes 2007). TNFR1B does not directly activate the caspase pathway, and is considered to 
promote anti-apoptotic pathways through activation of NFκB (Horie et al. 1999). Activation of 
this receptor is neuroprotective in ischaemia reperfusion models (Fontaine et al. 2002), and 
causes proliferation of T cells (Tartaglia et al. 1993a; Grell et al. 1998). However, activation of 
TNFR1B may cause apoptosis through “ligand passing” to activate TNFR1A (Tartaglia et al. 
1993b).  
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TNFR1A signalling has been shown to cause demyelination and oligodendrocyte apoptosis 
(Akassoglou et al. 1998; Kassiotis et al. 1999), whereas TNFR1B signalling was required for 
OPC differentiation and remyelination after cuprizone withdrawal (Arnett et al. 2001). 
Furthermore, knockout of TNFR1A was found to attenuate EAE by reducing oligodendrocyte 
apoptosis, while TNFR1B KO leads to reduced T cells apoptosis and exacerbated pathology 
(Eugster et al. 1999). Mouse knockout models have identified critical roles for TNFR1A and 
Fas in oligodendrocyte apoptosis. Only mice with oligodendrocytes lacking both molecules 
were completely protected from EAE and did not show signs of clinical disease or 
demyelination and had only mild CNS lymphocyte infiltration (Hövelmeyer et al. 2005).  
6.1.2.2	  IFNγ	  in	  MS	  and	  EAE	  
IFNγ is considered the key cytokine in T cell development and responses. It induces T cell 
proliferation and causes naive T-cells to differentiate into Th1 cells, which are implicated in 
EAE pathogenesis (McGeachy & Anderton 2005). Moreover, it is released predominantly by 
CD4+ Th cells and CD8+ cytotoxic cells (Imitola et al. 2005). IFNγ is also a key activator of 
macrophages and microglia, causing upregulation of TNF, increased expression of MHCII, 
CD40 and CD54, transforming microglia into highly efficient APCs (Aloisi et al. 1999a,b; Aloisi 
et al. 2000). It also increases expression of iNOS in microglia/macrophages, with release of 
NO radicals leading to cytotoxicity (Ding et al. 1988; Jana et al. 2001). Furthermore, IFNγ 
stimulates astrocyte proliferation, production of TNF and expression of MHCII and adhesion 
molecules (Shrikant et al. 1994; Yong et al. 1991; Aloisi et al. 1999a).  
A pathogenic role in MS has been suspected since clinical trials in which administration of the 
protein caused disease exacerbation in RR-MS patients (Panitch et al. 1987). Furthermore, 
the expression of IFNγ by activated lymphocytes has been detected at the leading edge of 
actively demyelinating WMLs (Vartanian et al. 1995). In EAE studies, CNS expression of 
IFNγ was highest during the peak of disease and lowest during remission (Issazadeh et al. 
1995b). Expression of IFNγ	   in oligodendrocytes of mice caused EAE-like disease, with 
demyelination, microglial activation and lymphocyte infiltration (Horwitz et al. 1997). 
Conditional IFNγ expression by astrocytes led to reduced remyelination and differentiation 
block of OPCs in a toxic model of demyelination (Lin et al. 2006). 
Differential effects of IFNγ on cell survival have been shown in in vitro systems. IFNγ has 
been shown not to be directly cytotoxic to human oligodendrocytes, but upregulated Fas, 
promoting FasL interactions and leading to increased susceptibility to apoptosis (Pouly et al. 
2000). In contrast, in another study rat oligodendrocyte apoptosis was directly induced by 
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IFNγ, whereas neuronal apoptosis was not (Vartanian et al. 1995). In mouse organotypic 
slice cultures, IFNγ application has been shown to be toxic to oligodendrocytes by inducing 
IFNR/AMPA receptor interactions and increasing susceptibility to glutamate excitotoxicity 
(Mizuno et al. 2008).  
6.1.2.3	  Nitric	  oxide	  in	  MS	  and	  EAE	  
The free radical molecule NO has many biological functions. In the context of MS and EAE, 
NO has been shown to mediate both pathogenic and protective processes (Smith & 
Lassmann 2002). An elevated concentration of NO metabolites has been detected in the CSF 
of MS patients compared to both the healthy population and patients with non-inflammatory 
neurological disease (Danilov et al. 2003; Rejdak et al. 2004). Furthermore, within the MS 
population, NO metabolites have been correlated with the extent of MRI visible lesions and 
disease activity (Danilov et al. 2003; Rejdak et al. 2004). NO is produced by nitric oxide 
synthase, the key isoform of which (iNOS) is induced upon cell activation. Expression of 
iNOS by phagocytic microglia/macrophages and activated astrocytes has been detected in 
actively demyelinating WM, GM and EAE lesions (Bö et al. 1994b; Tran et al. 1997; Hill et al. 
2004; Magliozzi et al. 2010). Expression of iNOS is increased by the pro-inflammatory 
cytokines TNF and IFNγ, as well as by myelin phagocytosis (van der Laan et al. 1996; Mosley 
& Cuzner 1996; Jana et al. 2001; Jana et al. 2005) and has been correlated with disease 
severity in mouse EAE models (Okuda et al. 1997).  
NO and NO donors have been shown to reduce the integrity of the BBB, implicating a role in 
the pathogenesis and propagation of MS and EAE (Hurst & Fritz 1996; Mayhan 2000). 
Among glial cells, oligodendrocytes were found to be particularly susceptible to microglia 
derived NO toxicity by induction of mitochondrial dysfunction and necrosis (Merrill et al. 1993; 
Mitrovic et al. 1995). The mechanism of damage in oligodendrocytes may be induction of 
DNA strand breaks (J Zhang et al. 1994), lipid peroxidation (van der Veen & Roberts 1999), 
activation of matrix metalloproteinases (MMPs, Maeda et al. 1998), or accumulation of 
intracellular Ca2+ precipitated by mitochondrial disruption (Kapoor et al. 2003; Bechtold et al. 
2004). NO has also been shown to cause apoptosis and necrosis of neurons in vitro at 
differing concentrations (Bonfoco et al. 1995), as well as conduction block and degeneration 
of demyelinated axons (Redford et al. 1997; Smith et al. 2001). These results implicate iNOS-
mediated NO production in the pathology and clinical manifestation of MS and EAE. 
However, studies have consistently shown that genetic knock-out of the iNOS gene, or 
pharmacological inhibition of iNOS activity, cause an increase in CNS inflammation and an 
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exacerbation of EAE implicating a regulatory role for NO (Kahl et al. 2003; Dalton & Wittmer 
2005). This regulatory role is likely to involve a role in T cell apoptosis (Okuda et al. 1997). 
6.1.3	  Mechanisms	  of	  cortical	  pathology	  in	  MS	  
In contrast to WMLs, GMLs have only mild lymphocyte infiltration to the cortex, a lack of 
complement/antibody deposition and a normally functioning BBB (Bö et al. 2003b; Brink et al. 
2005; Leech et al. 2007; Magliozzi et al. 2007; van Horssen et al. 2007; Frischer et al. 2009; 
Magliozzi et al. 2010). This data suggests that the pathogenesis of demyelination may be 
distinct in GM and WM. However, there are currently few studies that have fully quantified 
cellular pathology and gained insight into the mechanisms that may be responsible. Recently, 
a substantial proportion of SP-MS patients have been shown to have extensive inflammation 
supporting lymphoid-like follicle structures in the meninges (F+ SP-MS, Serafini et al. 2004; 
Magliozzi et al. 2010). F+ SP-MS cases have a high degree of cortical pathology, with 
extensive oligodendrocyte and neuronal loss and a high degree of microglial activation in 
lesions (Magliozzi et al. 2010). The observed gradient pattern of cell loss, glial activation and 
disruptions to the glial limitans is strong evidence that the pro-inflammatory environment in 
the meninges is directly toxic to cortical cells.  
Detailed molecular analysis has revealed that the expression of iNOS and TNF by 
macrophages and IFNγ by cytotoxic T cells is increased in the meninges of F+ SP-MS cases 
(unpublished data). An increased expression of iNOS by microglia has also been detected in 
GMLs of F+ SP-MS suggesting that microglia and NO may play a prominent role in mediating 
cortical pathology (Magliozzi et al. 2010). In the same samples TNF expression levels were 
found to be normal in the GMLs but significantly increased in the NAGM. However, TNF 
expression by microglia has been detected in highly active GMLs of F+ SP-MS cases 
(Magliozzi et al. 2010). Further work established a dysregulation of TNF signalling pathways 
in these cases. TNFR1A expression was upregulated in neurons and oligodendrocytes of F+ 
SP-MS GMLs and NAGM (unpublished data). Furthermore, the expression of multiple genes 
involved in the downstream apoptotic signalling pathway was also upregulated. Taken 
together these results strongly suggest the involvement of TNF-mediated apoptotic pathways 
in the cell loss found in GMLs of MS cases with extensive meningeal inflammation, and also 
implicate activated microglia as being important in the observed pathology. 
Due to the relatively inactive nature of GML in late-stage SP-MS cases, the lack of biopsy 
tissue in these cases and the absence of a suitable animal model, the pathogenesis of GML 
has proved difficult to elucidate. However, it has been suggested that diffusion of toxic 
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mediators from the inflamed meninges may cause cortical pathology. In support of this 
hypothesis an animal model of subpial demyelination elicited by inflammation in the meninges 
has been produced in this thesis. We have shown the induction of acute subpial 
demyelination following injection of TNF/IFNγ into the subarachnoid space of rmMOG-
immunised animals. The lesions produced are pathologically reminiscent of those seen in 
subpial GML of MS cortex, with pronounced infiltration of lymphocytes and macrophages in 
the meninges and extensive cortical microglial activation in a gradient pattern. The induced 
pathology requires the injection of cytokines, but may not be directly mediated by them, and 
also requires a pre-existing immune response against a myelin protein, which may implicate 
the role of humoral elements in demyelination. However, the mechanism of demyelination in 
the model is currently undetermined. 
6.1.4	  Laser	  Capture	  Microscopy	  
Laser capture microdissection (LCM) is a technique allowing the precise sampling of tissue 
and cells for downstream molecular analysis. The PALM system (Zeiss) uses an ultraviolet 
(UV) laser to achieve laser microdissection and pressure catapulting (LMPC). The laser is 
focused to a minute focal point (<1µm), and at high energy “transforms” tissue into atoms that 
are blown away at high velocity, a mechanism termed photofragmentation. Non-contact 
tissue isolation is accomplished according to the following steps; cells of interest are 
visualised by microscopy, areas to be isolated are selected, cut by laser ablation and 
extracted from the microscope slide into an overlying eppendorf cap by laser pressure 
catapult (Espina et al. 2006). This approach to tissue isolation minimises the risk of physical 
contamination by avoiding sample contact. LCM is performed at room temperature, can be a 
time-consuming procedure and requires staining of tissue to obtain optimum extraction 
efficiency, factors which may compromise RNA integrity. LCM has been used to isolate RNA 
from snap-frozen mouse brain sections (Wang et al. 2009), with optimum results obtained 
when isolating 20µm alcohol dehydrated sections stained with 1% cresyl violet in 70% 
alcohol. Storage of tissue for short periods of time at -80°C had little effect on RNA integrity 
(Wang et al. 2009).  
6.1.5	  Aims	  of	  this	  study	  
This study aimed to elucidate the mechanisms involved in cortical demyelination following 
subarachnoid injection of cytokines. It was hypothesised that there would be a lack of 
complement/myelin deposition, and that demyelination would involve the release of toxic 
mediators such as iNOS, TNF and IFNγ in the cortex. This study aimed to: 
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• Determine the involvement of complement and immunoglobulin in GMLs 
• Investigation of molecular mediators of demyelination 
• Quantitate expression of iNOS, TNF, IFNγ and TNFR1A and 
TNFR1B in GMLs using LCM and RT-PCR 
• Determine the cellular localisation of mediators of inflammation 
using IHC and IF 
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6.2	  Results	  
6.2.1	  The	  humoral	  immune	  system	  in	  demyelination	  
6.2.1.1	  Deposition	  of	  complement	  
The deposition of complement was studied using double-labelled IF for C9, in animals 
immunised with rmMOG and injected with cytokines and corresponding control animals. 
Samples taken from 1-7 days post-cytokine injection were analysed, as well as naive 
animals. 
Extensive complement deposition was observed in actively demyelinating lesions of the 
spinal cord of rats with clinically defined EAE, which acted as a positive control for 
subsequent study (Figure 6.1 A). Complement deposits were detected in the meningeal 
space of naive animals (Figure 6.1 B). Extensive complement deposition was detected in the 
demyelinated region of one animal immunised with rmMOG, 7 days post-cytokine injection 
(Figure 6.1 C). This deposition occurred in a perivascular region and the surrounding 
demyelinated cortex, with some deposition evident on myelin sheaths at the edge of the 
lesion. The area of deposition was located some distance from the dorsal pial surface, which 
appeared physiologically normal, implying that deposition is unlikely to have been caused by 
the injection. Complement was observed deposited on cells in close opposition to MHCII+ 
microglia/macrophages, within the demyelinated lesion of one animal (Figure 6.1 D). The 
illustrated cell had a small, spheroid morphology reminiscent of an oligodendrocyte. 
Deposition of complement components was not detected at earlier time-points or in control 
animals (not shown).  
6.2.1.2	  Deposition	  of	  immunoglobulin	  
The deposition of immunoglobulin was detected using double-IF for IgG and myelin proteins. 
IgG was detected in demyelinated spinal cord lesions (Figure 3.5 C). In the naive cortex IgG 
was observed in the meninges, lining cerebral blood vessels and in peri-vascular regions of 
the cortex (Figure 6.2 A, B). IgG deposits in the cortical parenchyma were rare, but were 
detected close to the pial surface in the demyelinated cortex of one animal (Figure 6.2 C), 
and detected on myelin at the lesion edge of another animal 7 days post-cytokine injection 
(Figure 6.3 D). The field shown in Figure 6.3. D is approximately the same field as Figure 6.1 
C. Deposition of immunoglobulin was not detected at earlier time-points. 
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6.2.2	  Quantitative	  RT-­‐PCR 
6.2.2.1	  Primer	  efficiencies	  
Snap frozen EAE and naive spinal cord was crysosectioned at 50µm and RNA was extracted 
immediately using RNeasy mini lipid tissue kit (Qiagen). RT-PCR was then carried out as 
described in Chapter 2. The efficiency of Quantitect primers (Qiagen) was calculated using 
four log dilutions of RNA from a pooled sample of EAE spinal cord cDNA.  
For each gene of interest the amplification and dissociation curves were examined (Figure 
6.3 A, B). Replicates at each dilution had little variation in Ct value. Ct values increased by 
approximately 3 for each log dilution (Figure 6.3 A). Dissociation curves for each gene of 
interest showed only a single peak, indicating efficient binding of primer to sample DNA, a 
lack of contamination and no primer dimer formation. The specificity of PCR products was 
tested by electrophoresis on a 2% agarose gel. PCR products for each gene of interest 
corresponded to the manufacturer’s predicted size (Figure 6.3 C Table 6.1). 
No data could be collected for the lowest dilution of cDNA (approximately 0.4ng) for TNF, 
IFNγ or iNOS (Figure 6.3 G-I). This indicates that at this dilution the expression of these 
genes is undetectable using this PCR system. Efficiency was therefore calculated on three 
dilutions for these genes. Efficiency was calculated as greater than 2 for each gene of 
interest, implying that the efficiency of PCR increases with dilution of the sample (Figure 6.3 
J). This may indicate the presence of inhibitors of replication present in the samples. A prime 
candidate for this would be ethanol, carried-over from the RNA extraction procedure. 
6.2.2.2	  RNA	  quality	  
Subpial GML were accurately isolated from 4-5 10µm thick sections using LCM. Samples 
were stored at -80°C for up to two weeks before extracting RNA from each sample using an 
RNeasy mini lipid kit. RNA concentration was measured using a Nanodrop 
spectrophotometer (Figure 6.4 A, B). RNA concentration for spinal cord samples averaged 
245.1ng/µl (range 178.8-287.1ng/µl). RNA concentration for experimental samples isolated 
using LCM averaged 6.4ng/µl (range 3.3-10.7ng/µl). Expression of each gene of interest was 
increased in EAE spinal cord compared to naive spinal cord (Figure 6.4 B, Table 6.2).  
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Table 6.1; Relative gene expression in EAE spinal cord compared to naive spinal cord. *No expression detected 
in naive spinal cord, values calculated using Ct value of 45.00, the number of PCR cycles in the protocol. 
Gene Ave. Fold Change 
TNF 10.1 
TNFR1A 8.2 
TNFR1B 14.6 
*IFNγ 9896.4 
iNOS 5.32 
 
Gel electrophoresis was used to assess the integrity of RNA samples. To allow detection 
using ethidium bromide, 5 cortical samples were pooled and concentrated using a speedvac 
centrifuge. 500ng RNA was added for each sample. Two bands, corresponding to 28S and 
18S RNA were visible for both spinal cord RNA and cortical RNA (Figure 6.4 D). The lack of 
smaller fragments indicates that RNA in samples was intact and suitable for RT-PCR.   
6.2.2.3	  Selection	  of	  an	  appropriate	  housekeeping	  gene	  
In completing the current study two housekeeping genes were tested; GAPDH and HPRT. 
Expression of both genes was assessed for each sample. HPRT had a lower variance than 
GAPDH across all experimental samples (Table 6.3). Therefore, HPRT was used as a 
housekeeping gene for the calculation of relative expression levels of each gene of interest. 
The high number of samples and genes of interest necessitated the use of multiple PCR 
plates. To control for experimental drift, positive control samples with HPRT specific primers 
were run on each plate and found to be closely matched (average Ct 26.41 ± 0.24). 
Table 6.2 Summary of housekeeping gene variation across experimental samples. 
 GAPDH HPRT 
Average Ct Value 22.00 27.04 
Standard deviation 0.64 0.57 
Variance 0.38 0.33 
Coefficient of variance (%) 2.89 2.09 
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6.2.2.4	  TNF	  
Expression of TNF mRNA was determined by qRT-PCR in demyelinated cortex isolated by 
LCM. Expression of TNF was not always detected (Figure 6.5 A). Where expression was not 
detected an early peak was observed in the dissociation curve (Figure 6.5 B), all samples 
with TNF expression had a single peak in the dissociation curve indicating specific primer 
annealing. Where expression was not detected the Ct value for that sample was recorded as 
45. TNF expression was non-significantly increased in demyelinated cortex (rmMOG-
immunised with cytokine injection) compared to a pooled sample of two naive animals 
(average fold change 2.25 ± 0.63, Figure 6.5 C) and animals injected with PBS (fold change 
2.12 ± 0.59, Figure 6.5 D and Table 6.3). TNF was also non-significantly increased in control 
animals immunised with IFA and injected with cytokines, relative to both naive (fold change 
2.44 ± 0.87) and control animals injected with PBS (fold change 2.29 ± 0.82 Figure 6.5 D and 
Table 6.3).  
TNF protein was detected by double-labelled IF in Iba1+ microglia/macrophages in the 
meninges and cortex close to the pial surface of demyelinated regions (Figure 6.5 E). TNF 
was only detected in the cortex of animals immunised with rmMOG and injected with 
cytokines and not in control animals. 
6.2.2.5	  TNF	  Receptors	  
Expression of TNFR1A was detected in each sample (Figure 6.6 A). All samples had a single 
peak in the dissociation curve (Figure 6.6 B). TNFR1A expression was upregulated in the 
demyelinated cortex of animals with a pre-existing anti-MOG response and injected with 
cytokines compared to naive animals (fold change 2.12 ± 0.23 Figure 6.6 C) and animals 
injected with PBS (fold change 1.94 ± 0.21 p<0.05 Figure 6.6 D Table 2.3). TNFR1A 
expression was significantly upregulated compared to IFA immunised animals injected with 
cytokines (p<0.05 Figure 6.6 C, D), which was not significantly different to expression in 
animals injected with PBS or naive animals. 
TNFR1A protein was detected on small, spheroid cells throughout the cortex (Figure 6.6 E). 
The characteristic “chain-like” distribution of positive cells in the corpus callosum is similar to 
that observed when staining for oligodendroglial markers (Figure 6.6 F). Therefore TNFR1 
appears to be expressed by oligodendrocytes. However, TNFR1A protein could not be 
detected using double-labelled IF that would confirm this. 
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Expression of TNFR1B was detected in each sample (Figure 6.7 A). All samples had a single 
peak in the dissociation curve (Figure 6.7 B). TNFR1B expression was upregulated in the 
demyelinated cortex of animals with a pre-existing anti-MOG response and injected with 
cytokines compared to naive animals (fold change 1.94 ± 0.28 Figure 6.7 C) and animals 
injected with PBS (fold change 2.47 ± 0.63 p<0.01 Figure 6.7 D Table 2.3). TNFR1B 
expression was significantly upregulated compared to IFA immunised animals injected with 
cytokines (p<0.03 Figure 6.7 C, D), which was not significantly different to expression in 
animals injected with PBS or naive animals. 
TNFR1B protein could not be detected by IF in the cortex. IHC analysis located the protein to 
the endothelial cells of intra-meningeal (Figure 6.7 E) and intracortical (Figure 6.7 F) blood 
vessels in the naive and demyelinated cortex. 
6.2.2.6	  IFNγ	  
Expression of IFNγ was not always detected by qRT-PCR (Figure 6.8 A). Where expression 
was not detected, an early peak was observed in the dissociation curve (Figure 6.8 B), all 
samples with IFNγ expression had a single peak in the dissociation curve. IFNγ expression 
was not detected in a pooled sample of two naive animals or in animals immunised with 
rmMOG and injected with PBS. It was detected in 3 of 6 animals immunised with IFA and 
injected with cytokines and in 4 of 8 animals immunised with rmMOG and injected with 
cytokines. In order to calculate differences between groups, animals with no expression 
detected were regarded as having a Ct of 45. IFNγ expression was upregulated compared to 
a naive animal (average fold change 577.2 ± 312.0 Figure 6.8 C) and compared to control 
animals immunised with rmMOG and injected with PBS (average fold change 247.2 ± 133.4 
Figure 6.8 D Table 6.3). These differences did not reach significance due to the high variation 
within each group. 
IFNγ expression was detected in the spinal cord of animals with EAE (Figure 6.8 E) and 
within the meninges and perivascular spaces of demyelinated cortex (Figure 6.8 F). 
Expression was found on small, spheroid cells that are likely to be T lymphocytes; 
unfortunately protein could not be detected by double labelling IF to confirm this. 
6.2.2.7	  iNOS	  
Expression of iNOS was not always detected (Figure 6.9 A). Where expression was not 
detected, an early peak was observed in the dissociation curve (Figure 6.9 B), all samples 
with IFNγ expression had a single peak in the dissociation curve. iNOS expression was not 
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detected in a pooled sample of two naive animals, or in animals immunised with rmMOG and 
injected with PBS. In order to calculate differences between groups, animals with no 
expression detected were regarded as having a Ct of 45. iNOS expression was upregulated 
compared to a naive animal (average fold change 1.33 ± 0.28 Figure 6.9 C) and compared to 
control animals immunised with rmMOG and injected with PBS (average fold change 3.0 ± 
0.63 Figure 6.9 D Table 6.3). Animals with immunised with IFA and injected with cytokines 
also had increased iNOS expression within the cortex (average fold change 4.5 compared to 
animals injected with PBS Table 6.3).  
IHC or IF could not detect INOS in the cortex of rats, regardless of experimental condition. 
Detection of protein was achieved in inflammatory demyelinated lesions of the spinal cord of 
animals with EAE. Double-labelled IF revealed iNOS expression by highly activated 
amoeboid MHCII+ microglia/macrophages (Figure 6.9 E).  
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6.3	  Discussion	  
6.3.1	  Subpial	  demyelination	  is	  not	  complement/antibody-­‐mediated	  
IgG and complement deposition was detected on vessels and the meninges of the brain in 
naive animals, similar to previous observations on human brain (Brink et al. 2005; Barnett et 
al. 2009). The presence of deposits of IgG and C9 in only one animal with demyelination 
indicates that subpial lesions in this model are likely to occur independently of deposition on 
myelin. Furthermore, these results provide additional evidence for the lack of 
complement/antibody involvement in the pathogenesis of GML of MS cases (Brink et al. 
2005). In the present study, C9 deposition was detected in the demyelinated cortex 
surrounding a blood vessel within a lesion of one animal and on the neighbouring myelin. 
Furthermore, IgG deposits were detected on the myelin sheath at the active edge of the same 
lesion. These results indicate a localised BBB disruption, with consequent leakage of 
complement and IgG proteins into the cortex (Litzenburger et al. 1998; Storch et al. 1998b). 
Due to the location of this vessel some distance from the injection site and pial surface, it is 
unlikely to have occurred as a result of surgery and the reason for this is unknown. Given that 
demyelination covered a wide area, appeared to emanate from the pial surface and that this 
deposition was only detected in one animal, localised BBB disruption and complement/IgG 
deposition is not thought to contribute significantly to the pathology. Terminal complement 
components were detected on a single oligodendrocyte-like cell in this study. C9neo 
deposition on oligodendrocyte cell bodies has been detected in WMLs in MS cases (Storch et 
al. 1998b; Lucchinetti et al. 2000), indicating MAC complex formation and potential lysis of 
the target cell. However, given that this pattern of staining was only observed on a single 
oligodendrocyte in a single animal, it is unlikely to constitute a significant mechanism of 
myelin loss in the model.   
The results in this study are in contrast to a similar focal model of demyelination in which 
acute perivascular deposition of C9 was detected following cytokine injection (Merkler et al. 
2006b). The most likely reason for this disparity is that the previous model involved direct 
intracortical injection, compromise of BBB integrity and tissue damage. Antibody-mediated 
demyelination is known to require disruption or opening of the BBB (Litzenburger et al. 1998). 
In this model the subarachnoid space injection does not lead to significant breakdown of BBB 
and CSF/serum leakage into the parenchyma at the height of demyelination (as shown in 
Chapter 4). Some acute disruptions to the integrity of the pial surface at the sagittal sulcus 
were detected at early time-points in a student project, and were thought to be a 
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consequence of injection (Appendix 1). However, given that this also occurred in control 
animals to a similar extent and no demyelination was present in these groups, it is not 
thought to play a significant role in subsequent pathology. 
As expected, deposition of immunoglobulin and complement components was detected on 
myelin and in macrophages in active WM lesions of spinal cord of rats with acute, 
disseminated EAE (Storch et al. 1998b; Rus et al. 2006). Studies on biopsies of MS WML 
suggest that antibody-mediated demyelination is one of the predominant mechanisms 
involved in the pathogenesis of a significant proportion of lesions (Lucchinetti et al. 2000). Co-
localisation of IgG and activated complement fragments at the active border of MS WML 
implicate the humoral immune system as effectors of WM demyelination (Prineas & Graham 
1981; Storch et al. 1998b). In this context, data presented here adds further weight to the 
growing body of evidence suggesting that GML form independently of humoral elements and 
that differential pathogenesis between WML and GML occurs in MS. 
Recent research has called into question the relevance of complement in MS, with a 
significant amount of deposition thought to be non-specific and therefore non-pathogenic 
(Barnett et al. 2009). This study utilised a range of post-mortem MS cases and found that 
tissue processing had a significant impact on the detection of immunoglobulin and 
complement in normally myelinated tissue; IgG was detected in numerous axons and 
oligodendrocytes of paraffin-embedded tissue but not in formalin fixed tissue. Furthermore, 
IgG and complement fragments were detected on disrupted myelin in ischaemic lesions in an 
identical manner to MS lesions, arguing against involvement of specific anti-myelin antibodies 
in the pathogenesis of lesions (Barnett et al. 2009). It is therefore suspected that the limited 
C9 deposition observed in this model is largely non-specific and not a reflection of an 
antibody/complement-mediated attack on myelin. 
Data presented in this thesis indicates that a humoral response to MOG is required, but also 
that deposition humoral elements is not the major mediator of demyelination. This may 
indicate that the pro-inflammatory function of B cells in the meninges is more important than 
the release of antibodies. B cells have been shown to have an important role in inflammation 
by acting as highly efficient APCs for T cell activation and releasing pro-inflammatory 
cytokines such as TNF, IFNγ and lymphotoxin (Tumanov et al. 2004; Rodríguez-Pinto 2005; 
Dilillo et al. 2010).    
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6.3.2	  Molecular	  mechanisms	  leading	  to	  demyelination	  
6.3.2.1	  TNF-­‐mediated	  pathways	  
The finding that TNF expression was non-significantly increased in the cortex of animals 
injected with cytokines, irrespective of the previous immunisation, indicates that the presence 
of increased expression of TNF within the cortex is not necessarily associated with 
demyelination. This result has been replicated in MS cases where TNF expression is 
significantly increased in the NAGM of the motor cortex of SPMS cases, but is not increased 
in GML (unpublished data). These results may indicate that TNF expression is transient and 
occurs prior to demyelination, that it is not the main pathogenic mechanism in GML, or that 
diffusion of soluble TNF (solTNF) into the cortex, following production by activated 
lymphocytes/macrophages in the meninges, causes cortical demyelination. Moreover, high 
expression of TNF and release by macrophages has been detected in the meninges of F+ 
SP-MS cases (Magliozzi et al. 2010). However, it may be expected that TNF would activate 
cortical microglia to express TNF (Veroni et al. 2010). In this study, TNF protein was detected 
in activated microglia in the demyelinated cortex close to the pial surface and in macrophages 
in the meninges, supporting a role for TNF in cortical demyelination. Expression of TNF has 
previously been correlated with disease activity in the spinal cord of rats with disseminated 
EAE (Issazadeh et al. 1995a), and with demyelination in the corpus callosum of mice during 
cuprizone feeding (Arnett et al. 2001). 
Due to the complexities of TNF signalling the lack of an increase in expression in the 
demyelinated cortex did not exclude the possibility that TNF was involved in the pathogenesis 
of lesions. TNFR1A has been shown to play a central role in EAE through direct induction of 
oligodendrocyte apoptosis and demyelination (Akassoglou et al. 1998; Probert et al. 2000). 
Furthermore, knockout of TNFR1A has been found to attenuate EAE through reduction in Fas 
induced oligodendrocyte apoptosis (Hövelmeyer et al. 2005). In the present study, the 
significant increase in TNFR1A expression by oligodendrocytes in the cortex of animals 
immunised with subpial lesions may leave this cell type more vulnerable to apoptosis than 
control animals. However, this study has failed to provide clear evidence of a significant 
reduction in oligodendrocyte numbers or large numbers of apoptotic cells (Chapter 5). 
The upregulation in TNFR1A observed here mirrors data from F+ SP-MS cases, where recent 
research has shown a significant upregulation of TNFR1A in GMLs (unpublished data). In 
these cases protein was detected on oligodendrocytes. Administration of either TNF or IFNγ 
has been shown to increase expression of TNFR1A by rat oligodendrocytes in vitro (Dopp et 
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al. 1997). In the present study, TNF expression in the cortex was not increased, which may 
implicate that cytokines diffusing from the inflamed meninges are responsible for the 
induction of receptor expression. The lack of upregulation following cytokine injection in non-
immunised animals implies that a secondary cytokine release from lymphocytes re-activated 
in the meninges is required to initiate TNFR1A expression on oligodendrocytes. Furthermore, 
they implicate TNF signalling as the pathogenic mechanism in the neurodegeneration and 
glial loss in F+ SP-MS cases. Upregulation of TNFR1A expression has also been observed in 
the NAGM of F+ SP-MS cases (unpublished data). These results may argue that although 
TNFR1A is upregulated solely in cases with inflammatory demyelination, the two processes 
are uncoupled and occur via different mechanisms. Alternatively, it could indicate that 
expression of TNFR1A by oligodendrocytes is a primary response to inflammatory conditions 
and increases susceptibility to apoptosis.   
Expression of the TNFR1B gene was increased in the demyelinated cortex of animals 
injected with cytokines, when compared to control animals. Significant upregulation of 
TNFR1B has also been detected in GML of SPMS cases (unpublished data) and in the 
demyelinated corpus callosum of mice, following cuprizone feeding (Arnett et al. 2001). TNF 
and IFNγ administration to rat primary cells caused increased expression of TNFR1B on 
microglia but not astrocytes or oligodendrocytes (Dopp et al. 1997), supporting findings in the 
present study localising expression of the protein to perivascular macrophages. Expression of 
TNFR1B was also detected on perivascular macrophages in the cortex of SPMS cases 
(unpublished data). However, in human cases the majority of protein expression was 
detected on astrocytes indicating species differences in the dynamics of protein expression 
that may have a bearing on the pathogenesis of GML. 
Studies with KO mice with cuprizone-mediated demyelination indicated that TNF signalling 
through TNFR1B signalling is required for OPC proliferation, differentiation and remyelination 
(Arnett et al. 2001). In addition, TNFR1B has been shown to play a critical role in lymphocyte 
regulation with an exacerbated disease course coupled with increased lymphocyte infiltration 
elicited in animals without this receptor (Eugster et al. 1999; Kassiotis & Kollias 2001). 
Therefore, the findings presented in this chapter indicate the concurrent upregulation of key 
pathogenic and non-pathogenic pathways at the peak of demyelination. These findings are 
supported by data from the cuprizone model of demyelination in which expression of IGF-1, a 
key protein in remyelination, expression of which peaks with the greatest extent of 
demyelination (Mason et al. 2000). Further studies will be required to elucidate the role that 
TNFR1B upregulation may play in the remyelination observed in this model.  
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6.3.2.2	  A	  role	  for	  IFNγ	  
In the present study, IFNγ was not detected in control animals, indicating a very low basal 
level of inflammatory activity of the naive CNS. Although it was highly expressed in a subset 
of animals injected with cytokines, the high variation among samples prevented significance 
being reached. Recent studies within this laboratory have detected increased levels of IFNγ 
in the meninges of F+ SP-MS patients, but not within the cortex (unpublished data). IFNγ 
expression has been observed on CD8+ cytotoxic cells in the meninges in this subset of 
patients (Serafini et al. 2004; Magliozzi et al. 2007). The upregulation detected in 
demyelinated samples is likely to reflect the release of IFNγ in the cerebral blood vessels and 
perivascular spaces. Indeed, in the present study IFNγ was located in cells associated with 
blood vessel endothelia and meninges of the demyelinated cortex, and is likely to be secreted 
by activated CD4+ or CD8+ cells, although double-IF studies were unsuccessful. However, the 
few cytotoxic cells found in the cortex may also contribute to the increased expression 
detected (Chapter 5). 
IFNγ has been linked to the pathogenesis of MS and EAE and is correlated with disease 
activity (Issazadeh et al. 1995b; Issazadeh et al. 1996; Beck et al. 1988). IFNγ has been 
shown to upregulate Fas and promote FasL interactions on oligodendrocytes, leading to 
apoptosis and inhibiting remyelination following induced WM lesions (Pouly et al. 2000; Lin et 
al. 2006). In the present study, cortical IFNγ expression was highest in animals with 
demyelination. IFNγ is known to be a potent activator of microglia and has been shown to 
induce a pathogenic phenotype (Aloisi et al. 1999; Kigerl et al. 2009). Therefore, it is likely 
that microglial activation by IFNγ plays a significant role in the demyelination observed in the 
model. 
IFNγ signals through the IFNγ receptor (IFNγR). Binding of ligand causes receptor 
dimerisation and activates the associated proteins Jak 1 and 2, leading to STAT1 
phosphorylation and effector gene transcription (reviewed in Hu & Ivashkiv 2009). To our 
knowledge no studies of receptor gene expression in the CNS of animals with EAE have 
been carried out, however it may be pertinent to investigate this. It may also be desirable to 
investigate the expression levels of key downstream genes such as the MHC class I and II 
molecules, which are induced by IFNγ (Wong et al. 1999; Aloisi et al. 1999a,b). These 
experiments may aid in the understanding of the mechanisms of demyelination in this model. 
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6.3.2.3	  Involvement	  of	  reactive	  oxygen	  species	  
Upregulation of iNOS by activated microglia/macrophages and astrocytes is responsible for 
increased NO production in the inflamed CNS (Smith & Lassmann 2002). Microglial iNOS 
expression has been detected in actively demyelinating WM, GML and EAE lesions (Bö et al. 
1994b; Hill et al. 2004; Magliozzi et al. 2010). In this study iNOS expression was not detected 
in every animal, resulting in a high variation in each experimental group. There were no 
significant differences between experimental groups. Furthermore, iNOS could not be 
detected by IHC in the cortex but was detected in WMLs in EAE spinal cord as described 
previously (Tran et al. 1997). These results argue against the involvement of iNOS induced 
NO release within the cortex as the pathogenic mechanism in this model of GML. The lack of 
iNOS expression in this model is in contrast to the increase in expression of iNOS by 
microglia in the GMLs of F+ SP-MS cases (Magliozzi et al. 2010). Furthermore, the 
phagocytosis of myelin has been shown to induce iNOS expression in rat macrophages in an 
in vitro system (van der Laan et al. 1996). However, the validity of these results compared to 
an in vivo system in the grey matter must be called into question. The differential results 
could also be due to the relatively low quantity of myelin in the grey matter. It must also be 
considered that the demyelination produced in this model is acute and may not be sufficient 
to induce iNOS expression by microglia. Maintaining the inflammatory response in the 
meninges may be expected to chronically activate microglia and lead to the expression of 
iNOS (Kigerl et al. 2009; Perry et al. 2010). 
The expression of iNOS is considered an indicator of a pathogenic phenotype in microglia, 
and is initiated by IFNγ signalling (Kigerl et al. 2009). These results may indicate that, in this 
model at the peak of demyelination, microglia have a protective phenotype. Furthermore, the 
phagocytosis of myelin has been shown to induce an anti-inflammatory, IL-10 producing, 
phenotype (Boven et al. 2006). Further work will be required to determine the phenotype of 
microglia throughout the study, but it is known that the phenotype can switch from toxic to 
protective over time (Stout et al. 2005; Colton 2009).  
6.3.3	  The	  mechanism	  of	  demyelination	  
Data from previous chapters has established that both a peripheral immune response to 
MOG protein and injection of TNF and IFNγ is required for demyelination. The fact that 
cytokines initiate lymphocyte infiltration to the subarachnoid space regardless of antigen 
specificity indicates that the key requirement for demyelination is the antigen specificity of 
those cells and/or their activation status. The results presented in this chapter indicate that 
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the demyelination produced in this model does not involve an antibody/complement-mediated 
attack on the myelin sheath. Therefore, the activation status of T and B lymphocytes in the 
meninges is likely to be the key to initiating demyelination. Re-activated lymphocytes release 
cytokines and other molecules that may be toxic to myelin. It is hypothesised that these 
constitute the mechanism of demyelination in this model. The molecules released may be 
directly toxic to oligodendrocytes/myelin or may activate resident microglia to a pathological 
phenotype. The dysregulation of TNF signalling pathways in the demyelinated cortex may 
implicate TNF in mediating demyelination. Microglia expressing TNF were detected in the 
demyelinated cortex and meninges of rmMOG/cytokine treated animals. Further work 
examining gene expression data at earlier time-points and for other markers will be 
necessary to test this hypothesised mechanism of demyelination.  
6.3.4	  Further	  elucidation	  of	  mechanisms	  of	  demyelination	  
6.3.4.1	  RT-­‐PCR	  at	  earlier	  time-­‐points	  
In this experiment samples were taken 7 days post-cytokine injection, corresponding to the 
greatest extent of demyelination in rmMOG-immunised animals. Previous results have shown 
that the number of activated/phagocytic microglia/macrophages at this time-point is also 
maximal, but the number of lymphocytes in the meninges and cortical parenchyma is lower 
than at previous time-points. It may be argued that the greatest expression of pathological 
mediators could occur before the greatest extent of phagocytic activity and demyelination 
occurs. Furthermore, it may be hypothesised that a shift from pathological mediators to 
mediators involved in resolution of demyelination may have already occurred at the peak of 
demyelination. For example, upregulation of TNF by cortical microglia occurs prior to 
demyelination in the cuprizone model (Arnett et al. 2001). Due to feasibility and cost issues 
earlier time-points and the expression of regenerative markers were not studied, although this 
would certainly be an interesting further study.  
6.3.4.2	  Assessment	  of	  the	  meningeal	  microenvironment	  
Due to the low quantity of meningeal tissue that could be harvested using the methods 
employed in this study, quantitation of gene expression in this compartment was not feasible. 
However, other approaches could be used to isolate meningeal tissue. For example, whole 
meningeal explants could be made by carefully dissecting the meninges from the brain 
(McMenamin 1999). This material was found to be suitable for IHC and RT-PCR analysis 
(McMenamin 1999). In addition, CSF samples from animals were taken across experimental 
groups and at a range of time-points. Analysis of the CSF was not feasible in the timeframe of 
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this study. However, in future studies ELISA or flow analysis may be conducted to assess the 
quantity of inflammatory mediators such as TNF present across groups. These studies would 
test the level of inflammatory infiltrates in the meninges and aim to identify molecules that 
may be pathogenic in this model.  
6.3.6	  Conclusions	  
Subpial demyelination following cytokine injection in rmMOG-immunised animals occurs 
independently of antibody/complement deposition on myelin. The increased expression of 
TNF receptors within the demyelinated cortex may implicate TNF signalling in the 
pathogenesis of demyelination in the model. The lack of TNF expression in demyelinated 
cortex may implicate solTNF diffusing into the cortex from the meninges in initiating 
demyelination. In order to test this hypothesis it will be necessary to pharmacologically inhibit 
TNFR1A/B and solTNF release. Work presented here cannot exclude the importance of other 
cytokines or potential mediators of demyelination that may be produced in the subarachnoid 
or perivascular spaces.  
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7.1	  The	  importance	  of	  cortical	  pathology	  in	  MS	  
Cortical lesions were first identified in the initial pathological studies of MS (Taylor 1892, 
Lumsden 1972 reviewed in (Kutzelnigg & Lassmann 2005). Due to difficulties detecting 
cortical lesions by histology, much of the subsequent research focused on WMLs. In the past 
decade, through the use of refined imaging and IHC technique, the full extent of cortical 
demyelination in MS has been revealed. 
Cortical atrophy has been visualised by MRI at the earliest stages of MS and has been 
associated with the cognitive impairments present in many MS patients (Chard & Miller, 2009; 
De Stefano et al., 2007; Amato et al., 2007). The strong correlation with the progression of 
disability in longitudinal MRI studies (Chen et al., 2004; Fisniku et al., 2008; Fisher et al. 
2008), underlines the importance of GM pathology in MS. Moreover, this data supports the 
hypothesis that progressive GM atrophy and neurodegeneration are largely responsible for 
progressive disability in MS and may explain the dichotomy between reducing WML load and 
progressive disability, the “clinical-radiological paradox” (Barkhof 2002).    
GMLs have been divided into three classifications, the most common of which (type III – 
subpial) extend from the pial surface into the cortical grey matter (Peterson et al. 2001; Bö et 
al. 2003a). An increasing appreciation of the extent of immunological compartmentalisation in 
the CNS has highlighted the influence of meningeal inflammation on GM pathology. 
Extensive meningeal inflammation with the presence of organised ectopic lymphoid follicle-
like structures has been found in the meninges of a significant number of SP-MS cases (40-
54%, Serafini et al. 2004; Frischer et al. 2009; Magliozzi et al. 2010). The presence of these 
structures was associated with an accelerated disease course, substantially worse clinical 
outcome and increased cortical pathology compared to patients with no detectable follicles (F- 
SP-MS, Serafini et al. 2004; Magliozzi et al. 2007; Magliozzi et al. 2010). The age at onset, 
age when confined to a wheelchair and age at death were all significantly earlier in F+ SP-MS 
vs. F- SP-MS (Magliozzi et al. 2007). 
Despite the clinical importance of GMLs in MS, there is currently no reliable animal model 
that replicates the pathological features that are distinct to GMLs. The creation of a valid and 
reliable model would lead to increased understanding of the pathogenesis of GMLs and 
identify new drug targets for the treatment of MS. 
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7.2	  A	  novel	  animal	  model	  of	  subpial	  demyelination	  
7.2.1	  Characteristics	  of	  subpial	  demyelination	  
The work described in this thesis has successfully produced a novel animal model of the 
cortical demyelination observed in MS. Subpial demyelination is elicited by injection of TNF 
and IFNγ into the cerebral subarachnoid space of animals with a pre-existing anti-MOG 
humoral immune response. This is the first reported instance of cortical demyelination elicited 
as a result of antigen-specific meningeal inflammation. This data not only confirms previous 
data showing that inflammation in the meninges can be transduced to the cortex via the 
action of inflammatory mediators (Furlan et al. 2001; Wu et al. 2005), but also establishes the 
pathological consequences when this is combined with a pre-existing anti-myelin immune 
response. This evidence indicates that the extensive immune response in the subarachnoid 
space of a subset of SP-MS cases may be antigen specific and directly responsible for the 
cortical pathology. 
The model reproduces many key pathological features of type III GMLs. Lesions appear to 
emanate from the pial surface and extend into the cortex (Peterson et al. 2001; Bö et al. 
2003a). Perivascular demyelination, reminiscent of type II intracortical GMLs, was only rarely 
observed (Peterson et al. 2001; Bö et al. 2003a). Perivascular infiltrates and amoeboid 
macrophages were also rare (Bo et al). Lesion formation is preceded by lymphocyte and 
macrophage infiltration into the meninges, supporting the hypothesis that inflammation in this 
compartment is a key requirement in the pathogenesis of GMLs (Frischer et al. 2009; 
Magliozzi et al. 2010). As observed in MS GMLs, CD8+ cells were the predominant T cell sub-
type in the demyelinated cortex, though numbers were low, especially when compared to 
WMLs in classical EAE models (Bö et al. 2003b; Frischer et al. 2009). Moreover, the 
restriction of B cells and plasma cells to the meninges in this model is also a feature of MS 
samples (Frischer et al. 2009). Furthermore, the lack of lymphocyte subtypes and 
complement/immunoglobulin deposition in the demyelinated cortex is highly reminiscent of 
subpial GMLs (Bö et al. 2003b; Frischer et al. 2009), supporting the hypothesis that GML 
pathogenesis is distinct to that found in WMLs (Lucchinetti et al. 2000). The upregulation of 
TNF receptors in the demyelinated cortex of the model mirrors data from human studies 
(unpublished data), and suggests a common pathogenesis. Furthermore, the upregulation of 
TNFR1A on oligodendrocytes implicates an increased sensitivity to apoptosis and may be 
responsible for demyelination and oligodendrocyte loss.  
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7.2.1.1	  The	  role	  of	  microglia	  in	  cortical	  pathology	  
In our new model, activated microglia are present in a gradient from the pial surface into the 
demyelinated cortex, replicating data from F+ SP-MS cases. This supports the hypothesis that 
mediators diffusing from the meninges into the cortex activate microglia and initiate 
demyelination (Magliozzi et al. 2010). Large numbers of microglia express the lysosomal 
protein CD68+, indicating that they are capable of phagocytosis (Bauer et al. 1994). Activated 
microglia can be seen contacting neurons, oligodendrocyte cell bodies and myelin within 
demyelinated lesions, which has also been observed in MS GML (Peterson et al. 2001; 
Magliozzi et al. 2010). The extent of demyelination was highly correlated with the presence of 
activated and total microglia/macrophages in the cortex and the meninges. Moreover, TNF 
was detected in microglia in demyelinated cortex and macrophages in the meninges, though 
due to high variability, expression levels were not significantly increased compared to control 
animals injected with cytokine. TNF production by microglia has been observed in active 
subpial GMLs (Magliozzi et al. 2010).  
Activated microglia/macrophages in the cortex are small and maintain short processes in this 
model, in keeping with data from GMLs in MS (Peterson et al. 2001; Bö et al. 2003b; 
Magliozzi et al. 2010), and in contrast with the large, foamy macrophages in WML in MS and 
EAE (Storch et al. 1998a; Lucchinetti et al. 2000). This data provides evidence that the 
pathogenesis of WML and GML are distinct, and may be related to the differential effects of 
inflammation on the BBB. In WMLs the permeability of the BBB is clear; lesions containing 
abundant complement and immunoglobulin deposits, leakage of serum proteins, infiltration of 
T cells and large foamy macrophages have been commonly detected (Lucchinetti et al. 2000; 
van Horssen et al. 2007). In GMLs, BBB disruptions are not evident, complement deposits 
have not been observed and the inflammatory infiltrate has been found to consist of activated 
microglia, with very few T cells (Peterson et al. 2001; Bö et al. 2003b; van Horssen et al. 
2007). Thus this model closely replicates the pathology observed in GMLs as opposed to 
WMLs and may provide a useful model of cortical pathology for future study.   
The results from the novel model strongly implicate the activation of microglia in the 
pathogenesis of subpial demyelination. However, it is also accepted that microglia play an 
important role in maintaining homeostasis (Sanders & De Keyser 2007). For example, 
differential effects of microglia/macrophages on remyelination have been observed 
depending on the mechanism of inflammation. Inhibition of microglia/macrophage activity has 
been shown to be beneficial in the cuprizone model of demyelination (Skripuletz et al. 2010), 
but prevented efficient remyelination in another toxin induced model (Li et al. 2005). Recent 
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research has distinguished these diverse actions into two functional macrophage phenotypes 
(Gordon & Martinez 2010). 
Differential stimulation of macrophages has been shown to result in two functionally distinct 
activation states. Activation via the “classical” or M1 pathway, for example by TLR activation 
or IFNγ signalling, results in the formation of a highly pathogenic phenotype, typified by 
expression of iNOS, TNF, IL-1β and release of MMPs (Gordon & Martinez 2003; Mantovani 
et al. 2004; Stout et al. 2005; Gordon & Martinez 2010). In contrast, activation via the 
“alternative” or M2 pathway, for example by IL-4, results in a non-pathogenic, restorative 
phenotype typified by expression of Ym1 and CD206 with the release of trophic factors and 
Th2-associated cytokines such as IL-10 and TGFβ (Kigerl et al. 2009; Stout et al. 2005; 
Gordon & Martinez 2010). An increase in the M1:M2 ratio is associated with increased 
disease activity in EAE (Mikita et al. 2011). Recent evidence has supported the hypothesis 
that microglia are also activated in this heterogeneous manner (Kigerl et al. 2009; Stout et al. 
2005; Gordon & Martinez 2010).  
The phenotype of microglia in this model is currently not established. The lack of iNOS 
upregulation 7 days post-cytokine injection is in contrast to the observed expression in GMLs 
and may illustrate the differences between chronically activated microglia in MS and the 
acutely activated microglia observed in this study (Magliozzi et al. 2010). Furthermore, it may 
indicate that the M2 phenotype is predominant at the peak of demyelination. Data from the 
cuprizone model of GML has indicated that at the peak of demyelination expression of 
proteins involved in remyelination is also at a peak (Mason et al. 2004). In addition, ingestion 
of myelin is required for efficient remyelination and results in release of anti-inflammatory 
cytokines such as IL-10, which is typical of M2 macrophage activity (Kotter et al. 2001; Kotter 
et al. 2005; Boven et al. 2006; Van Rossum et al. 2008)	  and microglial activity is required for 
remyelination in a toxin induced model (Li et al. 2005). The concept of class switching, from 
M1 pathogenic to a protective M2 phenotype has been proposed (Stout et al. 2005; Gordon & 
Martinez 2010; Dirscherl et al. 2010), and it may be hypothesised that microglia are initially 
M1 activated and pathogenic, but upon myelin phagocytosis switch classes to an M2 
phenotype at the peak of demyelination to facilitate remyelination.  
7.2.1.2	  Comparison	  to	  existing	  models	  of	  GML	  
A previous model of targeted cortical demyelination involved the injection of a lower quantity 
of TNF/IFNγ directly into the motor cortex of female Lewis rats (Merkler et al. 2006b). Sub-
clinical immunisation required injection of 50µg rrMOG in the Lewis rat, whereas 
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immunisation of DA rats with a similar quantity of rmMOG caused severe EAE symptoms. 
The suitable subclinical dose for the model presented in this thesis is 5µg. The most likely 
reason for this is the genetic influence over EAE susceptibility; DA rats with the RT1AV1 MHC 
haplotype are highly susceptible to autoimmune disease, whereas Lewis rats with the RT11 
haplotype are more resistant (Storch et al. 1998a; Weissert et al. 1998). 
Subpial demyelination was maximal 3 days post-motor cortex cytokine injection in the Lewis 
rat (Merkler et al. 2006b), in contrast to the peak at 7 days observed in this model following 
subarachnoid space injection. Demyelination following motor cortex injection was associated 
with infiltration of lymphocyte subtypes into the cortex and deposition of complement and 
immunoglobulin, in contrast to results presented in this thesis, and studies of GMLs in MS 
(Brink et al. 2005). A large number of axons with disrupted transport were present following 
motor cortex injection but were not present in this model. DA rats injected in the motor cortex 
had similar pathology to the previously published data, with abundant T cell infiltration and 
immunoglobulin/complement deposition. Therefore, it is likely that the location of the injection 
of cytokines is the primary reason for the differences between the models. Direct injection into 
the motor cortex severely disrupts the integrity of the BBB and leads to infiltration of 
serum/CSF components (e.g. fibrinogen, complement, immunoglobulin). Furthermore, 
necrotic tissue damage was observed following motor cortex injection in the DA rat. Thus, this 
model does not reproduce the mechanisms suggested to be responsible for the formation of 
MS GMLs (Merkler et al. 2006b). We propose that the injection of cytokines into the 
subarachnoid space more accurately reflects the physiological situation by avoiding cortical 
injury. Moreover, it more faithfully replicates MS cortical pathology by causing inflammation of 
the meningeal compartment in the absence of cortical infiltration and deposition of humoral 
elements, initiating extensive subpial lesions across both hemispheres, activating microglia in 
a gradient pattern and upregulating TNF signalling pathways in lesions. 
Demyelination in both models was highly correlated with the activity of microglia/ 
macrophages, implicating them as being central to pathogenesis of GMLs (Merkler et al. 
2006b). Furthermore, demyelination was acute in each model with resolution of inflammation 
and remyelination complete 14 days post-cytokine injection. This was in contrast to previously 
published work with a similar model following cytokine injection into the spinal cord WM 
(Kerschensteiner et al. 2004a), indicating differences in the remyelinating capacity of GM and 
WM. Remyelination has been described in the GML of chronic MS cases, and evidence 
describing the increased G ratio of NAGM indicates that remyelination may be extensive 
(Albert et al. 2007). 
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Addition of the copper-chelator cuprizone to the diet of mice causes mitochondrial dysfunction 
in oligodendrocytes, followed by apoptosis and demyelination of the corpus callosum 
(Matsushima & Morell 2001; Kipp et al. 2009). The dorsal cortex is completely demyelinated 
under some protocols (Skripuletz et al. 2008), in marked contrast to the demarcated lesions 
present in the model developed in this thesis and MS GMLs (Peterson et al. 2001; Bö et al. 
2003a). Demyelination is associated with microglial activity in a strain dependent manner and 
numbers are maximal at the peak of demyelination, reflective of the observations presented 
in this thesis (Peterson et al. 2001; Bö et al. 2003a; Skripuletz et al. 2008). Whilst the 
cuprizone model is very useful for the study of the dynamics of remyelination, the validity of 
inducing demyelination with dietary toxins must be called into question. The rapid and 
reversible oligodendrocyte loss observed in mice is not an accurate model of MS GMLs 
(Magliozzi et al. 2010). Moreover, the model can be induced in RAG1-/- mice lacking T and B 
cells, indicating that this approach does not replicate the involvement of meningeal 
lymphocytes in cortical pathology (Matsushima & Morell 2001). However, cuprizone feeding 
to C57Bl/6 mice offers huge potential for studies using KO animals, which might allow the 
dissection of some of the molecular pathways involved in GML formation. Though this 
represents an advantage over the specific model developed in this thesis, there is no 
fundamental reason why the protocol established here for the initiation of subpial 
demyelination could not be adapted for use in a mouse model.  
GMLs have been detected in the cerebral cortex of marmoset monkeys with MOG-induced 
EAE (Merkler et al. 2006a). Heterogeneity within GML subtypes was evident, with IgG 
leakage across the BBB and complement deposition on myelin in leukocortical and 
intracortical lesions, but not in subpial demyelinated areas. In agreement with findings in MS 
cases and this model, microglia/macrophages were the predominant immune cell in subpial 
lesions, with minimal lymphocyte infiltration (Peterson et al. 2001; Bö et al. 2003b; Merkler et 
al. 2006a). The model closely replicated the pathology observed in the cortex of MS cases 
and may prove useful for imaging studies. However the ethical implications, husbandry 
considerations and lack of molecular reagents for the species make this model an impractical 
solution for high throughput investigations. 
An increased prevalence of GMLs has been detected in MOG-induced EAE in the certain 
strains of Lewis rat and the SJL/J mouse (Merkler et al. 2006a). All three subtypes of GML 
(subpial, leukocortical and intracortical) were found in both models, with large numbers of 
activated microglia and a relative lack of lymphocyte infiltration. Complement and 
immunoglobulin were deposited on myelin at the lesion edge, which is a major discrepancy 
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with the model presented here, and MS GMLs (Brink et al. 2005; Frischer et al. 2009). 
However, all models of “naturally occurring” GML in EAE studies suffer from the same issue; 
the location, type and extent of lesions in these models are essentially random and vary 
widely between individual animals. Furthermore, this pathology only occurs in a subset of 
animals. Therefore, the variability is high, directly affecting results and reducing feasibility by 
the need to section large amounts of brain tissue to locate lesions and to include high 
numbers of animals in the studies. The model presented in this thesis has the distinct 
advantage of producing demyelinated subpial lesions that are highly reproducible in time and 
space, increasing the feasibility of high throughput studies. Furthermore, the model more 
accurately reflects the meningeal inflammation associated with MS subpial lesions (Magliozzi 
et al. 2010). 
7.2.2	  Disparities	  with	  MS	  pathology	  
Whilst the model developed in this thesis faithfully recreates many aspects of MS GML, there 
are some important discrepancies, indicating that further work on the model will be required 
to more accurately reflect MS cortical pathology. 
7.2.2.1	  Cytokine	  induced	  lesions	  are	  acute	  
Subpial grey matter demyelination is acute in this model, with full remyelination evident 14 
days post-cytokine injection. The concurrent resolution of inflammation in the meninges, 
(lymphocyte subtypes and macrophages) and cortex (activated microglia), indicates that a 
loss of pro-inflammatory signalling accompanies the remyelination. This is not altogether 
unexpected, as rapid dilution of the cytokines will occur after a single injection not the CSF. 
Maintaining pro-inflammatory signalling in the meningeal compartment is likely to be required 
to maintain cortical inflammation and to produce chronic demyelination. However, data from 
post-mortem MS cases represents a snapshot in time and, given the significant remyelination 
observed in the cortex (Albert et al. 2007), it could be suggested that GMLs that are assumed 
to be chronic are merely awaiting the onset of remyelination. The presence of apparently 
chronic GMLs, in the absence of microglial activity provides evidence against this hypothesis 
(Bö et al. 2003b). However, little is known about the mechanisms of remyelination in the grey 
matter. 
7.2.2.2	  Significant	  glial	  and	  neuronal	  cell	  loss	  are	  not	  detected	  in	  the	  model	  
Cortical atrophy has been highly correlated with the progression of disability in longitudinal 
MRI studies (Chen et al., 2004; Fisniku et al., 2008). The presence of transected neurites, 
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apoptotic neurons and significant synapse loss has been reported in GMLs (Peterson et al. 
2001; Wegner et al. 2006). Furthermore, substantial neuronal loss has been detected in 
subpial GMLs of F+ SP-MS cases and has been hypothesised to be a pathological correlate 
of the exacerbated disease course in these cases (Magliozzi et al. 2007; Magliozzi et al. 
2010). Neurodegeneration in MS is thought to occur as a consequence of persistent 
inflammation in the meninges and cortex and through Wallerian degeneration of chronically 
demyelinated axons (Frischer et al. 2009; Magliozzi et al. 2010). The gradient of neuronal 
loss in subpial GML and NAGM of F+ SP-MS cases strongly implicates the involvement of 
pathogenic soluble factors diffusing into the cortex as a result of chronic meningeal 
inflammation (Magliozzi et al. 2010). However, it may be hypothesised that the cell loss 
observed in the NAGM indicates either that cell loss has occurred independently of 
demyelination or that it has occurred in GML that were subsequently remyelinated. The 
diffuse cell loss observed in the absence of significant meningeal inflammation may indicate 
that the latter hypothesis more accurately describes pathology in the NAGM of F- SP-MS 
cases (Magliozzi et al. 2010). Furthermore, alterations to mitochondrial function and 
expression of glutamate receptors, in the absence of demyelination or inflammation, have 
been detected in the cortex of DA rats with EAE (Zeis et al. 2008). These observations were 
caused by chronic demyelination and axonal degeneration in the spinal cord. However, the 
diffuse cell loss observed in MS cortex may provide evidence against this being an important 
factor, cell loss due to spinal cord lesions would be expected to target specific cortical 
populations dependent on ascending/descending pathways. Due to the subclinical nature of 
the EAE initiated in this model, Wallerian degeneration of cortical neurons is not expected to 
occur. Axonal transection and neurodegeneration were not detected within the model 
developed in this thesis. 
A gradient of astrocyte cell loss has been detected in F+ SP-MS cases, together with 
disruptions to the astrocyte end feet forming the glia limitans at the pial surface (Magliozzi et 
al. 2010). Given the important function of astrocytes in maintaining the extracellular 
microenvironment and integrity of the pial surface, this loss may be a key step in the 
pathogenesis of these cases (Williams et al. 2007; Nair et al. 2008). Astrocyte numbers were 
not changed in response to cytokine injection in this model. However, acute disruption to the 
glia limitans was detected in each experimental condition immediately after injection 
(Appendix A1). It is known that CNS injection of LPS leads to reduction of GFAP expression 
in the end-feet of the glia limitans, and TNF and IFNγ have been shown to have activating 
effects on astrocytes that involve cytoskeleton remodelling (Selmaj et al. 1990; Sun et al. 
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2004; Merkler et al. 2006b). These studies may indicate a role for the injected cytokines in the 
changes observed in the pia mater in the model. 
The significant reduction in oligodendrocyte density in the upper cortical layers at early time-
points of MOG-immunised, cytokine-injected animals indicates that oligodendrocyte loss may 
precede demyelination in this model. Oligodendrocyte death prior to demyelination is a 
feature of toxin induced models of demyelination (Mason et al. 2000; Mason et al. 2004), and 
is a hallmark of a subset of WM MS lesions (Selmaj et al. 1990; Sun et al. 2004; Merkler et al. 
2006b). In this study, it may be hypothesised that soluble factors released by activated 
lymphocytes or macrophages in the meninges may diffuse into the cortex and cause 
demyelination. Furthermore, the upregulation of TNFR1A on oligodendrocytes may indicate 
an increased susceptibility to TNF induced apoptosis in this experimental group, although 
comparative data from early time-points is lacking. However, it must also be noted that the 
trend for reduction in cell density in control animals may indicate that the expression of APC 
is affected by cells stress initiated by surgery. Further work should include the quantification 
of oligodendrocytes using other markers. 
The number of oligodendrocytes was not different to naive animals or controls at the peak of 
demyelination. This data is contrasted with the confirmation of myelin loss by IHC for three 
different myelin proteins (MOG, CNPase, MBP), of differing abundance and location in the 
sheath. Studies from this laboratory of oligodendrocyte progenitor numbers in the cortical 
grey matter suggest that oligodendrocytes could be quickly replaced by only a single OPC 
cell division (Reynolds et al. 2003), which may account for both rapid remyelination and 
restoration of cell numbers at the peak of demyelination. In addition, in the cuprizone model 
of demyelination OPC numbers peak at the maximal extent of demyelination (Mason et al. 
2004). Together with data indicating the co-expression of APC and the OPC marker NG2 
(Kitada & Rowitch 2006), this data may imply that maturing, “pre-myelinating” OPC were 
included in the analysis. Alternatively, persistence of adult oligodendrocytes has been 
observed following antibody/complement-mediated demyelination in the spinal cord 
(Keirstead & Blakemore 1997), and they are also present in presumably chronic GMLs 
(Magliozzi et al. 2010), indicating that demyelination may occur without causing cell loss.   
It is thought that the failure to replicate the substantial neuronal and glial cell loss observed in 
F+ SP-MS is a direct consequence of the rapid resolution of inflammation and demyelination 
following the single injection of cytokines. Diffusion of the cytokines away from the injection 
site or removal by CSF proteases would lead to a rapid loss of the pro-inflammatory stimulus. 
Alternatively, it has recently been shown that the resolution of inflammation is an active 
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process which involves the expression of a large array of anti-inflammatory cytokines, such 
as IL-10, which may be released from microglia following myelin phagocytosis (Boven et al. 
2006). Moreover, it has been demonstrated that acute inflammation and removal of myelin by 
phagocytosis is a requirement for OPC recruitment and efficient remyelination, which 
prevents axonal degeneration and neuronal loss (Kotter et al. 2005; Irvine & Blakemore 2008; 
Neumann et al. 2009). 
Studies in Parkinson’s disease models have shown the importance of maintaining a pro-
inflammatory environment in producing neurodegeneration; high levels of TNF expression by 
a viral vector chronically maintained microglia/macrophage activation in the substantia nigra 
and led to an increase in the rate of neurodegeneration (Chertoff et al. 2011). In contrast, a 
bolus injection of TNF into the substantia nigra has been shown to have no affect on neuronal 
viability (Castaño et al. 2002). Therefore, we would suggest that the maintenance of 
meningeal inflammation over a longer period would lead to chronic demyelination associated 
with glial and neuronal cell loss.  
7.2.2.3	  No	  B	  cell	  aggregates	  were	  detected	  
It has recently been shown that the meninges of MS patients is able to support the formation 
of ectopic lymphoid-like germinal centre reactions similar to those occurring in the B cell 
zones of secondary lymphoid organs upon antigenic stimulation (Serafini et al. 2004).	  These 
formations can be found in a significant proportion (40-54%) of SP-MS cases (Serafini et al. 
2004; Magliozzi et al. 2007; Magliozzi et al. 2010). The presence of follicles in MS cases is 
associated with an accelerated disease course and exacerbated cortical pathology (Magliozzi 
et al. 2007; Magliozzi et al. 2010). It is highly likely that the effect of B cell follicles will be the 
maintenance of a compartmentalised immune response and a highly pro-inflammatory 
microenvironment (Uccelli et al. 2005; Aloisi & Pujol-Borrell 2006). Indeed, the presence of 
BrdU+ proliferating lymphocytes supports this hypothesis (Magliozzi et al. 2007).	  
B cell follicles consist of networks of proliferating memory B and T cells, antibody secreting 
plasma cells, and a network of supporting FDCs (Serafini et al. 2004; Magliozzi et al. 2007; 
Magliozzi et al. 2010). Follicles are associated with increases in the expression of TNF and 
IFNγ in the meninges by macrophages and cytotoxic T cells respectively (Magliozzi et al. 
2010; unpublished data). They are believed to form during chronic, high levels of 
inflammation and are associated with the expression of key attractant chemokines such as 
CXCL13 (B cell chemoattractant), BAFF and CCL21 (Serafini et al. 2004; Magliozzi et al. 
2004; Uccelli et al. 2005; Aloisi & Pujol-Borrell 2006). Studies in EAE models have 
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established that follicle formation occurred only in those animals experiencing a particularly 
high degree of meningeal inflammation, which is sustained in chronic disease (Magliozzi et al. 
2004). Furthermore, signalling by the TNF related cytokine lymphotoxin α1β2 is required to 
initiate follicle formation (Columba-Cabezas et al. 2006). 
Although the presence of FDCs in the meninges was not assessed in our model, B- and T-
lymphocytes appeared in isolation in the meninges, leading to the conclusion that 
aggregation into follicle-like structures had not occurred. This is exactly what would be 
expected in an acute inflammatory state. Further experimental studies utilising repeated or 
continuous delivery of the same and/or other cytokines known to be present in the CSF in MS 
will be required to answer the hypothesis concerning whether chronic pathology can result 
from chronic meningeal inflammation. A further explanation could be that injection of TNF and 
IFNγ does not cause sufficient release of molecules such as CXCL13, BAFF and lymphotoxin 
α1β2, which have been shown to be required for follicle formation (Serafini et al. 2004; 
Magliozzi et al. 2004; Columba-Cabezas et al. 2006; Aloisi & Pujol-Borrell 2006).  
7.3	  The	  mechanism	  of	  demyelination	  
7.3.1	  A	  hypothesis	  
Injection of cytokines into the subarachnoid space is required for infiltration of lymphocytes 
into this compartment. Due to the lack of comparable infiltration in animals injected with PBS, 
it is likely that this occurs as a result of cytokine action on meningeal vascular endothelial 
cells, causing upregulation of key adhesion molecules, such as ICAM-1, VCAM-1.  
In animals immunised with MOG, the re-activation of anti-MOG memory T cells occurs in the 
subarachnoid space, following re-encounter with cognate antigen presented by resident 
APCs (Kivisäkk et al. 2009). The requirement of an immune response to myelin protein and 
the observed “lag” time between cytokine injection and peak of demyelination argues against 
direct TNF/IFNγ-mediated demyelination and implicates the action of secondary factors 
released by activated lymphocytes/macrophages in the meninges as being central to the 
pathology (see Figure 7.1). The activity of lymphocytes could be investigated using flow 
cytometry for markers such as CD69 or IL-2 receptors.  
Recent research has highlighted the influence of a highly pathogenic sub-type of T cells 
termed Th17. These cells are characterised by production of IL-17A and the transcription 
factor RORγt (Korn et al. 2009). Tregs are another CD4+ T cell subset, which are essential for 
Chapter 7: General Summary 241 
 
the resolution of EAE (McGeachy et al. 2005). Tregs are characterised by expression of 
CD25 and the transcription factor FoxP3. It may be speculated that the ratio of T cell 
subtypes in the meninges is altered during the evolution of the demyelinated lesion, from high 
Th1/17 prior to demyelination, to high Treg numbers during resolution. In order to answer 
these questions, alternative detection techniques could be employed, such as flow cytometry 
of CSF or meningeal explants to detect cells within the meninges. 
Microglia were highly activated in the demyelinated cortex, and numbers correlated with 
demyelination, implicating them as being central to the pathogenesis. However, microglia can 
also have important functions in CNS repair mechanisms. The concept of microglial/ 
macrophage heterogeneity and class switching has been proposed to explain the dual role of 
this cell type in pathogenesis and repair (Gordon & Martinez 2010; Dirscherl et al. 2010). In 
this model, the phenotype of microglia/macrophages is unclear. IHC methods could be used 
to establish temporal changes in identity as the lesions develop. Classically (M1) activated 
macrophages express iNOS, IL-1β and TNF and release MMPs (Gordon & Martinez 2003; 
Mantovani et al. 2004; Colton 2009). In contrast, activation via the “alternative” or M2 
pathway leads to expression of Ym1 and CD206 (Gordon & Martinez 2010; Dirscherl et al. 
2010). 
The requirement for MOG immunisation to initiate demyelination provides evidence of the 
importance of anti-myelin humoral responses in cortical pathology. However, the detection of 
complement/ immunoglobulin myelin deposition in only one localised area of one animal with 
demyelination argues against the direct involvement of the humoral immune system in 
pathology. The prospect remains that memory B cells may play a role in cortical pathology by 
acting as efficient APCs in the subarachnoid space and increasing local activation of T cells 
(Rodríguez-Pinto 2005; Bouaziz et al. 2007). The establishment of the identity of APCs in the 
meninges could be achieved by co-localisation studies with markers such as CD40, MHCII 
and CD79a. The observation of MHCII+ macrophages and dendritic cells in the meninges may 
limit this role (Ponomarev et al. 2007; Kigerl et al. 2009; Colton 2009; Gordon &. Martinez 
2010). In addition, activated B cells may also play a role in cortical pathology via the release 
of pro-inflammatory molecules such as TNF and MMPs (Alter et al. 2003; Tumanov et al. 
2004). 
Expression of TNF is not increased in the demyelinated cortex, arguing against microglial 
derived TNF-mediated oligodendrocyte death as the primary mechanism of demyelination. 
However, TNFR1A receptor upregulation by oligodendrocytes may render them more 
susceptible to TNF-mediated apoptosis. The expression of levels of TNF in the meninges was 
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not quantified in this study, though expression by macrophages was detected by IHC, only in 
animals with demyelination. In addition, TNF expression by meningeal macrophages is 
upregulated in F+ SP-MS cases in the absence of cortical TNF expression. This data may 
lead to the hypothesis that solTNF produced in the subarachnoid space may diffuse across a 
damaged glia limitans and cause oligodendrocyte apoptosis and myelin damage.  
The lack of iNOS expression in the cortex or detection in the meninges by IHC implies that 
NO-mediated myelin damage is not responsible for demyelination. Further investigation will 
be required to rigorously assess this hypothesis. These results are based on a study 
performed on samples taken at the peak of demyelination. A pertinent future experiment 
would use similar techniques to investigate the expression of key pathological mediators prior 
to demyelination. In the cuprizone model for example, pathological mediators are maximally 
expressed prior to maximum demyelination being achieved (Mason et al. 2004).   
Other mediators may be involved in the demyelination observed in this model. For example, 
the enzyme MPO is secreted by activated microglia/macrophages and generates a variety of 
highly reactive molecules, such as NO (Lefkowitz & Lefkowitz 2008). Increased expression of 
MPO has been detected on activated microglia/macrophages in GML, but not in NAGM, of 
SP-MS cases (Gray et al. 2008). Expression of MPO by microglia/macrophages has been 
highly correlated with active demyelination in EAE (Chen et al. 2008). It may be speculated in 
this model that MPO expression is upregulated and may play a role in demyelination. 
Excessive release of the excitatory neurotransmitter glutamate has been shown to play a role 
in MS and EAE via toxicity to neurons and oligodendrocytes (Pitt et al. 2000; Werner et al. 
2001). Glutamate, which may cause reduced ATP production and mitochondrial dysfunction, 
and has been shown to be more neurotoxic than other cellular mediators released by 
microglia (Takeuchi et al. 2006; Yawata et al. 2008). TNF stimulates expression of the 
glutamate synthesising enzyme glutaminase, and glutamate release from microglia, via 
activation of the TNFR1A receptor (Takeuchi et al. 2006). Inhibition of glutaminase with 
specific antagonists effectively suppresses neuronal dysfunction caused by activated 
microglia/macrophages in vitro (Takeuchi et al. 2006; Yawata et al. 2008). The function of 
glutamate and its related receptors may be of interest in this model. 
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Figure 7.1 A hypothesised mechanism of demyelination. Peripheral immunisation with MOG protein produces 
anti-MOG memory T and B cells in the systemic circulation (A). Injection of cytokines into the subarachnoid space 
at the sagittal sulcus (B) upregulates adhesion molecules on meningeal vessels and leads to infiltration of 
lymphocytes and monocytes/macrophages (C). Memory T cells re-encounter cognate antigen following 
presentation by resident APC’s (D, Kivisäkk et al. 2009), become highly activated and release soluble factors (D). 
These soluble factors activate resident microglia (F), either directly following diffusion across the pia mater, or by 
activating meningeal endothelial cells which then transduce the signal into the cortex via the release of cytokines. 
Activated microglia then release factors (F e.g. cytokines, glutamate, MPO) that are toxic to 
myelin/oligodendrocytes and demyelination occurs (G).  
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7.3.2	  Testing	  the	  hypothesis	  
In order to test our hypothesis concerning a mechanism of demyelination in this model, it is 
necessary to demonstrate which molecular pathways are sufficient and necessary for 
demyelination to occur. Data presented thus far has shown that both an anti-myelin immune 
response and the presence of TNF/IFNγ in the meninges are required, but neither is sufficient 
to cause demyelination in isolation. In the absence of suitable KO models in this species, a 
variety of pharmacological inhibition studies will be required. 
7.3.2.1	  The	  requirement	  for	  an	  anti-­‐myelin	  response	  
Deposition of antibodies is not a pathological feature of this model. Therefore, the relevance 
of the requirement for anti-MOG antigen specificity is unresolved. It is likely that any 
reactivation of lymphocytes within the subarachnoid space would cause the release of the 
molecules that initiate demyelination. For example, transgenic mice have been produced with 
T cells specific for ovalbumin protein (OVA) and with subarachnoid space APCs expressing 
OVA antigen. T-OVA cells targeting were activated by OVA-APCs in the subarachnoid space 
and released high quantities of IL-17 and IFNγ (Bartholomäus et al. 2009). Furthermore, 
these T cells infiltrated the spinal cord parenchyma in increased numbers and led to mild 
clinical signs of EAE, but the presence or absence of demyelination was not reported. In this 
study no activation or infiltration of OVA-T cells was observed in the absence of OVA-APCs, 
which provides evidence that activation status rather than antigen specificity is important in 
producing subarachnoid inflammation and that re-activation of lymphocytes can have 
significant pathological effects. 
In the rat sophisticated genetic manipulation is currently not possible. Therefore, in order to 
answer this important question it may be necessary to target the immune response to other 
CNS antigens. Consideration must be given to the availability of the antigen in the 
subarachnoid space on APCs. The requirement for a CNS expressed antigen is likely, given 
that these are the only antigens that will be presented by APCs present in the meninges. 
7.3.2.2	  The	  requirement	  for	  TNF	  signalling	  
TNF is synthesized as a transmembrane protein (tmTNF) but may be cleaved by the TNF 
converting enzyme TACE, to a soluble form (solTNF, Aggarwal 2000; MacEwan 2002). 
SolTNF has been shown to preferentially signal through TNFR1A (Grell et al. 1995; Grell et 
al. 1998). Transgenic models demonstrate that tmTNF, in the absence of solTNF, suppress 
EAE through suppression of immune cells and reduced oligodendrocyte apoptosis (Kassiotis 
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& Kollias 2001; Alexopoulou et al. 2006). Specific inhibition of solTNF, using a dominant-
negative inhibitor (XENP345), attenuates apoptosis in mouse arthritis (Zalevsky et al. 2007), 
Alzheimer’s’ (Kassiotis & Kollias 2001; Alexopoulou et al. 2006) and Parkinson’s’ models 
(McCoy et al. 2006). No data is available with this pharmacological inhibition in EAE studies. 
It would be important to conduct pharmacological solTNF inhibition studies, not only in 
disseminated EAE models, but also in this model of GMLs. Furthermore, given the similar 
expression profiles of TNF in cytokine-injected control and experimental animals, it would be 
pertinent to assess the relative proportions of solTNF and tmTNF in each experimental 
condition. This would allow further dissection of the pathogenic mechanism in this model, and 
may increase the understanding of differential WM/GM pathogenesis. 
TNF signalling is mediated by two receptor subtypes, TNFR1A and TNFR1B (McAlpine et al. 
2010). TNFR1A plays a central role in EAE through direct induction of oligodendrocyte 
apoptosis and demyelination (Probert et al. 2000). Knockout of TNFR1A attenuates EAE 
through reduction in Fas induced oligodendrocyte apoptosis (Hövelmeyer et al. 2005). 
Therefore, pharmacological inhibition of this receptor sub-type is likely to attenuate EAE and 
may be beneficial in MS (Probert et al. 2000). Specific inhibition with TNFR1A neutralising 
antibodies attenuates the pathogenic effects of receptor activation in in vitro models 
(Kontermann et al. 2008). No studies on the effects of pharmacological TNFR1A inhibition in 
EAE are currently published, though it may be hypothesised to have a protective role in this 
model if TNF/TNFR1A interactions are a major mediator of myelin damage. 
7.3.2.3	  The	  requirement	  for	  microglia/macrophage	  activity	  
The number and activation state of microglia/macrophages are highly correlated with the 
extent of demyelination in this model, but due to the diverse roles of microglia, their precise 
role is open to debate. The classic pharmacological inhibitor of microglial/activity is 
minocycline. Minocycline is a tetracycline compound that has several distinct anti-
inflammatory effects separate from its anti-microbial properties. Studies have shown positive 
effects in many CNS disease models, including Huntington’s, Parkinson’s, Alzheimer’s, and 
spinal cord injury (Yong et al. 2004). Minocycline has been shown to attenuate EAE, and is 
associated with reduced lymphocyte and microglia/macrophage infiltration and reduced 
demyelination (Popovic et al. 2002). An important step in the attenuation of disease activity is 
downregulation of microglia/macrophage MHCII expression, which reduces T cell re-activation 
(Nikodemova et al. 2007; Nikodemova et al. 2010). Furthermore, minocycline administration 
reduces microglia-mediated axoglial disruption in EAE (Howell et al. 2010). Differential effects 
on remyelination in different toxin induced models have been detected (Li et al. 2005; 
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Skripuletz et al. 2010). However, minocycline is known to have pleiotropic effects on the 
inflammatory cascade, including mediating a switch from Th1 to Th2-mediated responses in 
the periphery (Popovic et al. 2002). Therefore, it may be necessary to use a more specific 
compound. 
 
Luteolin, 3′,4′,5,7-tetrahydroxyflavone, is a naturally occurring polyphenolic flavonoid. It is 
abundant in vegetables and fruits and has multiple biological effects that may be therapeutic 
in human disease (Lin et al. 2008). With relevance to CNS inflammation, luteolin suppresses 
TNF, IL-6 and CD40 upregulation in LPS or IFNγ treated microglial cell cultures (Chen et al. 
2008; Jang et al. 2008). This is achieved by the inhibition of nuclear factor kappa B (NFkB), 
JNK and activator protein 1 (AP1) signaling pathways (Chen et al. 2007; Jang et al. 2008). 
Furthermore, a recent study showed that administration of luteolin caused M1 activated 
microglia to switch classes, down-regulating key pro-inflammatory genes and upregulating 
anti-oxidant and chemotactic genes and taking on a resting-ramified morphology (Dirscherl et 
al. 2010). In the same study, luteolin treatment reduced NO secretion and neurotoxicity. Few 
in vivo studies are currently published, however luteolin has been shown to suppress LPS-
mediated mortality, and decrease TNF serum levels (Kotanidou et al. 2002). No data on the 
effects of luteolin treatment on the development of EAE or other neuroinflammatory 
conditions has been published, but it may be hypothesised that such treatment would 
attenuate disease by facilitating an anti-inflammatory, neuroprotective M2 
microglia/macrophage phenotype. In the model presented here, it is likely that inhibiting M1 
activation of microglia would suppress demyelination and/or enhance remyelination. 
7.3.1.4	  The	  involvement	  of	  complement	  
CVF is widely used for de-complementation in animal systems. It acts as a C3b analogue and 
initiates a false, non-pathogenic activation of the complement cascade in the periphery. This 
results in a transient elimination of C3 and C5 in the circulation. Complement depletion by 
CVF has been shown to delay the onset of EAE and reduce T cell and antibody responses in 
the rat and mouse (Linington et al. 1989a; Terényi et al. 2009). Decomplementation by 
administration of CVF in this model will test the hypothesis that cortical demyelination occurs 
independently of complement activity. 
7.3.1.5	  The	  role	  of	  B	  cells	  
B cells have a significant pathogenic role in EAE through release of antibodies and also act 
as highly efficient antigen presentation to activate T cells (Archelos et al. 2000; Rodríguez-
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Pinto 2005). B cell depletion by anti-CD20 antibodies is a successful treatment strategy in MS 
and has been shown to reduce CD4+ T cell activation/proliferation in autoimmune models. 
However, recent research has highlighted the potential regulatory role of B cells in MS/EAE, 
chiefly through the release of IL-10 from a subset of cells, designated B10 (Matsushita et al. 
2010; Anderton & Fillatreau 2008). The drug glatiramer acetate (Copaxone) partially functions 
to reduce T cell and microglia/macrophage function by the increasing the regulatory function 
of B cells (Kala et al. 2010). Due to the dual role of B cells in inflammation, it may be 
desirable to specifically inhibit antibody release. Application of nedocromil sodium (Kimata et 
al. 1994), or parathyroid hormone (Jiang et al. 1992) to cultured B cells reduces 
immunoglobulin production and release without affecting other functions. Administration of 
either of these substances could be used to test the hypothesis that antibodies are not 
responsible for demyelination in this model. 
7.3.1.6	  The	  requirement	  for	  lymphocyte	  infiltration	  to	  the	  meninges	  
Lymphocyte migration across activated BBB endothelia in the second wave of infiltration is a 
key step in the pathogenesis of EAE. The process of extravasation is dependent on 
interactions between CAMs that are upregulated on BBB endothelia after stimulation, 
following cytokine administration for example. The α4β1 T cell integrin has been shown to 
mediate initial tethering of circulating T cells to VCAM-1 on activated cerebral endothelia 
(Engelhardt & Ransohoff 2005). Inhibition of this interaction by antibodies produced excellent 
results in EAE models, reducing T cell infiltration of the CNS and attenuating disease course 
(Yednock et al. 1992; Kent et al. 1995). This led to the development of natalizumab, a highly 
efficacious monoclonal antibody against α4 integrin. Whilst results were initially promising, 3 
patients developed fatal progressive multifocal leukoencephalopathy, a fatal reactivation of 
the JC virus in the CNS, and the drug was voluntarily withdrawn pending further study (Miller 
et al. 2003; Hauser & Johnston 2009). It is now licensed as a monotherapy for severe RR-MS 
in patients who have failed to respond to other therapies.  
In the model presented in this thesis, entry of lymphocytes is almost certainly via meningeal 
vessels, which are activated by cytokine injection into the subarachnoid space. Inhibition of 
lymphocyte entry in the meninges by prophylactic anti-α4β1 antibody treatment might be 
expected to attenuate demyelination in this model, by reducing specific activation and 
subsequent release of pathogenic factors that activate cortical microglia or mediate direct 
oligodendrocyte/myelin damage. 
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7.3.3	  Demyelination	  via	  other	  mediators	  
Although TNF and IFNγ are important pro-inflammatory molecules and have been extensively 
studied in the pathophysiology of MS and EAE, they are by no means the only pro-
inflammatory mediators associated with these conditions. Given the synergistic actions of 
TNF and IFNγ identified in this model, it may be desirable to investigate the effects of 
combining other cytokines/chemokines. 
7.3.3.1	  Cytokines	  
Cytokines such as IL-1β, IL-6, IL-17 and lymphotoxin have all been shown to be important in 
the pathogenesis of EAE (for reviews see (Imitola et al. 2005; Ouyang et al. 2008), and could 
be investigated using this experimental model. Previously, injection of IL-1β into the naive 
striatum caused neutrophil infiltration and permeabilisation of the BBB (Blamire et al. 2000). 
Chronic expression of IL-1β in the striatum causes sustained BBB breakdown and neutrophil 
infiltration, accompanied with demyelination and activation of microglia and astrocytes 
(Ferrari et al. 2004). To date the effect of injection of IL-1β into the cortex, or into animals with 
a pre-existing immune response to MOG are not known. 
TRAIL is another cytokine linked to the pathogenesis of MS and EAE (Huang et al. 2005; 
Hoffmann et al. 2009). TRAIL and the associated death receptors were found in elevated 
levels in MS lesions (Cannella et al. 2007). TRAIL initiates oligodendrocyte apoptosis in vitro 
(Matyszak et al. 2002; Cannella et al. 2007), and IFNγ upregulates expression of TRAIL by 
microglia in vitro (Genc et al. 2003). However, studies have shown exacerbated EAE 
following administration of TRAIL inhibiting antibodies. This is due to a decreased apoptotic 
regulation of lymphocytes (Cretney et al. 2005). 
Inflammatory demyelination has been produced in the spinal cord of the Lewis rat following 
immunisation with MOG and injection with VEGF (Sasaki et al. 2010). VEGF mediates BBB 
disruption, allowing recruitment of anti-MOG lymphocytes and antibodies into the spinal cord 
(Dobrogowska et al. 1998; Proescholdt et al. 2002). Demyelinated lesions in this model were 
characterised by the presence of activated microglia, with scattered CD3+ T cells. Lesions 
resolve by remyelination 21 days post-injection (Sasaki et al. 2010). 
7.3.3.2	  Chemokines	  
Chemokines are a group of secreted proteins that are chemotactic for inflammatory cells and 
many of these have been identified as being involved in MS/EAE (Segal 2005; Tanuma et al. 
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2006; Szczuciński & Losy 2007). Of particular interest is CXCL13, also known as B-
lymphocyte chemoattractant. CXCL13 has been implicated in the ectopic B cell follicle 
neogenesis observed in MS patients and EAE animals (Magliozzi et al. 2004; Magliozzi et al. 
2007). It is released by macrophages following TNF activation and is observed in actively 
demyelinating WMLs in MS and EAE (Krumbholz et al. 2006; Bagaeva et al. 2006). 
Furthermore, the level of protein in the CSF of MS patients is highly correlated with the 
number of B cells, plasma cells and T cells as well as immunoglobulin production (Krumbholz 
et al. 2006). Lack of CXCL13 expression in KO mice has been shown to lead to an 
attenuated disease course (Bagaeva et al. 2006).  
MIP-1α and MCP-1 are two important chemokines in mediating monocyte/macrophage 
recruitment to the CNS in EAE (Vass et al. 1992; Kawakami et al. 2004). MIP-1α and MCP-1 
can be released by TNF activated microglia (McManus et al. 1998), and expression levels 
correlate with disease activity in EAE (Youssef et al. 1999). Furthermore, ablation of either 
using naked DNA vaccines has been shown to attenuate EAE. 
7.3.4	  Producing	  chronic	  cortical	  demyelination	  
Although this study has successfully created a model of type III subpial GML through 
meningeal inflammation, the pathology is acute and transitory. The pro-inflammatory 
environment in the cortex and meninges is not maintained following cytokine injection, and 
anti-inflammatory and repair mechanisms then come into play. Maintenance of the pro-
inflammatory environment in the subarachnoid space may prevent action of repair 
mechanisms and lead to chronic demyelination in the cortex. Chronic demyelination and a 
pro-inflammatory environment in the cortex may be hypothesised to lead to 
neurodegeneration and sustained oligodendrocyte and astrocyte loss (Magliozzi et al. 2010). 
Therefore, in order to produce a chronic model of cortical demyelination it would be 
necessary to create a chronic pro-inflammatory environment in the subarachnoid space 
surrounding the cortex. 
7.3.4.1	  Viral	  vectors	  for	  continual	  cytokine	  release	  
Genetically modified viral vectors have been widely used in animal models to chronically 
express proteins of interest. Injection of IFNγ expressing virus into the cisterna magna 
(subarachnoid space) resulted in widespread CNS distribution and expression in two different 
systems (Furlan et al. 2001; Millward et al. 2007). Infection was restricted to cells lining the 
subarachnoid space (e.g. leptomeningeal cells) rather than parenchymal cells. Furthermore, 
CSF concentrations of IFNγ were increased and caused MHCII upregulation in naive spinal 
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cord microglia in subpial regions (Furlan et al. 2001). Viral expression of IFNγ resulted in an 
earlier onset but milder EAE associated with increased TNFR1A-mediated T cell apoptosis 
(Furlan et al. 2001). These results were obtained in mouse, peptide induced EAE, which is a 
Th1 cell-mediated disease. Therefore, their applicability in a model with significant humoral 
and innate-mediated pathology presented in this thesis is unknown. Data illustrating the 
negative impacts on OPC differentiation and remyelination indicate that chronic expression of 
IFNγ may be a useful approach to maintain cortical demyelination in this model (Chew et al. 
2005; W. Lin et al. 2006). 
A recent study developed a viral vector for TNF and combined it with knock in mice to 
produce differential rates of TNF expression (Chertoff et al. 2011). A chronic low expression 
of TNF was not found to influence the level of inflammatory CNS infiltrates in the naive animal 
and was neuroprotective in the 6-hydroxydopamine (6-OHDA) toxin-induced model of 
Parkinson’s disease. In contrast, a chronic high release of TNF caused microglial activation, 
monocyte recruitment and neurodegeneration without 6-OHDA challenge. These results 
indicate the potential importance of chronic TNF administration and microglial activity in the 
process of neurodegeneration. They are also an indication that technical aspects, such as the 
level of gene expression, need to be thoroughly considered before in vivo studies begin.  
Collaborators in Rome (Dr F. Aloisi) have produced an adeno-associated viral vector 
expressing CXCL13, a key protein in B cell-mediated inflammation and follicle formation 
(Magliozzi et al. 2004; Krumbholz et al. 2006). It may be interesting to study the effects of this 
chemokine when introduced into the subarachnoid space, with or without the presence of 
other pro-inflammatory molecules. The development of viral vectors for TNF could also be 
investigated and may be expected to increase pathology, particularly if solTNF is exclusively 
produced. The co-administration of free cytokines and viral vectors could also be 
investigated, in order to initiate lymphocyte infiltration and then maintain intra-meningeal 
inflammation and cortical pathology. 
7.3.4.2	  Slow	  release	  formulations	  and	  drug	  delivery	  
It has been hypothesised that the extensive grey matter pathology observed in human tissue 
samples may result from factors diffusing into the cortex from the chronically inflamed 
meninges (Magliozzi et al. 2010). Data presented in this thesis shows subpial cortical 
demyelination following acute presence of TNF and IFNγ in the meninges. The resolution of 
inflammation and remyelination observed in this model of subpial GML may result from the 
loss of pro-inflammatory signalling within the meninges. Therefore, to produce chronic lesions 
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of the type observed in human samples, it may be necessary to maintain the inflammatory 
environment for some time. In order to achieve this, a slow release delivery system may be 
utilised.  
In recent years a huge amount of research has focused on the development of methods that 
control the release of drugs in a local environment over time. This type of approach may 
prove particularly useful for the treatment of tumours. The potential of synthetic vectors has 
recently been investigated due to the safety and scale-up issues associated with viral vectors. 
However, the use of liposomes, micelles and polymers often results in poor targeting of 
drugs, and low in vivo survival, attributed to the presence of surface charge, or inherent low 
shell stability (Rethore & Pandit 2010). The use of biocompatible natural polymers such as 
chitosan to form hollow nanoshells aims to circumvent these problems. Biodegradable 
nanoshells are cost-effective, relatively simple to produce and have vast potential for tailoring 
localisation and degradation rates, indicating a wide variety of applications (Rethore & Pandit 
2010). Structural characteristics, such as shell thickness, pore size, surface charge are 
engineered to release the captured protein slowly on degradation, over a period of several 
weeks. There is also the potential to be tethered to meningeal collagen to maintain their 
position in the subarachnoid space, and so counteract the dispersing effects of bulk CSF 
flow. Nanoshells constructed with the biodegradable polysaccharide, chitosan, and 
polyglutamic acid (PGA) have been used to encapsulate and deliver plasmid DNA and the 
anti-cancer drug doxorubicin (Hu et al. 2007; Rethore & Pandit 2010). The implications of 
injecting such a substance into the subarachnoid space would need to be investigated, as 
any blockage of the CSF flow could lead to hydrocephalus (Li et al. 2008). 
7.3.4.3	  Subarachnoid	  injection	  of	  FITC	  labelled	  nanoshells	  
Preliminary work has investigated the feasibility of using FITC-labelled chitosan/PGA for 
delivery of cytokines to the CNS (see Appendix A2). Nanoshells were successfully injected 
into the subarachnoid space of naïve female DA rats and were readily detectible by 
fluorescence microscopy. Nanoshells were present in large quantities up to 1mm from the 
injection site, and were persistent through to the end of the experiment 14 days post-injection. 
Pathological analysis revealed extensive infiltration of macrophages into the subarachnoid 
space. Macrophages are likely to be responsible for the removal of the nanoshells (Rethore & 
Pandit 2010; Dash et al. 2010), though due to the very high density of cells and nanoshells in 
this area, it was impossible to verify the ingestion of nanoshell fragments. The presence of 
high numbers of nanoshells surrounding the injection site was associated with small areas of 
demyelination in the molecular layer of the cortex. Although the mechanism of demyelination 
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is unknown, it is possible that it is an effect of pressure caused by the injection of a large 
quantity of a viscous substance into the sagittal sulcus. However, it is also possible that the 
activation of macrophages causes the release of mediators that cross the pia mater and are 
toxic to oligodendrocytes and myelin. Supporting this hypothesis, cortical microglia appear to 
be activated in areas with demyelination and neighbouring NAGM. 
This study represents the first steps to utilising slow-release formulations to maintain cytokine 
release within the meninges. The results indicate that future studies will need to be carefully 
controlled to account for the extensive infiltration of macrophages and activation of microglia 
in the cortex. Future studies will investigate the effect of unloaded nanoshells vs. TNF/IFNγ 
loaded nanoshells in IFA and rmMOG treated animals. 
7.4	  Final	  Conclusions	  
Data presented in this thesis demonstrates the successful creation of an animal model of 
Type III GMLs in the cortex of MS patients. To my knowledge it is the first animal model of 
subpial GMLs resulting from inflammatory processes in the meninges. It indicates that a pre-
existing response to myelin protein, coupled with pro-inflammatory signalling in the meninges 
are two essential factors in cortical demyelination. 
The model re-creates many aspects of GML pathology, with pronounced lymphocyte 
inflammation restricted to the meninges and extensive microglial activation in the cortex 
correlated with the extent of demyelination. Study of the mechanisms occurring in the model 
may shed light on the pathophysiology of MS GML formation. Evidence from studies of post-
mortem MS GMLs and this model implicate the upregulation of TNFR1A and cytokine 
signalling in the meninges, and argue against complement and antibody involvement. Further 
work with pharmacological inhibitors may elucidate the role of TNFR’s and microglia in the 
pathology occurring in this model. 
The model presented here elicits transient demyelination and it is likely that maintaining the 
pro-inflammatory environment in the cortex and meninges would cause chronic demyelination 
and loss of neurons, oligodendrocytes and astrocytes. A chronic model of cortical 
demyelination replicating all aspects of SP-MS GML could be used to study the influence of 
GML and neurodegeneration on the cognitive symptoms and progression of disability in SP-
MS. The model would also provide valuable tool for the testing of pharmaceutical agents 
aimed at preventing disability progression in MS.
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A1.1	  Introduction	  
A1.1.1	  Acknowledgement	  
The following research was conducted as part of a BSc research project supervised by the 
author.  
A1.2.1	  The	  structure	  of	  the	  pial	  surface	  
The pia mater is the structure separating the cortical parenchyma and the subarachnoid 
space. It is composed of the glia limitans and overlying basement membrane, the basal 
lamina. Traberculae join the basement membrane to the overlying arachnoid membrane. 
Finger-like astrocyte processes project towards the pial layer and are held together by 
junctional complexes to form a coherent structure parallel to this boundary. A basal lamina 
composed of matrix molecules including laminin, fibronectin and collagen adds a further 
aspect to the barrier (Shearer & Fawcett 2001). Systemic inflammation has been shown to 
activate leptomeningeal cells to express TNF, which then activates microglial cells of the 
cortical parenchyma and astrocytes of the glia limitans (Wu et al. 2005; Wu et al. 2008). 
Furthermore, IFNγ expression following viral transformation of leptomeningeal cells activates 
microglial cells (Furlan et al. 2001). 
Astrocytes at the glia limitans perform key functions in regulating the intracortical 
environment. Water homeostasis is achieved by aquaporin 4 (AQP) water channels in the cell 
membrane of astrocyte end-feet (Nielsen et al. 1997). This placement facilitates the 
movement of water in and out of the brain parenchyma, regulating the ionic and osmotic 
environment. A pertinent example of this disruption occurs in neuromyelitis optica (NMO), in 
which autoimmune targeting of AQP4 water channels causes damage to astrocytes in the glia 
limitans (Misu et al. 2007). The associated inflammatory reaction produces demyelinating 
lesions, located preferentially in the spinal cord and optic nerves (Hengstman et al. 2007).  
A1.3.1	  Aims	  
The present study aimed to investigate the integrity and functional capability of components 
of the pia mater within an animal model of subpial cortical demyelination. It was hypothesis 
that the pial surface would be disrupted at the peak of demyelination, as visualised by IHC. 
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A1.2	  Methods	  
A1.2.1	  Induction	  of	  subpial	  demyelination	  
Subpial demyelination was induced in female DA rats using the protocol described in Chapter 
2 (2.4).  
A1.2.2	  Assessment	  of	  pial	  surface	  integrity	  
Pathological assessment of pial surface integrity was carried out on the same samples as 
Chapter 5. 
Table A1.1: Number of animals in each investigation group. Animals were immunised with 5µg rmMOG or IFA and 
20 days later received an injection into the subarachnoid space at the sagittal sulcus of either 1.25µg TNF/ 75ng 
IFNγ or PBS. Animals were culled at different time-points post-injection and serial coronal brain sections were 
taken.  
Days Post Stereotactic 
Injection 
Investigation Group Number of animals 
(N) 
- Naive 3 
1 
rmMOG/Cytokine 8 
IFA/Cytokine 3 
rmMOG/PBS 4 
3 
rmMOG/Cytokine 8 
IFA/Cytokine 3 
rmMOG/PBS 3 
7 
rmMOG/Cytokine 10 
IFA/Cytokine 7 
rmMOG/PBS 4 
14 
rmMOG/Cytokine 6 
IFA/Cytokine 3 
rmMOG/PBS 3 
21 
rmMOG/Cytokine 4 
IFA/Cytokine 3 
rmMOG/PBS 3 
A1.2.2.1	  Double-­‐label	  IF	  
IF was carried out for various antigens to assess the integrity of the glia limitans. IF was 
carried out using the same method detailed in Chapter 2 (2.2.3). 
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Table A1.2 Antibodies used in double-labelling IF studies 
Antigen Cell Specificity Species Dilution Source 
Iba1 Microglia/Macrophages Rabbit 1:2000 Wako, Japan 
Fibrinogen Serum protein Rabbit 1:5000 Gift 
Laminin Pial membrane Rabbit 1:5000 Sigma 
GFAP Astrocytes Rabbit 1:2000 Dako 
GFAP Astrocytes Mouse 1:2000 Sigma 
AQP4 Astrocytes Mouse 1:500  
MOG1 Myelin/oligodendrocytes Mouse 1:50  
1Denotes air dry for 1 hour prior to rehydration and -20°C Methanol for 6 minutes retrieval prior to staining 
 
A1.2.2.2	  Analysis	  and	  Quantification	  
Digital images of sections were obtained using a at 10X magnification using a Nikon Eclipse 
50i microscope with Qimaging Qi-Cam digital camera, and analysed using Image Pro-Plus 
(Media Cybernetics). All sections were scanned using the same exposure, gain, gamma and 
offset functions to enable direct comparison. Quantitative and qualitative assessment of the 
integrity of the pial surface was carried out independently by both the research student and 
the author. 
A1.2.2.3	  Quantitative	  assessment	  of	  layer	  disruption	  in	  a	  defined	  area	  of	  interest	  
An AOI of 1mm along the midline (0.25mm dorsal to the corpus callosum) including the glia 
limitans was selected manually and a more defined area was specified on the basis of GFAP 
signal intensity above a defined threshold (21 on the 0-255 pixel intensity scale). Artefacts 
deemed unrelated to the glial membrane were removed using the “toggle-off” function. The 
remaining selection was analysed by measurements of area, width, diameter and density 
(intensity) derived from the GFAP signal. A similar protocol was used to analyse the basal 
lamina (Threshold: 9, 0-255 pixel intensity scale), with measurements of area, width, diameter 
and density (intensity) derived using the laminin signal.  
A1.2.2.4	  Semi-­‐quantitative	  assessment	  via	  a	  5-­‐point	  scoring	  system	  
A 5-point scoring system was defined, classifying disruption to the glia limitans (GFAP) and 
basal lamina (laminin, Table A1.3). Sections were assessed by two independent assessors in 
a blinded manner. Prior to assessment a representative image for each score was selected 
using the criteria highlighted in Table A1.3. Scores for each section were identical between 
assessors apart from two sections in which scores differed by a single point for which a 
consensus was achieved 
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Table A1.3 Semi-quantitative assessment of pial surface integrity, for the glia limitans (GFAP) and basal lamina 
(Laminin). 
Score Disruption criteria (GFAP/Laminin signal) 
0 Intact layer with no signal changes compared to naive animals 
1 Intact layer with some signal changes compared to naive animals 
2 Disrupted layer, mean disruption width 0-0.25mm 
3 Disrupted layer, mean disruption width 0.25-0.5mm 
4 Disrupted layer, mean disruption width > 0.5 mm 
	  
A1.2.2.5	  Statistical	  analysis	  
GraphPad Prism 4.0 was used in all cases to present data and conduct statistical analysis. All 
data represents the mean with together with standard error of the mean (SEM). Group 
comparisons were analysed by one-way analysis of variance (ANOVA) with Tukey correction. 
A p value of <0.05 was considered significant in all cases.	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A1.3	  Results	  
A1.3.1	   Quantitative	   analysis	   of	   glia	   limitans	   and	   basal	   lamina	  
disruption	  
Sections were analysed from the same experiments as Chapter 5. The integrity of the glia 
limitans (GFAP) and basal lamina (laminin) was assessed by double labelling-IF (Figure 
A1.1). A pixel threshold was added to an area of interest in the sagittal sulcus to quantify the 
area covered by the corresponding protein.  
A wide variation in signal intensity was obtained for both GFAP and laminin staining. This 
variation was independent of layer integrity, thus affecting comparability between 
experimental groups (Figure A1.1). Extensive variation occurred when using identical 
experimental conditions and analytical methods. These differences translated to area, 
intensity and width measurements that were independent of any visible disruption in either of 
the layers.  
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  A1.3.2	  Semi-­‐quantitative	  analysis	  of	  pial	  surface	  integrity 
Due to the limitations of a quantitative analysis, each section was evaluated using a semi-
quantitative method, which allowed visual assessment of the disruption to the GL and BL 
layers in each section. A 5-point scoring system was employed using pre-defined criteria 
(Table A1.3), with the aid of representative sections demonstrating the level of layer 
disruption (Figure A1.2 A-E, Figure A1.3 A-E). An increased score indicated decreased 
detection of protein or increasing disruption to the layer. Disruption of the glia limitans and 
basal lamina was assessed in animals immunised with rmMOG and injected in the 
subarachnoid space with cytokines. Scores were compared to control animals either 
immunised with IFA and injected with cytokines or immunised with rmMOG and injected with 
PBS. 
A1.3.2.1	  Assessment	  of	  the	  glia	  limitans	  
Naïve animals showed no evidence of glia limitans layer disruption. Disruption to the glia 
limitans occurs in each experimental condition and is most prominent on day following 
subarachnoid space injection and to a similar degree in each animal (Figure A1.2 F). 
Disruption was significantly higher one day post-injection than naive animals or subsequent 
time-points. The average score was approximately 2, corresponding to small areas with no 
GFAP staining, indicating loss of astrocyte end-feet and barrier integrity. Each group showed 
reduced scores at subsequent time-points, indicating possible regeneration of the glia 
limitans. Disruptions to the glia limitans were only found within the sagittal sulcus not in the 
dorsal cortex.  
A1.3.2.2	  Assessment	  of	  the	  basal	  lamina	  
Changes to the basal lamina were also prevalent at an early stage after cytokine injection. 
Both cytokine-injected groups showed an increased disruption score in the first week after 
cytokine injection, which was maintained at subsequent time-points without signs of repair 
(Figure A1.3 D). Alterations to the basal lamina were mild compared to the changes observed 
in the glia limitans, with continuous presence of laminin maintained. Only one instance of a 
breach of the lamina was observed, in an animal immunised with rmMOG and injected with 
cytokines, 3 days post-cytokine injection (Figure A1.3 C).  
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A1.3.3	  Functional	  assessment	  of	  pial	  surface	  integrity 
A1.3.3.1	  Aquaporin	  4	  expression	  is	  maintained	  following	  glia	  limitans	  disruption	  
 To confirm glia limitans disruption and consider the cause of the reduction in GFAP signal we 
performed double IF staining of GFAP and aquaporin 4 (AQP4). Both labelled similar loci, 
with additional AQP4 staining a web of finer glial processes in close proximity to the surface 
(Figure A1.4 A). Intense AQP4 staining was also observed surrounding cerebral blood 
vessels, where the limitans is also present (not shown). With glia limitans disruption, 
characterised by an absence of GFAP detection indicating loss of astrocyte end-feet, AQP4 
protein remained present (Figure A1.4 B). The ordered distribution observed in naive tissue 
was disrupted and seemingly removed from the pial surface, possibly indicating process 
withdrawal by astrocytes.   
A1.3.3.2	  Fibrinogen	  leakage	  as	  a	  consequence	  of	  glia	  limitans	  disruption	  
The functional effects of glia limitans disruption was investigated by double IF labelling with 
GFAP and fibrinogen, a serum protein present in CSF. In naive animals, and animals with an 
intact glia limitans, fibrinogen was detected exclusively within the subarachnoid space (Figure 
A1.4 C). Fibrinogen leakage in sections with glia limitans disruption, with the highest extent of 
parenchymal leakage noted in the most disrupted sections, one day post-injection (score 3-4, 
Figure A1.4 D). Fibrinogen in the parenchyma was principally located in cortical layer I of the 
cortex and formed a gradient of stain intensity, with greatest intensity in the subarachnoid 
space and at the pial surface and least intensity deeper in the cortex (Figure A1.4 D). 
 	  

Appendix A1: Pial surface responses to cytokine injection 265 
 
A1.3.3.3	  Glia	  limitans	  disruption	  is	  associated	  with	  subpial	  
demyelination 
To assess the effect of glia limitans disruption on cortical myelin we performed double IF 
staining using GFAP and MOG. Demyelination was most extensive at 7 days post-cytokine 
injection in animals immunised with rmMOG. This did not correlate with the time-period of 
most disruption to the glia limitans. However, alterations to myelin distribution were 
associated with the most extensive glia limitans disruption (A1.5 B). Specifically, myelin was 
lost in the molecular layer close to the pial surface and associated with many DAPI positive 
nuclei in animals with a glia limitans score of 3-4. 
A1.3.3.4	  Glia	  limitans	  disruption	  is	  associated	  with	  inflammatory	  activation	  in	  the	  
parenchyma	  
To further investigate the pathogenic effect of leakage across a disrupted glia limitans, double 
IF to GFAP and Iba1 was performed. Differences in morphology of Iba1-positive cells were 
noted between sections with glia limitans disruption and those without disruption. In sections 
with an intact glia limitans, microglia exhibited a ramified morphology with highly branched 
processes and were distributed evenly throughout the cortex (Figure A1.5 C). Where severe 
glia limitans disruption was present Iba1+ cells showed a spherical, amoeboid morphology 
and were closely associated with the area of disruption (Figure A1.5 D). 
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A1.4	  Discussion 
A1.4.1	   Disruption	   of	   the	   pia	   mater	   following	   subarachnoid	   space	  
injection	  
A1.4.1.1	  Variation	  in	  staining	  quality	  affected	  quantitative	  analysis	  
In considering the extent of glia limitans disruption, we encountered difficulty in identifying a 
method that would allow us to accurately define the glia limitans using IHC techniques. 
Initially, a quantitative method was employed involving isolation of the glia limitans and the 
basal lamina by selecting a pixel threshold from which measurements of layer density, width 
and area could be determined. However, variation in stain intensity observed in naïve control 
sections, stained and analysed using the same parameters, complicated the assessment of 
disruption and comparisons between different treatment groups using this method. These 
differences were exacerbated when analysing experimental sections, which had been in 
storage for varying periods of time and showed a huge variation in staining intensity. This 
variation made reliable quantitative analysis impossible, and a semi-quantitative method was 
used. 
A1.4.1.2	  Semi-­‐quantitative	  analysis	   revealed	  disruption	  of	  glia	   limitans	   following	  
subarachnoid	  space	  injection	  
All experimental groups showed an early disruption (one day post-injection) in both the glia 
limitans and basal lamina. This indicates an effect of the act of injection, rather than specific 
responses to either cytokines, or presence of a peripheral anti-MOG response. Histological 
analysis confirmed that the needle had not entered the parenchyma in any section, therefore 
other effects of the injection may be responsible, such as; disruption of meningeal blood 
vessels, bleeding following disturbance to the sagittal sinus during surgery, volume effect of 
the injected sample. 
Differences in pia mater disruption patterns are evident when comparing components of the 
layer. The glia limitans shows early disruption with subsequent resolution, whereas the basal 
lamina retains a low level of disruption across all time-points. These trends suggest that 
though early disruption in the glia limitans is seemingly repaired at later stages, the basal 
lamina only rarely shows a breach. Previous data (Chapter 5) indicated that astrocytes were 
not lost immediately after cytokine injection, indicating that either end-feet retraction had 
occurred, or that GFAP expression was modified. Differential staining of AQP4 and GFAP 
leads further weight to this argument. Previous studies have identified AQP4 in minor GFAP-
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negative astrocyte processes (Nielsen et al. 1997; Simard & Nedergaard 2004). TNF-induced 
reduction of GFAP expression in cultured astrocytes has been reported (Murphy et al. 2002). 
Moreover, CNS inflammation, induced by LPS injection, has been shown to reduce 
expression of GFAP in the glia limitans (Sharma et al. 2010). Furthermore, as GFAP is a 
cytoskeletal element, reduction in its expression has been shown to trigger changes in 
astrocyte morphology and process retraction (Kalman et al. 1999; Salm 2000). It may be 
hypothesised that downregulation of GFAP in astrocyte processes results in retraction of 
astrocyte end-feet, which may account for disruption seen in this layer.  
Functional disruption in the pia mater was detected by IF for the serum protein fibrinogen. In 
naive animals with an intact pia mater, small amounts of fibrinogen were detectable only in 
the meninges. In animals with severe glia limitans disruption fibrinogen was detected within 
the parenchyma, exhibiting a graduated pattern of diffusion from the pial surface into deeper 
cortical layers. Studies using human SPMS tissue have observed disruption to the glia 
limitans associated with subpial cortical demyelination in cases with high levels of meningeal 
inflammation (Magliozzi et al. 2010). Leakage of serum protein was detected following 
disruption to the glia limitans and may contribute to pathology. Fibrinogen can activate 
microglia by forming a complex with the microglial integrin receptor (Mac1), triggering an 
increase in phagocytosis (Adams et al. 2007). Leakage of albumin, another protein in serum 
and CSF, triggers iNOS expression (via a MAPK pathway), glutamate production and 
induction of a neurotoxic phenotype in microglia (Hooper et al. 2009).  
A1.4.2	  Conclusion	  
In this study there is evidence of microglial/macrophage accumulation and activation 
occurring with severe disruption to the glia limitans. This appears in a greater extent in 
animals with cytokine injection, indicating a role for the cytokines in activation. Direct effects 
of the injected cytokines on oligodendrocytes do not occur sufficiently to cause demyelination 
in animals without an immune response to myelin. Therefore, a key factor in causing 
demyelination appears to the peripheral anti-myelin response of B cells and presumably T 
cells. Upon cytokine injection these cells infiltrate the meninges in high numbers and will re-
encounter cognate antigen and become activated to secret pro-inflammatory molecules, 
which will activate microglia to a greater extent than controls and may lead to demyelination 
(Kivisäkk et al. 2009).  
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A2.1	  Introduction	  
A2.1.1	  Slow	  release	  mechanisms	  
In recent years a huge amount of research has focused on the development of methods 
that control the release of drugs in a local environment over time. This type of approach 
may prove particularly useful for the treatment of tumours (Hu et al. 2007). The potential of 
synthetic vectors has recently been investigated due to the safety and scale-up issues 
associated with viral vectors. However, the use of liposomes, micelles and polymers often 
results in poor targeting of drugs, and low in vivo survival, attributed to the presence of 
surface charge, or inherent low shell stability (Rethore & Pandit 2010). The use of 
biocompatible natural polymers such as chitosan to form hollow nanoshells aims to 
circumvent these problems. Biodegradable nanoshells are cost-effective, relatively simple 
to produce and have vast potential for tailoring localisation and degradation rates, 
indicating a wide variety of applications (Rethore & Pandit 2010). Structural characteristics, 
such as shell thickness, pore size, surface charge are engineered to release the captured 
protein slowly on degradation, over a period of several weeks. There is also the potential 
to be tethered to meningeal collagen to maintain their position in the subarachnoid space, 
and so counteract the dispersing effects of bulk CSF flow. Nanoshells constructed with the 
biodegradable polysaccharide, chitosan, and polyglutamic acid (PGA) have been used to 
encapsulate and deliver plasmid DNA and the anti-cancer drug doxorubicin (Hu et al. 
2007; Rethore & Pandit 2010). The implications of injecting such a substance into the 
subarachnoid space would need to be investigated, as any blockage of the CSF flow could 
lead to hydrocephalus (Li et al. 2008). 
A2.1.2	  Aims	  
The present study aimed to investigate the potential of nanoshells as a slow release 
mechanism for the delivery of cytokines into the subarachnoid space. FITC-labelled 
nanoshells will be injected into the subarachnoid space of naive DA rats, and their 
persistence in this compartment will be studied.  
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A2.2	  Methods	  
A2.2.1	  Injection	  of	  nanoshells	  
A2.2.1.1	  Preparation	  of	  nanoshells	  
FITC-labelled nanoshells (2mg/ml, diameter 500nm) were prepared by and obtained from 
a collaborator (G. Rethore, University of Galway, see Figure A2.1).  
	  
Figure A2.1: Preparation of FITC-labelled nanoshells. Soluble chitosan polymer was applied to sulfonated 
polystyrene beads and cross-linked with PGA (ratio 2:1). Nanoshells were tagged with FITC and the 
polystyrene template was removed to leave a hollow nanoshell (Rethore et al. 2009). 
A2.2.1.2	  Housing	  of	  animals	  
Female DA rats (Harlan, UK) were used in all experiments (8-12 weeks old, approximately 
160g). Animals were housed in Imperial College London CBS (Hammersmith Hospital 
campus), food and water were available ad libitum with a light: dark cycle of 12:12. All 
experiments were performed under UK Home Office project license 70/6282. Animals 
spent at least 5 days in the unit prior to immunisation.  
A2.2.1.3	  Surgical	  protocol	  
The subarachnoid space of the sagittal sulcus was targeted 0.9mm caudal to bregma and 
to	  a depth of 2.5mm (Paxinos & Watson, 1998). Rats were anaesthetised with isofluorane 
and mounted on a stereotactic frame. The skull surface was accessed and a fine hole was 
drilled. 2µl of nanoshell solution was injected via a finely calibrated glass capillary attached 
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to 26S Hamilton syringe. The sample was injected at a rate of 0.20µl/min using an 
automated injection system (KD Scientific) 
A2.2.1.4	  Tissue	  preparation	  
At varying time-points post-surgery, animals were injected into the peritoneal cavity with an 
overdose of 200mg/ml sodium pentobarbital. After confirmation of respiratory arrest 
animals were perfused through the left ventricle with sterile PBS. The brain was extracted, 
immediately placed in an OCT filled plastic mould and placed in ice-cold isopentane. 
Animals were culled 1, 3, 7 and 14 days post-injection, n = 3 each group.  
A2.2.2	  Assessment	  of	  nanoshell	  distribution	  
The presence of nanoshells was investigated throughout the brain. Brain sections were 
obtained using a cryostat. One 10µm section was taken every 200µm. The area sectioned 
corresponded to approximately plate 5 to plate 45 of a stereotactic atlas (Paxinos & 
Watson 1998).  
A2.2.2.1	  IF	  
Double-labelling IF was carried out according to the method detailed in Chapter 2.  
Table 6.2 Antibodies used in double-labelling IF studies. 
Antigen Specificity Species Dilution Source 
Iba1 Microglia/Macrophages Rabbit 1:2000 Wako, Japan 
MOG1 Myelin/oligodendrocytes Mouse 1:50 R. Reynolds, ICL 
1Denotes air dry for 1 hour prior to rehydration and -20°C Methanol for 6 minutes retrieval prior to staining 
A2.2.2.2	  Quantification	  of	  nanoshell	  spread	  	  
Tiled digital images of each section were obtained at 10x magnification, Nikon Eclipse 50i 
microscope with Qimaging Qi-Cam digital camera, and analysed using Image Pro-PLUS 
6.0 software (Media Cybernetics). Captured images were coded to ensure quantification 
was performed in a blinded manner. The images were converted to grey scale (8bpp). The 
total area covered by nanoshells was quantified automatically via the application of the 
pixel intensity function (0-40). All analyses were checked to remove artefacts and cells 
within vessels, using the “toggle off” function of the software. 
A2.2.2.3	  Statistical	  analysis	  
GraphPad Prism 4.0 was used in all cases to present data and conduct statistical analysis. 
All data represents the mean with together with standard error of the mean (SEM). The 
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area under the curve was calculated. Group comparisons were analysed by one-way 
analysis of variance (ANOVA) with Tukey correction. A p value of <0.05 was considered 
significant in all cases.	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A2.3	  Results	  
A2.3.1	  Nanoshell	  injection	  causes	  meningeal	  inflammation	  
Approximately 4µg 500nm FITC labelled nanoshells were injected into the sagittal sulcus 
of naive female DA rats. Recovery was uneventful in all cases, with normal behaviour and 
stable weight evident 2 days post-injection. Animals were culled 1, 3, 7 and 14 days post-
injection. 
Double IF was carried out on snap-frozen coronal brain cryosections to investigate 
presence of nanoshells, and the effects of these on the neighbouring cortex. Nanoshells 
were readily visible under fluorescence microscopy at 10X magnification. At the injection 
site they were present in large aggregates extending from the base of the sulcus to 
approximately 50% of the total extent. Nanoshells were rarely detected on the dorsal 
surface of the cortex (Figure A2.2 A). High numbers of Iba1+ macrophages were observed 
within the meninges of each animal studied, regardless of time-point (Figure A2.2 B). 
These cells and the nanoshells were present in such high density that it was difficult to 
define whether nanoshells had been ingested by macrophages or not (Figure A2.2 C).  
Immunofluorescence for MOG protein revealed myelin disruption in areas neighbouring 
the main aggregate of nanoshells in one animal 7 days post-injection (Figure A2.2 D, F). 
This area of myelin disruption was confined to the molecular layer of the ACg, and covered 
approximately 50% of the distance between the corpus callosum and dorsal cortex. 
Concurrently a large number of macrophages were present with the nanoshells (Figure 
A2.2 E, F). There was also evidence of microglia/macrophage infiltration/proliferation in the 
cortex close to the sulcus. 
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A2.3.2	  Nanoshells	  are	  present	  up	  to	  two	  weeks	  post-­‐injection	  
The distribution of nanoshells was quantified every 200µm throughout the brain from 
plates 5-45 (Paxinos & Watson 1998), Figure A2.3 A). This was accomplished by 
measuring the area covered by FITC fluorescence within the sagittal sulcus using Image 
Pro Plus software. 
Nanoshells were found in very small quantities far rostral (~2mm) and caudal (4mm) to the 
injection site. However, the vast majority of nanoshells were concentrated in a large 
aggregation 500µm either side of the injection site (Figure A2.3 B). At the injection site, the 
average area covered was approximately 78,000µm2 one day post-injection and was 
consistent to the end of the experiment 14 days post-injection. Area under the curve (AUC) 
analysis for the entire of the brain on an individual basis revealed consistent presence of 
nanoshells until 7 days post-injection (AUC = 48,523 – 52,337 Figure A2.3 C). This value 
was non-significantly reduced 14 days post-injection (AUC = 36,746). Further investigation 
showed that the main difference was not the area covered at the injection site, but rather 
that nanoshells were no longer detected as far from the injection site. This may be 
evidence of phagocytic clearance of nanoshells by macrophages within the subarachnoid 
space. 
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A2.4	  Discussion	  
A2.4.1	  FITC-­‐labelled	  nanoshells	  as	  a	  slow	  release	  mechanism	  
Data presented here provide evidence of the potential of FITC-labelled nanoshells as a 
slow release mechanism for delivery of cytokine into the subarachnoid space. Nanoshells 
were readily detectible by fluorescence microscopy as in previous reports using similar 
systems (Hu et al. 2007; Rethore et al. 2009). Nanoshells were present in large 
aggregates approximately 500µm either side of the injection site, and were persistent 
through to the end of the experiment. Pathological analysis revealed extensive infiltration 
of macrophages into the subarachnoid space. They are likely to be phagocytosing the 
nanoshells, though due to the very high density of cells and nanoshells in this area, it was 
impossible to verify the ingestion of nanoshell fragments. The non-significant reduction in 
nanoshell area 14 days post-injection is hypothesised to be caused by the phagocytic 
clearance of nanoshells far from the injection site. It is likely that the large aggregation of 
nanoshells seen in this study may prevent efficient degradation and release, therefore it 
may be necessary to develop new cross-linkers or alter the ratio in order to optimise 
cytokine release (Rethore & Pandit 2010). 
Presence of high numbers of nanoshells surrounding the injection sight was associated 
with small areas of demyelination in the molecular layer of the cortex. Though the 
mechanism of demyelination is unknown, it is possible that it is an effect of pressure 
caused by the injection of a large quantity of a viscous substance into the sagittal sulcus. 
However it is also possible that the activation of macrophages necessary to phagocytose 
causes the release of mediators that cross the pia mater and are toxic to oligodendrocytes 
and myelin. Supporting this hypothesis, cortical microglia also appear to be activated in 
areas with demyelination and neighbouring NAGM. 
We previously showed that injection of TNF/IFNγ into the subarachnoid space causes 
cortical demyelination in rats with a pre-existing anti-myelin immune response. Full 
remyelination occurs after 14 days. It is hypothesised that maintenance of the pro-
inflammatory environment in the subarachnoid space may prevent the action repair 
mechanisms responsible for remyelination, leading to chronic cortical demyelination. 
Chronic demyelination and a pro-inflammatory environment in the cortex may be expected 
to lead to neurodegeneration and sustained oligodendrocyte and astrocyte loss. Further 
studies will investigate the effects of cytokine-loaded nanoshells on cortical myelin integrity 
in animals with and without a pre-existing immune response to myelin. 
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